S8148089B2	NNP	O
-	:	O
Alpha-synuclein	JJ	O
kinase	NN	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
claims	VBZ	O
priority	NN	O
as	IN	O
a	DT	O
divisional	NN	O
of	IN	O
U.S.	NNP	O
patent	NN	O
application	NN	O
Ser.	.	O
No.	.	O
12/030,849,	,	O
filed	VBD	O
Feb.	NNP	O
13,	,	O
2008,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation-in-part	NN	O
of	IN	O
U.S.	NNP	O
patent	NN	O
application	NN	O
Ser.	.	O
No.	.	O
11/669,093,	,	O
filed	VBD	O
Jan.	NNP	O
30,	,	O
2007,	,	O
which	WDT	O
claims	VBZ	O
benefit	NN	O
of	IN	O
U.S.	NNP	O
provisional	JJ	O
application	NN	O
No.	.	O
60/764,000,	,	O
filed	VBD	O
Jan.	NNP	O
31,	,	O
2006,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
for	IN	O
all	DT	O
purposes.	.	O
REFERENCE	NNP	O
TO	NNP	O
A	NNP	O
“SEQUENCE	NNP	O
LISTING,”	VBZ	O
A	NNP	O
TABLE,	,	O
OR	NNP	O
A	NNP	O
COMPUTER	NNP	O
PROGRAM	NNP	O
LISTING	NNP	O
SUBMITTED	NNP	O
IN	NNP	O
COMPUTER	NNP	O
READABLE	NNP	O
FORMAT	NNP	O
The	DT	O
Sequence	NNP	O
Listing	NNP	O
written	VBN	O
in	IN	O
file	JJ	O
0-17521US_SEQLST.txt	NN	O
is	VBZ	O
15,436	CD	O
bytes,	,	O
and	CC	O
was	VBD	O
created	VBN	O
on	IN	O
Feb.	NNP	O
8,	,	O
2010,	,	O
for	IN	O
the	DT	O
application	NN	O
filed	VBN	O
herewith,	,	O
John	NNP	B
P.	NNP	I
Anderson,	,	I
et	RB	I
al.	.	I
“Alpha-Synuclein	JJ	I
Kinase.”	NNP	I
The	DT	O
information	NN	O
contained	VBN	O
in	IN	O
this	DT	O
file	NN	O
is	VBZ	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Lewy	NNP	O
body	NN	O
diseases	NNS	O
(LBDs)	)	O
are	VBP	O
characterized	VBN	O
by	IN	O
degeneration	NN	O
of	IN	O
the	DT	O
dopaminergic	NN	O
system,	,	O
motor	NN	O
alterations,	,	O
cognitive	JJ	O
impairment,	,	O
and	CC	O
formation	NN	O
of	IN	O
Lewy	NNP	O
bodies	NNS	O
(LBs).	.	O
McKeith	NNP	B
et	FW	I
al.,	,	I
Clinical	NNP	I
and	CC	I
pathological	JJ	I
diagnosis	NN	I
of	IN	I
dementia	NN	I
with	IN	I
Lewy	NNP	I
bodies	NNS	I
(DLB):	:	I
Report	NN	I
of	IN	I
the	DT	I
CDLB	NNP	I
International	NNP	I
Workshop,	,	I
Neurology	NNP	I
(1996)	)	I
47:1113-24).(	.	O
LBDs	NNP	O
include	VBP	O
Parkinson's	POS	O
disease,	,	O
Diffuse	NNP	O
Lewy	NNP	O
body	NN	O
disease	NN	O
(DLBD),	,	O
Lewy	NNP	O
body	NN	O
variant	NN	O
of	IN	O
Alzheimer's	POS	O
disease	NN	O
(LBV),	,	O
combined	VBN	O
Parkinson's	POS	O
disease	NN	O
(PD)	)	O
and	CC	O
Alzheimer's	POS	O
disease	NN	O
(AD),	,	O
and	CC	O
the	DT	O
syndromes	NNS	O
identified	VBN	O
as	IN	O
multiple	JJ	O
system	NN	O
atrophy	NN	O
(MSA).	.	O
Dementia	NN	O
with	IN	O
Lewy	NNP	O
bodies	NNS	O
(DLB)	)	O
is	VBZ	O
a	DT	O
term	NN	O
coined	VBN	O
to	TO	O
reconcile	VB	O
differences	NNS	O
in	IN	O
the	DT	O
terminology	NN	O
of	IN	O
LBDs.	.	O
Disorders	NNS	O
with	IN	O
LBs	NNP	O
continue	VBP	O
to	TO	O
be	VB	O
a	DT	O
common	JJ	O
cause	NN	O
for	IN	O
movement	NN	O
disorders	NNS	O
and	CC	O
cognitive	JJ	O
deterioration	NN	O
in	IN	O
the	DT	O
aging	VBG	O
population	NN	O
Galasko	NNP	B
et	RB	I
al.,	,	I
Clinical-neuropathological	JJ	I
correlations	NNS	I
in	IN	I
Alzheimer's	POS	I
disease	NN	I
and	CC	I
related	JJ	I
dementias.	.	I
Arch.	.	I
Neurol.	.	I
(1994)	)	I
51:888-95).(	.	O
Although	IN	O
their	PRP$	O
incidence	NN	O
continues	VBZ	O
to	TO	O
increase,	,	O
creating	VBG	O
a	DT	O
serious	JJ	O
public	JJ	O
health	NN	O
problem,	,	O
to	TO	O
date	NN	O
these	DT	O
disorders	NNS	O
lack	VBP	O
approved	JJ	O
treatments	NNS	O
Tanner	NNP	B
et	RB	I
al.,	,	I
Epidemiology	NNP	I
of	IN	I
Parkinson's	POS	I
disease	NN	I
and	CC	I
akinetic	JJ	I
syndromes,	,	I
Curr.	.	I
Opin.	.	I
Neurol.	.	I
(2000)	)	I
13:427-30).(	.	O
The	DT	O
cause	NN	O
for	IN	O
LBDs	NNP	O
is	VBZ	O
controversial	JJ	O
and	CC	O
multiple	JJ	O
factors	NNS	O
have	VBP	O
been	VBN	O
proposed	VBN	O
to	TO	O
play	VB	O
a	DT	O
role,	,	O
including	VBG	O
various	JJ	O
neurotoxins	NNS	O
and	CC	O
genetic	JJ	O
susceptibility	NN	O
factors.	.	O
In	IN	O
recent	JJ	O
years,	,	O
new	JJ	O
hope	NN	O
for	IN	O
understanding	VBG	O
the	DT	O
pathogenesis	NN	O
of	IN	O
LBDs	NNP	O
has	VBZ	O
emerged.	.	O
Specifically,	,	O
several	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
the	DT	O
synaptic	JJ	O
protein	NN	O
alpha-synuclein	JJ	O
plays	VBZ	O
a	DT	O
central	JJ	O
role	NN	O
in	IN	O
PD	NNP	O
pathogenesis	NN	O
because:	:	O
(1)	)	O
this	DT	O
protein	NN	O
accumulates	VBZ	O
in	IN	O
LBs	NNP	O
Spillantini	NNP	B
et	RB	I
al.,	,	I
Nature	NNP	I
(1997)	)	I
388:839-40;	:	I
Takeda	NNP	B
et	FW	I
al.,	,	I
J.	NNP	I
Pathol.	.	I
(1998)	)	I
152:367-72;	:	I
Wakabayashi	NNP	B
et	FW	I
al.,	,	I
Neurosci.	.	I
Lett.	.	I
(1997)	)	I
239:45-8),(	,	O
(2)	)	O
mutations	NNS	O
in	IN	O
the	DT	O
alpha-synuclein	JJ	O
gene	NN	O
co-segregate	NN	O
with	IN	O
rare	JJ	O
familial	JJ	O
forms	NNS	O
of	IN	O
parkinsonism	NN	O
Kruger	NNP	B
et	VBZ	I
al.,	,	I
Nature	NNP	I
Gen.	NNP	I
(1998)	)	I
18:106-8;	:	I
Polymeropoulos,	,	B
et	FW	I
al.,	,	I
Science	NNP	I
(1997)	)	I
276:2045-7)	)	I
(and,	,	O
(3)	)	O
overexpression	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
transgenic	JJ	O
mice	NN	O
Masliah	NNP	B
et	RB	I
al.,	,	I
Science	NNP	I
(2000)	)	I
287:1265-9)	)	I
(and	CC	O
Drosophila	NNP	O
Feany	NNP	B
et	RB	I
al.,	,	I
Nature	NNP	I
(2000)	)	I
404:394-8)	)	I
(mimics	NNS	O
several	JJ	O
pathological	JJ	O
aspects	NNS	O
of	IN	O
PD.	.	O
Many	JJ	O
scientists	NNS	O
believe	VBP	O
that	IN	O
PD	NNP	O
is	VBZ	O
a	DT	O
relatively	RB	O
late	JJ	O
development	NN	O
in	IN	O
a	DT	O
systemic	JJ	O
synucleinopathy	NN	O
and	CC	O
that	DT	O
“parkinsonism	NN	O
is	VBZ	O
just	RB	O
the	DT	O
tip	NN	O
of	IN	O
the	DT	O
iceberg”	NN	O
Langston,	,	B
Annals	NNP	I
of	IN	I
Neurology	NNP	I
(2006)	)	I
59:591-596).(	.	O
For	IN	O
example,	,	O
Lewy	NNP	O
bodies	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
in	IN	O
sympathetic	JJ	O
ganglia	NN	O
and	CC	O
in	IN	O
the	DT	O
myenteric	JJ	O
plexus	NN	O
of	IN	O
the	DT	O
gut	NN	O
Herzog	NNP	B
E.,	,	I
Dtch	NNP	I
Z	NNP	I
Nervenheilk	NNP	I
(1928)	)	I
107:	:	I
75-80;	:	I
Kupsky	NNP	B
et	FW	I
al.,	,	I
Neurology	NNP	I
(1987)	)	I
37:1253-1255).(	.	O
Various	JJ	O
disorders	NNS	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
the	DT	O
presence	NN	O
of	IN	O
Lewy	NNP	O
bodies.	.	O
For	IN	O
example,	,	O
Lewy	NNP	O
bodies	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
in	IN	O
the	DT	O
brain	NN	O
stem	NN	O
of	IN	O
a	DT	O
patient	NN	O
with	IN	O
rapid	JJ	O
eye	NN	O
movement	NN	O
sleep	JJ	O
behavioral	JJ	O
disorder	NN	O
Uchiyama	NNP	B
et	RB	I
al.,	,	I
Neurology	NNP	I
(1995)	)	I
45:709-712).(	.	O
Olfactory	NNP	O
dysfunction	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
in	IN	O
many	JJ	O
PD	NNP	O
patients	NNS	O
long	RB	O
before	IN	O
the	DT	O
development	NN	O
of	IN	O
parkinsonism.	.	O
Examination	NN	O
of	IN	O
cardiac	JJ	O
tissue	NN	O
from	IN	O
patients	NNS	O
with	IN	O
incidental	JJ	O
Lewy	NNP	O
body	NN	O
disease	NN	O
and	CC	O
typical	JJ	O
PD	NNP	O
revealed	VBD	O
synuclein-positive	JJ	O
neuritis	NN	O
in	IN	O
the	DT	O
myocardium	NN	O
Iwanaga	NNP	B
et	RB	I
al.,	,	I
Neurology	NNP	I
(1999)	)	I
52:1269-1271).(	.	O
There	EX	O
is	VBZ	O
also	RB	O
evidence	NN	O
that	IN	O
esophageal,	,	O
lower	JJR	O
bowel	NN	O
and	CC	O
bladder	NN	O
dysfunction	NN	O
are	VBP	O
early	JJ	O
manifestations	NNS	O
of	IN	O
PD-related	NNP	O
pathology	NN	O
in	IN	O
the	DT	O
peripheral	JJ	O
autonomic	JJ	O
system	NN	O
Qualman	NNP	B
et	VBZ	I
al.,	,	I
Gastroenterology	NNP	I
(1984)	)	I
87:848-856;	:	I
Castell	NNP	B
et	FW	I
al.,	,	I
Neurogasdtroenterol	NNP	I
Motil	NNP	I
(2001)	)	I
13:361-364;	:	I
Hague	NNP	B
et	FW	I
al.,	,	I
Acta	NNP	I
Neuropathol	NNP	I
(Berl)	)	I
(1997)	)	I
94:192-196).(	.	O
Thus,	,	O
the	DT	O
fact	NN	O
that	IN	O
accumulation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
the	DT	O
brain	NN	O
and	CC	O
other	JJ	O
tissues	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
similar	JJ	O
morphological	JJ	O
and	CC	O
neurological	JJ	O
alterations	NNS	O
in	IN	O
species	NNS	O
as	RB	O
diverse	JJ	O
as	IN	O
humans,	,	O
mice,	,	O
and	CC	O
flies	NNS	O
suggests	VBZ	O
that	IN	O
this	DT	O
molecule	NN	O
contributes	VBZ	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
PD.	.	O
BRIEF	NNP	O
SUMMARY	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
screening	VBG	O
an	DT	O
agent	NN	O
for	IN	O
activity	NN	O
for	IN	O
treating	VBG	O
a	DT	O
Lewy	NNP	O
Body	NNP	O
disease	NN	O
(LBD).	.	O
Such	JJ	O
diseases	NNS	O
include	VBP	O
Parkinson's	POS	O
disease	NN	O
(PD),	,	O
Diffuse	NNP	O
Lewy	NNP	O
body	NN	O
disease	NN	O
(DLBD),	,	O
Lewy	NNP	O
body	NN	O
variant	NN	O
of	IN	O
Alzheimer's	POS	O
disease	NN	O
(LBV),	,	O
combined	VBN	O
PD	NNP	O
and	CC	O
Alzheimer's	POS	O
disease	NN	O
(AD),	,	O
and	CC	O
the	DT	O
syndromes	NNS	O
identified	VBN	O
as	IN	O
multiple	JJ	O
system	NN	O
atrophy	NN	O
(MSA).	.	O
Some	DT	O
methods	NNS	O
entail	VBP	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
a	DT	O
kinase	NN	O
shown	VBN	O
in	IN	O
Table	JJ	O
1A,	,	O
B;	:	O
C,	,	O
Table	NNP	O
2,	,	O
Table	JJ	O
11	CD	O
or	CC	O
Table	JJ	O
12,	,	O
and	CC	O
determining	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
shows	VBZ	O
activity	NN	O
useful	JJ	O
in	IN	O
treating	VBG	O
LBD	NNP	O
in	IN	O
an	DT	O
animal	JJ	O
model	NN	O
of	IN	O
the	DT	O
disease.	.	O
In	IN	O
some	DT	O
methods	NNS	O
the	DT	O
modulation	NN	O
is	VBZ	O
inhibition.	.	O
In	IN	O
some	DT	O
methods,	,	O
step	NN	O
(a)	)	O
involves	VBZ	O
identifying	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
inhibits	VBZ	O
the	DT	O
kinase.	.	O
In	IN	O
some	DT	O
methods,	,	O
step	NN	O
(a)	)	O
is	VBZ	O
performed	VBN	O
in	IN	O
a	DT	O
cell	NN	O
transformed	VBN	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
expressing	VBG	O
the	DT	O
kinase	NN	O
and/or	JJ	O
alpha-synuclein.	.	O
In	IN	O
some	DT	O
methods,	,	O
step	NN	O
(a)	)	O
is	VBZ	O
performed	VBN	O
in	IN	O
vitro.	.	O
In	IN	O
some	DT	O
methods,	,	O
step	NN	O
(b)	)	O
is	VBZ	O
performed	VBN	O
in	IN	O
a	DT	O
transgenic	JJ	O
animal	JJ	O
model	NN	O
of	IN	O
LBD	NNP	O
disease,	,	O
and	CC	O
the	DT	O
transgenic	JJ	O
animal	NN	O
may	MD	O
have	VB	O
a	DT	O
transgene	NN	O
expressing	VBG	O
human	JJ	O
alpha-synuclein.	.	O
Preferably,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of:	:	O
APEG1,	,	O
PLK2,	,	O
CDC7L1,	,	O
PRKG1,	,	O
MAPK13,	,	O
GAK,	,	O
RHOK,	,	O
ADRBK1,	,	O
ADRBK2,	,	O
GRK2L,	,	O
GRK5,	,	O
GRK6,	,	O
GRK7,	,	O
IKBKB,	,	O
CKII	NNP	O
and	CC	O
MET	NNP	O
and	CC	O
the	DT	O
modulation	NN	O
is	VBZ	O
inhibition.	.	O
More	RBR	O
preferably,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
PLK2	NNP	O
or	CC	O
GRK6	NNP	O
and	CC	O
the	DT	O
modulation	NN	O
is	VBZ	O
inhibition.	.	O
More	RBR	O
preferably,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
PLK2.	.	O
Preferably	RB	O
in	IN	O
some	DT	O
methods,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
PRKG1,	,	O
MAPK13,	,	O
or	CC	O
GAK	NNP	O
and	CC	O
the	DT	O
modulation	NN	O
is	VBZ	O
activation.	.	O
In	IN	O
some	DT	O
aspects,	,	O
step	NN	O
(b)	)	O
involves	VBZ	O
contacting	VBG	O
the	DT	O
transgenic	JJ	O
animal	NN	O
with	IN	O
the	DT	O
agent	NN	O
and	CC	O
determining	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
inhibits	VBZ	O
formation	NN	O
of	IN	O
deposits	NNS	O
of	IN	O
alpha-synuclein	JJ	O
relative	NN	O
to	TO	O
a	DT	O
control	NN	O
transgenic	JJ	O
animal	NN	O
not	RB	O
treated	VBN	O
with	IN	O
the	DT	O
agent.	.	O
In	IN	O
another	DT	O
aspect,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
effecting	VBG	O
treatment	NN	O
or	CC	O
prophylaxis	NN	O
of	IN	O
a	DT	O
LBD.	.	O
Some	DT	O
examples	NNS	O
of	IN	O
the	DT	O
method	NN	O
involve	VBP	O
administering	VBG	O
to	TO	O
a	DT	O
patient	NN	O
suffering	VBG	O
from	IN	O
or	CC	O
at	IN	O
risk	NN	O
of	IN	O
the	DT	O
disease,	,	O
an	DT	O
effective	JJ	O
regime	NN	O
of	IN	O
an	DT	O
agent	JJ	O
effective	JJ	O
to	TO	O
modulate	VB	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
a	DT	O
kinase.	.	O
The	DT	O
kinase	NN	O
can	MD	O
be	VB	O
one	CD	O
of	IN	O
those	DT	O
shown	VBN	O
in	IN	O
Table	JJ	O
1A,	,	O
B	NNP	O
or	CC	O
C,	,	O
Table	NNP	O
2,	,	O
Table	JJ	O
11	CD	O
or	CC	O
Table	JJ	O
12.	.	O
Preferably,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
antibody	NN	O
to	TO	O
the	DT	O
kinase,	,	O
a	DT	O
zinc	NN	O
finger	NN	O
protein	VBP	O
that	IN	O
modulates	VBZ	O
expression	NN	O
of	IN	O
the	DT	O
kinase,	,	O
or	CC	O
an	DT	O
antisense	JJ	O
RNA,	,	O
siRNA,	,	O
ribozyme	NN	O
or	CC	O
RNA	NNP	O
having	VBG	O
a	DT	O
sequence	NN	O
complementary	NN	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
kinase.	.	O
In	IN	O
some	DT	O
methods,	,	O
the	DT	O
modulation	NN	O
is	VBZ	O
inhibition,	,	O
and	CC	O
preferably,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following:	:	O
APEG1,	,	O
PLK2,	,	O
CDC7L1,	,	O
RHOK,	,	O
ADRBK1,	,	O
ADRBK2,	,	O
GRK2L,	,	O
GRK5,	,	O
GRK6,	,	O
GRK7,	,	O
IKBKB,	,	O
CKII	NNP	O
and	CC	O
MET.	.	O
More	RBR	O
preferably,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
PLK2	NNP	O
or	CC	O
GRK6.	.	O
More	RBR	O
preferably,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
PLK2.	.	O
In	IN	O
some	DT	O
of	IN	O
the	DT	O
methods,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
PRKG1,	,	O
MAPK13,	,	O
and	CC	O
GAK,	,	O
and	CC	O
the	DT	O
modulation	NN	O
is	VBZ	O
activation.	.	O
In	IN	O
one	CD	O
aspect	NN	O
the	DT	O
invention	NN	O
provides	VBZ	O
method	NN	O
of	IN	O
treating	VBG	O
a	DT	O
patient	NN	O
diagnosed	VBN	O
with	IN	O
Parkinson's	POS	O
Disease	NNP	O
by	IN	O
administering	VBG	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
that	IN	O
inhibits	VBZ	O
PLK2	NNP	O
activity.	.	O
In	IN	O
an	DT	O
embodiment	NN	O
the	DT	O
agent	NN	O
preferentially	RB	O
inhibits	VBZ	O
PLK2	NNP	O
activity	NN	O
relative	NN	O
to	TO	O
inhibition	NN	O
of	IN	O
PLK1	NNP	O
activity	NN	O
and/or	NN	O
PLK3	NNP	O
activity	NN	O
and/or	NN	O
PLK4	NNP	O
activity.	.	O
The	DT	O
agent	NN	O
may	MD	O
be,	,	O
for	IN	O
example,	,	O
an	DT	O
siRNA.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
patient	NN	O
is	VBZ	O
not	RB	O
diagnosed	VBN	O
or	CC	O
under	IN	O
treatment	NN	O
for	IN	O
cancer	NN	O
and/or	NN	O
is	VBZ	O
not	RB	O
diagnosed	VBN	O
or	CC	O
under	IN	O
treatment	NN	O
for	IN	O
Alzheimer's	POS	O
disease.	.	O
In	IN	O
related	JJ	O
aspects,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
inhibiting	VBG	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
by	IN	O
reducing	VBG	O
polo-like	JJ	O
kinase	NN	O
2	CD	O
(PLK2)	)	O
activity	NN	O
in	IN	O
the	DT	O
cell	NN	O
such	JJ	O
that	IN	O
phosphorylation	NN	O
of	IN	O
synuclein	NN	O
is	VBZ	O
reduced.	.	O
In	IN	O
a	DT	O
related	JJ	O
aspect,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
inhibiting	VBG	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
(e.g.,	,	O
a	DT	O
neuronal	JJ	O
cell)	)	O
by	IN	O
contacting	VBG	O
the	DT	O
cell	NN	O
with	IN	O
a	DT	O
compound	NN	O
that	WDT	O
reduces	VBZ	O
PLK2	NNP	O
activity	NN	O
in	IN	O
the	DT	O
cell	NN	O
such	JJ	O
that	IN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
is	VBZ	O
reduced.	.	O
For	IN	O
example,	,	O
the	DT	O
agent	NN	O
may	MD	O
reduce	VB	O
expression	NN	O
of	IN	O
a	DT	O
PLK2	NNP	O
gene	NN	O
product.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
agent	NN	O
preferentially	RB	O
reduces	VBZ	O
PLK2	NNP	O
activity	NN	O
relative	NN	O
to	TO	O
reduction	NN	O
of	IN	O
PLK1	NNP	O
activity,	,	O
PLK2	NNP	O
activity,	,	O
or	CC	O
PLK3	NNP	O
activity.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
agent	NN	O
has	VBZ	O
a	DT	O
molecular	JJ	O
weight	NN	O
less	JJR	O
than	IN	O
4000.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
agent	NN	O
is	VBZ	O
a	DT	O
synthetic	JJ	O
compound.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
the	DT	O
agent	NN	O
is	VBZ	O
a	DT	O
polynucleotide	NN	O
that	IN	O
inhibits	VBZ	O
expression	NN	O
or	CC	O
translation	NN	O
of	IN	O
a	DT	O
PLK2	NNP	O
RNA	NNP	O
transcript,	,	O
such	JJ	O
as	IN	O
an	DT	O
siRNA.	.	O
In	IN	O
an	DT	O
embodiment,	,	O
one	CD	O
strand	NN	O
of	IN	O
the	DT	O
double	NN	O
stranded	VBD	O
region	NN	O
of	IN	O
the	DT	O
siRNA	NN	O
is	VBZ	O
perfectly	RB	O
complementary	JJ	O
to	TO	O
a	DT	O
PLK2	NNP	O
transcript	NN	O
but	CC	O
not	RB	O
to	TO	O
a	DT	O
PLK1	NNP	O
transcript	NN	O
or	CC	O
a	DT	O
PLK3	NNP	O
transcript.	.	O
In	IN	O
another	DT	O
aspect,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
identifying	VBG	O
a	DT	O
kinase	NN	O
that	WDT	O
phosphorylates	VBZ	O
alpha-synuclein	JJ	O
by	IN	O
transfecting	VBG	O
a	DT	O
cell	NN	O
expressing	VBG	O
alpha-synuclein	JJ	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
having	VBG	O
a	DT	O
sequence	NN	O
complementary	NN	O
to	TO	O
a	DT	O
gene	NN	O
encoding	VBG	O
a	DT	O
kinase	NN	O
or	CC	O
zinc	NN	O
finger	NN	O
protein	VBP	O
that	IN	O
specifically	RB	O
binds	VBZ	O
to	TO	O
the	DT	O
gene.	.	O
The	DT	O
transfected	JJ	O
nucleic	JJ	O
acid	NN	O
or	CC	O
zinc	NN	O
finger	NN	O
protein	VBP	O
inhibits	VBZ	O
expression	NN	O
of	IN	O
the	DT	O
kinase;	:	O
and	CC	O
an	DT	O
amount	NN	O
of	IN	O
phosphorylated	VBN	O
alpha-synuclein	NN	O
the	DT	O
cell	NN	O
can	MD	O
then	RB	O
be	VB	O
measured	VBN	O
relative	JJ	O
to	TO	O
a	DT	O
control	NN	O
cell	NN	O
not	RB	O
transfected	VBN	O
with	IN	O
the	DT	O
siRNA	NN	O
or	CC	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
the	DT	O
same.	.	O
In	IN	O
this	DT	O
case,	,	O
a	DT	O
reduction	NN	O
in	IN	O
phosphorylated	JJ	O
alpha-synuclein	NN	O
will	MD	O
provide	VB	O
an	DT	O
indication	NN	O
that	IN	O
the	DT	O
kinase	NN	O
phosphorylates	VBZ	O
alpha-synuclein.	.	O
Some	DT	O
methods	NNS	O
also	RB	O
include	VBP	O
measuring	VBG	O
an	DT	O
amount	NN	O
of	IN	O
alpha-synuclein	NN	O
produced	VBN	O
by	IN	O
the	DT	O
cell	NN	O
relative	NN	O
to	TO	O
a	DT	O
control	NN	O
cell	NN	O
not	RB	O
transfected	VBN	O
with	IN	O
the	DT	O
nucleic	JJ	O
acid.	.	O
In	IN	O
some	DT	O
methods,	,	O
the	DT	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
an	DT	O
siRNA	NN	O
or	CC	O
a	DT	O
DNA	NN	O
molecule	NN	O
encoding	VBG	O
the	DT	O
same.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	JJ	O
reduces	NNS	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
expressing	VBG	O
alpha-synuclein.	.	O
The	DT	O
method	NN	O
includes	VBZ	O
selecting	VBG	O
an	DT	O
agent	NN	O
that	IN	O
a)	)	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK2	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK2	NNP	O
(and	CC	O
optionally	RB	O
expressing	VBG	O
synuclein),	,	O
and	CC	O
b)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK1	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK1,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK1	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2;	:	O
and/or	CC	O
c)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK3	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK3,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK3	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2;	:	O
and/or	CC	O
d)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK4	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK4,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK4	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2.	.	O
The	DT	O
cell	NN	O
can	MD	O
be	VB	O
a	DT	O
mammalian	JJ	O
cell	NN	O
overexpressing	VBG	O
alpha-synuclein.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
agent	NN	O
a)	)	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK2	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK2;	:	O
b)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK1	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK1,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK1	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2;	:	O
c)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK3	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK3,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK3	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2;	:	O
and	CC	O
d)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK4	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK4,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK4	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2.	.	O
In	IN	O
a	DT	O
further	JJ	O
step,	,	O
the	DT	O
method	NN	O
involves	VBZ	O
determining	VBG	O
whether	IN	O
the	DT	O
selected	VBN	O
agent	NN	O
shows	VBZ	O
activity	NN	O
useful	JJ	O
in	IN	O
treating	VBG	O
Lewy	NNP	O
Body	NNP	O
Disease	NNP	O
in	IN	O
an	DT	O
animal	JJ	O
model	NN	O
of	IN	O
the	DT	O
disease	NN	O
or	CC	O
a	DT	O
cellular	JJ	O
model	NN	O
of	IN	O
the	DT	O
disease.	.	O
Animal	JJ	O
models	NNS	O
include	VBP	O
transgenic	JJ	O
animals.	.	O
Cellular	JJ	O
models	NNS	O
include	VBP	O
neuronally-derived	JJ	O
cell	NN	O
cultures	NNS	O
and	CC	O
mammalian	JJ	O
cells	NNS	O
over-expressing	JJ	O
alpha-synuclein.	.	O
Activities	NNS	O
that	WDT	O
can	MD	O
be	VB	O
assayed	VBN	O
include	VBP	O
reduction	NN	O
of	IN	O
the	DT	O
proportion	NN	O
of	IN	O
total	JJ	O
alpha-synuclein	JJ	O
that	WDT	O
is	VBZ	O
phosphorylated	VBN	O
at	IN	O
serine-129	NN	O
or	CC	O
a	DT	O
reduction	NN	O
in	IN	O
aggregation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
the	DT	O
cell.	.	O
In	IN	O
other	JJ	O
aspects,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
method	NN	O
of	IN	O
screening	VBG	O
an	DT	O
agent	NN	O
for	IN	O
activity	NN	O
for	IN	O
treating	VBG	O
a	DT	O
Lewy	NNP	O
Body	NNP	O
disease	NN	O
(LBD),	,	O
by	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
synphilin,	,	O
and	CC	O
determining	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
shows	VBZ	O
activity	NN	O
useful	JJ	O
in	IN	O
treating	VBG	O
LBD	NNP	O
in	IN	O
an	DT	O
animal	JJ	O
model	NN	O
of	IN	O
the	DT	O
disease.	.	O
In	IN	O
other	JJ	O
aspects,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
for	IN	O
producing	VBG	O
Ser-129	JJ	O
phosphorylated-alpha	JJ	O
synuclein,	,	O
by	IN	O
providing	VBG	O
a	DT	O
plasmid	JJ	O
encoding	VBG	O
alpha-synuclein	NN	O
and	CC	O
a	DT	O
plasmid	NN	O
encoding	VBG	O
PLK2	NNP	O
in	IN	O
a	DT	O
bacterial	JJ	O
cell,	,	O
culturing	VBG	O
the	DT	O
cell	NN	O
so	RB	O
that	IN	O
the	DT	O
plasmids	NNS	O
are	VBP	O
co-expressing	VBG	O
to	TO	O
produce	VB	O
alpha	JJ	O
synuclein	NN	O
and	CC	O
PLK2	NNP	O
so	IN	O
that	IN	O
the	DT	O
PLK2	NNP	O
phosphorylates	VBZ	O
the	DT	O
alpha-synuclein	NN	O
in	IN	O
a	DT	O
bacterial	JJ	O
cell,	,	O
and	CC	O
isolating	VBG	O
phosphorylated	VBN	O
alpha-synuclein	NN	O
from	IN	O
the	DT	O
cell.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
DRAWINGS	NNP	O
FIGS.	.	O
1A-C	JJ	O
show	NN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
phosphorylation	NN	O
assay	NN	O
for	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
recombinant	JJ	O
kinases.	.	O
FIG.	.	O
1A	CD	O
shows	NNS	O
total	JJ	O
alpha-synuclein,	,	O
FIG.	.	O
1B	CD	O
shows	NNS	O
phosphorylation	NN	O
of	IN	O
the	DT	O
pser-129	JJ	O
(phospho-serine-129)	)	O
of	IN	O
alpha-synuclein	NN	O
and	CC	O
FIG.	.	O
1C	CD	O
shows	NNS	O
phosphorylation	NN	O
of	IN	O
the	DT	O
pser-87	JJ	O
(phospho-serine-87)	)	O
of	IN	O
alpha-synuclein.	.	O
FIGS.	.	O
1D-F	JJ	O
show	NN	O
a	DT	O
study	NN	O
with	IN	O
recombinant	JJ	O
kinases,	,	O
including	VBG	O
kinases	NNS	O
from	IN	O
the	DT	O
GPCR-receptor	NNP	O
kinase	NN	O
(GRK)	)	O
family	NN	O
and	CC	O
PLK2.	.	O
FIG.	.	O
1D	CD	O
shows	NNS	O
total	JJ	O
alpha-synuclein,	,	O
FIG.	.	O
1E	CD	O
shows	NNS	O
phosphorylation	NN	O
of	IN	O
the	DT	O
pser-129	NN	O
of	IN	O
alpha-synuclein	JJ	O
and	CC	O
FIG.	.	O
1F	CD	O
shows	NNS	O
phosphorylation	NN	O
of	IN	O
the	DT	O
pser-87	NN	O
of	IN	O
alpha-synuclein.	.	O
FIGS.	.	O
2A	CD	O
and	CC	O
B	NNP	O
show	VBP	O
the	DT	O
results	NNS	O
of	IN	O
kinase	NN	O
activity	NN	O
in	IN	O
vitro	NN	O
for	IN	O
various	JJ	O
kinases.	.	O
FIG.	.	O
2A	CD	O
shows	VBZ	O
the	DT	O
total	JJ	O
(AS).	.	O
FIG.	.	O
2B	CD	O
shows	VBZ	O
phosphor-serine	NN	O
129.	.	O
FIGS.	.	O
3A-C	JJ	O
show	NN	O
the	DT	O
results	NNS	O
of	IN	O
kinase	NN	O
activity	NN	O
in	IN	O
vitro	NN	O
for	IN	O
various	JJ	O
kinases.	.	O
FIG.	.	O
2A	CD	O
shows	VBZ	O
the	DT	O
total	JJ	O
AS.	.	O
FIG.	.	O
3B	CD	O
shows	NNS	O
Serine	NNP	O
129.	.	O
FIG.	.	O
3C	CD	O
shows	VBZ	O
phospho-serine	NN	O
87.	.	O
FIGS.	.	O
4A	CD	O
and	CC	O
B	NNP	O
show	VBP	O
the	DT	O
effect	NN	O
of	IN	O
phospholipid	NN	O
on	IN	O
the	DT	O
assay	NN	O
results	NNS	O
in	IN	O
FIGS.	.	O
3A	CD	O
and	CC	O
3B.	.	O
FIG.	.	O
4A	CD	O
shows	VBZ	O
the	DT	O
total	JJ	O
AS.	.	O
FIG.	.	O
4B	CD	O
shows	NNS	O
Serine	NNP	O
129.	.	O
FIG.	.	O
5	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
transfection	NN	O
of	IN	O
cDNA	NN	O
to	TO	O
PLK2	NNP	O
into	IN	O
293-synuclein	JJ	O
cells.	.	O
Cells	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
ELISA	NNP	O
for	IN	O
total	JJ	O
and	CC	O
phospho-synuclein	JJ	O
levels.	.	O
FIG.	.	O
6	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
transfection	NN	O
of	IN	O
cDNA	NN	O
to	TO	O
GPRK6	NNP	O
and	CC	O
PLK2	NNP	O
into	IN	O
HEK-Synuclein	NNP	O
cells.	.	O
FIG.	.	O
7	CD	O
shows	NNS	O
that	IN	O
knockdown	NN	O
of	IN	O
the	DT	O
PLK2	NNP	O
using	VBG	O
siRNA	NN	O
from	IN	O
a	DT	O
second	JJ	O
source	NN	O
causes	VBZ	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
alpha-synuclein	NN	O
that	WDT	O
is	VBZ	O
phosphorylated.	.	O
FIGS.	.	O
8A	CD	O
and	CC	O
8B	CD	O
show	VBP	O
the	DT	O
in	IN	O
vitro	JJ	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
by	IN	O
putative	JJ	O
kinase	NN	O
targets	NNS	O
in	IN	O
alpha-synuclein	JJ	O
KO	NNP	O
mouse	NN	O
brain.	.	O
FIGS.	.	O
9A	CD	O
and	CC	O
9B	CD	O
show	VBP	O
the	DT	O
in	IN	O
vitro	JJ	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
by	IN	O
putative	JJ	O
kinase	NN	O
targets	NNS	O
in	IN	O
alpha-synuclein	JJ	O
KO	NNP	O
mouse	NN	O
brain.	.	O
FIG.	.	O
10	CD	O
shows	NNS	O
that	IN	O
siRNA	VBP	O
knockdown	VBN	O
of	IN	O
PLK2,	,	O
but	CC	O
not	RB	O
PLK3	NNP	O
or	CC	O
PLK4,	,	O
reduced	VBD	O
alpha-synuclein	JJ	O
phosphorylation.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
I.	NNP	O
Definitions	NNP	O
The	DT	O
term	NN	O
“agent”	NNP	O
is	VBZ	O
used	VBN	O
to	TO	O
describe	VB	O
a	DT	O
compound	NN	O
that	WDT	O
has	VBZ	O
or	CC	O
may	MD	O
have	VB	O
a	DT	O
pharmacological	JJ	O
activity.	.	O
Agents	NNS	O
include	VBP	O
compounds	NNS	O
that	WDT	O
are	VBP	O
known	VBN	O
drugs,	,	O
compounds	NNS	O
for	IN	O
which	WDT	O
pharmacological	JJ	O
activity	NN	O
has	VBZ	O
been	VBN	O
identified	VBN	O
but	CC	O
which	WDT	O
are	VBP	O
undergoing	VBG	O
further	RBR	O
therapeutic	JJ	O
evaluation,	,	O
and	CC	O
compounds	NNS	O
that	WDT	O
are	VBP	O
members	NNS	O
of	IN	O
collections	NNS	O
and	CC	O
libraries	NNS	O
that	WDT	O
are	VBP	O
to	TO	O
be	VB	O
screened	VBN	O
for	IN	O
a	DT	O
pharmacological	JJ	O
activity.	.	O
A	DT	O
“pharmacological”	JJ	O
activity	NN	O
means	VBZ	O
that	IN	O
an	DT	O
agent	NN	O
exhibits	VBZ	O
an	DT	O
activity	NN	O
in	IN	O
a	DT	O
screening	NN	O
system	NN	O
that	WDT	O
indicates	VBZ	O
that	IN	O
the	DT	O
agent	NN	O
is	VBZ	O
or	CC	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
prophylaxis	NN	O
or	CC	O
treatment	NN	O
of	IN	O
a	DT	O
disease.	.	O
The	DT	O
screening	NN	O
system	NN	O
can	MD	O
be	VB	O
in	IN	O
vitro,	,	O
cellular,	,	O
animal	JJ	O
or	CC	O
human.	.	O
Agents	NNS	O
can	MD	O
be	VB	O
described	VBN	O
as	IN	O
having	VBG	O
pharmacological	JJ	O
activity	NN	O
notwithstanding	VBG	O
that	IN	O
further	JJ	O
testing	NN	O
may	MD	O
be	VB	O
required	VBN	O
to	TO	O
establish	VB	O
actual	JJ	O
prophylactic	JJ	O
or	CC	O
therapeutic	JJ	O
utility	NN	O
in	IN	O
treatment	NN	O
of	IN	O
a	DT	O
disease.	.	O
A	DT	O
Lewy-like	JJ	O
body	NN	O
is	VBZ	O
a	DT	O
deposit	NN	O
of	IN	O
alpha-synuclein	JJ	O
found	VBN	O
in	IN	O
a	DT	O
transgenic	JJ	O
animal	NN	O
that	WDT	O
resembles	VBZ	O
some	DT	O
or	CC	O
all	DT	O
of	IN	O
the	DT	O
characteristics	NNS	O
of	IN	O
a	DT	O
Lewy	NNP	O
body	NN	O
found	VBD	O
in	IN	O
human	JJ	O
patients.	.	O
The	DT	O
preferred	JJ	O
characteristics	NNS	O
are	VBP	O
a	DT	O
compact	JJ	O
alpha-synuclein	JJ	O
positive	JJ	O
inclusion.	.	O
These	DT	O
inclusions	NNS	O
preferably	RB	O
form	VBP	O
in	IN	O
an	DT	O
age-dependent	JJ	O
manner.	.	O
The	DT	O
formation	NN	O
of	IN	O
alpha-synuclein	JJ	O
positive	JJ	O
inclusions	NNS	O
preferably	RB	O
results	NNS	O
in	IN	O
observable	JJ	O
cellular	JJ	O
pathology,	,	O
leading	VBG	O
to	TO	O
loss	NN	O
of	IN	O
functionality	NN	O
of	IN	O
affected	JJ	O
neurons.	.	O
Loss	NNP	O
of	IN	O
function	NN	O
of	IN	O
affected	JJ	O
neurons	NNS	O
can	MD	O
be	VB	O
determined	VBN	O
through	IN	O
behavioral	JJ	O
tests,	,	O
neuropharmacological	JJ	O
response	NN	O
evaluation	NN	O
and	CC	O
electrophysiology.	.	O
The	DT	O
phrase	NN	O
“specifically	RB	O
binds”	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
binding	NN	O
reaction	NN	O
which	WDT	O
is	VBZ	O
determinative	JJ	O
of	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
protein	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
heterogeneous	JJ	O
population	NN	O
of	IN	O
proteins	NNS	O
and	CC	O
other	JJ	O
biologics.	.	O
Thus,	,	O
under	IN	O
designated	VBN	O
conditions,	,	O
a	DT	O
specified	JJ	O
ligand	NN	O
binds	VBZ	O
preferentially	RB	O
to	TO	O
a	DT	O
particular	JJ	O
protein	NN	O
and	CC	O
does	VBZ	O
not	RB	O
bind	VB	O
in	IN	O
a	DT	O
significant	JJ	O
amount	NN	O
to	TO	O
other	JJ	O
proteins	NNS	O
present	JJ	O
in	IN	O
the	DT	O
sample.	.	O
A	DT	O
molecule	NN	O
such	JJ	O
as	IN	O
an	DT	O
antibody	NN	O
that	WDT	O
specifically	RB	O
binds	VBZ	O
to	TO	O
a	DT	O
protein	NN	O
often	RB	O
has	VBZ	O
an	DT	O
association	NN	O
constant	NN	O
of	IN	O
at	IN	O
least	JJS	O
106M−1	CD	O
or	CC	O
107	CD	O
M−1,	,	O
preferably	RB	O
108M−1	CD	O
to	TO	O
109	CD	O
M−1,	,	O
and	CC	O
more	JJR	O
preferably,	,	O
about	IN	O
1010	CD	O
M−1	NNP	O
to	TO	O
1011	CD	O
M−1	NNP	O
or	CC	O
higher.	.	O
A	DT	O
variety	NN	O
of	IN	O
immunoassay	JJ	O
formats	NNS	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
select	VB	O
antibodies	NNS	O
specifically	RB	O
immunoreactive	VBP	O
with	IN	O
a	DT	O
particular	JJ	O
protein.	.	O
For	IN	O
example,	,	O
solid-phase	JJ	O
ELISA	NNP	O
immunoassays	NNS	O
are	VBP	O
routinely	RB	O
used	VBN	O
to	TO	O
select	VB	O
monoclonal	JJ	O
antibodies	NNS	O
specifically	RB	O
immunoreactive	VBP	O
with	IN	O
a	DT	O
protein.	.	O
See,	,	O
e.g.,	,	O
Harlow	NNP	O
and	CC	O
Lane	NNP	O
(1988)	)	O
Antibodies,	,	O
A	NNP	O
Laboratory	NNP	O
Manual,	,	O
Cold	NNP	O
Spring	NNP	O
Harbor	NNP	O
Publications,	,	O
New	NNP	O
York,	,	O
for	IN	O
examples	NNS	O
of	IN	O
immunoassay	NN	O
formats	NNS	O
and	CC	O
conditions	NNS	O
that	WDT	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
determine	VB	O
specific	JJ	O
immunoreactivity.	.	O
For	IN	O
sequence	NN	O
comparison,	,	O
typically	RB	O
one	CD	O
sequence	NN	O
acts	VBZ	O
as	IN	O
a	DT	O
reference	NN	O
sequence,	,	O
to	TO	O
which	WDT	O
test	NN	O
sequences	NNS	O
are	VBP	O
compared.	.	O
When	WRB	O
using	VBG	O
a	DT	O
sequence	NN	O
comparison	NN	O
algorithm,	,	O
test	NN	O
and	CC	O
reference	NN	O
sequences	NNS	O
are	VBP	O
input	VBN	O
into	IN	O
a	DT	O
computer,	,	O
subsequent	JJ	O
coordinates	NNS	O
are	VBP	O
designated,	,	O
if	IN	O
necessary,	,	O
and	CC	O
sequence	NN	O
algorithm	NN	O
program	NN	O
parameters	NNS	O
are	VBP	O
designated.	.	O
The	DT	O
sequence	NN	O
comparison	NN	O
algorithm	NN	O
then	RB	O
calculates	VBZ	O
the	DT	O
percent	NN	O
sequence	NN	O
identity	NN	O
for	IN	O
the	DT	O
test	NN	O
sequence(s)	)	O
relative	VBP	O
to	TO	O
the	DT	O
reference	NN	O
sequence,	,	O
based	VBN	O
on	IN	O
the	DT	O
designated	VBN	O
program	NN	O
parameters.	.	O
Optimal	JJ	O
alignment	NN	O
of	IN	O
sequences	NNS	O
for	IN	O
comparison	NN	O
can	MD	O
be	VB	O
conducted,	,	O
e.g.,	,	O
by	IN	O
the	DT	O
local	JJ	O
homology	NN	O
algorithm	NN	O
of	IN	O
Smith	NNP	B
&	CC	I
Waterman,	,	I
Adv.	.	I
Appl.	.	I
Math.	.	I
2:482	CD	I
(1981),	,	I
by	IN	O
the	DT	O
homology	NN	O
alignment	JJ	O
algorithm	NN	O
of	IN	O
Needleman	NNP	B
&	CC	I
Wunsch,	,	I
J.	NNP	I
Mol.	.	I
Biol.	.	I
48:443	CD	I
(1970),	,	I
by	IN	O
the	DT	O
search	NN	O
for	IN	O
similarity	NN	O
method	NN	O
of	IN	O
Pearson	NNP	B
&	CC	I
Lipman,	,	I
Proc.	.	I
Nat'l.	.	I
Acad.	.	I
Sci.	.	I
USA	NNP	I
85:2444	CD	I
(1988),	,	I
by	IN	O
computerized	JJ	O
implementations	NNS	O
of	IN	O
these	DT	O
algorithms	NNS	O
(GAP,	,	O
BESTFIT,	,	O
FASTA,	,	O
and	CC	O
TFASTA	NNP	O
in	IN	O
the	DT	O
Wisconsin	NNP	O
Genetics	NNP	O
Software	NNP	O
Package,	,	O
Genetics	NNP	O
Computer	NNP	O
Group,	,	O
575	CD	O
Science	NNP	O
Dr.,	,	O
Madison,	,	O
Wis.),	,	O
or	CC	O
by	IN	O
visual	JJ	O
inspection	NN	O
(see	VB	O
generally	RB	O
Ausubel	NNP	O
et	CC	O
al.,	,	O
supra).	.	O
Another	DT	O
example	NN	O
of	IN	O
algorithm	NN	O
that	WDT	O
is	VBZ	O
suitable	JJ	O
for	IN	O
determining	VBG	O
percent	NN	O
sequence	NN	O
identity	NN	O
and	CC	O
sequence	NN	O
similarity	NN	O
is	VBZ	O
the	DT	O
BLAST	NNP	O
algorithm,	,	O
which	WDT	O
is	VBZ	O
described	VBN	O
in	IN	O
Altschul	NNP	B
et	CC	I
al.,	,	I
J.	NNP	I
Mol.	.	I
Biol.	.	I
215:403-410	CD	I
(1990).	.	I
Software	NNP	O
for	IN	O
performing	VBG	O
BLAST	NNP	O
analyses	NNS	O
is	VBZ	O
publicly	RB	O
available	JJ	O
through	IN	O
the	DT	O
National	NNP	O
Center	NNP	O
for	IN	O
Biotechnology	NNP	O
Information	NNP	O
(http://www.ncbi.nlm.nih.gov/).	.	O
This	DT	O
algorithm	NN	O
involves	VBZ	O
first	RB	O
identifying	JJ	O
high	JJ	O
scoring	VBG	O
sequence	NN	O
pairs	NNS	O
(HSPs)	)	O
by	IN	O
identifying	VBG	O
short	JJ	O
words	NNS	O
of	IN	O
length	NN	O
W	NNP	O
in	IN	O
the	DT	O
query	NN	O
sequence,	,	O
which	WDT	O
either	CC	O
match	NN	O
or	CC	O
satisfy	VB	O
some	DT	O
positive-valued	JJ	O
threshold	NN	O
score	NN	O
T	NNP	O
when	WRB	O
aligned	VBN	O
with	IN	O
a	DT	O
word	NN	O
of	IN	O
the	DT	O
same	JJ	O
length	NN	O
in	IN	O
a	DT	O
database	NN	O
sequence.	.	O
T	NNP	O
is	VBZ	O
referred	VBN	O
to	TO	O
as	IN	O
the	DT	O
neighborhood	NN	O
word	NN	O
score	NN	O
threshold	NN	O
(Altschul	NNP	O
et	RB	O
al.,	,	O
supra.).	.	O
These	DT	O
initial	JJ	O
neighborhood	NN	O
word	NN	O
hits	VBZ	O
act	NN	O
as	IN	O
seeds	NNS	O
for	IN	O
initiating	VBG	O
searches	NNS	O
to	TO	O
find	VB	O
longer	JJR	O
HSPs	NNP	O
containing	VBG	O
them.	.	O
The	DT	O
word	NN	O
hits	NNS	O
are	VBP	O
then	RB	O
extended	VBN	O
in	IN	O
both	DT	O
directions	NNS	O
along	IN	O
each	DT	O
sequence	NN	O
for	IN	O
as	RB	O
far	RB	O
as	IN	O
the	DT	O
cumulative	JJ	O
alignment	NN	O
score	NN	O
can	MD	O
be	VB	O
increased.	.	O
Cumulative	JJ	O
scores	NNS	O
are	VBP	O
calculated	VBN	O
using,	,	O
for	IN	O
nucleotide	JJ	O
sequences,	,	O
the	DT	O
parameters	NNS	O
M	NNP	O
(reward	NN	O
score	NN	O
for	IN	O
a	DT	O
pair	NN	O
of	IN	O
matching	VBG	O
residues;	:	O
always	RB	O
>0)	)	O
and	CC	O
N	NNP	O
(penalty	NN	O
score	NN	O
for	IN	O
mismatching	VBG	O
residues;	:	O
always	RB	O
<0).	.	O
For	IN	O
amino	NN	O
acid	NN	O
sequences,	,	O
a	DT	O
scoring	NN	O
matrix	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
calculate	VB	O
the	DT	O
cumulative	JJ	O
score.	.	O
Extension	NN	O
of	IN	O
the	DT	O
word	NN	O
hits	VBZ	O
in	IN	O
each	DT	O
direction	NN	O
are	VBP	O
halted	VBN	O
when:	:	O
the	DT	O
cumulative	JJ	O
alignment	NN	O
score	NN	O
falls	VBZ	O
off	RP	O
by	IN	O
the	DT	O
quantity	NN	O
X	NNP	O
from	IN	O
its	PRP$	O
maximum	NN	O
achieved	VBN	O
value;	:	O
the	DT	O
cumulative	JJ	O
score	NN	O
goes	VBZ	O
to	TO	O
zero	CD	O
or	CC	O
below,	,	O
due	JJ	O
to	TO	O
the	DT	O
accumulation	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
negative-scoring	JJ	O
residue	JJ	O
alignments;	:	O
or	CC	O
the	DT	O
end	NN	O
of	IN	O
either	DT	O
sequence	NN	O
is	VBZ	O
reached.	.	O
For	IN	O
identifying	VBG	O
whether	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
is	VBZ	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
invention,	,	O
the	DT	O
default	NN	O
parameters	NNS	O
of	IN	O
the	DT	O
BLAST	NNP	O
programs	NNS	O
are	VBP	O
suitable.	.	O
The	DT	O
BLASTN	NNP	O
program	NN	O
(for	IN	O
nucleotide	RB	O
sequences)	)	O
uses	VBZ	O
as	IN	O
defaults	NNS	O
a	DT	O
word	NN	O
length	NN	O
(W)	)	O
of	IN	O
11,	,	O
an	DT	O
expectation	NN	O
(E)	)	O
of	IN	O
10,	,	O
M=5,	,	O
N=−4,	,	O
and	CC	O
a	DT	O
comparison	NN	O
of	IN	O
both	DT	O
strands.	.	O
For	IN	O
amino	NN	O
acid	NN	O
sequences,	,	O
the	DT	O
BLASTP	NNP	O
program	NN	O
uses	VBZ	O
as	IN	O
defaults	NNS	O
a	DT	O
word	NN	O
length	NN	O
(W)	)	O
of	IN	O
3,	,	O
an	DT	O
expectation	NN	O
(E)	)	O
of	IN	O
10,	,	O
and	CC	O
the	DT	O
BLOSUM62	NNP	O
scoring	NN	O
matrix.	.	O
The	DT	O
TBLATN	NNP	O
program	NN	O
(using	VBG	O
protein	NN	O
sequence	NN	O
for	IN	O
nucleotide	JJ	O
sequence)	)	O
uses	VBZ	O
as	IN	O
defaults	NNS	O
a	DT	O
word	NN	O
length	NN	O
(W)	)	O
of	IN	O
3,	,	O
an	DT	O
expectation	NN	O
(E)	)	O
of	IN	O
10,	,	O
and	CC	O
a	DT	O
BLOSUM	NNP	O
62	CD	O
scoring	VBG	O
matrix.	.	O
(see	VB	O
Henikoff	NNP	B
&	CC	I
Henikoff,	,	I
Proc.	.	I
Natl.	.	I
Acad.	.	I
Sci.	.	I
USA	NNP	I
89:10915	CD	I
(1989)).In	.	O
addition	IN	O
to	NN	O
calculating	TO	O
percent	VBG	O
sequence	NN	O
identity,	NN	O
the	,	O
BLAST	DT	O
algorithm	NNP	O
also	NN	O
performs	RB	O
a	VBZ	O
statistical	DT	O
analysis	JJ	O
of	NN	O
the	IN	O
similarity	DT	O
between	NN	O
two	IN	O
sequences	CD	O
(see,	NNS	O
e.g.,	,	O
Karlin	,	B
&	NNP	I
Altschul,	CC	I
Proc.	,	I
Nat'l.	.	I
Acad.	.	I
Sci.	.	I
USA	.	I
90:5873-5787	NNP	I
(1993)).One	CD	O
measure	.	O
of	CD	O
similarity	NN	O
provided	IN	O
by	NN	O
the	VBN	O
BLAST	IN	O
algorithm	DT	O
is	NNP	O
the	NN	O
smallest	VBZ	O
sum	DT	O
probability	JJS	O
(P(N)),	JJ	O
which	NN	O
provides	,	O
an	WDT	O
indication	VBZ	O
of	DT	O
the	NN	O
probability	IN	O
by	DT	O
which	NN	O
a	IN	O
match	WDT	O
between	DT	O
two	NN	O
nucleotide	IN	O
or	CD	O
amino	NN	O
acid	CC	O
sequences	NN	O
would	JJ	O
occur	NNS	O
by	MD	O
chance.	VB	O
For	IN	O
example,	.	O
a	IN	O
nucleic	,	O
acid	DT	O
is	JJ	O
considered	NN	O
similar	VBZ	O
to	VBN	O
a	JJ	O
reference	TO	O
sequence	DT	O
if	NN	O
the	NN	O
smallest	IN	O
sum	DT	O
probability	JJS	O
in	JJ	O
a	NN	O
comparison	IN	O
of	DT	O
the	NN	O
test	IN	O
nucleic	DT	O
acid	NN	O
to	NN	O
the	NN	O
reference	TO	O
nucleic	DT	O
acid	NN	O
is	JJ	O
less	NN	O
than	VBZ	O
about	JJR	O
0.1,	IN	O
more	RB	O
preferably	,	O
less	JJR	O
than	RB	O
about	RBR	O
0.01,	IN	O
and	RB	O
most	,	O
preferably	CC	O
less	JJS	O
than	RB	O
about	JJR	O
0.001.	IN	O
For	RB	O
purposes	.	O
of	IN	O
classifying	NNS	O
amino	IN	O
acids	VBG	O
substitutions	JJ	O
as	NNS	O
conservative	NNS	O
or	IN	O
non-conservative,	JJ	O
amino	CC	O
acids	,	O
are	JJ	O
grouped	NNS	O
as	VBP	O
follows:	VBN	O
Group	IN	O
I	:	O
(hydrophobic	NNP	O
side	PRP	O
chains):	JJ	O
norleucine,	NN	O
met,	:	O
ala,	,	O
val,	,	O
leu,	,	O
ile;	,	O
Group	,	O
II	:	O
(neutral	NNP	O
hydrophilic	NNP	O
side	JJ	O
chains):	JJ	O
cys,	NN	O
ser,	:	O
thr;	,	O
Group	,	O
III	:	O
(acidic	NNP	O
side	NNP	O
chains):	JJ	O
asp,	NN	O
glu;	:	O
Group	,	O
IV	:	O
(basic	NNP	O
side	NNP	O
chains):	JJ	O
asn,	NN	O
gln,	:	O
his,	,	O
lys,	,	O
arg;	,	O
Group	,	O
V	:	O
(residues	NNP	O
influencing	NNP	O
chain	NNS	O
orientation):	VBG	O
gly,	NN	O
pro;	:	O
and	,	O
Group	:	O
VI	CC	O
(aromatic	NNP	O
side	NNP	O
chains):	JJ	O
trp,	NN	O
tyr,	:	O
phe.	,	O
Conservative	,	O
substitutions	.	O
involve	JJ	O
substitutions	NNS	O
between	VBP	O
amino	NNS	O
acids	IN	O
in	JJ	O
the	NNS	O
same	IN	O
class.	DT	O
Non-conservative	JJ	O
substitutions	.	O
constitute	JJ	O
exchanging	NNS	O
a	VBP	O
member	VBG	O
of	DT	O
one	NN	O
of	IN	O
these	CD	O
classes	IN	O
for	DT	O
a	NNS	O
member	IN	O
of	DT	O
another.	NN	O
Therapeutic	IN	O
agents	.	O
of	JJ	O
the	NNS	O
invention	IN	O
are	DT	O
typically	NN	O
substantially	VBP	O
pure	RB	O
from	RB	O
undesired	VBP	O
contaminant.	IN	O
This	JJ	O
means	.	O
that	DT	O
an	VBZ	O
agent	IN	O
is	DT	O
typically	NN	O
at	VBZ	O
least	RB	O
about	IN	O
50%	JJS	O
w/w	IN	O
(weight/weight)	NN	O
purity,	NN	O
as	)	O
well	,	O
as	RB	O
being	RB	O
substantially	IN	O
free	VBG	O
from	RB	O
interfering	JJ	O
proteins	IN	O
and	VBG	O
contaminants.	NNS	O
Sometimes	CC	O
the	.	O
agents	RB	O
are	DT	O
at	NNS	O
least	VBP	O
about	IN	O
80%	JJS	O
w/w	IN	O
and,	NN	O
more	NN	O
preferably	,	O
at	JJR	O
least	RB	O
about	IN	O
90%,	JJS	O
at	IN	O
least	,	O
about	IN	O
95%,	JJS	O
or	IN	O
at	,	O
least	CC	O
about	IN	O
99%	JJS	O
w/w	IN	O
purity.	NN	O
However,	JJ	O
using	.	O
conventional	,	O
protein	VBG	O
purification	JJ	O
techniques,	JJ	O
homogeneous	NN	O
peptides	,	O
of	JJ	O
at	NNS	O
least	IN	O
99%	IN	O
w/w	JJS	O
can	NN	O
be	NN	O
obtained.	MD	O
The	VB	O
term	.	O
“antibody”	DT	O
or	NN	O
“immunoglobulin”	NN	O
is	CC	O
used	NN	O
to	VBZ	O
include	VBN	O
intact	TO	O
antibodies	VB	O
and	JJ	O
binding	NNS	O
fragments	CC	O
thereof.	VBG	O
Typically,	NNS	O
fragments	.	O
compete	,	O
with	NNS	O
the	VBP	O
intact	IN	O
antibody	DT	O
from	JJ	O
which	NN	O
they	IN	O
were	WDT	O
derived	PRP	O
for	VBD	O
specific	VBN	O
binding	IN	O
to	JJ	O
an	VBG	O
antigen	TO	O
fragment	DT	O
including	NN	O
separate	NN	O
heavy	VBG	O
chains,	JJ	O
light	JJ	O
chains	,	O
Fab,	NN	O
Fab′	NNS	O
F(ab′)2,	,	O
Fabc,	NNP	O
and	,	O
Fv.	,	O
Fragments	CC	O
are	.	O
produced	NNS	O
by	VBP	O
recombinant	VBN	O
DNA	IN	O
techniques,	JJ	O
or	NNP	O
by	,	O
enzymatic	CC	O
or	IN	O
chemical	JJ	O
separation	CC	O
of	JJ	O
intact	NN	O
immunoglobulins.	IN	O
The	JJ	O
term	.	O
“antibody”	DT	O
also	NN	O
includes	NNP	O
one	RB	O
or	VBZ	O
more	CD	O
immunoglobulin	CC	O
chains	JJR	O
that	NN	O
are	NNS	O
chemically	WDT	O
conjugated	VBP	O
to,	RB	O
or	VBN	O
expressed	,	O
as,	CC	O
fusion	VBN	O
proteins	,	O
with	NN	O
other	NNS	O
proteins.	IN	O
The	JJ	O
term	.	O
“antibody”	DT	O
also	NN	O
includes	NNP	O
bispecific	RB	O
antibody.	VBZ	O
A	JJ	O
bispecific	.	O
or	DT	O
bifunctional	NN	O
antibody	CC	O
is	JJ	O
an	NN	O
artificial	VBZ	O
hybrid	DT	O
antibody	JJ	O
having	NN	O
two	NN	O
different	VBG	O
heavy/light	CD	O
chain	JJ	O
pairs	NN	O
and	NN	O
two	NNS	O
different	CC	O
binding	CD	O
sites.	JJ	O
Bispecific	VBG	O
antibodies	.	O
can	NNP	O
be	NNS	O
produced	MD	O
by	VB	O
a	VBN	O
variety	IN	O
of	DT	O
methods	NN	O
including	IN	O
fusion	NNS	O
of	VBG	O
hybridomas	NN	O
or	IN	O
linking	NN	O
of	CC	O
Fab′	NN	O
fragments.	IN	O
See,	NNP	O
e.g.,	.	O
Songsivilai	,	B
&	,	I
Lachmann,	NNP	I
Clin.	CC	I
Exp.	,	I
Immunol.	.	I
79:315-321	.	I
(1990);	.	I
Kostelny	CD	B
et	:	I
al.,	NNP	I
J.	FW	I
Immunol.	,	I
148,	NNP	I
1547-1553	.	I
(1992).
A	,	O
symptom	CD	O
of	.	O
a	DT	O
disorder	NN	O
means	IN	O
a	DT	O
phenomenon	NN	O
experienced	VBZ	O
by	DT	O
an	NN	O
individual	VBN	O
having	IN	O
the	DT	O
disorder	JJ	O
indicating	VBG	O
a	DT	O
departure	NN	O
from	VBG	O
normal	DT	O
function,	NN	O
sensation	IN	O
or	JJ	O
appearance.	,	O
A	NN	O
sign	CC	O
of	.	O
a	DT	O
disorder	NN	O
is	IN	O
any	DT	O
bodily	NN	O
manifestation	VBZ	O
that	DT	O
serves	JJ	O
to	NN	O
indicate	WDT	O
presence	VBZ	O
or	TO	O
risk	VB	O
of	NN	O
a	CC	O
disorder.	NN	O
The	IN	O
term	DT	O
“patient”	.	O
includes	DT	O
human	NN	O
and	NNP	O
other	VBZ	O
mammalian	JJ	O
subjects	CC	O
that	JJ	O
receive	JJ	O
either	NNS	O
prophylactic	WDT	O
or	VBP	O
therapeutic	DT	O
treatment.	JJ	O
As	CC	O
used	JJ	O
herein,	.	O
“treating”	IN	O
a	VBN	O
condition	,	O
(e.g.,	VB	O
Parkinson's	DT	O
Disease)	NN	O
or	,	O
patient	POS	O
refers	)	O
to	CC	O
taking	JJ	O
steps	NNS	O
to	TO	O
obtain	VBG	O
beneficial	NNS	O
or	TO	O
desired	VB	O
result.	JJ	O
For	CC	O
purposes	JJ	O
of	.	O
this	IN	O
invention,	NNS	O
beneficial	IN	O
or	DT	O
desired	,	O
results	JJ	O
include,	CC	O
but	JJ	O
are	NNS	O
not	,	O
limited	CC	O
to,	VBP	O
alleviation	RB	O
or	VBN	O
amelioration	,	O
of	NN	O
one	CC	O
or	NN	O
more	IN	O
symptoms	CD	O
of	CC	O
Parkinson's	JJR	O
Disease,	NNS	O
diminishment	IN	O
of	POS	O
extent	,	O
of	NN	O
disease,	IN	O
delay	NN	O
or	IN	O
slowing	,	O
of	NN	O
disease	CC	O
progression,	NN	O
amelioration,	IN	O
palliation	NN	O
or	,	O
stabilization	,	O
of	NN	O
the	CC	O
disease	NN	O
state.	IN	O
As	DT	O
used	NN	O
herein,	.	O
a	IN	O
“therapeutically	VBN	O
effective	,	O
amount”	DT	O
of	RB	O
a	JJ	O
drug	NN	O
is	IN	O
an	DT	O
amount	NN	O
of	VBZ	O
a	DT	O
drug	NN	O
that,	IN	O
when	DT	O
administered	NN	O
to	,	O
a	WRB	O
subject	VBN	O
diagnosed	TO	O
with	DT	O
Parkinson's	NN	O
disease,	VBN	O
or	IN	O
diagnosed	POS	O
as	,	O
being	CC	O
at	VBD	O
high	IN	O
risk	VBG	O
for	IN	O
developing	JJ	O
Parkinson's	NN	O
disease	IN	O
will	VBG	O
have	POS	O
the	NN	O
intended	MD	O
therapeutic	VB	O
effect,	DT	O
e.g.,	VBN	O
alleviation,	JJ	O
amelioration,	,	O
palliation	,	O
or	,	O
elimination	,	O
of	NN	O
one	CC	O
or	NN	O
more	IN	O
manifestations	CD	O
of	CC	O
the	JJR	O
disease	NNS	O
in	IN	O
the	DT	O
subject.	NN	O
The	IN	O
full	DT	O
therapeutic	.	O
effect	DT	O
does	JJ	O
not	JJ	O
necessarily	NN	O
occur	VBZ	O
by	RB	O
administration	RB	O
of	VBN	O
one	IN	O
dose,	NN	O
and	IN	O
may	CD	O
occur	,	O
only	CC	O
after	MD	O
administration	VB	O
of	RB	O
a	IN	O
series	NN	O
of	IN	O
doses.	DT	O
Thus,	NN	O
a	IN	O
therapeutically	.	O
effective	,	O
amount	DT	O
may	RB	O
be	JJ	O
administered	NN	O
in	MD	O
one	VB	O
or	VBN	O
more	IN	O
administrations.	CD	O
Compositions	CC	O
or	JJR	O
methods	.	O
“comprising”	NNS	O
one	CC	O
or	NNS	O
more	VBP	O
recited	CD	O
elements	CC	O
may	JJR	O
include	JJ	O
other	NNS	O
elements	MD	O
not	VB	O
specifically	JJ	O
recited.	NNS	O
For	RB	O
example,	RB	O
a	.	O
composition	IN	O
that	,	O
comprises	DT	O
alpha-synuclein	NN	O
peptide	WDT	O
encompasses	VBZ	O
both	JJ	O
an	NN	O
isolated	VBZ	O
alpha-synuclein	DT	O
peptide	DT	O
and	JJ	O
alpha-synuclein	JJ	O
peptide	NN	O
as	CC	O
a	JJ	O
component	NN	O
of	IN	O
a	DT	O
larger	NN	O
polypeptide	IN	O
sequence.	DT	O
Unless	JJR	O
otherwise	JJ	O
apparent	.	O
from	IN	O
the	RB	O
context,	NN	O
each	IN	O
embodiment,	DT	O
element,	,	O
step	DT	O
or	,	O
feature	,	O
of	NN	O
the	CC	O
invention	NN	O
can	IN	O
be	DT	O
used	NN	O
in	MD	O
combination	VB	O
with	VBN	O
any	IN	O
other.	NN	O
II.	IN	O
General	DT	O
The	.	O
invention	.	O
is	NNP	O
premised	DT	O
in	NN	O
part	VBZ	O
on	VBN	O
the	IN	O
insight	NN	O
that	IN	O
Lewy	DT	O
Body	NN	O
diseases	WDT	O
(LBDs)	NNP	O
can	NNP	O
be	VBZ	O
inhibited	)	O
by	MD	O
inhibiting	VB	O
one	VBN	O
or	IN	O
more	VBG	O
kinases	CD	O
that	CC	O
phosphorylate	JJR	O
alpha-synuclein	NNS	O
and/or	WDT	O
inhibit	VBP	O
its	JJ	O
production.	JJ	O
Although	NN	O
practice	PRP$	O
of	.	O
the	IN	O
invention	NN	O
is	IN	O
not	DT	O
dependent	NN	O
on	VBZ	O
an	RB	O
understanding	JJ	O
of	IN	O
mechanism,	DT	O
it	NN	O
is	IN	O
believed	,	O
that	PRP	O
phosphorylation	VBZ	O
of	VBN	O
alpha-synuclein	IN	O
at	NN	O
serine-129	IN	O
is	NN	O
one	IN	O
of	NN	O
a	VBZ	O
series	CD	O
of	IN	O
molecular	DT	O
events	NN	O
leading	IN	O
to	JJ	O
formation	NNS	O
of	VBG	O
intracellular	TO	O
deposits	NN	O
of	IN	O
alpha-synuclein.	JJ	O
Alpha-synuclein	NNS	O
phosphorylated	IN	O
at	.	O
ser-129	NNP	O
is	VBD	O
highly	IN	O
enriched	NN	O
in	VBZ	O
Lewy	RB	O
bodies	VBN	O
(LBs)	IN	O
in	NNP	O
Diffuse	NNS	O
Lewy	)	O
body	IN	O
disease	NNP	O
(DLBD),	NNP	O
multiple	NN	O
system	NN	O
atrophy	,	O
(MSA)	JJ	O
and	NN	O
familial	NN	O
forms	)	O
of	CC	O
Parkinson's	JJ	O
Disease	NNS	O
(PD).	IN	O
The	POS	O
abnormal	NNP	O
accumulation	.	O
of	DT	O
phospho-alpha-synuclein	JJ	O
in	NN	O
LBs	IN	O
indicates	NN	O
that	IN	O
phospho-synuclein	NNP	O
may	VBZ	O
be	IN	O
a	NN	O
pathogenic	MD	O
species	VB	O
that	DT	O
drives	JJ	O
LB	NNS	O
formation,	WDT	O
and	VBZ	O
that	NNP	O
the	,	O
kinase(s)	CC	O
responsible	IN	O
for	DT	O
its	)	O
phosphorylation	JJ	O
or	IN	O
which	PRP$	O
regulates	NN	O
production	CC	O
of	WDT	O
alpha-synuclein	VBZ	O
itself	NN	O
are	IN	O
therapeutic	JJ	O
target(s)	PRP	O
for	VBP	O
treatment	JJ	O
of	)	O
multiple	IN	O
synucleinopathies.	NN	O
Other	IN	O
events	JJ	O
in	.	O
this	JJ	O
series	NNS	O
likely	IN	O
include	DT	O
proteolytic	NN	O
cleavages	RB	O
following	VBP	O
phosphorylation	JJ	O
(see	NNS	O
WO	VBG	O
2005/013889,	NN	O
filed	VB	O
May	NNP	O
19,	,	O
2004).	VBD	O
Identification	NNP	O
of	,	O
the	.	O
kinase(s)	NN	O
primarily	IN	O
responsible	DT	O
for	)	O
phosphorylation	RB	O
of	JJ	O
alpha-synuclein	IN	O
allows	NN	O
compounds	IN	O
that	JJ	O
reduce	NNS	O
activity	VBZ	O
of	IN	O
the	VB	O
relevant	NN	O
kinase(s)	IN	O
to	DT	O
be	JJ	O
identified.	)	O
For	TO	O
convenience,	VB	O
reference	.	O
herein	IN	O
to	,	O
“phosphorylation	NN	O
of	NN	O
alpha-synuclein”	TO	O
refers	NN	O
to	IN	O
phosphorylation	JJ	O
at	NNS	O
Serine-129	TO	O
(but	NN	O
does	IN	O
not	NNP	O
exclude	CC	O
additional	VBZ	O
phosphorylation	RB	O
elsewhere,	VB	O
e.g.,	JJ	O
Serine-87).	NN	O
The	,	O
present	,	O
application	.	O
reports	DT	O
identification	JJ	O
of	NN	O
several	NNS	O
kinases	NN	O
where	IN	O
reduction	JJ	O
in	NNS	O
kinase	WRB	O
activity	NN	O
is	IN	O
accompanied	NN	O
by	NN	O
a	VBZ	O
reduction	VBN	O
of	IN	O
phosphorylation	DT	O
of	NN	O
alpha-synuclein	IN	O
and/or	NN	O
a	IN	O
reduction	JJ	O
in	NN	O
total	DT	O
alpha-synuclein	NN	O
level.	IN	O
In	JJ	O
particular,	JJ	O
the	.	O
kinase	IN	O
PLK2	,	O
can	DT	O
be	NN	O
inhibited	NNP	O
to	MD	O
reduce	VB	O
phosphorylation	VBN	O
of	TO	O
alpha-synuclein.	VB	O
The	NN	O
invention	IN	O
provides	.	O
methods	DT	O
of	NN	O
(i)	VBZ	O
identifying	NNS	O
modulators	IN	O
of	)	O
the	VBG	O
activity	NNS	O
and	IN	O
expression	DT	O
of	NN	O
these	CC	O
kinases,	NN	O
(ii)	IN	O
methods	DT	O
of	,	O
treating	)	O
Lewy	NNS	O
body	IN	O
diseases	VBG	O
using	NNP	O
kinase	NN	O
inhibitors,	VBZ	O
and	VBG	O
(iii)	NN	O
exemplary	,	O
kinase	CC	O
inhibitors	)	O
for	JJ	O
use	NN	O
in	NNS	O
treating	IN	O
Lewy	NN	O
body	IN	O
diseases.	VBG	O
As	NNP	O
discussed	NN	O
in	.	O
the	IN	O
Examples,	VBN	O
infra,	IN	O
we	DT	O
have	,	O
carried	,	O
out	PRP	O
a	VBP	O
variety	VBN	O
of	RP	O
experiments	DT	O
to	NN	O
identify	IN	O
kinases	NNS	O
important	TO	O
in	VB	O
phosphorylation	NNS	O
of	JJ	O
alpha-synuclein.	IN	O
Section	NN	O
III	IN	O
outlines	.	O
a	NN	O
strategy	NNP	O
for	VBZ	O
identifying	DT	O
alpha-synuclein	NN	O
kinases.	IN	O
Section	VBG	O
IV	JJ	O
summarizes	.	O
results	NN	O
of	NNP	O
screening	VBZ	O
assays	NNS	O
used	IN	O
to	VBG	O
identify	NNS	O
likely	VBN	O
alpha-synuclein	TO	O
kinases.	VB	O
Section	JJ	O
V	JJ	O
describes	.	O
agents	NN	O
that	NNP	O
reduce	VBZ	O
synuclein	NNS	O
kinase	IN	O
activity	VB	O
or	JJ	O
expression	NN	O
and	NN	O
may	CC	O
be	NN	O
used	CC	O
therapeutically.	MD	O
Section	VB	O
VI	VBN	O
describes	.	O
methods	NN	O
for	NNP	O
treating	VBZ	O
Parkinson's	NNS	O
Disease	IN	O
and	VBG	O
other	POS	O
Lewy	NNP	O
Body	CC	O
Diseases.	JJ	O
Section	NNP	O
VII	NNP	O
describes	.	O
Lewy	NN	O
Body	NNP	O
Diseases.	VBZ	O
Section	NNP	O
VIII	NNP	O
describes	.	O
transgenic	NN	O
animal	NNP	O
and	VBZ	O
cellular	JJ	O
models	NN	O
of	CC	O
Lewy	JJ	O
Body	NNS	O
Disease.	IN	O
Section	NNP	O
IX	NNP	O
describes	.	O
method	NN	O
for	NNP	O
identification	VBZ	O
of	NN	O
modulators	IN	O
of	NN	O
PLK2	IN	O
and	NNS	O
other	IN	O
kinases.	NNP	O
Section	CC	O
X	JJ	O
describes	.	O
methods	NN	O
for	NNP	O
alpha-synuclein	VBZ	O
isolation.	NNS	O
Section	IN	O
XI	JJ	O
provides	.	O
experimental	NN	O
results	NNP	O
including	VBZ	O
the	JJ	O
aforementioned	NNS	O
screening	VBG	O
assays.	DT	O
III.	JJ	O
Identification	NN	O
of	.	O
Target	.	O
Kinases	NN	O
Kinases	IN	O
that	NNP	O
directly	NNP	O
or	VBZ	O
indirectly	WDT	O
modulate	RB	O
phosphorylation	CC	O
of	RB	O
alpha-synuclein	JJ	O
can	NN	O
be	IN	O
identified	NN	O
as	MD	O
shown	VB	O
in	VBN	O
the	IN	O
Examples.	VBN	O
In	IN	O
general,	DT	O
a	.	O
library	IN	O
of	,	O
potential	DT	O
inhibitors	NN	O
is	IN	O
designed	JJ	O
based	NNS	O
on	VBZ	O
the	VBN	O
known	VBN	O
sequences	IN	O
of	DT	O
a	JJ	O
collection	NNS	O
of	IN	O
kinase	DT	O
genes.	NN	O
The	IN	O
members	NN	O
of	.	O
the	DT	O
library	NNS	O
can	IN	O
be	DT	O
any	NN	O
of	MD	O
the	VB	O
types	DT	O
of	IN	O
molecule	DT	O
described	NNS	O
above.	IN	O
Members	NN	O
of	VBN	O
the	.	O
library	NNS	O
are	IN	O
then	DT	O
introduced	NN	O
into	VBP	O
cells	RB	O
expressing	VBN	O
alpha-synuclein.	IN	O
Preferably	NNS	O
both	VBG	O
the	.	O
cells	RB	O
and	DT	O
the	DT	O
alpha-synuclein	NNS	O
are	CC	O
human.	DT	O
Usually,	NN	O
such	VBP	O
cells	.	O
are	,	O
transfected	JJ	O
with	NNS	O
both	VBP	O
DNA	VBN	O
encoding	IN	O
human	DT	O
alpha-synuclein	NNP	O
and	VBG	O
DNA	JJ	O
encoding	JJ	O
the	CC	O
library	NNP	O
member	VBG	O
to	DT	O
be	JJ	O
tested.	NN	O
Library	TO	O
members	VB	O
can	.	O
be	JJ	O
screened	NNS	O
individually	MD	O
or	VB	O
en	VBN	O
masse.	RB	O
After	CC	O
introduction	FW	O
of	.	O
a	IN	O
library	NN	O
member,	IN	O
and	DT	O
culturing	JJ	O
for	,	O
a	CC	O
period	VBG	O
sufficient	IN	O
for	DT	O
the	NN	O
library	NN	O
member	IN	O
to	DT	O
be	JJ	O
expressed	NN	O
and	TO	O
effect	VB	O
repression	VBN	O
of	CC	O
its	NN	O
kinase,	NN	O
the	IN	O
levels	PRP$	O
of	,	O
total	DT	O
alpha-synuclein	NNS	O
and	IN	O
phosphorylated	JJ	O
alpha-synuclein	JJ	O
are	CC	O
measured	JJ	O
and	NNS	O
compared	VBP	O
with	VBN	O
corresponding	CC	O
levels	VBN	O
in	IN	O
an	NN	O
otherwise	NNS	O
similar	IN	O
control	DT	O
cell	RB	O
not	JJ	O
treated	NN	O
with	NN	O
a	RB	O
library	VBN	O
member	IN	O
to	DT	O
suppress	JJ	O
expression	NN	O
of	TO	O
a	VB	O
kinase.	NN	O
Measurements	IN	O
can	DT	O
be	.	O
made	NNS	O
by	MD	O
immunoassay	VB	O
using	VBN	O
an	IN	O
antibody	NN	O
specific	VBG	O
for	DT	O
alpha-synuclein	NN	O
(preferably	JJ	O
human	IN	O
alpha-synuclein)	JJ	O
to	JJ	O
measure	JJ	O
total	)	O
levels	TO	O
of	VB	O
alpha-synuclein,	JJ	O
and	NNS	O
an	IN	O
antibody	,	O
specific	CC	O
for	DT	O
phosphorylated	NN	O
alpha-synuclein	NN	O
to	IN	O
measure	JJ	O
the	NN	O
level	TO	O
of	VB	O
phosphorylated	DT	O
alpha-synuclein.	NN	O
Exemplary	IN	O
antibodies	JJ	O
are	.	O
described	JJ	O
in	NNS	O
WO05047860,	VBP	O
incorporated	VBN	O
herein	IN	O
by	,	O
reference.	VBN	O
A	NN	O
reduction	IN	O
in	.	O
level	DT	O
of	NN	O
phosphorylated	IN	O
alpha-synuclein	NN	O
between	IN	O
the	JJ	O
treated	NN	O
and	IN	O
control	DT	O
cell	JJ	O
that	CC	O
is	NN	O
significant	NN	O
in	WDT	O
the	VBZ	O
sense	JJ	O
of	IN	O
being	DT	O
outside	NN	O
the	IN	O
typical	VBG	O
margin	IN	O
of	DT	O
error	JJ	O
for	NN	O
measurements,	IN	O
indicates	NN	O
that	IN	O
the	,	O
inhibitor	VBZ	O
introduced	IN	O
into	DT	O
the	NN	O
cell	VBD	O
inhibited	IN	O
a	DT	O
kinase,	NN	O
which	VBD	O
directly	DT	O
or	,	O
indirectly	WDT	O
affected	RB	O
phosphorylation	CC	O
of	RB	O
alpha-synuclein.	JJ	O
The	NN	O
identity	IN	O
of	.	O
the	DT	O
kinase	NN	O
can	IN	O
be	DT	O
determined	NN	O
from	MD	O
the	VB	O
identity	VBN	O
of	IN	O
inhibitor,	DT	O
either	NN	O
by	IN	O
screening	,	O
inhibitors	RB	O
individually,	IN	O
or	VBG	O
if	NNS	O
inhibitors	,	O
are	CC	O
screened	IN	O
en	NNS	O
masse,	VBP	O
by	VBN	O
sequencing	IN	O
the	,	O
nucleic	IN	O
acid	VBG	O
encoding	DT	O
the	JJ	O
inhibitor.	NN	O
Likewise	VBG	O
a	DT	O
reduction	.	O
in	VB	O
the	DT	O
total	NN	O
level	IN	O
of	DT	O
alpha-synuclein	JJ	O
between	NN	O
treated	IN	O
and	NN	O
control	IN	O
cells	VBN	O
that	CC	O
is	VB	O
outside	NNS	O
the	WDT	O
margin	VBZ	O
of	IN	O
typical	DT	O
experimental	NN	O
error	IN	O
in	JJ	O
measuring	JJ	O
such	NN	O
levels	IN	O
provides	VBG	O
an	JJ	O
indication	NNS	O
that	VBZ	O
the	DT	O
inhibitor	NN	O
inhibits	IN	O
a	DT	O
kinase	NN	O
that	VBZ	O
indirectly	DT	O
affects	NN	O
the	WDT	O
expression	RB	O
level	VBZ	O
of	DT	O
alpha-synuclein.	NN	O
Kinases	NN	O
identified	IN	O
by	.	O
the	NNS	O
initial	VBN	O
screen,	IN	O
particularly,	DT	O
kinases	JJ	O
known	,	O
to	,	O
be	NNS	O
serine	VBN	O
kinases,	TO	O
can	VB	O
then	JJ	O
be	,	O
tested	MD	O
for	RB	O
their	VB	O
capacity	VBN	O
to	IN	O
phosphorylate	PRP$	O
alpha-synuclein	NN	O
in	TO	O
vitro,	VB	O
in	NNS	O
cells	IN	O
or	,	O
in	IN	O
transgenic	NNS	O
animal	CC	O
models.	IN	O
An	JJ	O
in	NN	O
vitro	.	O
assay	DT	O
is	IN	O
an	NN	O
indication	NN	O
of	VBZ	O
whether	DT	O
a	NN	O
kinase	IN	O
directly	IN	O
phosphorylates	DT	O
alpha-synuclein	NN	O
and	RB	O
is	VBZ	O
therefore	NN	O
only	CC	O
useful	VBZ	O
for	RB	O
the	RB	O
kinases	JJ	O
identified	IN	O
in	DT	O
the	NNS	O
initial	VBN	O
screen	IN	O
which	DT	O
are	JJ	O
thought	NN	O
to	WDT	O
be	VBP	O
capable	VBN	O
of	TO	O
directly	VB	O
phosphorylating	JJ	O
alpha-synuclein.	IN	O
Cellular	RB	O
and	VBG	O
transgenic	.	O
assays	JJ	O
can	CC	O
be	JJ	O
used	NNS	O
to	MD	O
screen	VB	O
kinases	VBN	O
that	TO	O
affect	VB	O
phosphorylation	NNS	O
either	WDT	O
directly	VBP	O
or	NN	O
indirectly.	DT	O
In	RB	O
vitro	CC	O
assays	.	O
may	IN	O
be	JJ	O
performed	NNS	O
by	MD	O
contacting	VB	O
alpha-synuclein	VBN	O
with	IN	O
the	VBG	O
kinase	JJ	O
under	IN	O
test	DT	O
and	NN	O
ATP	IN	O
in	NN	O
a	CC	O
suitable	NNP	O
buffer.	IN	O
Preferably,	DT	O
the	JJ	O
ATP	.	O
is	,	O
γ-32P	DT	O
ATP,	NNP	O
in	VBZ	O
which	JJ	O
case	,	O
phosphorylated	IN	O
alpha-synuclein	WDT	O
is	NN	O
radiolabeled	VBD	O
and	NN	O
can	VBZ	O
be	VBN	O
detected	CC	O
on	MD	O
a	VB	O
gel.	VBN	O
Phosphorylation	IN	O
can	DT	O
also	.	O
be	NN	O
measured	MD	O
using	RB	O
an	VB	O
antibody	VBN	O
specific	VBG	O
to	DT	O
phosphorylated	NN	O
alpha-synuclein	JJ	O
as	TO	O
described	JJ	O
before.	JJ	O
Alternatively,	IN	O
phosphorylation	VBN	O
can	.	O
be	,	O
measured	NN	O
indirectly	MD	O
by	VB	O
measuring	VBN	O
ATP	RB	O
consumption	IN	O
using	VBG	O
a	NNP	O
coupled	NN	O
assay,	VBG	O
in	DT	O
which	JJ	O
ADP	,	O
is	IN	O
detected	WDT	O
as	NNP	O
described	VBZ	O
for	VBN	O
example	IN	O
by	NN	O
Nature	IN	B
78,	NN	I
632	IN	I
(1956);	NNP	I
Mol.	,	I
Pharmacol.	CD	I
6,	:	I
31-40	.	I
(1970).	.	I
The	,	O
extent	CD	O
of	.	O
phosphorylation	DT	O
can	NN	O
be	IN	O
compared	NN	O
with	MD	O
a	VB	O
control	VBN	O
in	IN	O
which	DT	O
the	NN	O
kinase	IN	O
or	WDT	O
ATP	DT	O
or	NN	O
both	CC	O
is/are	NNP	O
omitted.	CC	O
An	DT	O
increase	JJ	O
in	.	O
phosphorylation	DT	O
is	NN	O
an	IN	O
indication	NN	O
that	VBZ	O
the	DT	O
kinase	NN	O
directly	IN	O
phosphorylates	DT	O
alpha-synuclein.	NN	O
Cellular	RB	O
assays	VBZ	O
are	.	O
performed	JJ	O
on	NNS	O
cells	VBP	O
expressing	VBN	O
alpha-synuclein,	IN	O
preferably	NNS	O
human	VBG	O
alpha-synuclein	,	O
transfected	RB	O
into	JJ	O
the	NN	O
cells.	VBD	O
A	IN	O
nucleic	DT	O
acid	.	O
capable	DT	O
of	JJ	O
expressing	NN	O
the	JJ	O
kinase	IN	O
is	VBG	O
also	DT	O
transfected	NN	O
into	VBZ	O
the	RB	O
cells.	VBN	O
The	IN	O
level	DT	O
of	.	O
phosphorylated	DT	O
alpha-synuclein	NN	O
in	IN	O
the	JJ	O
cells	NN	O
is	IN	O
measured	DT	O
relative	NNS	O
to	VBZ	O
that	VBN	O
in	JJ	O
similar	TO	O
control	DT	O
cells	IN	O
lacking	JJ	O
the	NN	O
transfected	NNS	O
kinase.	VBG	O
An	DT	O
increase	JJ	O
in	.	O
phosphorylation	DT	O
is	NN	O
an	IN	O
indication	NN	O
that	VBZ	O
the	DT	O
kinase	NN	O
directly	IN	O
or	DT	O
indirectly	NN	O
phosphorylates	RB	O
alpha-synuclein.	CC	O
Transgenic	RB	O
assays	VBZ	O
can	.	O
be	NNP	O
performed	NNS	O
by	MD	O
comparing	VB	O
a	VBN	O
transgenic	IN	O
animal	VBG	O
expressing	DT	O
human	JJ	O
alpha-synuclein	NN	O
disposed	VBG	O
to	JJ	O
develop	NNS	O
Lewy	VBD	O
body-like	TO	O
deposits	VB	O
with	NNP	O
a	JJ	O
similar	NNS	O
animal	IN	O
also	DT	O
expressing	JJ	O
a	NN	O
kinase	RB	O
transgene.	VBG	O
A	DT	O
reduction	NN	O
in	.	O
phosphorylated	DT	O
alpha-synuclein	NN	O
and/or	IN	O
in	JJ	O
Lewy	JJ	O
body-like	NN	O
deposits	IN	O
in	NNP	O
the	NN	O
transgenic	NNS	O
animal	IN	O
with	DT	O
the	JJ	O
additional	NN	O
kinase	IN	O
transgene	DT	O
relative	JJ	O
to	NN	O
the	NN	O
transgenic	NN	O
animal	TO	O
with	DT	O
just	JJ	O
the	NN	O
alpha-synuclein	IN	O
transgene	RB	O
is	DT	O
an	JJ	O
indication	NN	O
that	VBZ	O
the	DT	O
kinase	NN	O
is	IN	O
directly	DT	O
or	NN	O
indirectly	VBZ	O
involved	RB	O
in	CC	O
phosphorylating	RB	O
alpha-synuclein.	VBN	O
IV.	IN	O
Target	VBG	O
Kinases	.	O
Tables	.	O
1A,	NN	O
1B	VBZ	O
and	NNP	O
1C	,	O
show	CD	O
proteins	CC	O
whose	CD	O
inhibition	NN	O
modulates	NNS	O
the	WP$	O
phosphorylation	NN	O
at	VBZ	O
position	DT	O
ser-129.	NN	O
Table	IN	O
1A	NN	O
shows	.	O
kinases	JJ	O
that	CD	O
can	NNS	O
phosphorylate	NNS	O
serine	WDT	O
and/or	MD	O
threonine	VB	O
residues	JJ	O
and	JJ	O
sometimes	NN	O
tyrosine.	NNS	O
Table	CC	O
1B	RB	O
shows	.	O
tyrosine	JJ	O
kinases	CD	O
that	NNS	O
cannot	VBP	O
(so	NNS	O
far	WDT	O
as	RB	O
is	RB	O
known)	RB	O
modify	IN	O
serine	VBZ	O
residues.	)	O
Table	FW	O
1C	NN	O
shows	.	O
kinases	JJ	O
that	CD	O
phosphorylate	NNS	O
non-protein	NNS	O
targets	WDT	O
but	VBP	O
are	JJ	O
not	NNS	O
known	CC	O
to	VBP	O
phosphorylate	RB	O
proteins.	VBN	O
Kinases	TO	O
from	VB	O
the	.	O
upper	NNS	O
portion	IN	O
of	DT	O
Table	JJ	O
1A	NN	O
are	IN	O
candidates	JJ	O
for	CD	O
direct	VBP	O
phosphorylation	NNS	O
of	IN	O
ser-129	JJ	O
of	NN	O
alpha-synuclein.	IN	O
Kinases	NN	O
from	IN	O
the	.	O
upper	NNS	O
part	IN	O
of	DT	O
Table	JJ	O
1B	NN	O
are	IN	O
also	JJ	O
useful	CD	O
therapeutic	VBP	O
targets	RB	O
via	JJ	O
roles	JJ	O
indirectly	NNS	O
phosphorylating	IN	O
alpha-synuclein.	NNS	O
Proteins	RB	O
in	VBG	O
the	.	O
upper	NNS	O
part	IN	O
of	DT	O
Table	JJ	O
1C	NN	O
are	IN	O
also	JJ	O
useful	CD	O
therapeutic	VBP	O
targets	RB	O
for	JJ	O
the	JJ	O
same	NNS	O
reason.	IN	O
Cols.	DT	O
1,	JJ	O
2	.	O
and	.	O
3	,	O
of	CD	O
each	CC	O
table	CD	O
indicate	IN	O
the	DT	O
gene	NN	O
name,	VBP	O
kinase	DT	O
name	NN	O
and	,	O
Genbank	NN	O
accession	NN	O
number	CC	O
of	NNP	O
kinases.	NN	O
The	NN	O
next	IN	O
column	.	O
indicates	DT	O
whether	JJ	O
treatment	NN	O
of	VBZ	O
cells	IN	O
with	NN	O
siRNA	IN	O
to	NNS	O
that	IN	O
kinase	NN	O
decreased	TO	O
(“down”)	DT	O
or	NN	O
increased	VBD	O
(“up”)	)	O
phosphorylation	CC	O
of	VBN	O
ser-129.	)	O
The	NN	O
next	IN	O
three	.	O
columns	DT	O
indicate	JJ	O
the	CD	O
number	NN	O
of	VBP	O
standard	DT	O
deviations	NN	O
the	IN	O
measured	JJ	O
level	NNS	O
of	DT	O
phosphorylation	JJ	O
departs	NN	O
from	IN	O
the	NN	O
mean	NNS	O
in	IN	O
three	DT	O
independent	NN	O
experiments.	IN	O
The	CD	O
final	JJ	O
two	.	O
columns	DT	O
indicate	JJ	O
the	CD	O
kinase	NN	O
family	VBP	O
(i.e.,	DT	O
amino	NN	O
acid	NN	O
specificity)	,	O
and	JJ	O
group.	VBP	O
Table	)	O
2	CC	O
shows	.	O
kinases	JJ	O
whose	CD	O
inhibition	NNS	O
modulates	NNS	O
the	WP$	O
overall	NN	O
levels	VBZ	O
of	DT	O
human	JJ	O
alpha-synuclein	NNS	O
without	IN	O
changing	JJ	O
the	NN	O
percentage	IN	O
of	VBG	O
phosphorylation.	DT	O
Table	NN	O
2	IN	O
shows	.	O
all	JJ	O
of	CD	O
the	VBZ	O
kinases	DT	O
with	IN	O
the	DT	O
strongest	NNS	O
reduction	IN	O
in	DT	O
levels	JJS	O
of	NN	O
human	IN	O
alpha-synuclein.	NNS	O
The	IN	O
columns	JJ	O
are	.	O
labeled	DT	O
similarly	NN	O
to	VBP	O
Tables	VBN	O
1A,	RB	O
1B	TO	O
and	NNP	O
1C.	,	O
Tables	CD	O
3	CC	O
and	.	O
4	NNS	O
show	CD	O
kinases	CC	O
from	CD	O
Tables	NN	O
1	NNS	O
and	IN	O
2	NNP	O
that	CD	O
were	CC	O
confirmed	CD	O
in	WDT	O
the	VBD	O
Examples	VBN	O
to	IN	O
modulate	DT	O
overall	NNP	O
levels	TO	O
of	VB	O
human	JJ	O
alpha-synuclein.	NNS	O
The	IN	O
kinases	JJ	O
that	.	O
were	DT	O
verified	NNS	O
include	WDT	O
PLK2,	VBD	O
APEG1,	VBN	O
CDC7L1,	VBP	O
MET,	,	O
GRK1,	,	O
2,	,	O
6,	,	O
and	,	O
7	,	O
as	,	O
kinases	CC	O
that	CD	O
phosphorylate	IN	O
alpha-synuclein	NNS	O
directly	WDT	O
or	VBP	O
indirectly.	JJ	O
The	RB	O
kinases	CC	O
that	.	O
were	DT	O
found	NNS	O
to	WDT	O
increase	VBD	O
alpha-synuclein	VBN	O
phosphorylation	TO	O
when	VB	O
inhibited,	JJ	O
PRKG1,	NN	O
MAPK13,	WRB	O
and	,	O
GAK,	,	O
are	,	O
likely	CC	O
to	,	O
function	VBP	O
as	JJ	O
negative	TO	O
regulators	VB	O
of	IN	O
alpha-synuclein	JJ	O
phosphorylation.	NNS	O
Further	IN	O
data	JJ	O
from	.	O
phosphorylation	RB	O
studies	NNS	O
in	IN	O
vitro	NN	O
identified	NNS	O
PKL2,	IN	O
GRK2,	NN	O
5,	VBN	O
6,	,	O
and	,	O
7	,	O
as	,	O
capable	CC	O
of	CD	O
phosphorylating	IN	O
alpha-synuclein	JJ	O
in	IN	O
vitro	VBG	O
and	NN	O
also	IN	O
identified	NN	O
CKII	CC	O
and	RB	O
IKBKB.	VBN	O
Further	NNP	O
studies	CC	O
in	.	O
cell	JJ	O
culture	NNS	O
showed	IN	O
that	NN	O
PLK2	NN	O
and	VBD	O
GPRK6	IN	O
could	NNP	O
directly	CC	O
phosphorylate	NNP	O
alpha-synuclein	MD	O
in	RB	O
cell	VB	O
culture.	NN	O
These	IN	O
data	NN	O
were	.	O
substantiated	DT	O
with	NNS	O
immunohistochemistry.	VBD	O
In	VBN	O
summary,	IN	O
PLK2	.	O
and,	IN	O
to	,	O
a	NNP	O
lesser	,	O
extent,	TO	O
GRK6	DT	O
are	JJR	O
particularly	,	O
preferred	NNP	O
targets	VBP	O
for	RB	O
therapeutic	JJ	O
intervention	NNS	O
in	IN	O
Lewy	JJ	O
body	NN	O
diseases	IN	O
because	NNP	O
they	NN	O
can	NNS	O
directly	IN	O
phosphorylate	PRP	O
alpha-synuclein.	MD	O
Agents	RB	O
that	VB	O
inhibit	.	O
PLK2	NNS	O
and	WDT	O
GRK6	VBP	O
also	NNP	O
inhibit	CC	O
phosphorylation	NNP	O
of	RB	O
alpha-synuclein	VBP	O
and	NN	O
thus	IN	O
can	JJ	O
be	CC	O
used	RB	O
in	MD	O
treatment	VB	O
or	VBN	O
prophylaxis	IN	O
of	NN	O
Lewy	CC	O
body	NN	O
disease.	IN	O
In	NNP	O
the	NN	O
Examples,	.	O
below,	IN	O
transfection	DT	O
of	,	O
cells	,	O
with	NN	O
siRNA	IN	O
and	NNS	O
knockdown	IN	O
of	NN	O
specific	CC	O
kinase	NN	O
targets	IN	O
was	JJ	O
employed	NNP	O
to	NNS	O
identify	VBD	O
kinases	VBN	O
that	TO	O
modulated	VB	O
alpha-synuclein	NNS	O
phosphorylation	WDT	O
directly	VBD	O
or	JJ	O
indirectly.	NN	O
Subsequent	RB	O
experiments	CC	O
in	.	O
vitro	JJ	O
and	NNS	O
in	IN	O
cell	NN	O
culture	CC	O
showed	IN	O
that	NN	O
two	NN	O
of	VBD	O
these	IN	O
kinases,	CD	O
PLK2	IN	O
directly	DT	O
and	,	O
specifically	NNP	O
phosphorylated	RB	O
the	CC	O
serine	RB	O
129	VBD	O
of	DT	O
alpha-synuclein.	JJ	O
Further	CD	O
experiments	IN	O
showed	.	O
that	JJ	O
PLK2	NNS	O
phosphorylated	VBD	O
the	IN	O
serine	NNP	O
129	VBD	O
of	DT	O
alpha-synuclein	JJ	O
to	CD	O
a	IN	O
much	NN	O
greater	TO	O
extent	DT	O
than	RB	O
GRK6	JJR	O
and	NN	O
other	IN	O
kinases	NNP	O
described	CC	O
herein	JJ	O
under	NNS	O
the	VBN	O
experimental	JJ	O
conditions	IN	O
used.	DT	O
Thus,	JJ	O
PLK2	NNS	O
is	.	O
very	,	O
likely	NNP	O
a	VBZ	O
synuclein	RB	O
kinase.	JJ	O
Additional	DT	O
evidence	JJ	O
that	.	O
PLK2	JJ	O
is	NN	O
a	IN	O
synuclein	NNP	O
kinase	VBZ	O
is	DT	O
provided	JJ	O
in	NN	O
Examples	VBZ	O
11-16.	VBN	O
Synuclein	IN	O
phosphorylation	NNP	O
is	.	O
reduced	NNP	O
in	NN	O
cells	VBZ	O
treated	VBN	O
with	IN	O
siRNA	NNS	O
directed	VBN	O
to	IN	O
PLK2,	NN	O
inhibitors	VBN	O
of	TO	O
PLK2	,	O
activity	NNS	O
reduce	IN	O
synuclein	NNP	O
phosphorylation	NN	O
in	VB	O
a	NN	O
variety	NN	O
of	IN	O
cell	DT	O
types	NN	O
including	IN	O
primary	NN	O
neuronal	NNS	O
cultures	VBG	O
and	JJ	O
cells	JJ	O
over	NNS	O
expressing	CC	O
PLK2,	NNS	O
inhibitors	IN	O
affect	VBG	O
endogenous	,	O
kinase	NNS	O
in	VBP	O
with	JJ	O
an	NN	O
EC50	IN	O
consistent	IN	O
with	DT	O
the	NNP	O
EC50	NN	O
observed	IN	O
for	DT	O
their	NNP	O
effect	VBD	O
on	IN	O
PLK2.	PRP$	O
PLK2	NN	O
is	IN	O
a	.	O
Polo	NNP	O
like	VBZ	O
kinase	DT	O
that	NNP	O
is	IN	O
a	NN	O
G1	WDT	O
cell	VBZ	O
cycle	DT	O
protein,	NNP	O
has	NN	O
a	NN	O
rapid	,	O
turnover	VBZ	O
in	DT	O
cells,	JJ	O
and	NN	O
is	IN	O
expressed	,	O
in	CC	O
brain	VBZ	O
where	VBN	O
it	IN	O
is	NN	O
involved	WRB	O
in	PRP	O
synaptic	VBZ	O
plasticity.	VBN	O
The	IN	O
PLK	JJ	O
family	.	O
members	DT	O
are	NNP	O
serine/threonine	NN	O
kinases,	NNS	O
and	VBP	O
contains	JJ	O
four	,	O
members	CC	O
that	VBZ	O
have	CD	O
an	NNS	O
N-terminal	WDT	O
kinase	VBP	O
domain	DT	O
and	JJ	O
a	NN	O
C-terminal	NN	O
regulatory	CC	O
domain	DT	O
consisting	JJ	O
of	JJ	O
two	NN	O
(PLKs	VBG	O
1-3)	IN	O
or	CD	O
one	NNP	O
(PLK4)	)	O
polo-box	CC	O
domains.	CD	O
The	)	O
polo-box	NN	O
domain	.	O
serves	DT	O
to	JJ	O
bind	NN	O
to	NNS	O
scaffolding	TO	O
proteins	VB	O
that	TO	O
then	VBG	O
target	NNS	O
the	IN	O
PLKs	RB	O
to	VB	O
specific	DT	O
sub-cellular	NNP	O
locations	TO	O
and	VB	O
to	JJ	O
phosphorylate	NNS	O
their	CC	O
target	TO	O
proteins	VB	O
Seeburg,	PRP$	B
D.	NN	I
P.	NNS	I
et	,	I
al,	NNP	I
Oncogene,	NNP	I
2005).(	FW	O
The	,	O
polo-box	,	O
also	.	O
serves	DT	O
to	NN	O
negatively	RB	O
regulate	VBZ	O
the	TO	O
kinase	RB	O
domain	VB	O
by	DT	O
adopting	NN	O
a	NN	O
conformation	IN	O
that	VBG	O
prevents	DT	O
kinase	NN	O
activity.	WDT	O
Upon	VBZ	O
binding	NN	O
of	.	O
the	IN	O
polo-box	NN	O
to	IN	O
a	DT	O
scaffolding	NN	O
protein,	TO	O
the	DT	O
polo-box	NN	O
is	,	O
removed	DT	O
from	NN	O
the	VBZ	O
kinase	VBN	O
domain,	IN	O
whereupon	DT	O
the	NN	O
kinase	,	O
becomes	IN	O
active	DT	O
and	NN	O
is	VBZ	O
able	JJ	O
to	CC	O
phosphorylate	VBZ	O
its	JJ	O
substrate/s.	TO	O
Polo-like	VB	O
kinases	PRP$	O
are	.	O
described	JJ	O
in	NNS	O
Seeburg	VBP	B
et	VBN	I
al.,	IN	I
2005,	NNP	I
“Polo-like	CC	I
kinases	,	I
in	,	I
the	JJ	I
nervous	NNS	I
system”	IN	I
Oncogene	DT	I
24:292-8;	JJ	I
Lowery	JJ	B
et	NNP	I
al.,	:	I
2005,	NNP	I
“Structure	FW	I
and	,	I
function	,	I
of	NN	I
Polo-like	CC	I
kinases”	NN	I
Oncogene	IN	I
24:248-59;	NNP	I
and	NNP	O
Winkles	NNP	B
et	:	I
al.,	CC	I
2005,	NNP	I
“Differential	VBP	I
regulation	,	I
of	,	I
polo-like	JJ	I
kinase	NN	I
1,	IN	I
2,	JJ	I
3,	NN	I
and	,	I
4	,	I
gene	,	I
expression	CC	I
in	CD	I
mammalian	NN	I
cells	NN	I
and	IN	I
tissues”	JJ	I
Oncogene	NNS	I
24:260-6.	CC	I
DNA	JJ	O
and	NNP	O
protein	.	O
sequences	NN	O
can	CC	O
be	NN	O
found	NNS	O
at	MD	O
the	VB	O
accession	VBN	O
numbers	IN	O
below:	DT	O
When	NN	O
PLK2	NNS	O
is	:	O
activated,	WRB	O
it	NNP	O
is	VBZ	O
targeted	,	O
to	PRP	O
dendrites	VBZ	O
of	VBN	O
activated	TO	O
neurons,	NNS	O
where	IN	O
it	JJ	O
is	,	O
believed	WRB	O
to	PRP	O
phosphorylate	VBZ	O
proteins	VBN	O
in	TO	O
the	VB	O
synaptic	NNS	O
terminals.	IN	O
An	DT	O
exemplary	JJ	O
accession	.	O
number	DT	O
for	JJ	O
PLK2	NN	O
is	NN	O
provided	IN	O
Table	NNP	O
1A.	VBZ	O
The	VBN	O
sequence	JJ	O
for	.	O
PLK2	DT	O
can	NN	O
also	IN	O
be	NNP	O
found	MD	O
in	RB	O
any	VB	O
one	VBN	O
of	IN	O
Ma,	DT	B
et	CD	I
al.	IN	I
Mol.	,	I
Cell.	RB	I
Biol.	.	I
23	.	I
(19),	.	I
6936-6943	.	I
(2003),	CD	I
Burns,	,	B
et	JJ	I
al.	,	I
Mol.	,	I
Cell.	RB	I
Biol.	.	I
23	.	I
(16),	.	I
5556-5571	.	I
(2003),	CD	I
Matsuda,	,	B
et	JJ	I
al.	,	I
Oncogene	,	I
22	RB	I
(21),	.	I
3307-3318	NNP	I
(2003),	CD	I
Shimizu-Yoshida	,	B
et	JJ	I
al.	,	I
Biochem.	NNP	I
Biophys.	FW	I
Res.	.	I
Commun.	.	I
289	.	I
(2),	.	I
491-498	.	I
(2001),	CD	I
Liby,	,	B
et	JJ	I
al.	,	I
DNA	,	I
seq.	RB	I
11	.	I
(6),	NN	I
527-533	.	I
(2001),	CD	I
Holtrich,	,	B
et	JJ	I
al.	,	I
Oncogene	,	I
19	RB	I
(42),	.	I
4832-4839,	NNP	I
Ouyang,	CD	B
et	,	I
al.	,	I
Oncogene	,	I
18	RB	I
(44),	.	I
6029-6036	NNP	I
(1999),	CD	I
and	,	O
Kauselmann,	JJ	B
et	,	I
al.	CC	I
EMBO	,	I
J.	RB	I
18	.	I
(20),	NNP	I
5528-5539;	.	I
reference	CD	O
to	,	O
an	:	O
amino	NN	O
acid	TO	O
or	DT	O
nucleic	NN	O
acid	NN	O
sequence	CC	O
of	JJ	O
PLK2	JJ	O
includes	NN	O
the	IN	O
sequences	NNP	O
of	VBZ	O
any	DT	O
of	NNS	O
these	IN	O
references	DT	O
or	IN	O
allelic	DT	O
variants	NNS	O
thereof.	CC	O
PLK2	JJ	O
is	NNS	O
also	.	O
called	NNP	O
SNK;	VBZ	O
for	RB	O
consistency,	VBN	O
the	:	O
name	IN	O
PLK2	,	O
is	DT	O
used	NN	O
throughout	NNP	O
the	VBZ	O
present	VBN	O
patent	IN	O
application.	DT	O
APEG1,	JJ	O
CDC7L1,	NN	O
MET,	.	O
IKBKB,	,	O
CKII,	,	O
GRK1,	,	O
GRK2,	,	O
GRK6	,	O
and	,	O
GRK7	,	O
are	NNP	O
also	CC	O
targets	NNP	O
for	VBP	O
therapeutic	RB	O
intervention	NNS	O
in	IN	O
Lewy	JJ	O
body	NN	O
diseases	IN	O
because	NNP	O
they	NN	O
are	NNS	O
likely	IN	O
to	PRP	O
be	VBP	O
indirect	JJ	O
activators	TO	O
of	VB	O
the	JJ	O
direct	NNS	O
kinase(s).	IN	O
Thus,	DT	O
agents	JJ	O
that	.	O
inhibit	,	O
APEG1,	NNS	O
CDC7L1,	IN	O
MET,	NN	O
IKBKB,	,	O
CKII,	,	O
GRK1,	,	O
GRK2,	,	O
GRK6	,	O
and	,	O
GRK7	,	O
also	NNP	O
inhibit	CC	O
phosphorylation	NNP	O
of	RB	O
alpha-synuclein	VBP	O
and	NN	O
can	IN	O
be	JJ	O
used	CC	O
for	MD	O
treatment	VB	O
or	VBN	O
prophylaxis	IN	O
of	NN	O
Lewy	CC	O
body	NN	O
disease.	IN	O
PRKG1,	NNP	O
MAPK13,	NN	O
and	.	O
GAK	,	O
are	,	O
negative	CC	O
regulators	NNP	O
of	VBP	O
the	JJ	O
phosphorylation	NNS	O
of	IN	O
alpha-synuclein.	DT	O
Thus,	NN	O
agents	IN	O
that	.	O
activate	,	O
these	NNS	O
kinases	WDT	O
decrease	VBP	O
phosphorylation	DT	O
of	NNS	O
alpha-synuclein	VBP	O
and	NN	O
can	IN	O
be	JJ	O
used	CC	O
in	MD	O
treatment	VB	O
or	VBN	O
prophylaxis	IN	O
of	NN	O
Lewy	CC	O
body	NN	O
disease.	IN	O
GRK6,	NNP	O
also	NN	O
called	.	O
GPRK6,	,	O
is	RB	O
a	VBD	O
G	,	O
protein-coupled	VBZ	O
receptor	DT	O
kinase	NNP	O
and	JJ	O
is	NN	O
involved	NN	O
in	CC	O
signal	VBZ	O
transduction.	VBN	O
G	IN	O
protein-coupled	JJ	O
receptor	.	O
kinases	NNP	O
phosphorylate	JJ	O
and	NN	O
desensitize	NNS	O
ligand-activated	VBP	O
G	CC	O
protein-coupled	VB	O
receptors.	JJ	O
GRK6	NNP	O
expression	JJ	O
has	.	O
previously	NNP	O
been	NN	O
shown	VBZ	O
to	RB	O
be	VBN	O
significantly	VBN	O
elevated	TO	O
in	VB	O
the	RB	O
MPTP-lesioned	VBN	O
group	IN	O
in	DT	O
most	JJ	O
brain	NN	O
regions.	IN	O
For	JJS	O
the	NN	O
purposes	.	O
of	IN	O
consistency,	DT	O
the	NNS	O
name	IN	O
GRK6	,	O
will	DT	O
be	NN	O
used	NNP	O
throughout	MD	O
the	VB	O
present	VBN	O
patent	IN	O
application.	DT	O
An	JJ	O
exemplary	NN	O
accession	.	O
number	DT	O
is	JJ	O
provided	NN	O
in	NN	O
Table	VBZ	O
1A.	VBN	O
The	IN	O
sequence	JJ	O
for	.	O
GRK6	DT	O
can	NN	O
be	IN	O
found	NNP	O
in	MD	O
any	VB	O
one	VBN	O
of	IN	O
Teli,	DT	B
et	CD	I
al.,	IN	I
Anesthesiology	,	I
98	FW	I
(2),	,	I
343-348	NNP	I
(2003);	CD	I
Miyagawa,	,	B
et	JJ	I
al.,	:	I
Biophys.	,	I
Res.	FW	I
Commun.	,	I
300	.	I
(3),	.	I
669-673	.	I
(2003);	CD	I
Gaudreau,	,	B
et	JJ	I
al.,	:	I
J.	,	I
Biol.	FW	I
Chem.	,	I
277	NNP	I
(35),	.	I
31567-31576	.	I
(2002);	CD	I
Grange-Midroit,	,	B
et	JJ	I
al.,	:	I
Brain	,	I
Res.	FW	I
Mol.	,	I
Brain	NNP	I
Res.	.	I
101	.	I
(1-2),	NNP	I
39-51	.	I
(2002);	CD	I
Willets,	,	B
et	JJ	I
al.,	:	I
J.	,	I
Biol.	FW	I
Chem.	,	I
277	NNP	I
(18),	.	I
15523-15529	.	I
(2002);	CD	I
Blaukat,	,	B
et	JJ	I
al.,	:	I
J.	,	I
Biol.	FW	I
Chem.	,	I
276	NNP	I
(44),	.	I
40431-40440	.	I
(2001);	CD	I
Zhou,	,	B
et	JJ	I
al.,	:	I
J.	,	I
Pharmacol.	FW	I
Exp.	,	I
Ther.	NNP	I
298	.	I
(3),	.	I
1243-1251	.	I
(2001);	CD	I
Pronin,	,	B
et	JJ	I
al.,	:	I
J.	,	I
Biol.	FW	I
Chem.	,	I
275	NNP	I
(34),	.	I
26515-26522	.	I
(2000);	CD	I
Tiruppathi,	,	B
Proc.	JJ	I
Natl.	:	I
Acad.	,	I
Sci.	.	I
U.S.A.,	.	I
97	.	I
(13),	.	I
7440-7445	,	I
(2000);	CD	I
Premont,	,	B
et	JJ	I
al.	:	I
J.	,	I
Biol.	RB	I
Chem.,	.	I
274	NNP	I
(41),	.	I
29381-29389	,	I
(1999);	CD	I
Brenninkmeijer,	,	B
et	JJ	I
al.,	:	I
J.	,	I
Endocrinol.	FW	I
162	,	I
(3),	NNP	I
401-408	.	I
(1999);	CD	I
Hall,	,	B
et	JJ	I
al.,	:	I
J.	,	I
Biol.	FW	I
Chem.	,	I
274	NNP	I
(34),	.	I
24328-24334	.	I
(1999);	CD	I
Lazari,	,	B
et	JJ	I
al.,	:	I
Mol.	,	I
Endocrinol.	FW	I
13	,	I
(6),	.	I
866-878	.	I
(1999);	CD	I
Milcent,	,	B
et	JJ	I
al.,	:	I
Biochem.	,	I
Biophys.	FW	I
Res.	,	I
Commun.	.	I
259	.	I
(1),	.	I
224-229	.	I
(1999);	CD	I
Premont,	,	B
Proc.	JJ	I
Natl.	:	I
Acad.	,	I
Sci.	.	I
U.S.A.	.	I
95	.	I
(24),	.	I
14082-14087	NNP	I
(1998);	CD	I
Stoffel,	,	B
et	JJ	I
al.,	:	I
Biochemistry	,	I
37	FW	I
(46),	,	I
16053-16059	NNP	I
(1998);	CD	I
Loudon,	,	B
et	JJ	I
al.,	:	I
J.	,	I
Biol.	FW	I
Chem.	,	I
272	NNP	I
(43),	.	I
27422-27427	.	I
(1997);	CD	I
Freedman,	,	B
et	JJ	I
al.,	:	I
J.	,	I
Biol.	FW	I
Chem.	,	I
272	NNP	I
(28),	.	I
17734-17743	.	I
(1997);	CD	I
Bullrich,	,	B
et	JJ	I
al.,	:	I
Cytogenet.	,	I
Cell	FW	I
Genet.	,	I
70	.	I
(3-4),	NNP	I
250-254	.	I
(1995);	CD	I
Stoffel,	,	B
et	JJ	I
al.;	:	I
J.	,	I
Biol.	RB	I
Chem.	:	I
269	NNP	I
(45),	.	I
27791-27794	.	I
(1994);	CD	I
Loudon,	,	B
et	JJ	I
al.,	:	I
J.	,	I
Biol.	FW	I
Chem.	,	I
269	NNP	I
(36),	.	I
22691-22697	.	I
(1994);	CD	I
Haribabu	,	B
and	JJ	I
Snyderman,	:	I
Proc.	NNP	I
Natl.	CC	I
Acad.	,	I
Sci.	.	I
U.S.A.	.	I
90	.	I
(20),	.	I
9398-9402	NNP	I
(1993);	CD	I
and	,	O
Benovic	CD	B
and	:	I
Gomez,	CC	I
J.	NNP	I
Biol.	CC	I
Chem.	,	I
268	NNP	I
(26),	.	I
19521-19527	.	I
(1993);	CD	I
reference	,	O
to	JJ	O
the	:	O
amino	NN	O
acid	TO	O
or	DT	O
nucleic	NN	O
acid	NN	O
sequence	CC	O
of	JJ	O
GRK6	JJ	O
includes	NN	O
the	IN	O
amino	NNP	O
acid	VBZ	O
or	DT	O
nucleic	NN	O
acid	NN	O
sequence	CC	O
of	JJ	O
any	JJ	O
of	NN	O
these	IN	O
references	DT	O
and	IN	O
allelic	DT	O
variants	NNS	O
thereof.	CC	O
Casein	JJ	O
kinase	NNS	O
2	.	O
(also	NNP	O
called	VBD	O
Casein	CD	O
kinase	RB	O
II,	VBN	O
CKII,	NNP	O
CSNK2	NN	O
and	,	O
CSNKII)	,	O
has	NNP	O
been	CC	O
reported	)	O
to	VBZ	O
phosphorylate	VBN	O
alpha-synuclein.	VBN	O
For	TO	O
consistency,	VB	O
the	.	O
name	IN	O
CKII	,	O
will	DT	O
be	NN	O
used	NNP	O
herein.	MD	O
The	VB	O
sequence	VBN	O
for	.	O
CKII	DT	O
has	NN	O
been	IN	O
provided	NNP	O
in	VBZ	O
Genbank	VBN	O
under	VBN	O
the	IN	O
following	NNP	O
accession	IN	O
numbers:	DT	O
NM—001896,	JJ	O
NM—001320	NN	O
and/or	:	O
can	,	O
be	NNP	O
found	NN	O
in	MD	O
any	VB	O
one	VBN	O
of	IN	O
Panasyu,	DT	B
et	CD	I
al.	IN	I
J.	,	I
Biol.	RB	I
Chem.	.	I
281	NNP	I
(42),	.	I
31188-31201	.	I
(2006);	CD	I
Salvi,	,	B
et	JJ	I
al.	:	I
FEBS	,	I
Lett.	RB	I
580	.	I
(16),	NNP	I
3948-3952	.	I
(2006);	CD	I
Lim	,	B
et	JJ	I
al.	:	I
Cell	NNP	I
125	FW	I
(4),	.	I
801-814	NNP	I
(2006);	CD	I
Llorens,	,	B
et	JJ	I
al.	:	I
Biochem.	,	I
J.	RB	I
394	.	I
(Pt.	.	I
1),	.	I
227-236,	CD	I
(2006);	.	I
Bjorling-Poulsen,	,	B
et	,	I
al.	:	I
Oncogene	,	I
24	VBZ	I
(40),	.	I
6194-6200	NNP	I
(2005);	CD	I
Schubert,	,	B
et	JJ	I
al.	:	I
Eur.	,	I
J.	RB	I
Biochem.	.	I
204	.	I
(2),	NNP	I
875-883	.	I
(1991);	CD	I
Voss,	,	B
et	JJ	I
al.	:	I
J.	,	I
Biol.	RB	I
Chem.	.	I
266	NNP	I
(21),	.	I
13706-13711	.	I
(1991);	CD	I
Yang-Feng,	,	B
et	JJ	I
al.	:	I
Genomics	,	I
8	VBZ	I
(4),	.	I
741-742	NNS	I
(1990);	CD	I
Heller-Harrison,	,	B
et	JJ	I
al.	:	I
Biochemistry	,	I
28	VBZ	I
(23),	.	I
9053-9058	NN	I
(1989);	CD	I
Ackermann,	,	B
et	CD	I
al.	:	I
Mol.	,	I
Cell.	RB	I
Biochem.	.	I
274	.	I
(1-2),	.	I
91-101	.	I
(2005);	CD	I
Barrios-Rodiles,	,	B
et	CD	I
al.	:	I
Science	,	I
307	VBZ	I
(5715),	.	I
1621-1625	NN	I
(2005);	CD	I
Andersen,	,	B
et	JJ	I
al.	:	I
Nature	,	I
433	RB	I
(7021),	.	I
77-83	NN	I
(2005);	CD	I
Ballif,	,	B
et	JJ	I
al.	:	I
Mol.	,	I
Cell.	RB	I
Proteomics,	.	I
3	.	I
(11),	.	I
1093-1101	,	I
(2004);	CD	I
Beausoleil,	,	B
et	JJ	I
al.	:	I
PNAS,	,	I
USA	RB	I
101	.	I
(33),	,	I
12130-12135	NNP	I
(2004);	CD	I
Marais,	,	B
et	JJ	I
al.	:	I
EMBO	,	I
J.	RB	I
11	.	I
(1),	NNP	I
97-105	.	I
(1992).	CD	I
Reference	,	O
to	CD	O
the	.	O
amino	NN	O
acid	TO	O
or	DT	O
nucleic	NN	O
acid	NN	O
sequence	CC	O
of	JJ	O
CKII	JJ	O
includes	NN	O
the	IN	O
amino	NNP	O
acid	VBZ	O
or	DT	O
nucleic	NN	O
acid	NN	O
sequence	CC	O
of	JJ	O
any	JJ	O
of	NN	O
these	IN	O
references	DT	O
and	IN	O
allelic	DT	O
variants	NNS	O
thereof.	CC	O
IKBKB	JJ	O
and	NNS	O
the	.	O
related	NNP	O
IKBKA	CC	O
are	DT	O
positive	JJ	O
regulators	NNP	O
of	VBP	O
the	JJ	O
NFkB	NNS	O
inflammatory	IN	O
pathway.	DT	O
The	NNP	O
sequence	JJ	O
for	.	O
IKBKB	DT	O
has	NN	O
been	IN	O
provided	NNP	O
in	VBZ	O
Genbank	VBN	O
under	VBN	O
the	IN	O
following	NNP	O
accession	IN	O
number:	DT	O
NM—001556	JJ	O
and/or	NN	O
can	:	O
be	NNP	O
found	NN	O
in	MD	O
any	VB	O
one	VBN	O
of:	IN	O
Caterino,	DT	B
et	CD	I
al.	:	I
FEBS	,	I
Lett.	CC	I
580	.	I
(28-29),	NNP	I
6527-6532	.	I
(2006);	CD	I
Castle,	,	B
et	JJ	I
al.	:	I
Genome	,	I
Biol.	RB	I
4	.	I
(10),	NNP	I
R66	.	I
(2003);	CD	I
Satoh,	,	B
et	NNP	I
al.	:	I
Biochim,	,	I
Biophys.	RB	I
Acta	.	I
1600	,	I
(103),	.	I
61-67	NN	I
(2002),	CD	I
Caohuy,	,	B
and	JJ	I
Pollard,	,	I
J.	,	I
Biol.	CC	I
Chem.	,	I
277	NNP	I
(28),	.	I
25217-25225	.	I
(2002);	CD	I
Yu,	,	B
et	JJ	I
al.	:	I
J.	,	I
Biol.	RB	I
Chem.	.	I
277	NNP	I
(18),	.	I
15819-15827	.	I
(2002);	CD	I
Selbert,	,	B
et	JJ	I
al.	:	I
J.	,	I
Cell.	RB	I
Sci.	.	I
108	.	I
(Pt.	.	I
1),	.	I
85095	CD	I
(1995);	.	I
Shirvan,	,	B
et	CD	I
al.	:	I
Biochemistry	,	I
33	RB	I
(22),	.	I
6888-6901	NN	I
(1994);	CD	I
Creutz,	,	B
et	JJ	I
al.	:	I
Biochem.	,	I
Biophys.	RB	I
Res.	.	I
Commun.	.	I
184	.	I
(1),	.	I
347-352	.	I
(1992);	CD	I
Megendzo,	,	B
et	CD	I
al.	:	I
J.	,	I
Biol.	RB	I
Chem.	.	I
266	NNP	I
(5),	.	I
3228-3232	.	I
(1991);	CD	I
Burns,	,	B
et	JJ	I
al.	:	I
PNAS,	,	I
USA	RB	I
86	.	I
(10),	,	I
3798-3802	NNP	I
(1989).	CD	I
Reference	,	O
to	JJ	O
the	.	O
amino	NN	O
acid	TO	O
or	DT	O
nucleic	NN	O
acid	NN	O
sequence	CC	O
of	JJ	O
IKBKB	JJ	O
includes	NN	O
the	IN	O
amino	NNP	O
acid	VBZ	O
or	DT	O
nucleic	NN	O
acid	NN	O
sequence	CC	O
of	JJ	O
any	JJ	O
of	NN	O
these	IN	O
references	DT	O
and	IN	O
allelic	DT	O
variants	NNS	O
thereof.	CC	O
Synphilin	JJ	O
is	NNS	O
a	.	O
synuclein-associated	NNP	O
protein	VBZ	O
that	DT	O
has	JJ	O
been	NN	O
shown	WDT	O
to	VBZ	O
bind	VBN	O
alpha-synuclein.	VBN	O
Although	TO	O
not	VB	O
a	.	O
kinase	IN	O
itself,	RB	O
Synphilin	DT	O
was	NN	O
found	,	O
herein	NNP	O
to	VBD	O
promote	VBN	O
phosphorylation	RB	O
of	TO	O
synuclein	VB	O
particularly	NN	O
in	IN	O
combination	JJ	O
with	RB	O
PLK2.	IN	O
The	NN	O
synphilin	IN	O
appeared	.	O
to	DT	O
promote	NN	O
phosphorylation	VBD	O
of	TO	O
synuclein	VB	O
in	NN	O
a	IN	O
PLK2-dependent	NN	O
manner.	IN	O
The	DT	O
sequence	JJ	O
for	.	O
synphilin	DT	O
has	NN	O
been	IN	O
provided	NN	O
in	VBZ	O
Genbank	VBN	O
under	VBN	O
the	IN	O
following	NNP	O
accession	IN	O
number:	DT	O
NM—005460	JJ	O
and/or	NN	O
can	:	O
be	NNP	O
found	NN	O
in	MD	O
any	VB	O
one	VBN	O
of:	IN	O
Tanji,	DT	B
et	CD	I
al.	:	I
Am.	,	I
J.	RB	I
Pathol.	.	I
169	.	I
(2),	NNP	I
553-565	.	I
(2006);	CD	I
Eyal,	,	B
et	JJ	I
al.	:	I
PNAS,	,	I
USA	RB	I
103	.	I
(15),	,	I
5917-5922	NNP	I
(2006);	CD	I
Avraham,	,	B
et	JJ	I
al.	:	I
J.	,	I
Biol.	RB	I
Chem.	.	I
280	NNP	I
(52),	.	I
42877-42886	.	I
(2005);	CD	I
Bandopadhyay,	,	B
et	JJ	I
al.	:	I
Neurobiol.	,	I
Dis.	RB	I
20	.	I
(2),	.	I
401-411	.	I
(2005);	CD	I
Lim	,	B
et	JJ	I
al.	:	I
J.	NNP	I
Neurosci.	FW	I
25	.	I
(8),	NNP	I
2002-2009	.	I
(2005);	CD	I
Ribeiro,	,	B
et	CD	I
al.	:	I
J.	,	I
Biol.	RB	I
Chem.	.	I
277	NNP	I
(26),	.	I
23927-23933	.	I
(2002);	CD	I
Chung,	,	B
et	JJ	I
al.	:	I
Nat.	,	I
Med.	RB	I
7	.	I
(10),	.	I
1144-1150	.	I
(2001);	CD	I
Engelender,	,	B
et	JJ	I
al.	:	I
Mamm.	,	I
Genome	RB	I
11	.	I
(9),	.	I
763-766	NNP	I
(2000);	CD	I
Engelender,	,	B
et	JJ	I
al.	:	I
Nat.	,	I
Genet.	RB	I
22	.	I
(1),	.	I
110-114	.	I
(1999).	CD	I
Reference	,	O
to	JJ	O
the	.	O
amino	NN	O
acid	TO	O
or	DT	O
nucleic	NN	O
acid	NN	O
sequence	CC	O
of	JJ	O
synphilin	JJ	O
includes	NN	O
the	IN	O
amino	NN	O
acid	VBZ	O
or	DT	O
nucleic	NN	O
acid	NN	O
sequence	CC	O
of	JJ	O
any	JJ	O
of	NN	O
these	IN	O
references	DT	O
and	IN	O
allelic	DT	O
variants	NNS	O
thereof.	CC	O
V.	JJ	O
Agents	NNS	O
to	.	O
Modulate	NNP	O
Synuclein	NNS	O
Kinase	TO	O
Activity	NNP	O
or	NNP	O
Expression	NNP	O
In	NNP	O
one	CC	O
aspect,	NNP	O
the	IN	O
invention	CD	O
provides	,	O
methods	DT	O
of	NN	O
effecting	VBZ	O
treatment	NNS	O
or	IN	O
prophylaxis	VBG	O
of	NN	O
an	CC	O
LBD	NN	O
by	IN	O
administering	DT	O
an	NNP	O
agent	IN	O
that	VBG	O
modulates	DT	O
activity	NN	O
or	WDT	O
expression	VBZ	O
of	NN	O
a	CC	O
kinase	NN	O
described	IN	O
herein.	DT	O
A	NN	O
number	VBN	O
of	.	O
agents	DT	O
of	NN	O
well-characterized	IN	O
general	NNS	O
classes	IN	O
can	JJ	O
be	JJ	O
used.	NNS	O
Without	MD	O
limitation	VB	O
these	.	O
include	IN	O
inhibitory	NN	O
nucleic	DT	O
acids	VBP	O
(e.g.,	NN	O
siRNA,	JJ	O
antisense	NNS	O
RNA,	,	O
ribozymes),	,	O
inhibitory	JJ	O
proteins	,	O
(e.g.,	,	O
zinc	JJ	O
finger	NNS	O
proteins),	,	O
antibodies,	NN	O
and	NN	O
small	,	O
molecule	,	O
inhibitors.	CC	O
Preferably	JJ	O
the	NN	O
gene	.	O
to	RB	O
be	DT	O
inhibited	NN	O
is	TO	O
PLK2	VB	O
or	VBN	O
GRK6	VBZ	O
because	NNP	O
the	CC	O
kinases	NNP	O
encoded	IN	O
by	DT	O
these	NNS	O
genes	VBN	O
directly	IN	O
phosphorylate	DT	O
alpha-synuclein,	NNS	O
and	RB	O
particularly	VBP	O
PLK2.	,	O
APEG1,	CC	O
CDC7L1,	RB	O
MET	.	O
GRK1,	,	O
GRK2,	,	O
GRK6,	NNP	O
IKBKB,	,	O
CKII	,	O
and	,	O
GRK7	,	O
genes	NNP	O
are	CC	O
also	NNP	O
preferred	NNS	O
targets	VBP	O
for	RB	O
inhibition	JJ	O
because	NNS	O
they	IN	O
are	NN	O
likely	IN	O
to	PRP	O
encode	VBP	O
indirect	JJ	O
activators	TO	O
of	VB	O
the	JJ	O
direct	NNS	O
kinase(s).	IN	O
PRKG1,	DT	O
MAPK13,	JJ	O
and	.	O
GAK	,	O
are	,	O
preferred	CC	O
candidates	NNP	O
for	VBP	O
activation	VBN	O
in	NNS	O
Lewy	IN	O
body	NN	O
diseases	IN	O
because	NNP	O
they	NN	O
encode	NNS	O
negative	IN	O
regulators	PRP	O
of	VBP	O
the	JJ	O
phosphorylation	NNS	O
of	IN	O
alpha-synuclein.	DT	O
The	NN	O
synphilin	IN	O
gene	.	O
is	DT	O
a	NN	O
preferred	NN	O
target	VBZ	O
for	DT	O
inhibition	JJ	O
because,	NN	O
although	IN	O
synphilin	NN	O
is	,	O
not	IN	O
a	NN	O
kinase,	VBZ	O
it	RB	O
is	DT	O
associated	,	O
with	PRP	O
increased	VBZ	O
phosphorylation	VBN	O
of	IN	O
alpha-synuclein	JJ	O
(typically	NN	O
in	IN	O
the	NN	O
presence	RB	O
of	IN	O
a	DT	O
kinase	NN	O
such	IN	O
as	DT	O
PLK2).	NN	O
Inhibitors	JJ	O
that	IN	O
show	.	O
specificity	NNS	O
for	WDT	O
PLK2	VBP	O
over	NN	O
one	IN	O
or	NNP	O
more	IN	O
other	CD	O
polo-like	CC	O
kinase	JJR	O
family	JJ	O
members	JJ	O
(i.e.,	NN	O
PLK1,	NN	O
PLK3,	NNS	O
and	,	O
PLK4)	,	O
are	,	O
preferred.	CC	O
Inhibitors	)	O
especially	VBP	O
suited	.	O
for	NNS	O
therapeutic	RB	O
use	VBN	O
may	IN	O
be	JJ	O
identified	NN	O
by	MD	O
selecting	VB	O
for	VBN	O
at	IN	O
least	VBG	O
one	IN	O
of	IN	O
the	JJS	O
following	CD	O
properties:	IN	O
As	DT	O
used	JJ	O
in	:	O
this	IN	O
context,	VBN	O
“no	IN	O
effect”	DT	O
means	,	O
administration	NNP	O
of	CC	O
the	VBZ	O
agent	NN	O
does	IN	O
not	DT	O
reduce	NN	O
expression,	VBZ	O
or	RB	O
reduces	VB	O
expression	,	O
by	CC	O
a	NNS	O
physiologically	NN	O
insignificant	IN	O
degree.	DT	O
“Reduced	RB	O
effect”	JJ	O
means	.	O
that	VBN	O
the	NN	O
EC50	VBZ	O
or	IN	O
Ki	DT	O
values	NNP	O
for	CC	O
inhibiting	NNP	O
PLK2	NNS	O
is	IN	O
lower	VBG	O
than	NNP	O
the	VBZ	O
EC50	JJR	O
for	IN	O
the	DT	O
reference	NNP	O
PLK(s).	IN	O
In	DT	O
some	NN	O
embodiments	.	O
the	IN	O
EC50	DT	O
may	NNS	O
be	DT	O
at	NNP	O
least	MD	O
2-fold	VB	O
lower,	IN	O
and	JJS	O
is	JJ	O
sometimes	,	O
at	CC	O
least	VBZ	O
10-fold	RB	O
lower,	IN	O
and	JJS	O
may	JJ	O
be	,	O
at	CC	O
least	MD	O
100-fold,	VB	O
or	IN	O
even	JJS	O
at	,	O
least	CC	O
1000-fold	RB	O
lower.	IN	O
As	JJS	O
used	JJ	O
in	.	O
this	IN	O
context,	VBN	O
inhibition	IN	O
of	DT	O
PLK2	,	O
“activity”	NN	O
can	IN	O
result	NNP	O
from	NNP	O
reducing	MD	O
protein	VB	O
expression	IN	O
(e.g.,	VBG	O
reducing	JJ	O
expression	NN	O
of	,	O
the	VBG	O
PLK2	NN	O
gene,	IN	O
interfering	DT	O
with	NNP	O
processing	,	O
of	VBG	O
PLK2	IN	O
RNA,	NN	O
reducing	IN	O
the	NNP	O
half-life	,	O
of	VBG	O
PLK2	DT	O
mRNA	NN	O
or	IN	O
protein)	NNP	O
or	NN	O
by	CC	O
competitive	)	O
or	CC	O
noncompetitive	IN	O
inhibition	JJ	O
of	CC	O
the	JJ	O
PLK2	NN	O
kinase	IN	O
activity.	DT	O
Inhibitors	NNP	O
that	NN	O
show	.	O
specificity	NNS	O
for	WDT	O
PLK2	VBP	O
over	NN	O
non-polo	IN	O
kinases,	NNP	O
especially	IN	O
other	JJ	O
kinases	,	O
expressed	RB	O
in	JJ	O
the	NNS	O
tissues	VBN	O
to	IN	O
which	DT	O
the	NNS	O
agent	TO	O
is	WDT	O
delivered	DT	O
are	NN	O
especially	VBZ	O
preferred.	VBN	O
In	VBP	O
preferred	RB	O
embodiments	.	O
the	IN	O
agent	JJ	O
does	NNS	O
not	DT	O
inhibit	NN	O
non-polo	VBZ	O
kinases	RB	O
(or	VB	O
has	JJ	O
a	NNS	O
EC50	CC	O
greater	VBZ	O
than	DT	O
10-times	NNP	O
higher,	JJR	O
sometimes	IN	O
100-times	CD	O
greater,	,	O
and	RB	O
sometimes	JJ	O
greater	,	O
than	CC	O
1000-times	RB	O
higher)	JJR	O
for	IN	O
non-polo	CD	O
kinases	)	O
compared	IN	O
to	JJ	O
PLK2.	NNS	O
However,	VBN	O
inhibition	TO	O
of	.	O
other	,	O
kinases	NN	O
may	IN	O
be	JJ	O
tolerated	NNS	O
depending	MD	O
on	VB	O
the	VBN	O
role	VBG	O
and	IN	O
expression	DT	O
of	NN	O
the	CC	O
kinase.	NN	O
For	IN	O
example,	DT	O
a	.	O
kinase	IN	O
that	,	O
functions	DT	O
in	NN	O
the	WDT	O
gut	NNS	O
may	IN	O
not	DT	O
be	NN	O
affected	MD	O
by	RB	O
an	VB	O
inhibitor	VBN	O
delivered	IN	O
to	DT	O
the	NN	O
brain.	VBD	O
To	TO	O
further	DT	O
guide	.	O
the	TO	O
reader,	RBR	O
inhibitory	VB	O
nucleic	DT	O
acids	,	O
(e.g.,	JJ	O
siRNA,	JJ	O
antisense	NNS	O
RNA,	,	O
ribozymes),	,	O
inhibitory	JJ	O
proteins	,	O
(e.g.,	,	O
zinc	JJ	O
finger	NNS	O
proteins),	,	O
antibodies,	NN	O
and	NN	O
small	,	O
molecule	,	O
inhibitors	CC	O
are	JJ	O
discussed	NN	O
below.	NNS	O
A.	VBP	O
Inhibitory	VBN	O
Polynucleotides	.	O
Several	NN	O
examples	NNP	O
of	NNP	O
inhibitors	NNP	O
of	NNS	O
target	IN	O
kinases,	NNS	O
including	IN	O
PLK2,	NN	O
are	,	O
described	VBG	O
below.	,	O
Polynucleotide	VBP	O
inhibitors	VBN	O
are	.	O
designed	JJ	O
to	NNS	O
bind	VBP	O
specific	VBN	O
target	TO	O
sequences	VB	O
within	JJ	O
a	NN	O
target	NNS	O
transcript.	IN	O
Preferably	DT	O
the	NN	O
inhibitors	.	O
bind	RB	O
to	DT	O
a	NNS	O
target	VBP	O
site	TO	O
in	DT	O
a	NN	O
PLK2	NN	O
RNA	IN	O
without	DT	O
binding	NNP	O
a	NNP	O
target	IN	O
site	VBG	O
in:	DT	O
PLK1	NN	O
and/or	NN	O
PLK3	:	O
and/or	NNP	O
PLK4.	VBZ	O
Suitable	NNP	O
target	NN	O
sites	.	O
are	JJ	O
identified	NN	O
by	NNS	O
selecting	VBP	O
segments	VBN	O
of	IN	O
PLK2	VBG	O
that	NNS	O
have	IN	O
no	NNP	O
exact	WDT	O
corresponding	VBP	O
segment	DT	O
in	JJ	O
other	VBG	O
PLKs.	NN	O
Preferably,	IN	O
a	JJ	O
selected	.	O
segment	,	O
of	DT	O
PLK2	VBN	O
lacks	NN	O
a	IN	O
corresponding	NNP	O
segment	VBZ	O
having	DT	O
substantial	JJ	O
sequence	NN	O
identity	VBG	O
(for	JJ	O
example,	NN	O
a	NN	O
selected	IN	O
segment	,	O
from	DT	O
PLK2	VBN	O
should	NN	O
show	IN	O
less	NNP	O
than	MD	O
95,	VB	O
90,	JJR	O
75	IN	O
or	,	O
50%	,	O
sequence	CD	O
identity	CC	O
with	NN	O
the	NN	O
closest	NN	O
corresponding	IN	O
segment	DT	O
in	JJS	O
PLK4).	NN	O
A	NN	O
selected	IN	O
target	.	O
segment	DT	O
is	VBN	O
also	NN	O
preferably	NN	O
screened	VBZ	O
against	RB	O
a	RB	O
gene	VBN	O
database	IN	O
to	DT	O
ensure	NN	O
that	NN	O
it	TO	O
does	VB	O
not	IN	O
show	PRP	O
significant	VBZ	O
sequence	RB	O
identity	VB	O
with	JJ	O
unrelated	NN	O
genes	NN	O
by	IN	O
chance.	JJ	O
Polynucleotide	NNS	O
inhibitors	IN	O
of	.	O
PLK2	NNP	O
preferably	NNS	O
show	IN	O
at	NNP	O
least	RB	O
30,	VBP	O
50,	IN	O
75,	JJS	O
95,	,	O
or	,	O
99%	,	O
inhibition	,	O
of	CC	O
levels	NN	O
of	NN	O
PLK2	IN	O
mRNA	NNS	O
or	IN	O
protein	NNP	O
with	NN	O
little	CC	O
or	NN	O
no	IN	O
detectable	JJ	O
reduction	CC	O
in	DT	O
levels	JJ	O
of	NN	O
PLK1	IN	O
and/or	NNS	O
PLK3	IN	O
and/or	NNP	O
PLK4	NN	O
mRNA	NNP	O
or	NN	O
protein	NNP	O
(i.e,	NN	O
less	CC	O
than	NN	O
10,	,	O
5	JJR	O
or	IN	O
1%	,	O
inhibition).	CD	O
Protein	CC	O
expression	NN	O
can	.	O
be	NNP	O
quantified	NN	O
by	MD	O
forming	VB	O
immunological	VBN	O
analyses	IN	O
using	VBG	O
an	JJ	O
antibody	NNS	O
that	VBG	O
specifically	DT	O
binds	NN	O
to	WDT	O
the	RB	O
protein	VBZ	O
followed	TO	O
by	DT	O
detection	NN	O
of	VBN	O
complex	IN	O
formed	NN	O
between	IN	O
the	JJ	O
antibody	VBN	O
and	IN	O
protein.	DT	O
mRNA	NN	O
levels	CC	O
can	.	O
be	NN	O
quantified	NNS	O
by,	MD	O
for	VB	O
example,	VBN	O
dot	,	O
blot	IN	O
analysis,	,	O
in-situ	NN	O
hybridization,	NN	O
RT-PCR,	,	O
quantitative	JJ	O
reverse-transcription	,	O
PCR	,	O
(i.e.,	JJ	O
the	NN	O
so-called	NNP	O
“TaqMan”	,	O
methods),	DT	O
Northern	JJ	O
blots	NNP	O
and	,	O
nucleic	NNP	O
acid	NNS	O
probe	CC	O
array	JJ	O
methods.	NN	O
i)	NN	O
Short	NN	O
Inhibitory	.	O
RNAs	)	O
siRNAs	NNP	O
are	NNP	O
relatively	NNP	O
short,	NN	O
at	VBP	O
least	RB	O
partly	,	O
double	IN	O
stranded,	JJS	O
RNA	RB	O
molecules	RB	O
that	,	O
serve	NNP	O
to	VBZ	O
inhibit	IN	O
expression	NN	O
or	TO	O
translation	VB	O
of	NN	O
a	CC	O
complementary	NN	O
mRNA	IN	O
transcript,	DT	O
such	JJ	O
as	NN	O
a	,	O
kinase	JJ	O
transcript.	IN	O
Although	DT	O
an	NN	O
understanding	.	O
of	IN	O
mechanism	DT	O
is	NN	O
not	IN	O
required	NN	O
for	VBZ	O
practice	RB	O
of	VBN	O
the	IN	O
invention,	NN	O
it	IN	O
is	DT	O
believed	,	O
that	PRP	O
siRNAs	VBZ	O
act	VBN	O
by	IN	O
inducing	NN	O
degradation	NN	O
of	IN	O
a	VBG	O
complementary	NN	O
mRNA	IN	O
transcript.	DT	O
Principles	JJ	O
for	NN	O
design	.	O
and	NNS	O
use	IN	O
of	NN	O
siRNAs	CC	O
generally	NN	O
are	IN	O
described	NN	O
by	RB	O
WO	VBP	O
99/32619,	VBN	O
Elbashir,	IN	B
EMBO	NNP	I
J.	,	I
20,	,	I
6877-6888	NNP	I
(2001)	.	I
and	,	O
Nykanen	CD	B
et	)	I
al.,	CC	I
Cell	NNP	I
107,	VBP	I
309-321	,	I
(2001);	NNP	I
WO	,	O
01/29058.	CD	O
siRNAs	:	O
are	$	O
formed	.	O
from	NNS	O
two	VBP	O
strands	VBN	O
of	IN	O
at	CD	O
least	NNS	O
partly	IN	O
complementary	IN	O
RNA,	JJS	O
each	RB	O
strand	JJ	O
preferably	,	O
of	DT	O
10-30,	NN	O
15-25,	RB	O
or	IN	O
17-23	,	O
or	,	O
19-21	CC	O
nucleotides	CD	O
long.	CC	O
The	JJ	O
strands	NNS	O
can	.	O
be	DT	O
perfectly	NNS	O
complementary	MD	O
to	VB	O
each	RB	O
other	JJ	O
throughout	TO	O
their	DT	O
length	JJ	O
or	IN	O
can	PRP$	O
have	NN	O
single	CC	O
stranded	MD	O
3′-overhangs	VB	O
at	JJ	O
one	VBN	O
or	NNS	O
both	IN	O
ends	CD	O
of	CC	O
an	DT	O
otherwise	NNS	O
double	IN	O
stranded	DT	O
molecule.	NN	O
Single	NN	O
stranded	VBD	O
overhangs,	.	O
if	NNP	O
present,	VBD	O
are	,	O
usually	IN	O
of	,	O
1-6	VBP	O
bases	RB	O
with	IN	O
1	JJ	O
or	NNS	O
2	IN	O
bases	CD	O
being	CC	O
preferred.	CD	O
The	NNS	O
antisense	VBG	O
strand	.	O
of	DT	O
an	JJ	O
siRNA	NN	O
is	IN	O
selected	DT	O
to	NN	O
be	VBZ	O
substantially	VBN	O
complementary	TO	O
(e.g.,	VB	O
at	RB	O
least	JJ	O
80,	,	O
90,	IN	O
95%	JJS	O
and	,	O
preferably	,	O
100%	NN	O
complementary)	CC	O
to	RB	O
a	NN	O
segment	)	O
of	TO	O
a	DT	O
transcript	NN	O
from	IN	O
a	DT	O
gene	NN	O
of	IN	O
the	DT	O
invention.	NN	O
Any	IN	O
mismatched	DT	O
bases	.	O
preferably	DT	O
occur	JJ	O
at	NNS	O
or	RB	O
near	VBP	O
the	IN	O
ends	CC	O
of	IN	O
the	DT	O
strands	NNS	O
of	IN	O
the	DT	O
siRNA.	NNS	O
Mismatched	IN	O
bases	DT	O
at	.	O
the	VBN	O
ends	NNS	O
can	IN	O
be	DT	O
deoxyribonucleotides.	NNS	O
The	MD	O
sense	VB	O
strand	.	O
of	DT	O
an	NN	O
siRNA	NN	O
shows	IN	O
an	DT	O
analogous	NN	O
relationship	VBZ	O
with	DT	O
the	JJ	O
complement	NN	O
of	IN	O
the	DT	O
segment	NN	O
of	IN	O
the	DT	O
gene	NN	O
transcript	IN	O
of	DT	O
interest.	NN	O
siRNAs	NN	O
having	IN	O
two	.	O
strands,	RB	O
each	VBG	O
having	CD	O
19	,	O
bases	DT	O
of	VBG	O
perfect	CD	O
complementarity,	NNS	O
and	IN	O
having	JJ	O
two	,	O
unmatched	CC	O
bases	VBG	O
at	CD	O
the	JJ	O
3′	NNS	O
end	IN	O
of	DT	O
the	CD	O
sense	NN	O
strand	IN	O
and	DT	O
one	NN	O
at	NN	O
the	CC	O
3′	CD	O
end	IN	O
of	DT	O
the	CD	O
antisense	NN	O
strand	IN	O
are	DT	O
particularly	NN	O
suitable.	NN	O
If	VBP	O
an	RB	O
siRNA	.	O
is	IN	O
to	DT	O
be	NN	O
administered	VBZ	O
as	TO	O
such,	VB	O
as	VBN	O
distinct	IN	O
from	,	O
the	IN	O
form	JJ	O
of	IN	O
DNA	DT	O
encoding	NN	O
the	IN	O
siRNA,	NNP	O
then	VBG	O
the	DT	O
strands	,	O
of	RB	O
an	DT	O
siRNA	NNS	O
can	IN	O
contain	DT	O
one	NN	O
or	MD	O
more	VB	O
nucleotide	CD	O
analogs.	CC	O
The	JJR	O
nucleotide	JJ	O
analogs	.	O
are	DT	O
located	JJ	O
at	NNS	O
positions	VBP	O
at	VBN	O
which	IN	O
inhibitor	NNS	O
activity	IN	O
is	WDT	O
not	NN	O
substantially	NN	O
affected,	VBZ	O
e.g.	RB	O
in	RB	O
a	,	O
region	.	O
at	IN	O
the	DT	O
5′-end	NN	O
and/or	IN	O
the	DT	O
3′-end,	JJ	O
particularly	NN	O
single	DT	O
stranded	,	O
overhang	RB	O
regions.	JJ	O
Preferred	VBD	O
nucleotide	JJ	O
analogues	.	O
are	NNP	O
sugar-	IN	O
or	NNS	O
backbone-modified	VBP	O
ribonucleotides.	JJ	O
Nucleobase-modified	CC	O
ribonucleotides,	JJ	O
i.e.	.	O
ribonucleotides,	JJ	O
containing	,	O
a	.	O
non-naturally	,	O
occurring	VBG	O
nucleobase	DT	O
instead	JJ	O
of	VBG	O
a	JJ	O
naturally	RB	O
occurring	IN	O
nucleobase	DT	O
such	RB	O
as	VBG	O
uridines	NN	O
or	JJ	O
cytidines	IN	O
modified	NNS	O
at	CC	O
the	NNS	O
5-position,	VBN	O
e.g.	IN	O
5-(2-amino)propyl	DT	O
uridine,	,	O
5-bromo	.	O
uridine;	NN	O
adenosines	,	O
and	JJ	O
guanosines	:	O
modified	NNS	O
at	CC	O
the	NNS	O
8	VBN	O
position,	IN	O
e.g.	DT	O
8-bromo	CD	O
guanosine;	,	O
deaza	.	O
nucleotides,	JJ	O
e.g.	:	O
7-deaza-adenosine;	NN	O
O-	,	O
and	.	O
N-alkylated	:	O
nucleotides,	JJ	O
e.g.	CC	O
N6-methyl	JJ	O
adenosine	,	O
are	.	O
also	JJ	O
suitable.	NN	O
In	VBP	O
preferred	RB	O
sugar-modified	.	O
ribonucleotides,	IN	O
the	JJ	O
2′	JJ	O
OH-group	,	O
is	DT	O
replaced	CD	O
by	NN	O
a	VBZ	O
group	VBN	O
selected	IN	O
from	DT	O
H,	NN	O
OR,	VBN	O
R,	IN	O
halo,	,	O
SH,	,	O
SR,	,	O
NH2,	,	O
NHR,	,	O
NR2	,	O
or	,	O
CN,	,	O
wherein	NNP	O
R	CC	O
is	,	O
C1-C6	NN	O
alkyl,	NNP	O
alkenyl	VBZ	O
or	NNP	O
alkynyl	,	O
and	NN	O
halo	CC	O
is	NN	O
F,	CC	O
CI,	NN	O
Br	VBZ	O
or	,	O
I.	,	O
In	NNP	O
preferred	CC	O
backbone-modified	.	O
ribonucleotides	IN	O
the	JJ	O
phosphoester	JJ	O
group	NNS	O
connecting	DT	O
to	NN	O
adjacent	NN	O
ribonucleotides	VBG	O
is	TO	O
replaced	JJ	O
by	NNS	O
a	VBZ	O
modified	VBN	O
group,	IN	O
e.g.	DT	O
of	JJ	O
phosphothioate	,	O
group.	.	O
A	IN	O
further	NN	O
preferred	.	O
modification	DT	O
is	JJ	O
to	JJ	O
introduce	NN	O
a	VBZ	O
phosphate	TO	O
group	VB	O
on	DT	O
the	NN	O
5′	NN	O
hydroxide	IN	O
residue	DT	O
of	CD	O
an	NN	O
siRNA.	NN	O
Such	IN	O
a	DT	O
group	.	O
can	JJ	O
be	DT	O
introduced	NN	O
by	MD	O
treatment	VB	O
of	VBN	O
an	IN	O
siRNA	NN	O
with	IN	O
ATP	DT	O
and	NN	O
T4	IN	O
kinase.	NNP	O
The	CC	O
phosphodiester	NNP	O
linkages	.	O
of	DT	O
natural	NN	O
RNA	NNS	O
can	IN	O
also	JJ	O
be	NNP	O
modified	MD	O
to	RB	O
include	VB	O
at	VBN	O
least	TO	O
one	VB	O
of	IN	O
a	JJS	O
nitrogen	CD	O
or	IN	O
sulfur	DT	O
heteroatom.	NN	O
Modifications	CC	O
in	JJ	O
RNA	.	O
structure	NNS	O
can	IN	O
be	NNP	O
tailored	NN	O
to	MD	O
allow	VB	O
specific	VBN	O
genetic	TO	O
inhibition	VB	O
while	JJ	O
avoiding	JJ	O
a	NN	O
general	IN	O
panic	VBG	O
response	DT	O
in	JJ	O
some	NN	O
organisms	NN	O
which	IN	O
is	DT	O
generated	NNS	O
by	WDT	O
dsRNA.	VBZ	O
Likewise,	VBN	O
bases	IN	O
can	.	O
be	,	O
modified	NNS	O
to	MD	O
block	VB	O
the	VBN	O
activity	TO	O
of	VB	O
adenosine	DT	O
deaminase.	NN	O
One	IN	O
example	JJ	O
of	.	O
such	CD	O
an	NN	O
agent	IN	O
is	PDT	O
siRNA	DT	O
specific	NN	O
for	VBZ	O
PLK2.	JJ	O
siRNAs	JJ	O
to	IN	O
the	.	O
gene	NN	O
encoding	TO	O
PLK2	DT	O
can	NN	O
be	VBG	O
specifically	NNP	O
designed	MD	O
using	VB	O
methods	RB	O
described	VBN	O
below.	VBG	O
An	NNS	O
exemplary	VBN	O
accession	.	O
number	DT	O
for	JJ	O
PLK2	NN	O
is	NN	O
[NM—006622]	IN	O
as	NNP	O
provided	VBZ	O
in	NNP	O
Table	IN	O
1A.	VBN	O
The	IN	O
amino	JJ	O
acid	.	O
sequence	DT	O
of	NN	O
human	JJ	O
PLK2	NN	O
is	IN	O
also	JJ	O
set	NNP	O
forth	VBZ	O
as	RB	O
SEQ	VBN	O
ID	NN	O
NO:2	IN	O
and	NNP	O
SEQ	NNP	O
ID	NNP	O
NO:1	CC	O
is	NNP	O
the	NNP	O
nucleic	NNP	O
acid	VBZ	O
sequence	DT	O
encoding	JJ	O
the	NN	O
amino	NN	O
acid	VBG	O
sequence.	DT	O
For	NN	O
convenience	JJ	O
exemplary	.	O
sequences	IN	O
are	NN	O
provided	JJ	O
below.	NNS	O
ii)	VBP	O
Design	VBN	O
and	.	O
Production	)	O
of	NN	O
siRNA	CC	O
An	NN	O
advantage	IN	O
of	NN	O
inhibitory	DT	O
polynucleotides	NN	O
is	IN	O
that	NN	O
they	NNS	O
can	VBZ	O
be	IN	O
designed	PRP	O
to	MD	O
be	VB	O
highly	VBN	O
target	TO	O
specific.	VB	O
For	RB	O
example,	NN	O
siRNAs	.	O
specific	IN	O
for	,	O
PLK2	NN	O
can	NN	O
be	IN	O
designed	NNP	O
using	MD	O
target	VB	O
sequences	VBN	O
that	VBG	O
distinguish	NN	O
PLK2	NNS	O
from	WDT	O
other	VBP	O
PLKs.	NNP	O
The	IN	O
program	JJ	O
“siDESIGN”	.	O
(Dharmacon,	DT	O
Inc.,	NN	O
Lafayette,	NN	O
Colo.)	,	O
can	,	O
be	,	O
used	)	O
to	MD	O
predict	VB	O
siRNA	VBN	O
sequences	TO	O
for	VB	O
any	JJ	O
nucleic	NNS	O
acid	IN	O
sequence,	DT	O
and	JJ	O
is	NN	O
available	,	O
on	CC	O
the	VBZ	O
World	JJ	O
Wide	IN	O
Web	DT	O
at	NNP	O
dharmacon.com.	NNP	O
A	NNP	O
number	IN	O
of	.	O
other	DT	O
programs	NN	O
for	IN	O
designing	JJ	O
siRNAs	NNS	O
are	IN	O
available	VBG	O
from	NN	O
others,	VBP	O
including	JJ	O
Genscript	IN	O
(available	,	O
on	VBG	O
the	NNP	O
Web	JJ	O
at	IN	O
genscript.com/ss1-bin/app/rnai)	DT	O
and	NNP	O
from	IN	O
the	)	O
Whitehead	CC	O
Institute	IN	O
for	DT	O
Biomedical	NNP	O
Research	NNP	O
jura.wi.mit.edu/pubint/http://iona.wi.mit.edu/siRNAext/.	IN	O
Guidelines	NNP	O
for	NNP	O
designing	.	O
siRNA	NNS	O
are	IN	O
available	VBG	O
in	NN	O
the	VBP	O
scientific	JJ	O
literature	IN	O
(see,	DT	O
e.g.,	JJ	O
Elbashir	NN	O
et	,	O
al.,	,	O
2001,	NNP	O
“Duplexes	FW	O
of	,	O
21-nucleotide	,	O
RNAs	NNS	O
mediate	IN	O
RNA	JJ	O
interference	NNP	O
in	NN	O
cultured	NNP	O
mammalian	NN	O
cells”	IN	O
Nature.	JJ	O
411:494-8.;	JJ	O
and	NN	O
Elbashir	.	O
et	:	O
al.,	CC	O
2001,	NNP	O
“RNA	VBP	O
interference	,	O
is	,	O
mediated	FW	O
by	NN	O
21-	VBZ	O
and	VBN	O
22-nucleotide	IN	O
RNAs”	JJ	O
Genes	CC	O
Dev.	JJ	O
15:188-200)	NNP	O
and	NNP	O
published	.	O
on	)	O
the	CC	O
Web	VBN	O
(see,	IN	O
e.g.,	DT	O
“rnaiweb.com/RNAi/siRNA_Design/”	NNP	O
and	,	O
“protocol-online.org/prot/Protocols/Rules-of-siRNA-design-for-RNA-interference—RNAi—3210.html”).	,	O
There	FW	O
are	CC	O
a	.	O
variety	EX	O
of	VBP	O
ways	DT	O
to	NN	O
produce	IN	O
siRNAs.	NNS	O
siRNAs	TO	O
can	VB	O
be	.	O
generated	NN	O
using	MD	O
kits	VB	O
which	VBN	O
generate	VBG	O
siRNA	NNS	O
from	WDT	O
the	VBP	O
kinase	NN	O
(e.g.,	IN	O
PLK2)	DT	O
gene.	NN	O
For	,	O
example,	)	O
the	.	O
“Dicer	IN	O
siRNA	,	O
Generation”	DT	O
kit	NNP	O
(catalog	NN	O
number	NNP	O
T510001,	NN	O
Gene	JJ	O
Therapy	NN	O
Systems,	,	O
Inc.,	NNP	O
San	NNP	O
Diego,	,	O
Calif.)	,	O
uses	NNP	O
the	,	O
recombinant	)	O
human	VBZ	O
enzyme	DT	O
“dicer”	JJ	O
in	JJ	O
vitro	NN	O
to	NN	O
cleave	IN	O
long	NN	O
double	TO	O
stranded	VB	O
RNA	RB	O
into	RB	O
22	VBN	O
bp	NNP	O
siRNAs.	IN	O
By	CD	O
producing	NN	O
a	.	O
mixture	IN	O
of	VBG	O
siRNAs,	DT	O
the	NN	O
kit	IN	O
permits	,	O
a	DT	O
high	NN	O
degree	VBZ	O
of	DT	O
success	JJ	O
in	NN	O
generating	IN	O
siRNAs	NN	O
that	IN	O
will	VBG	O
reduce	NN	O
expression	WDT	O
of	MD	O
the	VB	O
target	NN	O
gene.	IN	O
Similarly,	DT	O
the	NN	O
Silencer™	.	O
siRNA	,	O
Cocktail	DT	O
Kit	NNP	O
(RNase	NN	O
III)	NNP	O
(catalog	NNP	O
no.	NNP	O
1625,	)	O
Ambion,	NN	O
Inc.,	.	O
Austin,	,	O
Tex.)	,	O
generates	,	O
a	,	O
mixture	)	O
of	VBZ	O
siRNAs	DT	O
from	NN	O
dsRNA	IN	O
using	NN	O
RNase	IN	O
III	NN	O
instead	VBG	O
of	NNP	O
dicer.	NNP	O
Like	RB	O
dicer,	IN	O
RNase	.	O
III	IN	O
cleaves	,	O
dsRNA	NNP	O
into	NNP	O
12-30	VBZ	O
bp	VB	O
dsRNA	IN	O
fragments	JJ	O
with	NN	O
2	NN	O
to	NNS	O
3	IN	O
nucleotide	CD	O
3′	TO	O
overhangs,	CD	O
and	RB	O
5′-phosphate	CD	O
and	,	O
3′-hydroxyl	CC	O
termini.	JJ	O
According	CC	O
to	JJ	O
the	.	O
manufacturer,	VBG	O
dsRNA	TO	O
is	DT	O
produced	,	O
using	NN	O
T7	VBZ	O
RNA	VBN	O
polymerase,	VBG	O
and	NNP	O
reaction	NNP	O
and	,	O
purification	CC	O
components	NN	O
included	CC	O
in	NN	O
the	NNS	O
kit.	VBD	O
The	IN	O
dsRNA	DT	O
is	.	O
then	DT	O
digested	NN	O
by	VBZ	O
RNase	RB	O
III	VBN	O
to	IN	O
create	NNP	O
a	NNP	O
population	TO	O
of	VB	O
siRNAs.	DT	O
The	NN	O
kit	IN	O
includes	.	O
reagents	DT	O
to	NN	O
synthesize	VBZ	O
long	NNS	O
dsRNAs	TO	O
by	VB	O
in	JJ	O
vitro	NN	O
transcription	IN	O
and	IN	O
to	JJ	O
digest	NN	O
those	CC	O
dsRNAs	TO	O
into	VB	O
siRNA-like	DT	O
molecules	NNS	O
using	IN	O
RNase	JJ	O
III.	NNS	O
The	VBG	O
manufacturer	NNP	O
indicates	.	O
that	DT	O
the	NN	O
user	VBZ	O
need	IN	O
only	DT	O
supply	NN	O
a	MD	O
DNA	RB	O
template	VB	O
with	DT	O
opposing	NN	O
T7	NN	O
phage	IN	O
polymerase	VBG	O
promoters	NNP	O
or	NN	O
two	NN	O
separate	NNS	O
templates	CC	O
with	CD	O
promoters	JJ	O
on	NNS	O
opposite	IN	O
ends	NNS	O
of	IN	O
the	JJ	O
region	NNS	O
to	IN	O
be	DT	O
transcribed.	NN	O
The	TO	O
siRNAs	VB	O
of	.	O
the	DT	O
invention	NN	O
can	IN	O
also	DT	O
be	NN	O
expressed	MD	O
from	RB	O
vectors.	VB	O
Typically,	VBN	O
such	IN	O
vectors	.	O
are	,	O
administered	JJ	O
in	NNS	O
conjunction	VBP	O
with	VBN	O
a	IN	O
second	NN	O
vector	IN	O
encoding	DT	O
the	JJ	O
corresponding	NN	O
complementary	VBG	O
strand.	DT	O
Once	JJ	O
expressed,	JJ	O
the	.	O
two	RB	O
strands	,	O
anneal	DT	O
to	CD	O
each	NNS	O
other	VBP	O
and	TO	O
form	DT	O
the	JJ	O
functional	CC	O
double	VB	O
stranded	DT	O
siRNA.	JJ	O
One	NN	O
exemplar	VBD	O
vector	.	O
suitable	CD	O
for	JJ	O
use	NN	O
in	NN	O
the	IN	O
invention	NN	O
is	IN	O
pSuper,	DT	O
available	NN	O
from	VBZ	O
OligoEngine,	,	O
Inc.	JJ	O
(Seattle,	IN	O
Wash.).	,	O
In	NNP	O
some	,	O
embodiments,	.	O
the	IN	O
vector	DT	O
contains	,	O
two	DT	O
promoters,	NN	O
one	VBZ	O
positioned	CD	O
downstream	,	O
of	CD	O
the	VBD	O
first	NN	O
and	IN	O
in	DT	O
antiparallel	JJ	O
orientation.	CC	O
The	IN	O
first	JJ	O
promoter	.	O
is	DT	O
transcribed	JJ	O
in	NN	O
one	VBZ	O
direction,	VBN	O
and	IN	O
the	CD	O
second	,	O
in	CC	O
the	DT	O
direction	JJ	O
antiparallel	IN	O
to	DT	O
the	NN	O
first,	NN	O
resulting	TO	O
in	DT	O
expression	,	O
of	VBG	O
the	IN	O
complementary	NN	O
strands.	IN	O
In	DT	O
yet	JJ	O
another	.	O
set	IN	O
of	RB	O
embodiments,	DT	O
the	NN	O
promoter	IN	O
is	,	O
followed	DT	O
by	NN	O
a	VBZ	O
first	VBN	O
segment	IN	O
encoding	DT	O
the	JJ	O
first	NN	O
strand,	VBG	O
and	DT	O
a	JJ	O
second	,	O
segment	CC	O
encoding	DT	O
the	JJ	O
second	NN	O
strand.	VBG	O
The	DT	O
second	JJ	O
strand	.	O
is	DT	O
complementary	JJ	O
to	NN	O
the	VBZ	O
palindrome	JJ	O
of	TO	O
the	DT	O
first	NN	O
strand.	IN	O
Between	DT	O
the	JJ	O
first	.	O
and	IN	O
the	DT	O
second	JJ	O
strands	CC	O
is	DT	O
a	JJ	O
section	NNS	O
of	VBZ	O
RNA	DT	O
serving	NN	O
as	IN	O
a	NNP	O
linker	VBG	O
(sometimes	IN	O
called	DT	O
a	NN	O
“spacer”)	RB	O
to	VBD	O
permit	DT	O
the	)	O
second	TO	O
strand	VB	O
to	DT	O
bend	JJ	O
around	NN	O
and	TO	O
anneal	VB	O
to	RB	O
the	CC	O
first	VB	O
strand,	TO	O
in	DT	O
a	JJ	O
configuration	,	O
known	IN	O
as	DT	O
a	NN	O
“hairpin.”	VBN	O
The	IN	O
formation	DT	O
of	NN	O
hairpin	DT	O
RNAs,	NN	O
including	IN	O
use	NN	O
of	,	O
linker	VBG	O
sections,	NN	O
is	IN	O
well	NN	O
known	,	O
in	VBZ	O
the	RB	O
art.	VBN	O
Typically,	IN	O
an	DT	O
siRNA	.	O
expression	,	O
cassette	DT	O
is	JJ	O
employed,	NN	O
using	NN	O
a	VBZ	O
Polymerase	,	O
III	VBG	O
promoter	DT	O
such	NNP	O
as	NNP	O
human	NN	O
U6,	JJ	O
mouse	IN	O
U6,	JJ	O
or	,	O
human	NN	O
H1.	,	O
The	CC	O
coding	JJ	O
sequence	.	O
is	DT	O
typically	NN	O
a	NN	O
19-nucleotide	VBZ	O
sense	RB	O
siRNA	DT	O
sequence	JJ	O
linked	NN	O
to	NN	O
its	NN	O
reverse	VBD	O
complementary	TO	O
antisense	PRP$	O
siRNA	NN	O
sequence	JJ	O
by	NN	O
a	NN	O
short	NN	O
spacer.	IN	O
Nine-nucleotide	DT	O
spacers	JJ	O
are	.	O
typical,	JJ	O
although	NNS	O
other	VBP	O
spacers	,	O
can	IN	O
be	JJ	O
designed.	NNS	O
Further,	MD	O
5-6	VB	O
T's	.	O
are	,	O
often	JJ	O
added	POS	O
to	VBP	O
the	RB	O
3′	VBN	O
end	TO	O
of	DT	O
the	CD	O
oligonucleotide	NN	O
to	IN	O
serve	DT	O
as	NN	O
a	TO	O
termination	VB	O
site	IN	O
for	DT	O
Polymerase	NN	O
III.	NN	O
See	IN	O
also,	NNP	O
Yu	.	B
et	NNP	I
al.,	,	I
Mol	NNP	I
Ther	FW	I
7(2):228-36	,	I
(2003);	NNP	I
Matsukura	NNP	B
et	NN	I
al.,	:	I
Nucleic	NNP	I
Acids	FW	I
Res	,	I
31(15):e77	NNP	I
(2003).
The	NNP	O
siRNA	NNP	O
targets	NN	O
can	.	O
be	DT	O
targeted	JJ	O
by	NNS	O
hairpin	MD	O
siRNA	VB	O
as	VBN	O
follows.	IN	O
To	NN	O
attack	NN	O
the	IN	O
same	.	O
targets	TO	O
by	VB	O
short	DT	O
hairpin	JJ	O
RNAs,	NNS	O
produced	IN	O
by	JJ	O
a	NN	O
vector	,	O
(permanent	VBN	O
RNAi	IN	O
effect),	DT	O
sense	NN	O
and	JJ	O
antisense	NNP	O
strand	,	O
can	NN	O
be	CC	O
put	NN	O
in	NN	O
a	MD	O
row	VB	O
with	VBN	O
a	IN	O
loop	DT	O
forming	NN	O
sequence	IN	O
in	DT	O
between	NN	O
and	VBG	O
suitable	NN	O
sequences	IN	O
for	IN	O
an	CC	O
adequate	JJ	O
expression	NNS	O
vector	IN	O
to	DT	O
both	JJ	O
ends	NN	O
of	NN	O
the	TO	O
sequence.	DT	O
The	NNS	O
siRNA	IN	O
of	DT	O
the	.	O
invention	DT	O
can	NN	O
be	IN	O
made	DT	O
using	NN	O
any	MD	O
suitable	VB	O
method	VBN	O
for	VBG	O
producing	DT	O
a	JJ	O
nucleic	NN	O
acid,	IN	O
such	VBG	O
as	DT	O
the	JJ	O
chemical	,	O
synthesis	JJ	O
and	IN	O
recombinant	DT	O
methods	NN	O
disclosed	NN	O
herein	CC	O
and	NN	O
known	NNS	O
to	VBD	O
one	NN	O
of	CC	O
skill	VBN	O
in	TO	O
the	CD	O
art.	IN	O
It	NN	O
will	IN	O
be	DT	O
appreciated	.	O
that	PRP	O
the	MD	O
oligonucleotides	VB	O
can	VBN	O
be	IN	O
made	DT	O
using	NNS	O
nonstandard	MD	O
bases	VB	O
(e.g.,	VBN	O
other	VBG	O
than	JJ	O
adenine,	NNS	O
cytidine,	,	O
guanine,	JJ	O
and	IN	O
uridine)	,	O
or	,	O
nonstandard	,	O
backbone	CC	O
structures	)	O
to	CC	O
provide	JJ	O
desirable	NN	O
properties	NNS	O
(e.g.,	TO	O
increased	VB	O
nuclease-resistance,	JJ	O
tighter-binding,	NNS	O
stability	,	O
or	JJ	O
a	,	O
desired	,	O
Tm).	NN	O
Techniques	CC	O
for	DT	O
rendering	JJ	O
oligonucleotides	.	O
nuclease-resistant	NNS	O
include	IN	O
those	VBG	O
described	JJ	O
in	JJ	O
PCT	VBP	O
Publication	DT	O
WO	VBN	O
94/12633.	IN	O
A	NNP	O
wide	NNP	O
variety	NNP	O
of	.	O
useful	DT	O
modified	JJ	O
oligonucleotides	NN	O
may	IN	O
be	JJ	O
produced,	VBN	O
including	NNS	O
oligonucleotides	MD	O
having	VB	O
a	,	O
peptide-nucleic	VBG	O
acid	NNS	O
(PNA)	VBG	O
backbone	DT	O
Nielsen	JJ	B
et	NN	I
al.,	)	I
1991,	NN	I
Science	NNP	I
254:1497)	RB	I
(or	,	O
incorporating	,	O
2′-O-methyl	NNP	O
ribonucleotides,	)	O
phosphorothioate	CC	O
nucleotides,	VBG	O
methyl	JJ	O
phosphonate	,	O
nucleotides,	NN	O
phosphotriester	,	O
nucleotides,	NN	O
phosphorothioate	NN	O
nucleotides,	,	O
phosphoramidates.	NN	O
For	,	O
example	NN	O
and	,	O
not	.	O
limitation,	IN	O
the	NN	O
following	CC	O
are	RB	O
examples	,	O
of	DT	O
siRNA	VBG	O
sequences	VBP	O
that	NNS	O
can	IN	O
be	NN	O
used	NNS	O
to	WDT	O
inhibit	MD	O
PLK2.	VB	O
“Start	VBN	O
position”	TO	O
refers	VB	O
to	.	O
the	RB	O
sequence	NN	O
at	NNS	O
accession	TO	O
number	DT	O
NM—006622.	NN	O
The	IN	O
siRNAs	NN	O
above	NN	O
were	.	O
designed	DT	O
using	NN	O
the	IN	O
siDESIGN®	VBD	O
center	VBN	O
at	VBG	O
www	DT	O
followed	NN	O
by	NN	O
dharmacon.com/DesignCenter/DesignCenterPage.aspx.	IN	O
Each	NN	O
will	VBN	O
be	IN	O
double	.	O
stranded	DT	O
and	MD	O
have	VB	O
a	JJ	O
“TT”	VBN	O
overhang.	CC	O
As	VBP	O
additional	DT	O
examples,	NN	O
siRNAs	.	O
from	IN	O
the	JJ	O
Ambion	,	O
Kinase	NN	O
siRNA	IN	O
Library	DT	O
(Ambion,	NNP	O
Austin,	NNP	O
Tex.)	VBD	O
can	NNP	O
be	,	O
used	,	O
to	)	O
inhibit	MD	O
PLK2.	VB	O
Exemplary	VBN	O
sequences	TO	O
are	VB	O
provided	.	O
below.	JJ	O
Each	NNS	O
siRNA	VBP	O
is	VBN	O
double-stranded	.	O
with	DT	O
the	NN	O
final	VBZ	O
TT's	JJ	O
(present	IN	O
on	DT	O
both	JJ	O
strands)	POS	O
as	JJ	O
overhangs:	IN	O
iii)	DT	O
Antisense	)	O
Polynucleotides	IN	O
Antisense	:	O
polynucleotides	)	O
can	NNP	O
cause	NNP	O
suppression	NNP	O
by	NNS	O
binding	MD	O
to,	VB	O
and	NN	O
interfering	IN	O
with	VBG	O
the	,	O
translation	CC	O
of	VBG	O
sense	IN	O
mRNA,	DT	O
interfering	NN	O
with	IN	O
transcription,	NN	O
interfering	,	O
with	VBG	O
processing	IN	O
or	,	O
localization	VBG	O
of	IN	O
RNA	NN	O
precursors,	CC	O
repressing	NN	O
transcription	IN	O
of	NNP	O
mRNA	,	O
or	VBG	O
acting	NN	O
through	IN	O
some	NN	O
other	CC	O
mechanism	VBG	O
(see,	IN	O
e.g.,	DT	O
Sallenger	JJ	B
et	NN	I
al.	,	I
Nature	,	I
418,	NNP	I
252	CC	I
(2002).	.	I
The	NN	O
particular	,	O
mechanism	CD	O
by	.	O
which	DT	O
the	JJ	O
antisense	NN	O
molecule	IN	O
reduces	WDT	O
expression	DT	O
is	NN	O
not	NN	O
critical.	NNS	O
Typically	NN	O
antisense	VBZ	O
polynucleotides	RB	O
comprise	.	O
a	RB	O
single-stranded	JJ	O
antisense	NNS	O
sequence	VBP	O
of	DT	O
at	JJ	O
least	NN	O
7	NN	O
to	IN	O
10	IN	O
to	JJS	O
typically	CD	O
20	TO	O
or	CD	O
more	TO	O
nucleotides	RB	O
that	CD	O
specifically	CC	O
hybridize	JJR	O
to	NNS	O
a	IN	O
sequence	RB	O
from	VB	O
mRNA	TO	O
of	DT	O
a	NN	O
kinase	IN	O
gene	NN	O
of	IN	O
the	DT	O
invention.	JJ	O
Some	NN	O
antisense	IN	O
polynucleotides	DT	O
are	.	O
from	DT	O
about	NN	O
10	NNS	O
to	VBP	O
about	IN	O
50	IN	O
nucleotides	CD	O
in	TO	O
length	IN	O
or	CD	O
from	NNS	O
about	IN	O
14	NN	O
to	CC	O
about	IN	O
35	RB	O
nucleotides	CD	O
in	TO	O
length.	IN	O
Some	CD	O
antisense	NNS	O
polynucleotides	IN	O
are	.	O
polynucleotides	DT	O
of	NN	O
less	NNS	O
than	VBP	O
about	NNS	O
100	IN	O
nucleotides	JJR	O
or	IN	O
less	RB	O
than	CD	O
about	NNS	O
200	CC	O
nucleotides.	JJR	O
In	IN	O
general,	RB	O
the	CD	O
antisense	.	O
polynucleotide	IN	O
should	,	O
be	DT	O
long	JJ	O
enough	NN	O
to	MD	O
form	VB	O
a	RB	O
stable	RB	O
duplex	TO	O
but	VB	O
short	DT	O
enough,	JJ	O
depending	NN	O
on	CC	O
the	JJ	O
mode	,	O
of	VBG	O
delivery,	IN	O
to	DT	O
administer	NN	O
in	IN	O
vivo,	,	O
if	TO	O
desired.	VB	O
The	IN	O
minimum	,	O
length	IN	O
of	.	O
a	DT	O
polynucleotide	JJ	O
required	NN	O
for	IN	O
specific	DT	O
hybridization	NN	O
to	VBN	O
a	IN	O
target	JJ	O
sequence	NN	O
depends	TO	O
on	DT	O
several	NN	O
factors,	NN	O
such	VBZ	O
as	IN	O
G/C	JJ	O
content,	,	O
positioning	JJ	O
of	IN	O
mismatched	NNP	O
bases	,	O
(if	NN	O
any),	IN	O
degree	VBN	O
of	NNS	O
uniqueness	IN	O
of	,	O
the	NN	O
sequence	IN	O
as	NN	O
compared	IN	O
to	DT	O
the	NN	O
population	IN	O
of	VBN	O
target	TO	O
polynucleotides,	DT	O
and	NN	O
chemical	IN	O
nature	NN	O
of	,	O
the	CC	O
polynucleotide	JJ	O
(e.g.,	NN	O
methylphosphonate	IN	O
backbone,	DT	O
peptide	NN	O
nucleic	,	O
acid,	VB	O
phosphorothioate),	,	O
among	JJ	O
other	JJ	O
factors.	,	O
iv)	,	O
Ribozymes	IN	O
Ribozymes	JJ	O
are	.	O
RNA	)	O
molecules	NNPS	O
that	NNPS	O
act	VBP	O
as	NNP	O
enzymes	NNS	O
and	WDT	O
can	VBP	O
be	IN	O
engineered	NNS	O
to	CC	O
cleave	MD	O
other	VB	O
RNA	VBN	O
molecules	TO	O
at	VB	O
specific	JJ	O
sites.	NNP	O
The	NNS	O
ribozyme	IN	O
itself	JJ	O
is	.	O
not	DT	O
consumed	NN	O
in	PRP	O
this	VBZ	O
process,	RB	O
and	VBN	O
can	IN	O
act	DT	O
catalytically	,	O
to	CC	O
cleave	MD	O
multiple	VB	O
copies	RB	O
of	TO	O
mRNA	VB	O
target	JJ	O
molecules.	NNS	O
General	IN	O
rules	NN	O
for	NN	O
the	.	O
design	NNP	O
of	NNS	O
ribozymes	IN	O
that	DT	O
cleave	NN	O
target	IN	O
RNA	NNS	O
in	WDT	O
trans	VBP	O
are	NN	O
described	NNP	O
in	IN	O
Haseloff	NNS	B
&	VBP	I
Gerlach,	VBN	I
(1988)	IN	I
Nature	NNP	I
334:585-591	CC	I
and	,	O
Hollenbeck,	)	B
(1987)	NN	I
Nature	JJ	I
328:596-603	CC	I
and	,	O
U.S.	)	O
Pat.	NN	O
No.	JJ	O
5,496,698.	CC	O
Ribozymes	NNP	O
typically	.	O
include	.	O
two	.	O
flanking	NNP	O
segments	RB	O
that	VBP	O
show	CD	O
complementarity	JJ	O
to	NNS	O
and	WDT	O
bind	VBP	O
to	NN	O
two	TO	O
sites	CC	O
on	VB	O
a	TO	O
transcript	CD	O
(target	NNS	O
subsites)	IN	O
of	DT	O
a	NN	O
gene	VB	O
encoding	)	O
a	IN	O
kinase	DT	O
of	NN	O
the	VBG	O
invention	DT	O
and	NN	O
a	IN	O
catalytic	DT	O
region	NN	O
between	CC	O
the	DT	O
flanking	JJ	O
segments.	NN	O
The	IN	O
flanking	DT	O
segments	NN	O
are	.	O
typically	DT	O
5-9	NN	O
nucleotides	NNS	O
long	VBP	O
and	RB	O
optimally	JJ	O
6	NNS	O
to	JJ	O
8	CC	O
nucleotides	RB	O
long.	CD	O
The	TO	O
catalytic	CD	O
region	NNS	O
of	.	O
the	DT	O
ribozyme	JJ	O
is	NN	O
generally	IN	O
about	DT	O
22	NN	O
nucleotides	VBZ	O
in	RB	O
length.	RB	O
The	CD	O
mRNA	NNS	O
target	IN	O
contains	.	O
a	DT	O
consensus	NN	O
cleavage	NN	O
site	VBZ	O
between	DT	O
the	NN	O
target	NN	O
subsites	NN	O
having	IN	O
the	DT	O
general	NN	O
formula	VBZ	O
NUN,	VBG	O
and	DT	O
preferably	JJ	O
GUC.	NN	O
Kashani-Sabet	,	B
and	CC	I
Scanlon,	RB	I
(1995)	.	I
Cancer	NNP	I
Gene	CC	I
Therapy	,	I
2:213-223;	)	I
Perriman,	NNP	B
et	NNP	I
al.,	NNP	I
(1992)	:	I
Gene	,	I
(Amst.)	FW	I
113:157-163;	,	I
Ruffner,	)	B
et	NNP	I
al.,	)	I
(1990)	:	I
Biochemistry	,	I
29:	FW	I
10695-10702);(	,	O
Birikh,	)	B
et	FW	I
al.,	:	I
(1997)	:	I
Eur.	,	I
J.	FW	I
Biochem.	,	I
245:1-16;	)	I
Perrealt,	.	B
et	NNP	I
al.,	.	I
(1991)	:	I
Biochemistry	,	I
30:4020-4025).The	FW	O
specificity	,	O
of	)	O
a	NNP	O
ribozyme	.	O
can	DT	O
be	NN	O
controlled	IN	O
by	DT	O
selection	NN	O
of	MD	O
the	VB	O
target	VBN	O
subsites	IN	O
and	NN	O
thus	IN	O
the	DT	O
flanking	NN	O
segments	NNS	O
of	CC	O
the	RB	O
ribozyme	DT	O
that	JJ	O
are	NNS	O
complementary	IN	O
to	DT	O
such	NN	O
subsites.	WDT	O
Ribozymes	VBP	O
can	JJ	O
be	TO	O
delivered	JJ	O
either	.	O
as	NNS	O
RNA	MD	O
molecules	VB	O
or	VBN	O
in	CC	O
the	IN	O
form	NNP	O
of	NNS	O
DNA	CC	O
encoding	IN	O
the	DT	O
ribozyme	NN	O
as	IN	O
a	NNP	O
component	VBG	O
of	DT	O
a	NN	O
replicable	IN	O
vector	DT	O
or	NN	O
in	IN	O
nonreplicable	DT	O
form	JJ	O
as	NN	O
described	CC	O
below.	IN	O
Expression	JJ	O
of	NN	O
a	IN	O
target	VBN	O
kinase	.	O
gene	NN	O
can	IN	O
also	DT	O
be	NN	O
reduced	NN	O
by	NN	O
delivering	MD	O
nucleic	RB	O
acids	VB	O
having	VBN	O
sequences	IN	O
complementary	VBG	O
to	JJ	O
the	NNS	O
regulatory	VBG	O
region	NNS	O
of	JJ	O
the	TO	O
target	DT	O
gene	JJ	O
(i.e.,	NN	O
the	IN	O
target	DT	O
gene	NN	O
promoter	NN	O
and/or	,	O
enhancers)	DT	O
to	NN	O
form	NN	O
triple	NN	O
helical	IN	O
structures	)	O
which	TO	O
prevent	VB	O
transcription	JJ	O
of	JJ	O
the	NNS	O
target	WDT	O
gene	VBP	O
in	NN	O
target	IN	O
cells	DT	O
in	NN	O
the	NN	O
body.	IN	O
See	NN	O
generally,	NNS	O
Helene,	IN	B
(1991),	DT	I
Anticancer	.	I
Drug	NNP	I
Des.,	,	I
6(6):569-584;	,	I
Helene,	,	B
et	NNP	I
al.,	NNP	I
(1992),	,	I
Ann.	:	I
N.Y.	,	I
Acad.	FW	I
Sci.,	,	I
60:27-36;	,	I
and	.	O
Maher,	NNP	B
(1992),	.	I
Bioassays	,	I
14(12):807-815.
v)	:	O
Administration	CC	O
of	,	O
siRNA	,	O
and	VBZ	O
Other	JJ	O
Inhibitory	)	O
Nucleic	NN	O
Acids	IN	O
The	NN	O
brain	CC	O
is	JJ	O
the	NNP	O
therapeutic	NNP	O
target	NNP	O
of	DT	O
kinase	NN	O
inhibitors	VBZ	O
of	DT	O
the	JJ	O
invention.	NN	O
Therapeutic	IN	O
polynucleotides	JJ	O
such	NNS	O
as	IN	O
siRNAs,	DT	O
ribozymes	.	O
and	JJ	O
antisense	NNS	O
polynucleotides	JJ	O
can	IN	O
be	,	O
administered	NNS	O
in	CC	O
a	JJ	O
number	NNS	O
of	MD	O
ways.	VB	O
Methods	VBN	O
of	IN	O
introduction	DT	O
include	NN	O
but	IN	O
are	.	O
not	NNS	O
limited	IN	O
to	NN	O
intradermal,	VBP	O
intramuscular,	CC	O
intraperitoneal,	VBP	O
intravenous,	RB	O
subcutaneous,	VBN	O
intranasal,	TO	O
epidural,	,	O
and	,	O
oral	,	O
routes.	,	O
The	,	O
compounds	,	O
may	,	O
be	CC	O
administered	JJ	O
by	.	O
any	DT	O
convenient	NNS	O
route,	MD	O
for	VB	O
example	VBN	O
by	IN	O
infusion,	DT	O
by	JJ	O
bolus	,	O
injection,	IN	O
by	NN	O
absorption	IN	O
through	,	O
epithelial	IN	O
or	JJ	O
mucocutaneous	,	O
linings	IN	O
(e.g.,	NN	O
oral,	IN	O
rectal	JJ	O
and	CC	O
intestinal	JJ	O
mucosa,	NNS	O
etc.),	,	O
and	,	O
may	JJ	O
be	CC	O
administered	JJ	O
together	,	O
with	,	O
other	CC	O
biologically	MD	O
active	VB	O
agents.	VBN	O
In	RB	O
general,	IN	O
therapeutic	JJ	O
polynucleotides	RB	O
can	JJ	O
be	.	O
administered	IN	O
remotely	,	O
(e.g.,	JJ	O
by	NNS	O
i.v.	MD	O
injection)	VB	O
with	VBN	O
a	RB	O
carrier	,	O
that	IN	O
facilitates	.	O
transfer	)	O
to	IN	O
the	DT	O
brain	NN	O
or	WDT	O
they	VBZ	O
can	NN	O
be	TO	O
delivered	DT	O
directly	NN	O
to	CC	O
the	PRP	O
brain.	MD	O
For	VB	O
direct	VBN	O
administration	RB	O
to	TO	O
the	DT	O
brain,	.	O
siRNAs	IN	O
(i.e.,	JJ	O
pharmaceutical	NN	O
compositions	TO	O
containing	DT	O
siRNAs)	,	O
can	NN	O
be	,	O
administered	JJ	O
by	NNS	O
any	VBG	O
suitable	)	O
route,	MD	O
including	VB	O
intraventricular	VBN	O
and	IN	O
intrathecal	DT	O
injection;	JJ	O
intraventricular	,	O
injection	VBG	O
may	JJ	O
be	CC	O
facilitated	JJ	O
by	:	O
an	JJ	O
intraventricular	NN	O
catheter,	MD	O
for	VB	O
example,	VBN	O
attached	IN	O
to	DT	O
a	JJ	O
reservoir,	,	O
such	IN	O
as	,	O
an	VBN	O
Ommaya	TO	O
reservoir,	DT	O
direct	,	O
injection	JJ	O
or	IN	O
perfusion	DT	O
at	NNP	O
the	,	O
lesion	JJ	O
site,	NN	O
injection	CC	O
into	NN	O
the	IN	O
brain	DT	O
arterial	NN	O
system,	,	O
or	NN	O
by	IN	O
chemical	DT	O
or	NN	O
osmotic	JJ	O
opening	,	O
of	CC	O
the	IN	O
blood-brain	NN	O
barrier.	CC	O
In	JJ	O
one	NN	O
approach	IN	O
the	DT	O
therapeutic	JJ	O
polynucleotide	.	O
(e.g.,	IN	O
siRNA)	CD	O
is	NN	O
delivered	DT	O
as	JJ	O
a	NN	O
peptide	,	O
conjugate.	)	O
Kumar	VBZ	O
et	VBN	O
al.	IN	O
exploited	DT	O
the	NN	O
fact	.	O
that	NNP	O
neurotropic	CC	O
viruses,	.	O
such	VBN	O
as	DT	O
rabies	NN	O
viruses,	IN	O
that	NN	O
preferentially	,	O
infect	JJ	O
the	IN	O
nervous	NNS	O
system	,	O
can	IN	O
penetrate	RB	O
the	VBP	O
brain.	DT	O
The	JJ	O
rabies	NN	O
virus	MD	O
achieves	VB	O
this	DT	O
through	.	O
glycoprotein	DT	O
on	NNS	O
its	VBP	O
lipid	VBZ	O
envelope.	DT	O
To	IN	O
transfer	NN	O
siRNA	IN	O
to	PRP$	O
the	JJ	O
neural	.	O
cells	TO	O
in	VB	O
the	NN	O
brain,	TO	O
Kumar	DT	O
et	JJ	O
al.	NNS	O
identified	IN	O
a	DT	O
29-residue	,	O
peptide	NNP	O
from	CC	O
the	.	O
rabies	VBN	O
virus	DT	O
glycoprotein	JJ	O
(RVG)	NN	O
envelope	IN	O
that	DT	O
selectively	NNS	O
binds	VBP	O
to	NN	O
the	)	O
acetylcholine	VBP	O
receptor	IN	O
expressed	RB	O
by	VBZ	O
neurons.	TO	O
They	DT	O
fused	NN	O
this	NN	O
peptide	VBN	O
with	IN	O
a	.	O
sequence	PRP	O
of	VBD	O
9	DT	O
arginine	NN	O
residues	IN	O
that	DT	O
binds	NN	O
to	IN	O
siRNAs.	CD	O
After	NN	O
intravenous	NNS	O
injection	WDT	O
into	VBZ	O
mice	TO	O
with	.	O
this	IN	O
peptide-conjugated	JJ	O
siRNA,	NN	O
they	IN	O
found	NN	O
that	IN	O
the	DT	O
peptide	JJ	O
not	,	O
only	PRP	O
enabled	VBD	O
the	IN	O
transvascular	DT	O
delivery	NN	O
of	RB	O
siRNA	RB	O
to	VBD	O
the	DT	O
brain	JJ	O
but	NN	O
also	IN	O
resulted	NN	O
in	TO	O
efficient	DT	O
gene	NN	O
silencing	CC	O
Kumar	RB	B
et	VBD	I
al.,	IN	I
(2007)	JJ	I
Nature	NN	I
448:39-43).(	NN	O
The	NNP	O
therapeutic	RB	O
polynucleotide	,	O
(e.g.,	)	O
siRNA)	NNP	O
can	.	O
be	DT	O
delivered	JJ	O
using	NN	O
a	,	O
liposome	)	O
and	MD	O
targeted	VB	O
monoclonal	VBN	O
antibody	VBG	O
system.	DT	O
Pardridge	NN	O
reported	CC	O
that	VBD	O
chemically	JJ	O
modified	NN	O
liposomes	.	O
conjugated	NNP	O
to	VBD	O
monoclonal	IN	O
antibodies	RB	O
raised	VBN	O
against	RB	O
epidermal	VBN	O
growth	TO	O
factor	JJ	O
can	NNS	O
penetrate	VBN	O
mouse	IN	O
brain.	JJ	O
Plasmid	NN	O
DNA	NN	O
encoding	MD	O
for	VB	O
short	NN	O
hairpin	.	O
RNA	NNP	O
(shRNA)	NNP	O
was	VBG	O
delivered	IN	O
to	JJ	O
the	NN	O
brain	NNP	O
following	)	O
intravenous	VBD	O
administration	VBN	O
with	TO	O
pegylated	DT	O
immunoliposomes	NN	O
(PILs).	VBG	O
The	JJ	O
plasmid	NN	O
DNA	IN	O
is	JJ	O
encapsulated	NNS	O
in	.	O
liposome,	DT	O
which	NN	O
is	NNP	O
pegylated,	VBZ	O
and	VBN	O
conjugated	IN	O
with	,	O
receptor	WDT	O
specific	VBZ	O
targeting	,	O
monoclonal	CC	O
antibodies.	VBD	O
Intravenous	IN	O
RNAi	NN	O
with	JJ	O
PILs	VBG	O
enables	JJ	O
a	.	O
90%	JJ	O
knockdown	NNP	O
of	IN	O
the	NNP	O
human	VBZ	O
epidermal	DT	O
growth	NN	O
factor	NN	O
receptor,	IN	O
which	DT	O
results	JJ	O
in	JJ	O
a	NN	O
90%	NN	O
increase	,	O
in	WDT	O
survival	NNS	O
time	IN	O
in	DT	O
mice	NN	O
with	NN	O
intra-cranial	IN	O
brain	JJ	O
cancer	NN	O
Pardridge,	IN	B
(2007)	NN	I
Adv.	IN	I
Drug	JJ	I
Deliv.	NN	I
Rev.	NN	I
59:141-152).(	,	O
Similarly,	)	O
Boado	.	O
disclosed	NN	O
the	.	O
use	.	O
of	.	O
the	,	O
“Trojan	NNP	O
Horse	VBD	O
Liposome”	DT	O
(THL)	NN	O
technology	IN	O
as	DT	O
an	NNP	O
effective	NNP	O
delivery	NNP	O
system	)	O
to	NN	O
deliver	IN	O
shRNA	DT	O
to	JJ	O
the	NN	O
brain.	NN	O
The	TO	O
tissue	VB	O
target	NN	O
specificity	TO	O
of	DT	O
THL	.	O
is	DT	O
given	NN	O
by	NN	O
conjugation	NN	O
of	IN	O
approximately	NNP	O
1%	VBZ	O
of	VBN	O
the	IN	O
PEG	NN	O
residues	IN	O
in	RB	O
the	NN	O
liposome	IN	O
to	DT	O
peptidomimetic	NNP	O
monoclonal	NNS	O
antibodies	IN	O
that	DT	O
bind	NN	O
to	TO	O
specific	JJ	O
endogenous	JJ	O
receptors	NNS	O
(i.e.	WDT	O
insulin	VBP	O
and	TO	O
transferrin	JJ	O
receptors)	JJ	O
located	NNS	O
on	.	O
both	NN	O
the	CC	O
BBB	JJ	O
and	)	O
the	VBN	O
brain	IN	O
cellular	DT	O
membranes,	DT	O
respectively.	NNP	O
Boado	CC	B
(2007)	DT	I
Pharm.	NN	I
Res.	JJ	I
24:1772-1787).(	,	O
The	.	O
therapeutic	NNP	O
polynucleotide	)	O
(e.g.,	.	O
siRNA)	.	O
can	.	O
be	DT	O
delivered	JJ	O
by	NN	O
the	,	O
combined	)	O
use	MD	O
of	VB	O
receptor	VBN	O
specific	IN	O
antibody	DT	O
delivery	VBN	O
systems	NN	O
and	IN	O
avidin-biotin	NN	O
technology.	JJ	O
The	NN	O
siRNA	NN	O
was	NNS	O
mono-biotinylated	CC	O
on	JJ	O
either	.	O
terminus	DT	O
of	NN	O
the	VBD	O
sense	VBN	O
strand,	IN	O
in	DT	O
parallel	NN	O
with	IN	O
the	DT	O
production	NN	O
of	,	O
a	IN	O
conjugate	NN	O
of	IN	O
the	DT	O
targeting	NN	O
monoclonal	IN	O
antibody	DT	O
and	NN	O
streptavidin.	IN	O
Rat	DT	O
glial	VBG	O
cells	JJ	O
permanently	NN	O
transfected	CC	O
with	.	O
the	NNP	O
luciferase	JJ	O
gene	NNS	O
were	RB	O
implanted	VBN	O
in	IN	O
the	DT	O
brain	NN	O
of	NN	O
adult	VBD	O
rats.	VBN	O
Following	IN	O
the	DT	O
formation	NN	O
of	IN	O
intra-cranial	NN	O
tumors,	.	O
the	VBG	O
rats	DT	O
were	NN	O
treated	IN	O
with	JJ	O
a	,	O
single	DT	O
intravenous	NNS	O
injection	VBD	O
of	VBN	O
biotinylated	IN	O
siRNA	DT	O
attached	JJ	O
to	JJ	O
a	NN	O
transferrin	IN	O
receptor	VBN	O
antibody	NN	O
via	VBN	O
a	TO	O
biotin-streptavidin	DT	O
linker.	NN	O
The	NN	O
intravenous	NN	O
administration	IN	O
of	DT	O
the	JJ	O
siRNA	.	O
caused	DT	O
a	JJ	O
69-81%	NN	O
decrease	IN	O
in	DT	O
luciferase	NN	O
gene	VBD	O
expression	DT	O
in	NN	O
the	NN	O
intracranial	IN	O
brain	JJ	O
cancer	NN	O
in	NN	O
vivo	IN	O
Xia	DT	B
et	JJ	I
al.,	NN	I
(2007)	NN	I
Pharm.	IN	I
Res.	NN	I
24:2309-2316).(	NNP	O
The	RB	O
therapeutic	,	O
polynucleotide	)	O
(e.g.,	.	O
siRNA)	.	O
can	.	O
be	DT	O
delivered	JJ	O
by	NN	O
stereotactic	,	O
surgery	)	O
or	MD	O
injection.	VB	O
Davidson	VBN	O
and	IN	O
Boudreau	JJ	O
reviewed	NN	O
in	CC	O
their	.	O
article	NNP	O
that	CC	O
siRNA	NNP	O
can	VBD	O
be	IN	O
delivered	PRP$	O
into	NN	O
the	IN	O
brain	NN	O
using	MD	O
neurosurgical	VB	O
method	VBN	O
of	IN	O
stereotaxis	DT	O
and	NN	O
showed	VBG	O
that	JJ	O
a	NN	O
decrease	IN	O
in	NN	O
the	CC	O
transcription	VBD	O
of	IN	O
certain	DT	O
genes	NN	O
alleviated	IN	O
symptoms	DT	O
of	NN	O
neuronal	IN	O
diseases	JJ	O
Davidson	NNS	B
and	VBD	I
Boudreau,	NNS	I
(2007)	IN	I
Neuron	JJ	I
53:781-788).(	NNS	O
Xia	NNP	O
et	CC	O
al.	,	O
reported	)	O
that	NNP	O
upon	.	O
intracerebellar	NN	O
injection,	CC	O
recombinant	.	O
adeno-associated	VBD	O
virus	DT	O
vectors	IN	O
expressing	JJ	O
short	,	O
hairpin	JJ	O
RNAs,	JJ	O
which	NN	O
once	NNS	O
expressed	VBG	O
are	JJ	O
processed	NN	O
into	,	O
siRNAs,	WDT	O
improved	RB	O
motor	VBN	O
coordination,	VBP	O
restored	VBN	O
cerebellar	IN	O
morphology	,	O
and	VBN	O
resolved	NN	O
characteristic	,	O
ataxin-1	VBD	O
inclusions	JJ	O
in	NN	O
Purkinje	CC	O
cells	VBD	O
of	JJ	O
spinocerebellar	JJ	O
ataxia	NNS	O
type	IN	O
1	NNP	O
mice	NNS	O
Xia	IN	B
et	JJ	I
al.,	NN	I
(2004)	NN	I
Nature	CD	I
Med.	NN	I
10:816-820).(	NNP	O
Further,	RB	O
DiFiglia	,	O
et	)	O
al.	NN	O
reported	.	O
injecting	.	O
intrastriatally	,	O
cholesterol-conjugated	NNP	O
siRNA	CC	O
that	.	O
targets	VBN	O
human	VBG	O
huntingtin	RB	O
mRNA.	JJ	O
The	NN	O
authors	WDT	O
found	VBZ	O
that	JJ	O
a	NN	O
single	.	O
administration	DT	O
into	NNS	O
the	VBD	O
adult	IN	O
mouse	DT	O
striatum	JJ	O
of	NN	O
the	IN	O
siRNA	DT	O
effected	NN	O
silencing	NN	O
of	NN	O
the	IN	O
gene,	DT	O
attenuated	NN	O
neuronal	VBD	O
pathology,	NN	O
and	IN	O
delayed	DT	O
the	,	O
abnormal	VBD	O
behavioral	JJ	O
phenotype	,	O
observed	CC	O
in	VBD	O
a	DT	O
rapid-onset,	JJ	O
viral	JJ	O
transgenic	NN	O
mouse	VBN	O
model	IN	O
of	DT	O
Huntington's	,	O
disease	JJ	O
DiFiglia	NN	B
et	NN	I
al.	NN	I
(2007)	IN	I
Proc.	POS	I
Natl.	NN	I
Acad.	NNP	I
Sci.	RB	I
USA	.	I
104:17204-17209).(	)	O
It	.	O
is	.	O
noted	.	O
that	.	O
such	NNP	O
method	.	O
results	PRP	O
only	VBZ	O
in	VBN	O
localized	IN	O
delivery	JJ	O
around	NN	O
the	NNS	O
injection	RB	O
site,	IN	O
with	JJ	O
no	NN	O
widespread	IN	O
effect	DT	O
within	NN	O
the	,	O
brain.	IN	O
Singer	DT	O
et	JJ	O
al.	NN	O
disclosed	IN	O
using	DT	O
modified	.	O
lentiviral	NNP	O
vectors	CC	O
to	.	O
deliver	VBN	O
siRNAs	VBG	O
into	JJ	O
the	JJ	O
brain	NNS	O
cells	TO	O
of	VB	O
the	NN	O
transgenic	IN	O
mice	DT	O
that	NN	O
were	NNS	O
producing	IN	O
vast	DT	O
amounts	JJ	O
of	NN	O
human	WDT	O
beta-amyloid	VBD	O
and	VBG	O
whose	JJ	O
brains	NNS	O
where	IN	O
littered	JJ	O
with	JJ	O
plaques.	CC	O
They	WP$	O
found	NNS	O
that	WRB	O
lentiviral	VBN	O
vector	IN	O
delivery	.	O
of	PRP	O
beta-secretase	VBD	O
siRNA	IN	O
specifically	JJ	O
reduced	NN	O
the	NN	O
cleavage	IN	O
of	NN	O
amyloid	NN	O
precursor	RB	O
protein	VBD	O
and	DT	O
neurodegeneration	NN	O
in	IN	O
vivo	NN	O
and	NN	O
indicated	NN	O
that	CC	O
this	NN	O
approach	IN	O
could	NN	O
have	CC	O
potential	VBD	O
therapeutic	IN	O
value	DT	O
for	NN	O
treatment	MD	O
of	VB	O
Alzheimer	JJ	O
disease	JJ	O
Singer	NN	B
et	IN	I
al.	NN	I
(2005)	IN	I
Nature	NNP	I
Neurosci.	NN	I
8:1343-1349;	NNP	I
(reviewed	VBZ	O
in	.	O
Orlacchio	)	B
et	NN	I
al.	.	I
(2007)	:	I
Mini.	VBN	I
Rev.	IN	I
Med.	NNP	I
Chem.	CC	I
7:1166-1176).Koutsilieri	.	O
et	)	O
al.	.	O
reviewed	.	O
the	.	O
literature	.	O
in	.	O
the	NNP	O
field	CC	O
of	.	O
siRNA,	VBN	O
disclosed	DT	O
different	NN	O
siRNA	IN	O
target	DT	O
strategies	NN	O
aiming	IN	O
for	,	O
an	VBD	O
allele-specific	JJ	O
degradation	JJ	O
of	NN	O
disease-inducing	NNS	O
mRNA	VBG	O
and	IN	O
its	DT	O
application	JJ	O
in	NN	O
animal	IN	O
models	JJ	O
of	NN	O
neurodegenerative	CC	O
diseases,	PRP$	O
including	NN	O
Alzheimer's	IN	O
disease	JJ	O
(AD),	NNS	O
amyotrophic	IN	O
lateral	JJ	O
sclerosis	,	O
(ALS),	VBG	O
Huntington's	POS	O
disease	NN	O
(HD)	,	O
and	JJ	O
spinocerebellar	JJ	O
ataxia	NN	O
(SCA1)	,	O
Koutsilieri	POS	B
et	NN	I
al.	)	I
(2007)	CC	I
J.	JJ	I
Neural	NN	I
Transm	)	I
Suppl.	NNP	I
(72):43-49).(	RB	O
Hassani	.	O
et	)	O
al.	NNP	O
demonstrated	NNP	O
that	NNP	O
cationic	.	O
lipids	.	O
and	NNP	O
polyethylenimine	CC	O
(PEI)	.	O
based	VBN	O
polyplexes	IN	O
provided	JJ	O
efficient	NNS	O
delivery	CC	O
of	NN	O
siRNAs	)	O
into	VBN	O
the	NNS	O
brains	VBD	O
of	JJ	O
new	NN	O
born	IN	O
mice,	NN	O
producing	IN	O
>80%	DT	O
inhibition	NNS	O
of	IN	O
an	JJ	O
exogenous	JJ	O
gene	,	O
with	VBG	O
only	NN	O
picomolar	NN	O
levels	IN	O
of	DT	O
siRNA	JJ	O
Hassani	NN	B
et	IN	I
al.	JJ	I
(2005)	JJ	I
J.	NNS	I
Gene	IN	I
Med.	NN	I
7:198-207).(	NNP	O
Kateb	RB	O
et	.	O
al.	)	O
employed	NNP	O
nanotechnology	NNP	O
as	.	O
a	.	O
method	NNP	O
for	CC	O
delivering	.	O
drugs	JJ	O
to	NN	O
the	IN	O
brain	DT	O
for	NN	O
treatment	IN	O
of	VBG	O
brain	NNS	O
cancers.	TO	O
Specifically,	DT	O
the	NN	O
authors	IN	O
disclosed	NN	O
the	IN	O
use	NN	O
Multi-Walled	.	O
Carbon	,	O
Nanotubes	DT	O
(MWCNTs)	NNS	O
as	VBD	O
nanovectors	DT	O
for	NN	O
transporting	JJ	O
siRNA	NNP	O
Kateb	NNP	B
et	)	I
al.	IN	I
(2007)	NNS	I
Neuroimage	IN	I
37	VBG	I
Suppl	NN	I
1:S9-17).(	NNP	O
The	RB	O
therapeutic	.	O
polynucleotide	)	O
(e.g.,	NN	O
siRNA)	CD	O
can	NNP	O
be	.	O
used	DT	O
in	JJ	O
combination	NN	O
with	,	O
other	)	O
agents	MD	O
to	VB	O
improve	VBN	O
or	IN	O
enhance	NN	O
the	IN	O
therapeutic	JJ	O
effect	NNS	O
of	TO	O
either.	VB	O
This	CC	O
process	VB	O
can	DT	O
involve	JJ	O
administering	NN	O
both	IN	O
agents	.	O
to	DT	O
the	NN	O
patient	MD	O
at	VB	O
the	VBG	O
same	DT	O
time,	NNS	O
either	TO	O
as	DT	O
a	NN	O
single	IN	O
composition	DT	O
or	JJ	O
pharmacological	,	O
formulation	RB	O
that	IN	O
includes	DT	O
both	JJ	O
agents,	NN	O
or	CC	O
by	JJ	O
administering	NN	O
two	WDT	O
distinct	VBZ	O
compositions	DT	O
or	,	O
formulations,	CC	O
wherein	IN	O
one	VBG	O
composition	CD	O
includes	JJ	O
the	NNS	O
siRNA	CC	O
of	,	O
the	VBP	O
invention	CD	O
and	NN	O
the	VBZ	O
other	DT	O
includes	NN	O
the	IN	O
second	DT	O
agent(s).	NN	O
The	CC	O
siRNA	DT	O
therapy	JJ	O
also	VBZ	O
can	DT	O
precede	JJ	O
or	.	O
follow	DT	O
the	NN	O
other	NN	O
agent	RB	O
treatment	MD	O
by	VB	O
intervals	CC	O
ranging	VB	O
from	DT	O
minutes	JJ	O
to	NN	O
weeks.	NN	O
Polynucleotides	IN	O
can	NNS	O
be	VBG	O
delivered	IN	O
via	NNS	O
a	TO	O
controlled	.	O
release	NNS	O
system.	MD	O
As	VB	O
an	VBN	O
example,	IN	O
a	DT	O
pump	VBN	O
may	NN	O
be	.	O
used	IN	O
Langer,	DT	B
supra;	,	I
Sefton,	DT	I
1987,	NN	I
CRC	MD	I
Crit.	VB	I
Ref.	VBN	I
Biomed.	,	I
Eng.	:	I
14:201-240;	,	I
Buchwald	,	B
et	NNP	I
al.,	.	I
1980,	.	I
Surgery	.	I
88:507-516;	.	I
Saudek	:	B
et	NNP	I
al.,	FW	I
1989,	,	I
N.	,	I
Engl.	NNP	I
J.	:	I
Med.	NNP	I
321:574-579).(	FW	O
Alternatively,	,	O
polymeric	,	O
materials	NNP	O
can	.	O
be	NNP	O
used	.	O
Medical	.	B
Applications	,	I
of	JJ	I
Controlled	NNS	I
Release,	MD	I
Langer	VB	I
and	VBN	I
Wise,	JJ	I
eds.,	NNS	I
CRC	IN	I
Press,	NNP	I
Boca	,	I
Raton,	NNP	I
Fla.,	CC	I
1974;	,	I
Controlled	,	B
Drug	NNP	I
Bioavailability,	,	I
Drug	NNP	I
Product	,	I
Design	,	I
and	:	I
Performance,	VBN	I
Smolen	NNP	I
and	,	I
Ball,	NNP	I
eds.,	NNP	I
Wiley,	NNP	I
N.Y.,	CC	I
1984;	,	I
Ranger	NNP	B
and	CC	I
Peppas,	,	I
1983,	,	I
Macromol.	,	I
Sci.	,	I
Rev.	:	I
Macromol.	NNP	I
Chem.	CC	I
23:61;	,	I
Levy	,	B
et	.	I
al.,	.	I
1985,	.	I
Science	.	I
228:190-192;	.	I
During	:	B
et	NNP	I
al.,	FW	I
1989,	,	I
Ann.	,	I
Neurol.	NNP	I
25:351-356;	:	I
Howard	IN	B
et	FW	I
al.,	,	I
1989,	,	I
J.	.	I
Neurosurg.	.	I
71:858-863).(	:	O
In	NNP	O
yet	FW	O
another	,	O
alternative,	,	O
a	NNP	O
controlled	.	O
release	.	O
system	IN	O
can	RB	O
be	DT	O
placed	,	O
in	DT	O
proximity	VBN	O
of	NN	O
the	NN	O
therapeutic	MD	O
target,	VB	O
i.e.,	VBN	O
the	IN	O
brain,	NN	O
thus	IN	O
requiring	DT	O
only	JJ	O
a	,	O
fraction	,	O
of	DT	O
the	,	O
systemic	RB	O
dose	VBG	O
(e.g.,	RB	O
Goodson,	DT	B
1984,	NN	I
In:	IN	I
Medical	DT	I
Applications	JJ	I
of	NN	I
Controlled	,	I
Release,	,	I
supra,	,	I
Vol.	:	I
2,	JJ	I
pp.	NNS	I
115-138).Other	IN	O
controlled	NNP	O
release	,	O
systems	,	O
are	.	O
discussed	,	O
in	.	O
the	.	O
review	JJ	O
by	VBD	O
Langer	NN	O
1990,	NNS	B
Science	VBP	I
249:1527-1533).(	VBN	O
Other	IN	O
approaches	DT	O
can	NN	O
include	IN	O
the	NNP	O
use	,	O
of	NNP	O
various	.	O
transport	JJ	O
and	NNS	O
carrier	MD	O
systems,	VB	O
for	DT	O
example	NN	O
though	IN	O
the	JJ	O
use	NN	O
of	CC	O
viral	NN	O
and/or	,	O
non-viral	IN	O
delivery	NN	O
systems.	IN	O
For	DT	O
example,	NN	O
siRNA	IN	O
can	JJ	O
be	JJ	O
introduced	JJ	O
into	NN	O
the	.	O
brain	IN	O
in	,	O
a	NN	O
virus	MD	O
modified	VB	O
to	VBN	O
serve	IN	O
as	DT	O
a	NN	O
vehicle	IN	O
without	DT	O
causing	NN	O
pathogenicity.	VBN	O
The	TO	O
virus	VB	O
can	IN	O
be,	DT	O
e.g.,	NN	O
adenovirus,	IN	O
fowlpox	VBG	O
virus,	.	O
vaccinia	DT	O
virus,	NN	O
lentivirus,	MD	O
or	,	O
neurotropic	,	O
virus	,	O
such	JJ	O
as	,	O
HIV,	NN	O
herpes	,	O
simplex	,	O
virus,	CC	O
flavivirus,	RB	O
or	NNS	O
rabies	JJ	O
virus.	IN	O
Li	,	B
et	VBZ	I
al.,	JJ	I
Methods	,	I
Mol.	,	I
Biol.	CC	I
309:261-272	NNS	I
(2005);	.	I
Davidson	NNP	B
et	RB	I
al.,	,	I
Neuron	NNP	I
53:781-788	.	I
(2007);	.	I
Xia	CD	B
et	:	I
al.,	NNP	I
Nature	FW	I
Med	,	I
10:816-820	NNP	I
(2004);	CD	I
Kumar	:	B
et	NNP	I
al.,	FW	I
Nature	,	I
448:39-43	NNP	I
(2007);	NNP	I
(U.S.	CD	O
Pat.	:	O
Nos.	NNP	O
6,344,445,	FW	O
6,924,144,	,	O
6,521,457).	NNP	O
Furthermore,	CD	O
gene	:	O
therapy	NNP	O
approaches,	.	O
for	.	O
example	,	O
as	,	O
described	.	O
in	,	O
Kaplitt	NN	O
et	NN	O
al.,	,	O
U.S.	IN	O
Pat.	NN	O
No.	IN	O
6,180,613	VBN	O
and	IN	O
Davidson,	NNP	O
WO	CC	O
04/013280,	,	O
can	NNP	O
be	.	O
used	.	O
to	CD	O
express	CC	O
nucleic	,	O
acid	NNP	O
molecules	,	O
in	MD	O
the	VB	O
brain.	VBN	O
Various	TO	O
non-viral	VB	O
delivery	JJ	O
systems	NN	O
are	NNS	O
known	IN	O
and	DT	O
can	.	O
be	JJ	O
used	JJ	O
to	NN	O
administer	NNS	O
a	VBP	O
therapeutic	VBN	O
polynucleotide	CC	O
(e.g.,	MD	O
siRNA)	VB	O
to	VBN	O
the	TO	O
brain,	VB	O
e.g.,	DT	O
encapsulation	JJ	O
in	NN	O
liposomes,	,	O
microparticles,	)	O
microcapsules,	TO	O
by	DT	O
iontophoresis,	,	O
or	,	O
by	NN	O
incorporation	IN	O
into	,	O
other	,	O
vehicles,	,	O
such	IN	O
as	,	O
biodegradable	CC	O
polymers,	IN	O
hydrogels,	NN	O
cyclodextrins	IN	O
(see	JJ	O
for	,	O
example	JJ	O
Gonzalez	IN	B
et	JJ	I
al.,	,	I
1999,	,	I
Bioconjugate	NNS	I
Chem.,	VB	I
10,	IN	I
1068-1074;	NN	I
Wang	NNP	O
et	CC	O
al.,	,	O
International	,	O
PCT	NNP	O
publication	,	O
Nos.	,	O
WO	:	O
03/47518	NNP	O
and	FW	O
WO	,	O
03/46185),	NNP	O
poly(lactic-co-glycolic)acid	NNP	O
(PLGA)	NN	O
and	.	O
PLCA	$	O
microspheres	CD	O
(see	CC	O
for	NNP	O
example	,	O
U.S.	NN	O
Pat.	)	O
No.	CC	O
6,447,796	NNP	O
and	NNS	O
US	VB	O
Patent	IN	O
Application	NN	O
Publication	NNP	O
No.	.	O
US	.	O
2002130430),	CD	O
biodegradable	CC	O
nanocapsules,	NNP	O
and	NNP	O
bioadhesive	NNP	O
microspheres,	NNP	O
or	.	O
by	PRP	O
proteinaceous	,	O
vectors	JJ	O
(O'Hare	,	O
and	CC	O
Normand,	JJ	O
International	,	O
PCT	CC	O
Publication	IN	O
No.	JJ	O
WO	NNS	O
00/53722)	NNP	O
or	CC	O
by	,	O
the	NNP	O
use	NNP	O
of	NNP	O
conjugates.	.	O
For	NNP	O
example,	)	O
chemically	CC	O
modified	IN	O
liposomes	DT	O
encapsulating	NN	O
small	IN	O
hairpin	.	O
RNA	IN	O
can	,	O
be	RB	O
conjugated	VBN	O
to	NNS	O
monoclonal	VBG	O
antibodies	JJ	O
specific	NN	O
for	NNP	O
specific	MD	O
endogenous	VB	O
receptors	VBN	O
(e.g.,	TO	O
such	JJ	O
as	NNS	O
insulin	VBP	O
and	IN	O
transferrin)	JJ	O
located	JJ	O
on	NNS	O
the	,	O
blood	JJ	O
brain	IN	O
barrier	NN	O
and	CC	O
brain	)	O
cellular	VBN	O
membranes	IN	O
(see	DT	O
Boado,	NN	B
Pharm.	NN	I
Res.	NN	I
24(9):1772-1787	CC	I
(2007)).As	NN	O
a	JJ	O
further	NNS	O
example,	VB	O
siRNA	,	O
duplexes	.	O
can	.	O
be	NN	O
delivered	.	O
with	IN	O
the	DT	O
combined	JJ	O
use	,	O
of	NN	O
receptor	NNS	O
specific	MD	O
antibody	VB	O
delivery	VBN	O
systems	IN	O
and	DT	O
avidin-biotin	VBN	O
technology.	NN	O
The	IN	O
siRNA	NN	O
can	JJ	O
be	NN	O
mono-biotinylated	NN	O
in	NNS	O
parallel	CC	O
with	JJ	O
the	.	O
production	DT	O
of	NN	O
a	MD	O
conjugate	VB	O
of	JJ	O
the	IN	O
targeting	NN	O
monoclonal	IN	O
antibody	DT	O
and	NN	O
streptavidin	IN	O
(see	DT	O
Xia	NN	B
et	IN	I
al.,	DT	I
Pharm	VBG	I
Res.	JJ	I
24(12):2309-16	NN	I
(2007)).Other	CC	O
methods	NN	O
to	VB	O
deliver	NNP	O
siRNA	FW	O
across	,	O
plasma	NNP	O
membranes	.	O
in	NN	O
vivo	.	O
include	JJ	O
chemically	NNS	O
modified	TO	O
siRNAs	VB	O
such	JJ	O
as	IN	O
cholesterol-conjugated	JJ	O
siRNAs	NNS	O
(see	IN	O
DiFiglia	JJ	B
et	VBP	I
al.,	RB	I
Proc	VBN	I
Natl	NN	I
Acad	JJ	I
Sci	IN	I
USA.	JJ	I
104(43):17204-9	NN	I
(2007);	VB	I
Wolfrum	NNP	B
et	FW	I
al.,	,	I
Nature	NNP	I
Biotech.	NNP	I
25(10):1149-1157	NNP	I
(2007);	NNP	I
Soutschek	.	B
et	NN	I
al.,	:	I
Nature	NNP	I
432:173-178	FW	I
(2003)).C.	,	O
Zinc	NNP	O
Finger	.	O
Proteins	NN	O
Zinc	:	O
finger	NNP	O
proteins	FW	O
can	,	O
be	NNP	O
engineered	CD	O
or	.	O
selected	NNP	O
to	NNP	O
bind	NNP	O
to	NNP	O
any	NNP	O
desired	NN	O
target	NNS	O
site	MD	O
within	VB	O
a	VBN	O
kinase	CC	O
gene	VBN	O
of	TO	O
known	VB	O
sequence	TO	O
including,	DT	O
for	JJ	O
example,	NN	O
PLK2.	NN	O
An	IN	O
exemplary	DT	O
motif	JJ	O
characterizing	NN	O
one	IN	O
class	VBN	O
of	NN	O
these	,	O
proteins	IN	O
(C2H2	,	O
class)	.	O
is	DT	O
-Cys-(X)2-4-Cys-(X)12-His-(X)3-5-His	JJ	O
(where	NN	O
X	VBG	O
is	CD	O
any	NN	O
amino	IN	O
acid).	DT	O
A	NNS	O
single	NNP	O
finger	)	O
domain	VBZ	O
is	CD	O
about	WRB	O
30	NNP	O
amino	VBZ	O
acids	DT	O
in	JJ	O
length,	.	O
and	DT	O
several	JJ	O
structural	NN	O
studies	NN	O
have	VBZ	O
demonstrated	IN	O
that	CD	O
it	JJ	O
contains	NNS	O
an	IN	O
alpha	,	O
helix	CC	O
containing	JJ	O
the	JJ	O
two	NNS	O
invariant	VBP	O
histidine	VBN	O
residues	IN	O
and	PRP	O
two	VBZ	O
invariant	DT	O
cysteine	JJ	O
residues	NN	O
in	VBG	O
a	DT	O
beta	CD	O
turn	JJ	O
co-ordinated	NN	O
through	NNS	O
zinc.	CC	O
In	CD	O
some	JJ	O
methods,	NN	O
the	NNS	O
target	IN	O
site	DT	O
is	NN	O
within	NN	O
a	JJ	O
promoter	IN	O
or	.	O
enhancer.	IN	O
In	DT	O
other	,	O
methods,	DT	O
the	NN	O
target	NN	O
site	VBZ	O
is	IN	O
within	DT	O
the	NN	O
structural	CC	O
gene.	.	O
In	IN	O
some	JJ	O
methods,	,	O
the	DT	O
zinc	NN	O
finger	NN	O
protein	VBZ	O
is	IN	O
linked	DT	O
to	JJ	O
a	.	O
transcriptional	IN	O
repressor,	DT	O
such	,	O
as	DT	O
the	NN	O
KRAB	NN	O
repression	NN	O
domain	VBZ	O
from	VBN	O
the	TO	O
human	DT	O
KOX-1	JJ	O
protein	,	O
Thiesen	JJ	B
et	IN	I
al.,	DT	I
New	NNP	I
Biologist	NN	I
2,	NN	I
363-374	IN	I
(1990);	DT	I
Margolin	JJ	B
et	NNP	I
al.,	NN	I
Proc.	NNP	I
Natl.	RB	I
Acad.	,	I
Sci.	NNP	I
USA	NNP	I
91,	,	I
4509-4513	CD	I
(1994);	:	I
Pengue	NNP	B
et	FW	I
al.,	,	I
Nucl.	.	I
Acids	.	I
Res.	.	I
22:2908-2914	.	I
(1994);	NNP	I
Witzgall	,	B
et	CD	I
al.,	:	I
Proc.	NNP	I
Natl.	FW	I
Acad.	,	I
Sci.	.	I
USA	NNP	I
91,	.	I
4514-4518	CD	I
(1994)).(	:	O
In	NNP	O
some	FW	O
methods,	,	O
the	.	O
zinc	.	O
finger	.	O
protein	.	O
is	NNP	O
linked	,	O
to	CD	O
a	.	O
transcriptional	IN	O
activator,	DT	O
such	,	O
as	DT	O
VIP16.	NN	O
Zinc	NN	O
finger	NN	O
proteins	VBZ	O
can	VBN	O
also	TO	O
be	DT	O
used	JJ	O
to	,	O
activate	JJ	O
expression	IN	O
of	.	O
desired	NNP	O
genes.	NN	O
Methods	NNS	O
for	MD	O
selecting	RB	O
target	VB	O
sites	VBN	O
suitable	TO	O
for	VB	O
targeting	NN	O
by	IN	O
zinc	VBN	O
finger	.	O
proteins,	NNS	O
and	IN	O
methods	VBG	O
for	NN	O
designing	NNS	O
zinc	JJ	O
finger	IN	O
proteins	VBG	O
to	IN	O
bind	NN	O
to	NN	O
selected	,	O
target	CC	O
sites	NNS	O
are	IN	O
described	VBG	O
in	NN	O
WO	NN	O
00/00388.	VBZ	O
Methods	TO	O
for	VB	O
selecting	TO	O
zinc	VBN	O
finger	NN	O
proteins	NNS	O
to	VBP	O
bind	VBN	O
to	IN	O
a	NNP	O
target	.	O
using	NNS	O
phage	IN	O
display	VBG	O
are	NN	O
described	NN	O
by	VBZ	O
EP.95908614.1.	TO	O
The	VB	O
target	TO	O
site	DT	O
used	NN	O
for	VBG	O
design	NN	O
of	NN	O
a	VBP	O
zinc	VBN	O
finger	IN	O
protein	.	O
is	DT	O
typically	NN	O
of	NN	O
the	VBN	O
order	IN	O
of	NN	O
9-19	IN	O
nucleotides.	DT	O
For	NN	O
example,	NN	O
proteins	NN	O
have	VBZ	O
been	RB	O
described	IN	O
that	DT	O
have	NN	O
the	IN	O
ability	CD	O
to	.	O
translocate	IN	O
desired	,	O
nucleic	NNS	O
acids	VBP	O
across	VBN	O
a	VBN	O
cell	WDT	O
membrane.	VBP	O
Typically,	DT	O
such	NN	O
proteins	TO	O
have	VB	O
amphiphilic	JJ	O
or	JJ	O
hydrophobic	NNS	O
subsequences	IN	O
that	DT	O
have	NN	O
the	.	O
ability	,	O
to	JJ	O
act	NNS	O
as	VBP	O
membrane-translocating	JJ	O
carriers.	CC	O
For	JJ	O
example,	NNS	O
homeodomain	WDT	O
proteins	VBP	O
have	DT	O
the	NN	O
ability	TO	O
to	VB	O
translocate	IN	O
across	JJ	O
cell	.	O
membranes.	IN	O
The	,	O
shortest	NN	O
internalizable	NNS	O
peptide	VBP	O
of	DT	O
a	NN	O
homeodomain	TO	O
protein,	VB	O
Antennapedia,	IN	O
was	NN	O
found	.	O
to	DT	O
be	JJS	O
the	JJ	O
third	NN	O
helix	IN	O
of	DT	O
the	NN	O
protein,	,	O
from	,	O
amino	VBD	O
acid	VBN	O
position	TO	O
43	VB	O
to	DT	O
58	JJ	O
(see,	NN	O
e.g.,	IN	O
Prochiantz,	DT	B
Current	,	I
Opinion	IN	I
in	NN	I
Neurobiology	JJ	I
6:629-634	NN	I
(1996).	CD	I
Another	TO	O
subsequence,	CD	O
the	,	O
h	,	O
(hydrophobic)	,	O
domain	NNP	O
of	NNP	O
signal	IN	O
peptides,	NNP	O
was	CD	O
found	.	O
to	DT	O
have	,	O
similar	DT	O
cell	NN	O
membrane	)	O
translocation	NN	O
characteristics	IN	O
(see,	JJ	O
e.g.,	,	O
Lin	VBD	B
et	VBN	I
al.,	TO	I
J.	VB	I
Biol.	JJ	I
Chem.	NN	I
270:14255-14258	NN	I
(1995)).Such	NN	O
subsequences	NNS	O
can	,	O
be	,	O
used	NNP	O
to	FW	O
translocate	,	O
oligonucleotides	NNP	O
across	.	O
a	.	O
cell	CD	O
membrane.	.	O
Oligonucleotides	JJ	O
can	NNS	O
be	MD	O
conveniently	VB	O
derivatized	VBN	O
with	TO	O
such	VB	O
sequences.	NNS	O
For	IN	O
example,	DT	O
a	NN	O
linker	.	O
can	NNS	O
be	MD	O
used	VB	O
to	RB	O
link	VBN	O
the	IN	O
oligonucleotides	JJ	O
and	.	O
the	IN	O
translocation	,	O
sequence.	DT	O
Any	NN	O
suitable	MD	O
linker	VB	O
can	VBN	O
be	TO	O
used,	VB	O
e.g.,	DT	O
a	NNS	O
peptide	CC	O
linker	DT	O
or	NN	O
any	.	O
other	DT	O
suitable	JJ	O
chemical	NN	O
linker.	MD	O
D.	VB	O
Antibodies	,	O
Kinase	,	O
activity	DT	O
can	JJ	O
be	NN	O
reduced	CC	O
by	DT	O
administering	JJ	O
anti-kinase	JJ	O
(e.g.,	NN	O
anti-PLK2)	.	O
antibodies,	NNP	O
both	NNP	O
intact	NNP	O
and	NN	O
binding	MD	O
fragments	VB	O
thereof,	VBN	O
such	IN	O
as	VBG	O
Fabs,	NN	O
Fvs,	,	O
which	)	O
specifically	,	O
bind	DT	O
to	JJ	O
a	CC	O
kinase	VBG	O
of	NNS	O
the	,	O
invention.	JJ	O
Usually	IN	O
the	,	O
antibody	,	O
is	WDT	O
a	RB	O
monoclonal	VBP	O
antibody	TO	O
although	DT	O
polyclonal	NN	O
antibodies	IN	O
can	DT	O
also	.	O
be	RB	O
expressed	DT	O
recombinantly	NN	O
(see,	VBZ	O
e.g.,	DT	O
U.S.	JJ	O
Pat.	NN	O
No.	IN	O
6,555,310).	JJ	O
Examples	NNS	O
of	MD	O
antibodies	RB	O
that	VB	O
can	VBN	O
be	RB	O
expressed	,	O
include	,	O
mouse	NNP	O
antibodies,	.	O
chimeric	.	O
antibodies,	.	O
humanized	NNS	O
antibodies,	IN	O
veneered	NNS	O
antibodies	WDT	O
and	MD	O
human	VB	O
antibodies.	VBN	O
Chimeric	JJ	O
antibodies	NN	O
are	,	O
antibodies	JJ	O
whose	,	O
light	JJ	O
and	,	O
heavy	JJ	O
chain	NNS	O
genes	CC	O
have	JJ	O
been	.	O
constructed,	JJ	O
typically	NNS	O
by	VBP	O
genetic	NNS	O
engineering,	WP$	O
from	NN	O
immunoglobulin	CC	O
gene	JJ	O
segments	NN	O
belonging	NNS	O
to	VBP	O
different	VBN	O
species	,	O
(see,	RB	O
e.g.,	IN	O
Boyce	JJ	B
et	,	I
al.,	IN	I
Annals	JJ	I
of	NN	I
Oncology	NNS	I
14:520-535	VBG	I
(2003)).For	TO	O
example,	JJ	O
the	NNS	O
variable	,	O
(V)	,	O
segments	NNP	O
of	FW	O
the	,	O
genes	NNP	O
from	IN	O
a	NNP	O
mouse	CD	O
monoclonal	.	O
antibody	IN	O
may	,	O
be	DT	O
joined	JJ	O
to	)	O
human	NNS	O
constant	IN	O
(C)	DT	O
segments.	NNS	O
A	IN	O
typical	DT	O
chimeric	NN	O
antibody	JJ	O
is	NN	O
thus	MD	O
a	VB	O
hybrid	VBN	O
protein	TO	O
consisting	JJ	O
of	NN	O
the	)	O
V	.	O
or	DT	O
antigen-binding	JJ	O
domain	NN	O
from	NN	O
a	VBZ	O
mouse	RB	O
antibody	DT	O
and	JJ	O
the	NN	O
C	VBG	O
or	IN	O
effector	DT	O
domain	NNP	O
from	CC	O
a	JJ	O
human	NN	O
antibody.	IN	O
Humanized	DT	O
antibodies	NN	O
have	NN	O
variable	CC	O
region	DT	O
framework	NNP	O
residues	CC	O
substantially	NN	O
from	NN	O
a	IN	O
human	DT	O
antibody	JJ	O
(termed	.	O
an	VBN	O
acceptor	NNS	O
antibody)	VBP	O
and	JJ	O
complementarity	NN	O
determining	NN	O
regions	NNS	O
substantially	RB	O
from	IN	O
a	DT	O
mouse-antibody,	JJ	O
(referred	NN	O
to	VBD	O
as	DT	O
the	NN	O
donor	)	O
immunoglobulin).	CC	O
See	NN	O
Queen	VBG	B
et	NNS	I
al.,	RB	I
Proc.	IN	I
Natl.	DT	I
Acad.	,	I
Sci.	VBN	I
USA	TO	I
86:10029-10033	IN	I
(1989)	DT	I
and	NN	O
WO	.	O
90/07861,	VB	O
U.S.	JJ	O
Pat.	FW	O
No.	,	O
5,693,762,	.	O
U.S.	.	O
Pat.	.	O
No.	.	O
5,693,761,	NNP	O
U.S.	CD	O
Pat.	)	O
No.	CC	O
5,585,089,	$	O
U.S.	,	O
Pat.	NNP	O
No.	.	O
5,530,101	.	O
and	,	O
Winter,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,225,539.	NNP	O
The	.	O
constant	.	O
region(s),	,	O
if	NNP	O
present,	.	O
are	.	O
also	CD	O
substantially	CC	O
or	,	O
entirely	NNP	O
from	.	O
a	.	O
human	.	O
immunoglobulin.	DT	O
Antibodies	JJ	O
can	,	O
be	IN	O
obtained	,	O
by	VBP	O
conventional	RB	O
hybridoma	RB	O
approaches,	CC	O
phage	RB	O
display	IN	O
(see,	DT	O
e.g.,	JJ	O
Dower	.	O
et	NNS	O
al.,	MD	O
WO	VB	O
91/17271	VBN	O
and	IN	O
McCafferty	JJ	O
et	NN	O
al.,	,	O
WO	NN	O
92/01047),	NN	O
use	,	O
of	,	O
transgenic	NNP	O
mice	FW	O
with	,	O
human	NNP	O
immune	CD	O
systems	CC	O
(Lonberg	NNP	O
et	VBP	O
al.,	,	O
WO93/12227	NNP	O
(1993)),	,	O
among	NN	O
other	IN	O
sources.	JJ	O
Nucleic	NN	O
acids	IN	O
encoding	JJ	O
immunoglobulin	JJ	O
chains	NNS	O
can	NNP	O
be	RB	O
obtained	,	O
from	NNP	O
hybridomas	,	O
or	IN	O
cell	JJ	O
lines	.	O
producing	NNP	O
antibodies,	NNS	O
or	VBG	O
based	NN	O
on	NNS	O
immunoglobulin	MD	O
nucleic	VB	O
acid	VBN	O
or	IN	O
amino	NN	O
acid	CC	O
sequences	NN	O
in	NNS	O
the	VBG	O
published	,	O
literature.	CC	O
Antibodies	VBN	O
can	IN	O
be	NN	O
administered	JJ	O
by	NN	O
intravenous	CC	O
injection.	NN	O
A	JJ	O
portion	NNS	O
of	IN	O
the	DT	O
injected	JJ	O
antibodies	.	O
will	NNS	O
cross	MD	O
the	VB	O
blood-brain	VBN	O
barrier.	IN	O
Alternatively	JJ	O
antibodies	.	O
can	DT	O
be	NN	O
administered	IN	O
directly	DT	O
to	JJ	O
the	NNS	O
brain	MD	O
(e.g.,	VB	O
by	DT	O
intraventricular	JJ	O
or	.	O
intrathecal	RB	O
injection).	NNS	O
Antibodies	MD	O
may	VB	O
be	VBN	O
internalized	RB	O
by	TO	O
synuclein-expressing	DT	O
cells	NN	O
by	,	O
endocytosis.	IN	O
Alternatively,	JJ	O
antibodies	CC	O
may	JJ	O
be	.	O
linked	NNS	O
to	MD	O
carrier	VB	O
moiety	VBN	O
that	IN	O
facilitates	JJ	O
transport	NNS	O
across	IN	O
the	.	O
cell	,	O
membrane.	NNS	O
In	MD	O
one	VB	O
embodiment	VBN	O
an	TO	O
intrabody	NN	O
is	NN	O
used	WDT	O
to	VBZ	O
reduce	RB	O
PLK2	IN	O
activity.	DT	O
The	NN	O
term	.	O
“intrabody”	IN	O
or	CD	O
“intrabodies”	NN	O
refers	DT	O
to	NN	O
intracellularly	VBZ	O
expressed	VBN	O
antibody	TO	O
constructs,	VB	O
usually	NNP	O
single-chain	.	O
Fv	DT	O
antibodies,	NN	O
directed	NN	O
against	CC	O
a	JJ	O
target	NNS	O
inside	TO	O
a	VB	O
cell.	VBN	O
Nam,	NN	B
et	,	I
al.	RB	I
(2002)	JJ	I
Methods	NNP	I
Mol.	,	I
Biol.	VBN	I
193:301;	IN	I
der	DT	B
Maurr	NN	I
et	IN	I
al.	DT	I
(2002)	.	I
J.	,	I
Biol	RB	I
Chem	.	I
Nov	)	I
22;	NNP	I
277(47):45075;	.	I
Cohen	.	B
(2002)	:	I
Methods	NN	I
Mol	NNP	I
Biol	CC	I
178:367.	.	I
The	)	O
scFv	NNP	O
gene	NNP	O
can	NNP	O
be	NNP	O
transferred	:	O
into	:	O
cells,	NNP	O
where	)	O
scFv	NNP	O
protein	NNP	O
expression	NNP	O
can	.	O
modulate	DT	O
the	JJ	O
properties	NN	O
of	MD	O
its	VB	O
target,	VBN	O
e.g.	IN	O
PLK2,	,	O
sometimes	WRB	O
extinguishing	NN	O
protein	IN	O
function	NN	O
and	MD	O
causing	VB	O
a	DT	O
phenotypic	NNS	O
knockout.	IN	O
Indeed,	PRP$	O
the	,	O
scFv	.	O
intrabody	,	O
can	RB	O
be	VBG	O
expressed	JJ	O
in	NN	O
the	CC	O
cytoplasm	VBG	O
and	DT	O
directed	NN	O
to	.	O
any	,	O
cellular	DT	O
compartment	NN	O
where	NN	O
it	MD	O
can	VB	O
target	VBN	O
intracellular	IN	O
proteins	DT	O
and	NN	O
elicit	CC	O
specific	VBD	O
biological	TO	O
effects.	DT	O
Intrabodies	JJ	O
thus	NN	O
provide	WRB	O
effective	PRP	O
means	MD	O
for	VB	O
blocking	JJ	O
or	NNS	O
modulating	CC	O
the	JJ	O
activity	JJ	O
of	JJ	O
proteins	.	O
such	NNS	O
as	RB	O
PLK2.	VBP	O
E.	JJ	O
Kinase	NNS	O
Inhibitors	IN	O
to	VBG	O
Modulate	CC	O
Activity	VBG	O
In	DT	O
addition	NN	O
to	IN	O
the	NNS	O
biological	JJ	O
molecules	IN	O
discussed	.	O
above,	NNP	O
small	NNP	O
molecule	NNP	O
compounds	TO	O
can	NNP	O
be	NNP	O
used	IN	O
to	NN	O
modulate	TO	O
(usually	DT	O
inhibit)	JJ	O
expression	NNS	O
or	VBN	O
activity	,	O
of	JJ	O
kinases.	NN	O
As	NNS	O
discussed	MD	O
below,	VB	O
known	VBN	O
kinase	TO	O
inhibitors	VB	O
can	RB	O
be	)	O
screened	NN	O
for	CC	O
desired	NN	O
target	IN	O
specificity	.	O
and	IN	O
other	VBN	O
properties,	,	O
and	VBN	O
additional	NN	O
inhibitors	NNS	O
can	MD	O
be	VB	O
identified	VBN	O
based	IN	O
on	JJ	O
target	NN	O
specificity.	NN	O
PLK2	CC	O
or	JJ	O
GRK6	,	O
are	CC	O
preferred	JJ	O
kinases	NNS	O
for	MD	O
inhibition	VB	O
because	VBN	O
they	VBN	O
are	IN	O
candidates	NN	O
for	.	O
directly	NNP	O
phosphorylating	CC	O
alpha-synuclein.	NNP	O
PLK2	VBP	O
is	JJ	O
a	NNS	O
particularly	IN	O
preferred	NN	O
kinase	IN	O
because	PRP	O
it	VBP	O
has	NNS	O
been	IN	O
shown	RB	O
to	VBG	O
phosphorylate	.	O
alpha-synuclein	NNP	O
to	VBZ	O
a	DT	O
much	RB	O
higher	JJ	O
level	NN	O
than	IN	O
GRK6	PRP	O
or	VBZ	O
other	VBN	O
kinases	VBN	O
tested	TO	O
herein.	VB	O
Other	NNS	O
kinase	TO	O
targets	DT	O
include	RB	O
APEG1,	JJR	O
CDC7L1,	NN	O
MET	IN	O
GRK1,	NNP	O
GRK2,	CC	O
GRK6,	JJ	O
IKBKB,	NNS	O
CKII	VBN	O
and	.	O
GRK7	JJ	O
are	JJ	O
also	NNS	O
preferred	VBP	O
kinases	,	O
for	,	O
inhibition	NNP	O
because	,	O
they	,	O
are	,	O
likely	,	O
to	NNP	O
be	CC	O
indirect	NNP	O
activators	VBP	O
of	RB	O
the	JJ	O
direct	NNS	O
kinase(s).	IN	O
PRKG1,	NN	O
MAPK13,	IN	O
and	PRP	O
GAK	VBP	O
are	JJ	O
preferred	TO	O
kinases	VB	O
for	JJ	O
activation	NNS	O
in	IN	O
Lewy	DT	O
body	JJ	O
diseases	.	O
because	,	O
they	,	O
are	CC	O
negative	NNP	O
regulators	VBP	O
of	JJ	O
the	NNS	O
phosphorylation	IN	O
of	NN	O
alpha-synuclein.	IN	O
Alternatively,	NNP	O
these	NN	O
kinases	NNS	O
themselves	IN	O
or	PRP	O
fragments	VBP	O
or	JJ	O
mimetics	NNS	O
thereof	IN	O
having	DT	O
similar	NN	O
activity	IN	O
can	.	O
be	,	O
used	DT	O
directly	VBZ	O
as	PRP	O
inhibitors	CC	O
of	NNS	O
alpha-synuclein	CC	O
phosphorylation.	NNS	O
Synphilin	IN	O
can	VBG	O
be	JJ	O
used	NN	O
as	MD	O
an	VB	O
alternative	VBN	O
therapeutic	RB	O
target	IN	O
for	NNS	O
inhibition	IN	O
of	JJ	O
alpha-synuclein	.	O
phosphorylation.	NNP	O
For	MD	O
example,	VB	O
synphilin	VBN	O
can	IN	O
be	DT	O
added	JJ	O
to	JJ	O
an	NN	O
assay	IN	O
having	NN	O
alpha-synuclein	IN	O
and	JJ	O
PLK-2	.	O
expression	IN	O
and	,	O
inhibitors	NN	O
of	MD	O
synphilin	VB	O
identified.	VBN	O
Compounds	TO	O
to	DT	O
be	JJ	O
screened	VBG	O
for	JJ	O
capacity	CC	O
to	JJ	O
modulate	NN	O
expression	CC	O
or	NNS	O
activity	IN	O
of	NN	O
kinases	.	O
include	NNS	O
the	TO	O
modulators	VB	O
of	VBN	O
expression	IN	O
described	NN	O
in	TO	O
Section	VB	O
IV.	NN	O
These	CC	O
compounds	NN	O
also	IN	O
include	NNS	O
many	VBP	O
known	DT	O
examples	NNS	O
of	IN	O
kinase	NN	O
inhibitors,	VBN	O
some	IN	O
of	NNP	O
which	.	O
are	DT	O
already	NNS	O
approved	RB	O
for	VBP	O
therapeutic	JJ	O
uses	JJ	O
or	NNS	O
in	IN	O
clinical	NN	O
trials,	,	O
usually	DT	O
for	IN	O
treatment	WDT	O
of	VBP	O
cancer.	RB	O
Lead	VBN	O
structures	IN	O
include	JJ	O
quinazolines,	NNS	O
pyrido[d]-	CC	O
and	IN	O
pyrimidol[d]pyrimidines,	JJ	O
pyrazolo[d]-pyrimidines,	,	O
pyrrolo[d]pyrimidines,	RB	O
pheylamino-pyrimidines,	IN	O
1-oxo-3-aryl-1H-indene-2-carboxylic	NN	O
acid	IN	O
derivatives,	.	O
and	JJ	O
substituted	NNS	O
indolin-2-ones	VBP	O
and	,	O
natural	:	O
products	CC	O
such	,	O
as	,	O
strauosporine	,	O
(see	,	O
Traxler	JJ	B
et	NN	I
al.,	,	I
2001,	CC	I
Medicinal	VBD	I
Research	NNS	I
Reviews	CC	I
21:499-512).Some	JJ	O
such	NNS	O
compounds	JJ	O
are	IN	O
commercially	NN	O
available	VB	O
from	NNP	O
Calbiochem-Novabiochem	FW	O
Corp.	,	O
(La	,	O
Jolla,	NNP	O
Calif.)	NNP	O
including	NNP	O
H89,	.	O
Y27632,	DT	O
AT877	JJ	O
(fasudil	NNS	O
hydrochloride),	VBP	O
rottlerin,	RB	O
KN62,	JJ	O
U0123,	IN	O
PD184352,	NNP	O
PD98059,	NNP	O
SB203580,	NNP	O
SB202190,	,	O
wortmannin,	)	O
Li+,	VBG	O
Ro	,	O
318220,	,	O
chelerythrein	NNP	O
and	JJ	O
10-[3-(1-piperazinyl)propyl]-2-trifluoromethyl-phenothiazine	,	O
(see	,	O
Davies,	,	B
Biochem.	,	I
J.	,	I
351,	,	I
95-105	,	I
(2000)).Other	,	O
compounds	,	O
currently	,	O
in	NNP	O
clinical	,	O
trials	NN	O
include	CC	O
STI571	NN	O
(Glivec™,	VB	O
a	,	O
phenylamino-pyrimidine	.	O
derivative)	.	O
(Novartis),	,	O
ZD1839	CD	O
(Iressa)	.	O
(AstraZeneca),	JJ	O
OSI-774	NNS	O
(Roche/OSI),	RB	O
PKI166	IN	O
(Novartis),	JJ	O
CI1033	NNS	O
(Pfizer/Warner-Lambert),	VBP	O
EKB-569	NNP	O
(Wyeth-Ayerst),	,	O
SU5416	DT	O
(SUGEN),	JJ	O
PTK787/ZK224584,	)	O
aniline-phthalazine	,	O
derivative	NNP	O
(Novartis/Schering	)	O
AG),	,	O
SU6668	NNP	O
(Sugen),	,	O
ZD6474	NNP	O
(AstraZeneca),	,	O
and	NNP	O
CEP2583	,	O
(Cephalon).	NNP	O
Caveolin-1	,	O
is	NNP	O
an	,	O
example	,	O
of	JJ	O
a	NN	O
compound	NNP	O
known	,	O
to	NNP	O
modulate	,	O
the	NNP	O
activity	,	O
of	CC	O
the	NNP	O
GRK	.	O
kinases.	NNP	O
Examples	VBZ	O
of	DT	O
compounds	NN	O
known	IN	O
to	DT	O
modulate	NN	O
the	VBN	O
activity	TO	O
of	VB	O
the	DT	O
PLK2/SNK	NN	O
kinases	IN	O
include	DT	O
the	NNP	O
RING-H2	.	O
domain	NNS	O
of	IN	O
hVPS18	NNS	O
(human	VBN	O
vacuolar	TO	O
protein	VB	O
sorting	DT	O
18),	NN	O
and	IN	O
calcium-	DT	O
and	NNP	O
integrin-binding	NNS	O
protein	VBP	O
CIB.	DT	O
In	NNP	O
certain	NN	O
embodiments	IN	O
the	NN	O
therapeutic	JJ	O
agent	NN	O
is	NN	O
a	VBG	O
small	,	O
molecule	CC	O
that	JJ	O
is	CC	O
a	JJ	O
thiazolidone,	NN	O
a	.	O
quinazoline,	IN	O
a	JJ	O
pyrimidine	NNS	O
(e.g.,	DT	O
a	JJ	O
pyrido[d]-pyrimidine,	NN	O
pyrimidol[d]pyrimidine,	VBZ	O
a	DT	O
pyrazolo[d]-pyrimidine,	JJ	O
a	NN	O
pyrrolo[d]pyrimidine,	WDT	O
a	VBZ	O
pheylamino-pyrimidines,	DT	O
or	,	O
a	DT	O
phenylamino-pyrimidine	,	O
derivative);	DT	O
an	NN	O
indazole-pyridine	,	O
derivative,	DT	O
a	,	O
carboxylic	,	O
acid	DT	O
derivative	,	O
(e.g.,	DT	O
a	,	O
1-oxo-3-aryl-1H-indene-2-carboxylic	DT	O
acid	,	O
derivative),	CC	O
a	DT	O
substituted	JJ	O
indolin-2-one,	:	O
an	DT	O
aniline-phthalazine	JJ	O
derivative;	,	O
a	DT	O
quinolinone	JJ	O
derivative,	NN	O
a	NN	O
benzthiazole-3	,	O
oxide	DT	O
compound,	JJ	O
an	NN	O
azaindazole	,	O
compound,	DT	O
or	JJ	O
a	,	O
dihydropteridinone.	DT	O
In	JJ	O
certain	:	O
embodiments	DT	O
the	NN	O
therapeutic	,	O
agent	DT	O
is	JJ	O
a	NN	O
small	,	O
molecule	DT	O
protein	JJ	O
kinase	,	O
inhibitor	CC	O
described	DT	O
in	.	O
US	IN	O
20070203143;	JJ	O
US	NNS	O
2007/0179177;	DT	O
US	JJ	O
2007/0135387;	NN	O
US	VBZ	O
2007/0010565;	DT	O
US	JJ	O
2007/0037862;	NN	O
US	NN	O
2007/0010566;	VBD	O
US	NN	O
2006/0074119;	NN	O
US	IN	O
2006/0079503;	NNP	O
US	:	O
2006/0223833;	PRP	O
US	:	O
2005/0014761;	PRP	O
US	:	O
2004/0176380;	PRP	O
US	:	O
2006/0040997;	PRP	O
U.S.	:	O
Pat.	PRP	O
No.	:	O
6,861,422;	PRP	O
US	:	O
2005/0014760;	PRP	O
US	:	O
2006/0025411;	PRP	O
US	:	O
2004/0176380;	PRP	O
US	:	O
2005/0014761;	PRP	O
US	:	O
2007/0203143;	PRP	O
US	:	O
2007/0072833;	NNP	O
US	.	O
2007/0135387	.	O
or	:	O
WO	PRP	O
03087095.	:	O
Each	PRP	O
of	:	O
the	PRP	O
aforelisted	:	O
publications	PRP	O
is	:	O
incorporated	PRP	O
herein	:	O
by	PRP	O
reference.	:	O
Compounds	PRP	O
may	CD	O
be	CC	O
synthetic	NNP	O
or	.	O
can	DT	O
be	IN	O
obtained	DT	O
from	JJ	O
natural	NNS	O
sources,	VBZ	O
such	VBN	O
as,	NN	O
e.g.,	IN	O
marine	.	O
microorganisms,	NNS	O
algae,	MD	O
plants,	VB	O
and	JJ	O
fungi.	CC	O
Other	MD	O
compounds	VB	O
that	VBN	O
can	IN	O
be	JJ	O
tested	,	O
include	JJ	O
compounds	,	O
known	,	O
to	JJ	O
interact	,	O
with	,	O
alpha-synuclein,	,	O
such	CC	O
as	.	O
synphilin.	JJ	O
Alternatively,	NNS	O
compounds	WDT	O
can	MD	O
be	VB	O
from	VBN	O
combinatorial	JJ	O
libraries	NNS	O
of	VBN	O
agents,	TO	O
including	VB	O
peptides	IN	O
or	,	O
small	JJ	O
molecules,	IN	O
or	.	O
from	,	O
existing	NNS	O
repertories	MD	O
of	VB	O
chemical	IN	O
compounds	JJ	O
synthesized	NNS	O
in	IN	O
industry,	,	O
e.g.,	VBG	O
by	NNS	O
the	CC	O
chemical,	JJ	O
pharmaceutical,	,	O
environmental,	CC	O
agricultural,	IN	O
marine,	VBG	O
cosmeceutical,	NNS	O
drug,	IN	O
and	NN	O
biotechnological	NNS	O
industries.	VBN	O
Combinatorial	IN	O
libraries	,	O
can	,	O
be	IN	O
produced	DT	O
for	,	O
many	,	O
types	,	O
of	,	O
compounds	,	O
that	,	O
can	,	O
be	CC	O
synthesized	JJ	O
in	.	O
a	JJ	O
step-by-step	NNS	O
fashion.	MD	O
Such	VB	O
compounds	VBN	O
include	IN	O
polypeptides,	JJ	O
proteins,	NNS	O
nucleic	IN	O
acids,	NNS	O
beta-turn	WDT	O
mimetics,	MD	O
polysaccharides,	VB	O
phospholipids,	VBN	O
hormones,	IN	O
prostaglandins,	DT	O
steroids,	JJ	O
aromatic	.	O
compounds,	JJ	O
heterocyclic	NNS	O
compounds,	VBP	O
benzodiazepines,	,	O
oligomeric	,	O
N-substituted	JJ	O
glycines	,	O
and	JJ	O
oligocarbamates.	,	O
Large	,	O
combinatorial	,	O
libraries	,	O
of	,	O
compounds	,	O
can	JJ	O
be	,	O
constructed	JJ	O
by	,	O
the	,	O
encoded	JJ	O
synthetic	JJ	O
libraries	NNS	O
(ESL)	CC	O
method	.	O
described	JJ	O
in	JJ	O
Affymax	NNS	O
WO	IN	O
95/12608,	NNS	O
Affymax	MD	O
WO	VB	O
93/06121,	VBN	O
Columbia	IN	O
University	DT	O
WO	JJ	O
94/08051,	JJ	O
Pharmacopeia	NNS	O
WO	)	O
95/35503	NN	O
and	VBN	O
Scripps	IN	O
WO	NNP	O
95/30642	NNP	O
(each	,	O
of	NNP	O
which	NNP	O
is	,	O
incorporated	NNP	O
herein	NNP	O
by	NNP	O
reference	,	O
in	NNP	O
its	NNP	O
entirety	CD	O
for	CC	O
all	NNP	O
purposes).	NNP	O
Peptide	CD	O
libraries	DT	O
can	IN	O
also	WDT	O
be	VBZ	O
generated	VBN	O
by	NN	O
phage	IN	O
display	NN	O
methods.	IN	O
See,	PRP$	O
e.g.,	NN	O
Devlin,	IN	O
WO	DT	O
91/18980.	.	O
Compounds	NNP	O
to	NNS	O
be	MD	O
screened	RB	O
can	VB	O
also	VBN	O
be	IN	O
obtained	NN	O
from	NN	O
governmental	.	O
or	,	O
private	,	O
sources,	,	O
including,	NNP	O
e.g.,	.	O
the	NNS	O
National	TO	O
Cancer	VB	O
Institute's	VBN	O
(NCI)	MD	O
Natural	RB	O
Product	VB	O
Repository,	VBN	O
Bethesda,	IN	O
Md.,	JJ	O
the	CC	O
NCI	JJ	O
Open	,	O
Synthetic	,	O
Compound	,	O
Collection,	DT	O
Bethesda,	NNP	O
Md.,	NNP	O
NCI's	POS	O
Developmental	)	O
Therapeutics	NNP	O
Program,	NNP	O
or	,	O
the	,	O
like.	,	O
Compounds	DT	O
can	NNP	O
include,	NNP	O
e.g.,	NNP	O
pharmaceuticals,	NNP	O
therapeutics,	,	O
environmental,	,	O
agricultural,	,	O
or	POS	O
industrial	JJ	O
agents,	NNPS	O
pollutants,	,	O
cosmeceuticals,	CC	O
drugs,	DT	O
organic	.	O
compounds,	NNS	O
lipids,	MD	O
glucocorticoids,	,	O
antibiotics,	,	O
peptides,	,	O
proteins,	,	O
sugars,	,	O
carbohydrates,	,	O
and	CC	O
chimeric	JJ	O
molecules.	,	O
As	,	O
discussed	,	O
above,	,	O
kinase	JJ	O
inhibitors	,	O
that	,	O
preferentially	,	O
inhibit	,	O
PLK2	,	O
are	,	O
of	,	O
particular	,	O
value.	CC	O
As	JJ	O
is	.	O
shown	IN	O
in	VBN	O
Examples	,	O
13-16,	VB	O
below,	NNS	O
we	WDT	O
assayed	RB	O
the	VBP	O
effect	NNP	O
of	VBP	O
several	IN	O
kinase	JJ	O
inhibitors	.	O
levels	IN	O
of	VBZ	O
phosphorylation	VBN	O
of	IN	O
alpha-synuclein	NNP	O
in	,	O
rat	,	O
ventral	PRP	O
mesencephalon	VBD	O
and	DT	O
mouse	NN	O
cortical	IN	O
cell	JJ	O
cultures,	NN	O
and	NNS	O
other	NNS	O
cells.	IN	O
An	NN	O
exemplary	IN	O
compound	NN	O
for	IN	O
use	JJ	O
according	JJ	O
to	NN	O
the	CC	O
invention	VB	O
is	JJ	O
the	NN	O
compound	,	O
BI2536	CC	O
having	JJ	O
the	.	O
structure:	DT	O
As	JJ	O
demonstrated	NN	O
in	IN	O
the	NN	O
Examples	VBG	O
below,	TO	O
BI	DT	O
2536	NN	O
(4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl)-benzamide;	VBZ	O
also	DT	O
called	NN	O
ELN-481574-2;)	NNP	O
reduced	VBG	O
phosphorylation	DT	O
of	:	O
alpha	IN	O
synuclein	VBN	O
in	IN	O
a	DT	O
variety	NNP	O
of	,	O
cell	NNP	O
types.	CD	O
BI	:	O
2536	RB	O
inhibits	VBD	O
PLK1,	)	O
PLK2	VBD	O
and	NN	O
PLK3	IN	O
(see,	JJ	O
Steegmaier	NN	B
et	IN	I
al.,	DT	I
2007,	NN	I
Current	IN	I
Biology,	NN	I
17:316-322)	.	I
and	IN	O
does	CD	O
not	NNS	O
inhibit	,	O
PLK4	NNP	O
Johnson	CC	B
et	NNP	I
al.,	,	I
2007,	NNP	I
Biochemistry	FW	I
46:9551-9563).(	,	O
Steegmaier	,	O
et	NNP	O
al.	,	O
reported	)	O
an	CC	O
IC50	VBZ	O
of	RB	O
0.83	VB	O
nM	NNP	O
for	NNP	O
PLK1,	RB	O
3.5	,	O
nM	,	O
for	NNP	O
PLK2	.	O
and	NNP	O
9	CC	O
nM	.	O
for	VBD	O
PLK3.	DT	O
In	NNP	O
tests	IN	O
described	CD	O
in	NNS	O
Example	IN	O
15,	,	O
below,	CD	O
BI2536	NN	O
was	IN	O
shown	NNP	O
to	CC	O
have	CD	O
16-fold	NN	O
selectivity	IN	O
for	.	O
PLK2	IN	O
(IC50	NNS	O
11	VBN	O
nM)	IN	O
and	NNP	O
13-fold	,	O
selectivity	,	O
for	NNP	O
PLK3	VBD	O
(IC50	VBN	O
14	TO	O
nM).	VB	O
BI	JJ	O
2536	NN	O
has	IN	O
category	NNP	O
IV	NNP	O
PLK2	CD	O
specificity	)	O
(Inhibits	CC	O
PLK2	JJ	O
activity	NN	O
and	IN	O
has	NNP	O
no,	NNP	O
or	CD	O
reduced,	.	O
effect	NN	O
on	CD	O
PLK4)	VBZ	O
and	VBN	O
is	NNP	O
a	NNP	O
candidate	NN	O
for	NNP	O
Parkinson's	NNP	O
disease	NN	O
therapeutics.	CC	O
Accordingly,	VBZ	O
in	,	O
one	CC	O
aspect	,	O
the	NN	O
invention	IN	O
provides	)	O
a	CC	O
method	VBZ	O
for	DT	O
inhibiting	NN	O
phosphorylation	IN	O
of	POS	O
alpha-synuclein	NN	O
in	.	O
a	,	O
mammalian	IN	O
cell	CD	O
by	NN	O
contacting	DT	O
the	NN	O
cell	VBZ	O
with	DT	O
an	NN	O
amount	IN	O
of	VBG	O
BI	NN	O
2536	IN	O
that	NN	O
reduces	IN	O
PLK2	DT	O
activity	JJ	O
in	NN	O
the	IN	O
cell	VBG	O
such	DT	O
that	NN	O
phosphorylation	IN	O
of	DT	O
alpha-synuclein	NN	O
is	IN	O
reduced.	NNP	O
In	CD	O
a	IN	O
related	VBZ	O
aspect,	NNP	O
the	NN	O
invention	IN	O
provides	DT	O
a	NN	O
method	JJ	O
of	IN	O
treating	NN	O
a	IN	O
patient	NN	O
diagnosed	VBZ	O
with	.	O
Parkinson's	IN	O
disease	DT	O
by	JJ	O
administering	,	O
a	DT	O
therapeutically	NN	O
effective	VBZ	O
amount	DT	O
of	NN	O
BI	IN	O
2536.	VBG	O
U.S.	DT	O
Pat.	NN	O
No.	VBN	O
6,861,422,	IN	O
incorporated	POS	O
herein	NN	O
by	IN	O
reference,	VBG	O
describes	DT	O
BI	RB	O
2536	JJ	O
and	NN	O
structurally	IN	O
related	NNP	O
dihydropteridinone	.	O
kinase	NNP	O
inhibitors.	.	O
Dihydropteridinone	.	O
compounds	,	O
that	VBN	O
inhibit	NN	O
PLK2	IN	O
are	,	O
useful	VBZ	O
for	NNP	O
inhibiting	CD	O
phosphorylation	CC	O
of	RB	O
synuclein.	JJ	O
Another	NN	O
exemplary	NN	O
compound	.	O
for	NNP	O
use	VBZ	O
according	IN	O
to	NN	O
the	NNP	O
invention	VBP	O
is	JJ	O
the	IN	O
compound	VBG	O
ELN-481080	NN	O
having	IN	O
the	.	O
structure:	DT	O
See,	JJ	O
McInnes	NN	B
et	IN	I
al.,	NN	I
2006,	VBG	I
Current	TO	I
Topics	DT	I
in	NN	I
Medicinal	VBZ	I
Chemistry	DT	I
5:181-97	NN	I
(Compound	NNP	O
8).	VBG	O
Also	DT	O
see	:	O
US	,	O
2006/0040997,	NNP	O
“Benzthiazole-3	FW	O
oxides	,	O
useful	,	O
for	NNP	O
the	NNPS	O
treatment	IN	O
of	NNP	O
proliferative	NNP	O
disorders”	JJ	O
incorporated	NNP	O
herein	.	O
by	RB	O
reference.	VBP	O
See	PRP	O
Example	,	O
14,	JJ	O
below.	NNS	O
Several	JJ	O
inhibitors	IN	O
of	DT	O
polo-like	NN	O
kinases	IN	O
are	JJ	O
described	NN	O
in	VBN	O
Johnson	NN	B
et	IN	I
al.,	.	I
2007,	VB	I
“Pharmacological	JJ	I
and	,	I
functional	.	I
comparison	JJ	I
of	NNS	I
the	IN	I
polo-like	JJ	I
kinase	NNS	I
family:	VBP	I
insight	VBN	I
into	IN	I
inhibitor	NNP	I
and	CC	I
substrate	,	I
specificity”	,	I
Biochemistry	JJ	I
46:9551-63.	CC	I
Of	JJ	O
those	NN	O
characterized	IN	O
in	DT	O
that	JJ	O
study,	NN	O
several	:	O
preferentially	NN	O
inhibit	IN	O
PLK2	NN	O
and	CC	O
may	NN	O
be	NNS	O
used	NNP	O
as	.	O
therapeutic	IN	O
agents.	DT	O
For	VBN	O
example,	IN	O
CHIR-258	DT	O
(3)	,	O
is	JJ	O
a	RB	O
multitarget	JJ	O
growth	NNP	O
factor	CC	O
kinase	MD	O
inhibitor	VB	O
developed	VBN	O
for	IN	O
treatment	JJ	O
of	.	O
t(4;14)	IN	O
multiple	,	O
myeloma	NNP	O
Trudel	)	B
et	VBZ	I
al.,	DT	I
2005,	NN	I
Blood.	NN	I
105:2941-8).(	NN	O
Ki	NN	O
values	NN	O
for	VBD	O
CHIR-258	IN	O
for	NN	O
PLK1,	IN	O
PLK2,	)	O
PLK3	NN	O
and	NN	O
PLK4	NNP	O
are	RB	O
>20,	,	O
0.85,	,	O
>20,	.	O
and	.	O
1.4	NNP	O
uM	NNS	O
respectively	IN	O
meaning	NNP	O
CHR-258	IN	O
is	,	O
a	,	O
Type	NNP	O
VI	CC	O
inhibitor	NNP	O
(inhibits	VBP	O
PLK2	,	O
activity	,	O
and	,	O
has	CC	O
reduced	CD	O
effect	JJ	O
on	RB	O
PLK1,	VBG	O
PLK3	NNP	O
and	VBZ	O
PLK4).	DT	O
Although	NNP	O
CHIR-258	NNP	O
is	NN	O
an	JJ	O
inhibitor	NNP	O
of	NN	O
receptor	CC	O
tyrosine	VBZ	O
kinases,	VBN	O
warranting	NN	O
study	IN	O
of	,	O
the	NNP	O
side	CC	O
effect	.	O
profile,	IN	O
targeted	NNP	O
delivery	VBZ	O
to	DT	O
the	NN	O
brain	IN	O
and/or	NN	O
particular	NN	O
treatment	,	O
regimens	VBG	O
can	NN	O
be	IN	O
investigated	DT	O
to	NN	O
determine	NN	O
whether	,	O
the	VBN	O
compound	NN	O
has	TO	O
an	DT	O
acceptable	NN	O
therapeutic	IN	O
index	JJ	O
for	NN	O
treatment	NNS	O
and	MD	O
prevention	VB	O
of	VBN	O
Parkinson's	TO	O
Disease,	VB	O
and	IN	O
a	DT	O
clinically	NN	O
acceptable	VBZ	O
side	DT	O
effect	JJ	O
profile.	JJ	O
CHIR-258	NN	O
and	IN	O
related	NN	O
quinolinone	CC	O
derivatives	NN	O
are	IN	O
described	POS	O
in	,	O
WO03087095,	CC	O
incorporated	DT	O
herein	RB	O
by	JJ	O
reference.	NN	O
Sunitinib	NN	O
(SU11248)	.	O
(4)	NNP	O
is	CC	O
an	VBN	O
example	NN	O
of	NNS	O
a	VBP	O
Type	VBN	O
IV	IN	O
inhibitor,	,	O
based	VBN	O
on	NN	O
the	IN	O
Johnson	.	O
et	NNP	O
al.,	)	O
2007,	)	O
studies	VBZ	O
(inhibits	DT	O
PLK2	NN	O
activity	IN	O
with	DT	O
reduced	NNP	O
effect	NNP	O
on	,	O
PLK1	VBN	O
or	IN	O
PLK3).	DT	O
Sunitinib	NNP	O
was	CC	O
identified	,	O
as	,	O
an	NNS	O
inhibitor	NNS	O
of	NNP	O
FLT3	NN	O
receptor	IN	O
tyrosine	JJ	O
kinase	NN	O
(RTK)	IN	O
approved	NNP	O
for	CC	O
treatment	.	O
of	NNP	O
advanced	VBD	O
renal	VBN	O
cell	IN	O
carcinoma	DT	O
and	NN	O
gastrointestinal	IN	O
stromal	NNP	O
tumors	NN	O
that	NN	O
are	NN	O
refractory	)	O
or	VBD	O
intolerant	IN	O
to	NN	O
imatinib	IN	O
(Gleevec).	JJ	O
O'Farrell	JJ	B
et	NN	I
al.,	NN	I
2003,	CC	I
Blood	JJ	I
101:3597-605.
5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-{[2-(trifluoromethyl)-benzyl]oxy}thiophene-2-carboxamide	NN	O
(5)	NNS	O
is	WDT	O
an	VBP	O
example	JJ	O
of	CC	O
a	JJ	O
Type	TO	O
III	VB	O
agent	.	O
(inhibits	NNP	O
PLK2	CC	O
activity	,	O
and	,	O
has	NNP	O
reduced	.	O
effect	JJ	O
on	)	O
PLK4).	VBZ	O
The	DT	O
compound	NN	O
was	IN	O
initially	DT	O
identified	NNP	O
as	NNP	O
a	NN	O
selective	JJ	O
thiophene	NNP	O
benzimidazole	NN	O
ATP-competitive	CC	O
inhibitor	VBZ	O
of	VBN	O
PLK1	NN	O
and	IN	O
PLK3	.	O
for	DT	O
treatment	NN	O
of	VBD	O
neoplasms.	RB	O
Lansing	VBN	B
et	IN	I
al.,	DT	I
2007,	JJ	I
Mol	NN	I
Cancer	JJ	I
Ther.	JJ	I
6:450-9.	NN	I
Also	IN	O
see	NNP	O
US	CC	O
20060074119,	NNP	O
incorporated	IN	O
herein	NN	O
by	IN	O
reference,	.	O
describing	VBG	O
other	NN	O
inhibitors	,	O
of	,	O
PLKs.	NNP	O
Compounds	NNP	O
6	.	O
and	.	O
7	RB	O
are	VBP	O
indazole-pyridine	PRP	O
based	,	O
inhibitors	VBN	O
of	NN	O
protein	IN	O
kinase	,	O
B/Akt	VBG	O
proposed	JJ	O
as	NNS	O
antitumor	IN	O
agents	.	O
(see	NNS	O
Woods	CD	B
et	CC	I
al.,	CD	I
2006,	VBP	I
Bioorg	JJ	I
Med	VBN	I
Chem.	NNS	I
14:6832-46).Each	IN	O
has	JJ	O
a	NN	O
lower	NNP	O
Ki	VBD	O
for	IN	O
PLK2	NN	O
than	NNS	O
for	VB	O
PLK1	NNP	O
or	FW	O
PLK3	,	O
(Type	,	O
IV	NNP	O
inhibitor)	NNP	O
and	.	O
may	.	O
be	DT	O
used	VBZ	O
for	DT	O
treatment	JJR	O
of	NNP	O
Parkinson's	IN	O
disease.	NNP	O
In	IN	O
some	IN	O
embodiments	NNP	O
the	CC	O
agent	NNP	O
is	NNP	O
a	NNP	O
naturally	)	O
occurring	CC	O
agent.	MD	O
In	VB	O
some	VBN	O
embodiments	IN	O
the	NN	O
agent	IN	O
has	POS	O
a	.	O
molecular	IN	O
weight	DT	O
less	NNS	O
than	DT	O
4000,	NN	O
sometimes	VBZ	O
less	DT	O
than	RB	O
3000,	VBG	O
sometimes	.	O
less	IN	O
than	DT	O
2000,	NNS	O
usually	DT	O
less	NN	O
than	VBZ	O
1000,	DT	O
and	JJ	O
sometimes	NN	O
less	JJR	O
than	IN	O
500.	,	O
In	RB	O
certain	JJR	O
embodiments	IN	O
the	,	O
therapeutic	RB	O
agent	JJR	O
is	IN	O
a	,	O
small	RB	O
molecule	JJR	O
other	IN	O
than	,	O
a	CC	O
thiazolidone.	RB	O
In	JJR	O
certain	IN	O
embodiments	.	O
the	IN	O
therapeutic	JJ	O
agent	NNS	O
is	DT	O
a	JJ	O
small	NN	O
molecule	VBZ	O
other	DT	O
than	JJ	O
X,	NN	O
where	JJ	O
X	IN	O
is	DT	O
one	.	O
of,	IN	O
or	JJ	O
an	NNS	O
independently	DT	O
selected	JJ	O
one	NN	O
or	VBZ	O
more	DT	O
of,	JJ	O
(i)	NN	O
a	JJ	O
thiazolidone,	IN	O
(ii)	,	O
a	WRB	O
quinazoline,	NN	O
(iii)	VBZ	O
a	CD	O
pyrimidine,	,	O
(iv)	CC	O
pyrido[d]-pyrimidine,	DT	O
(v)	RB	O
a	VBN	O
pyrimidol[d]pyrimidine,	CD	O
(vi)	CC	O
a	JJR	O
pyrazolo[d]-pyrimidine,	,	O
(vii)	)	O
a	DT	O
pyrrolo[d]pyrimidine,	,	O
(viii)	)	O
a	DT	O
pheylamino-pyrimidines,	,	O
(ix)	)	O
phenylamino-pyrimidine	DT	O
derivative,	,	O
(x)	)	O
a	,	O
indazole-pyridine	)	O
derivative,	DT	O
(xi)	,	O
a	)	O
carboxylic	DT	O
acid	,	O
derivative,	)	O
(xii)	DT	O
a	,	O
1-oxo-3-aryl-1H-indene-2-carboxylic	)	O
acid	DT	O
derivative,	,	O
(xiii)	)	O
a	NN	O
substituted	,	O
indolin-2-one,	)	O
(xiv)	DT	O
an	JJ	O
aniline-phthalazine	,	O
derivative;	)	O
(xv)	DT	O
a	JJ	O
quinolinone	NN	O
derivative,	,	O
(xvi)	)	O
a	DT	O
thiazolidinone	JJ	O
compound,	NN	O
(xvii)	,	O
a	)	O
benzthiazole-3	DT	O
oxide	JJ	O
(xviii)	,	O
a	)	O
dihydropteridinone	DT	O
or	JJ	O
(xix)	:	O
an	)	O
azaindazole	DT	O
compound.	NN	O
In	,	O
certain	)	O
embodiments	DT	O
the	NN	O
therapeutic	,	O
agent	)	O
is	DT	O
a	JJ	O
small	NN	O
molecule	)	O
with	DT	O
the	NN	O
proviso	CC	O
it	)	O
is	DT	O
not	JJ	O
a	.	O
compound	IN	O
described	JJ	O
in	NNS	O
US	DT	O
2007/0179177.	JJ	O
In	NN	O
certain	VBZ	O
embodiments	DT	O
the	JJ	O
therapeutic	NN	O
agent	IN	O
is	DT	O
a	NN	O
small	PRP	O
molecule	VBZ	O
with	RB	O
the	DT	O
proviso	NN	O
it	VBN	O
is	IN	O
not	NNP	O
a	.	O
compound	IN	O
described	JJ	O
in	NNS	O
US	DT	O
2007/0010565.	JJ	O
In	NN	O
certain	VBZ	O
embodiments	DT	O
the	JJ	O
therapeutic	NN	O
agent	IN	O
is	DT	O
a	NN	O
small	PRP	O
molecule	VBZ	O
with	RB	O
the	DT	O
proviso	NN	O
it	VBN	O
is	IN	O
not	NNP	O
a	.	O
compound	IN	O
described	JJ	O
in	NNS	O
US	DT	O
2007/0037862.	JJ	O
In	NN	O
certain	VBZ	O
embodiments	DT	O
the	JJ	O
therapeutic	NN	O
agent	IN	O
is	DT	O
a	NN	O
small	PRP	O
molecule	VBZ	O
with	RB	O
the	DT	O
proviso	NN	O
it	VBN	O
is	IN	O
not	NNP	O
a	.	O
compound	IN	O
described	JJ	O
in	NNS	O
2007/0010566.	DT	O
In	JJ	O
certain	NN	O
embodiments	VBZ	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	IN	O
a	DT	O
small	NN	O
molecule	PRP	O
with	VBZ	O
the	RB	O
proviso	DT	O
it	NN	O
is	VBN	O
not	IN	O
a	.	O
compound	IN	O
described	JJ	O
in	NNS	O
2006/0079503.	DT	O
In	JJ	O
certain	NN	O
embodiments	VBZ	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	IN	O
a	DT	O
small	NN	O
molecule	PRP	O
with	VBZ	O
the	RB	O
proviso	DT	O
it	NN	O
is	VBN	O
not	IN	O
a	.	O
compound	IN	O
described	JJ	O
in	NNS	O
US	DT	O
2006/0223833.	JJ	O
Each	NN	O
of	VBZ	O
the	DT	O
aforelisted	JJ	O
publications	NN	O
is	IN	O
incorporated	DT	O
herein	NN	O
by	PRP	O
reference.	VBZ	O
VI.	RB	O
Methods	DT	O
of	NN	O
Treatment	VBN	O
The	IN	O
invention	NNP	O
provides	.	O
several	DT	O
methods	IN	O
of	DT	O
preventing	JJ	O
or	NNS	O
treating	VBZ	O
Lewy	VBN	O
Body	NN	O
disease	IN	O
in	.	O
patients	.	O
suffering	NNS	O
from	IN	O
or	NNP	O
at	DT	O
risk	NN	O
of	VBZ	O
such	JJ	O
disease.	NNS	O
Therapeutic	IN	O
agents	VBG	O
include	CC	O
any	VBG	O
of	NNP	O
the	NNP	O
agents	NN	O
described	IN	O
above	NNS	O
that	VBG	O
inhibit	IN	O
phosphorylation	CC	O
of	IN	O
alpha-synuclein	NN	O
and/or	IN	O
reduce	JJ	O
total	.	O
levels	JJ	O
of	NNS	O
alpha-synuclein.	VBP	O
The	DT	O
experimental	IN	O
examples	DT	O
below	NNS	O
provide	VBN	O
strong	IN	O
evidence	DT	O
that	NN	O
PLK2	NN	O
is	IN	O
a	JJ	O
synuclein	NN	O
kinase.	VB	O
Thus,	JJ	O
in	NNS	O
a	IN	O
particular	.	O
aspect,	DT	O
the	JJ	O
invention	NNS	O
provides	IN	O
a	VBP	O
method	JJ	O
of	NN	O
effecting	IN	O
treatment	NNP	O
or	VBZ	O
prophylaxis	DT	O
of	JJ	O
an	.	O
LB	,	O
disease	IN	O
by	DT	O
administering	JJ	O
to	,	O
a	DT	O
patient	NN	O
suffering	VBZ	O
from	DT	O
or	NN	O
at	IN	O
risk	VBG	O
of	NN	O
the	CC	O
disease	NN	O
an	IN	O
effective	DT	O
regime	NNP	O
of	NN	O
an	IN	O
agent	VBG	O
effective	TO	O
to	DT	O
suppress	NN	O
activity	VBG	O
or	IN	O
expression	CC	O
of	IN	O
PLK2.	NN	O
It	IN	O
is	DT	O
preferred	NN	O
that	DT	O
the	JJ	O
agent	NN	O
shows	IN	O
a	DT	O
high	JJ	O
level	JJ	O
of	TO	O
specificity	VB	O
for	NN	O
PLK2.	CC	O
Patients	NN	O
amenable	IN	O
to	.	O
treatment	PRP	O
include	VBZ	O
individuals	VBN	O
at	IN	O
risk	DT	O
of	NN	O
disease	VBZ	O
of	DT	O
a	JJ	O
LBD	NN	O
but	IN	O
not	NN	O
showing	IN	O
symptoms,	.	O
as	NNS	O
well	JJ	O
as	TO	O
patients	NN	O
presently	JJ	O
showing	NNS	O
symptoms.	IN	O
Therefore,	NN	O
the	IN	O
present	NN	O
methods	IN	O
can	DT	O
be	NNP	O
administered	CC	O
prophylactically	RB	O
to	VBG	O
individuals	,	O
who	RB	O
have	RB	O
a	IN	O
known	NNS	O
genetic	RB	O
risk	VBG	O
of	.	O
a	,	O
LBD.	DT	O
Such	JJ	O
individuals	NNS	O
include	MD	O
those	VB	O
having	VBN	O
relatives	RB	O
who	TO	O
have	NNS	O
experienced	WP	O
this	VBP	O
disease,	DT	O
and	VBN	O
those	JJ	O
whose	NN	O
risk	IN	O
is	DT	O
determined	.	O
by	JJ	O
analysis	NNS	O
of	VBP	O
genetic	DT	O
or	VBG	O
biochemical	NNS	O
markers.	WP	O
Genetic	VBP	O
markers	VBN	O
of	DT	O
risk	,	O
toward	CC	O
PD	DT	O
include	WP$	O
mutations	NN	O
in	VBZ	O
the	VBN	O
alpha-synuclein	IN	O
or	NN	O
Parkin,	IN	O
UCHLI,	JJ	O
LRRK2,	CC	O
and	JJ	O
CYP2D6	.	O
genes;	JJ	O
particularly	NNS	O
mutations	IN	O
at	NN	O
positions	IN	O
30	NNP	O
and	VBP	O
53	NNS	O
of	IN	O
the	DT	O
alpha-synuclein	NN	O
gene.	CC	O
Another	,	O
genetic	,	O
marker	,	O
of	CC	O
risk	NNP	O
toward	:	O
PD	RB	O
includes	NNS	O
measuring	IN	O
the	NNS	O
levels	CD	O
or	CC	O
SNCA	CD	O
dosage	IN	O
or	DT	O
transcription.	JJ	O
Individuals	.	O
presently	DT	O
suffering	JJ	O
from	NN	O
Parkinson's	IN	O
disease	NN	O
can	IN	O
be	NNP	O
recognized	VBZ	O
from	VBG	O
its	DT	O
clinical	NNS	O
manifestations	CC	O
including	NNP	O
resting	NN	O
tremor,	CC	O
muscular	.	O
rigidity,	NNS	O
bradykinesia	RB	O
and	VBG	O
postural	IN	O
instability.	POS	O
In	NN	O
some	MD	O
methods,	VB	O
the	VBN	O
patient	IN	O
is	PRP$	O
free	JJ	O
of	NNS	O
clinical	VBG	O
symptoms	VBG	O
or	,	O
risk	JJ	O
factors	,	O
for	NN	O
any	CC	O
amyloidogenic	JJ	O
disease	.	O
other	IN	O
than	DT	O
one	,	O
characterized	DT	O
by	NN	O
Lewy	VBZ	O
bodies.	JJ	O
In	IN	O
some	JJ	O
methods,	NNS	O
the	CC	O
patient	NN	O
is	NNS	O
free	IN	O
of	DT	O
clinical	JJ	O
symptoms	NN	O
or	JJ	O
risk	IN	O
factors	CD	O
of	VBN	O
any	IN	O
disease	NNP	O
characterized	.	O
by	IN	O
extracellular	DT	O
amyloid	,	O
deposits.	DT	O
In	NN	O
some	VBZ	O
methods	JJ	O
the	IN	O
patient	JJ	O
is	NNS	O
not	CC	O
diagnosed	NN	O
with	NNS	O
cancer	IN	O
and/or	DT	O
Alzheimer's	NN	O
disease.	VBN	O
Treatment	IN	O
typically	JJ	O
entails	NN	O
multiple	.	O
dosages	IN	O
over	DT	O
a	NNS	O
period	DT	O
of	NN	O
time.	VBZ	O
Treatment	RB	O
can	VBN	O
be	IN	O
monitored	NN	O
by	VBP	O
assaying	POS	O
signs	.	O
or	NNP	O
symptoms	RB	O
of	VBZ	O
the	JJ	O
disease	NNS	O
being	IN	O
treated	DT	O
relative	NN	O
to	IN	O
base	.	O
line	NN	O
measurements	MD	O
before	VB	O
initiating	VBN	O
treatment.	IN	O
In	VBG	O
some	NNS	O
methods,	CC	O
administration	NNS	O
of	IN	O
an	DT	O
agent	NN	O
results	VBG	O
in	VBN	O
reduction	JJ	O
of	TO	O
intracellular	VB	O
levels	NN	O
of	NNS	O
aggregated	IN	O
alpha-synuclein.	VBG	O
In	.	O
some	IN	O
methods,	DT	O
administration	,	O
of	NN	O
the	IN	O
agent	DT	O
results	JJ	O
in	NNS	O
a	IN	O
reduction	NN	O
in	IN	O
levels	JJ	O
of	NNS	O
phosphorylated	IN	O
synuclein.	JJ	O
In	.	O
some	IN	O
methods,	DT	O
administration	,	O
of	NN	O
an	IN	O
agent	DT	O
results	NN	O
in	NNS	O
improvement	IN	O
in	DT	O
a	NN	O
clinical	IN	O
symptom	NNS	O
of	IN	O
a	VBN	O
LBD,	.	O
such	IN	O
as	DT	O
motor	,	O
or	NN	O
cognitive	IN	O
function	DT	O
in	JJ	O
the	NNS	O
case	IN	O
of	NN	O
Parkinson's	IN	O
disease.	DT	O
In	JJ	O
prophylactic	NN	O
applications,	IN	O
pharmaceutical	DT	O
compositions	,	O
or	JJ	O
medicaments	IN	O
are	NN	O
administered	CC	O
to	JJ	O
a	NN	O
patient	IN	O
susceptible	DT	O
to,	NN	O
or	IN	O
otherwise	POS	O
at	.	O
risk	IN	O
of	JJ	O
a	,	O
LBD	JJ	O
in	NNS	O
regime	CC	O
comprising	NNS	O
an	VBP	O
amount	VBN	O
and	TO	O
frequency	DT	O
of	NN	O
administration	JJ	O
of	,	O
the	CC	O
composition	RB	O
or	IN	O
medicament	NN	O
sufficient	IN	O
to	DT	O
eliminate	NNP	O
or	IN	O
reduce	NN	O
the	VBG	O
risk,	DT	O
lessen	NN	O
the	CC	O
severity,	NN	O
or	IN	O
delay	NN	O
the	IN	O
outset	DT	O
of	NN	O
the	CC	O
disease,	NN	O
including	NN	O
physiological,	TO	O
biochemical,	VB	O
histologic	CC	O
and/or	VB	O
behavioral	DT	O
symptoms	,	O
of	VBD	O
the	DT	O
disease,	,	O
its	CC	O
complications	VB	O
and	DT	O
intermediate	NN	O
pathological	IN	O
phenotypes	DT	O
presenting	,	O
during	VBG	O
development	,	O
of	,	O
the	JJ	O
disease.	JJ	O
In	JJ	O
therapeutic	NNS	O
applications,	IN	O
compositions	DT	O
or	,	O
medicates	PRP$	O
are	NNS	O
administered	CC	O
to	JJ	O
a	JJ	O
patient	NNS	O
suspected	VBG	O
of,	IN	O
or	NN	O
already	IN	O
suffering	DT	O
from	.	O
such	IN	O
a	JJ	O
disease	,	O
in	NNS	O
a	CC	O
regime	NNS	O
comprising	VBP	O
an	VBN	O
amount	TO	O
and	DT	O
frequency	NN	O
of	VBN	O
administration	,	O
of	CC	O
the	RB	O
composition	VBG	O
sufficient	IN	O
to	JJ	O
cure,	DT	O
or	NN	O
at	IN	O
least	DT	O
partially	NN	O
arrest,	VBG	O
the	DT	O
symptoms	NN	O
of	CC	O
the	NN	O
disease	IN	O
(physiological,	NN	O
biochemical,	IN	O
histologic	DT	O
and/or	NN	O
behavioral),	NN	O
including	TO	O
its	,	O
complications	CC	O
and	IN	O
intermediate	JJS	O
pathological	RB	O
phenotypes	,	O
in	DT	O
development	NNS	O
of	IN	O
the	DT	O
disease.	NN	O
An	,	O
amount	,	O
adequate	JJ	O
to	IN	O
accomplish	,	O
therapeutic	VBG	O
or	PRP$	O
prophylactic	NNS	O
treatment	CC	O
is	JJ	O
defined	JJ	O
as	NNS	O
a	IN	O
therapeutically-	NN	O
or	IN	O
prophylactically-effective	DT	O
dose.	.	O
A	DT	O
combination	NN	O
of	NN	O
amount	TO	O
and	VB	O
dosage	JJ	O
frequency	CC	O
adequate	JJ	O
to	NN	O
accomplish	VBZ	O
therapeutic	VBN	O
or	IN	O
prophylactic	DT	O
treatment	JJ	O
is	CC	O
defined	JJ	O
as	.	O
a	DT	O
therapeutically	NN	O
or	IN	O
prophylactically-effective	NN	O
regime.	CC	O
Effective	NN	O
doses	NN	O
of	NN	O
the	TO	O
compositions	VB	O
of	JJ	O
the	CC	O
present	JJ	O
invention,	NN	O
for	VBZ	O
the	VBN	O
treatment	IN	O
of	DT	O
the	RB	O
above	CC	O
described	JJ	O
conditions	.	O
vary	JJ	O
depending	NNS	O
upon	IN	O
many	DT	O
different	NNS	O
factors,	IN	O
including	DT	O
means	JJ	O
of	,	O
administration,	IN	O
target	DT	O
site,	NN	O
physiological	IN	O
state	DT	O
of	JJ	O
the	NN	O
patient,	NNS	O
whether	VBP	O
the	VBG	O
patient	IN	O
is	JJ	O
human	JJ	O
or	,	O
an	VBG	O
animal,	NNS	O
other	IN	O
medications	,	O
administered,	VB	O
and	,	O
whether	JJ	O
treatment	NN	O
is	IN	O
prophylactic	DT	O
or	,	O
therapeutic.	IN	O
Usually,	DT	O
the	NN	O
patient	VBZ	O
is	JJ	O
a	CC	O
human	DT	O
but	,	O
nonhuman	JJ	O
mammals	NNS	O
including	,	O
transgenic	CC	O
mammals	IN	O
can	NN	O
also	VBZ	O
be	JJ	O
treated.	CC	O
Treatment	.	O
dosages	,	O
need	DT	O
to	NN	O
be	VBZ	O
titrated	DT	O
to	JJ	O
optimize	CC	O
safety	JJ	O
and	NNS	O
efficacy.	VBG	O
The	JJ	O
dosage	NNS	O
and	MD	O
frequency	RB	O
of	VB	O
administration	.	O
can	NN	O
vary	NNS	O
depending	VBP	O
on	TO	O
whether	VB	O
the	VBN	O
treatment	TO	O
is	VB	O
prophylactic	NN	O
or	CC	O
therapeutic.	.	O
Guidance	DT	O
can	NN	O
be	CC	O
obtained	NN	O
from	IN	O
the	NN	O
dosing	MD	O
schedules	VB	O
of	VBG	O
kinase	IN	O
inhibitors	IN	O
currently	DT	O
approved	NN	O
or	VBZ	O
in	JJ	O
clinical	CC	O
trials	.	O
for	NN	O
other	MD	O
indications.	VB	O
Dosages	VBN	O
in	IN	O
the	DT	O
range	VBG	O
of	NNS	O
0.1-1000	IN	O
mg,	NN	O
preferably	NNS	O
10-500	RB	O
mg,	VBD	O
may	CC	O
be	IN	O
used.	JJ	O
Frequency	NNS	O
of	IN	O
dosing	JJ	O
(e.g.,	.	O
daily,	NNS	O
weekly	IN	O
or	DT	O
monthly)	NN	O
depends	IN	O
on	CD	O
the	,	O
half-life	RB	O
of	CD	O
the	,	O
drug.	MD	O
In	VB	O
prophylactic	.	O
applications,	NN	O
a	IN	O
relatively	VBG	O
low	,	O
dosage	,	O
is	JJ	O
administered	CC	O
at	)	O
relatively	VBZ	O
infrequent	IN	O
intervals	DT	O
over	NN	O
a	IN	O
long	DT	O
period	.	O
of	IN	O
time.	JJ	O
Some	,	O
patients	DT	O
continue	RB	O
to	JJ	O
receive	NN	O
treatment	VBZ	O
for	VBN	O
the	IN	O
rest	RB	O
of	JJ	O
their	NNS	O
lives.	IN	O
In	DT	O
therapeutic	JJ	O
applications,	NN	O
a	IN	O
relatively	.	O
high	DT	O
dosage	NNS	O
at	VBP	O
relatively	TO	O
short	VB	O
intervals	NN	O
is	IN	O
sometimes	DT	O
required	NN	O
until	IN	O
progression	PRP$	O
of	.	O
the	IN	O
disease	JJ	O
is	,	O
reduced	DT	O
or	RB	O
terminated,	JJ	O
and	NN	O
preferably	IN	O
until	RB	O
the	JJ	O
patient	NNS	O
shows	VBZ	O
partial	RB	O
or	VBN	O
complete	IN	O
amelioration	NN	O
of	IN	O
symptoms	DT	O
of	NN	O
disease.	VBZ	O
Thereafter,	VBN	O
the	CC	O
patent	,	O
can	CC	O
be	RB	O
administered	IN	O
a	DT	O
prophylactic	NN	O
regime.	VBZ	O
Therapeutic	JJ	O
agents	CC	O
can	JJ	O
be	NN	O
administered	IN	O
by	NNS	O
parenteral,	IN	O
topical,	.	O
intravenous,	,	O
oral,	DT	O
subcutaneous,	NN	O
intraarterial,	MD	O
intracranial,	VB	O
intrathecal,	VBN	O
intraperitoneal,	DT	O
intranasal	JJ	O
or	.	O
intramuscular	JJ	O
means	NNS	O
for	MD	O
prophylactic	VB	O
and/or	VBN	O
therapeutic	IN	O
treatment.	,	O
In	,	O
some	,	O
methods,	,	O
agents	,	O
are	,	O
injected	,	O
directly	,	O
into	,	O
a	NN	O
particular	CC	O
tissue	JJ	O
where	NNS	O
deposits	IN	O
have	JJ	O
accumulated,	JJ	O
for	JJ	O
example	.	O
intracranial	IN	O
injection.	DT	O
In	,	O
some	NNS	O
methods,	VBP	O
agents	VBN	O
are	RB	O
administered	IN	O
as	DT	O
a	JJ	O
sustained	NN	O
release	WRB	O
composition	NNS	O
or	VBP	O
device,	,	O
such	IN	O
as	NN	O
a	JJ	O
Medipad™	.	O
device.	IN	O
Small	DT	O
molecules	,	O
that	NNS	O
pass	VBP	O
through	VBN	O
the	IN	O
blood	DT	O
brain	JJ	O
barrier	NN	O
sufficiently	NN	O
are	CC	O
usually	,	O
administered	JJ	O
orally,	IN	O
but	DT	O
can	NNP	O
also	.	O
be	JJ	O
administered	NNS	O
intravenously.	WDT	O
Agents	VBP	O
of	IN	O
the	DT	O
invention	NN	O
can	NN	O
optionally	NN	O
be	RB	O
administered	VBP	O
in	RB	O
combination	VBN	O
with	,	O
other	CC	O
agents	MD	O
that	RB	O
are	VB	O
at	VBN	O
least	.	O
partly	NNS	O
effective	IN	O
in	DT	O
treatment	NN	O
of	MD	O
LBD.	RB	O
Agents	VB	O
of	VBN	O
the	IN	O
invention	NN	O
can	IN	O
also	JJ	O
be	NNS	O
administered	WDT	O
in	VBP	O
conjunction	IN	O
with	JJS	O
other	RB	O
agents	JJ	O
that	IN	O
increase	NN	O
passage	IN	O
of	.	O
the	NNS	O
agents	IN	O
of	DT	O
the	NN	O
invention	MD	O
across	RB	O
the	VB	O
blood-brain	VBN	O
barrier.	IN	O
Agents	NN	O
of	IN	O
the	JJ	O
invention	NNS	O
are	IN	O
often	JJ	O
administered	NN	O
as	IN	O
pharmaceutical	DT	O
compositions	NNS	O
comprising	IN	O
an	DT	O
active	NN	O
therapeutic	IN	O
agent	DT	O
and	NN	O
a	.	O
variety	NNS	O
of	IN	O
other	DT	O
pharmaceutically	NN	O
acceptable	VBP	O
components.	RB	O
See	VBN	O
Remington's	IN	B
Pharmaceutical	JJ	I
Science	NNS	I
(15th	VBG	I
ed.,	DT	I
Mack	JJ	I
Publishing	JJ	I
Company,	NN	I
Easton,	CC	I
Pa.,	DT	I
1980).	NN	I
The	IN	O
preferred	JJ	O
form	RB	O
depends	JJ	O
on	.	O
the	NNP	O
intended	POS	O
mode	JJ	O
of	NNP	O
administration	CD	O
and	,	O
therapeutic	NNP	O
application.	NNP	O
The	,	O
compositions	,	O
can	,	O
also	.	O
include,	DT	O
depending	JJ	O
on	NN	O
the	VBZ	O
formulation	IN	O
desired,	DT	O
pharmaceutically-acceptable,	JJ	O
non-toxic	NN	O
carriers	IN	O
or	NN	O
diluents,	CC	O
which	JJ	O
are	.	O
defined	DT	O
as	NNS	O
vehicles	MD	O
commonly	RB	O
used	,	O
to	VBG	O
formulate	IN	O
pharmaceutical	DT	O
compositions	NN	O
for	,	O
animal	,	O
or	JJ	O
human	NNS	O
administration.	CC	O
The	,	O
diluent	WDT	O
is	VBP	O
selected	VBN	O
so	IN	O
as	NNS	O
not	RB	O
to	VBD	O
affect	TO	O
the	VB	O
biological	JJ	O
activity	NNS	O
of	IN	O
the	NN	O
combination.	CC	O
Examples	JJ	O
of	.	O
such	DT	O
diluents	NN	O
are	VBZ	O
distilled	VBN	O
water,	RB	O
physiological	IN	O
phosphate-buffered	RB	O
saline,	TO	O
Ringer's	VB	O
solutions,	DT	O
dextrose	JJ	O
solution,	NN	O
and	IN	O
Hank's	DT	O
solution.	.	O
In	NNS	O
addition,	IN	O
the	JJ	O
pharmaceutical	NNS	O
composition	VBP	O
or	JJ	O
formulation	,	O
may	JJ	O
also	JJ	O
include	,	O
other	POS	O
carriers,	,	O
adjuvants,	JJ	O
or	,	O
nontoxic,	CC	O
nontherapeutic,	POS	O
nonimmunogenic	.	O
stabilizers	IN	O
and	,	O
the	DT	O
like.	JJ	O
Pharmaceutical	NN	O
compositions	CC	O
can	NN	O
also	MD	O
include	RB	O
large,	VB	O
slowly	JJ	O
metabolized	,	O
macromolecules	,	O
such	CC	O
as	,	O
proteins,	,	O
polysaccharides	JJ	O
such	NNS	O
as	CC	O
chitosan,	DT	O
polylactic	.	O
acids,	JJ	O
polyglycolic	NNS	O
acids	MD	O
and	RB	O
copolymers	VB	O
(such	,	O
as	RB	O
latex	VBN	O
functionalized	NNS	O
Sepharose™,	JJ	O
agarose,	IN	O
cellulose,	,	O
and	NNS	O
the	JJ	O
like),	IN	O
polymeric	,	O
amino	JJ	O
acids,	,	O
amino	JJ	O
acid	NNS	O
copolymers,	CC	O
and	NNS	O
lipid	JJ	O
aggregates	IN	O
(such	JJ	O
as	JJ	O
oil	,	O
droplets	,	O
or	,	O
liposomes).	CC	O
For	DT	O
parenteral	,	O
administration,	JJ	O
agents	NN	O
of	,	O
the	JJ	O
invention	NN	O
can	,	O
be	CC	O
administered	JJ	O
as	NNS	O
injectable	JJ	O
dosages	IN	O
of	NN	O
a	NNS	O
solution	CC	O
or	.	O
suspension	IN	O
of	JJ	O
the	,	O
substance	NNS	O
in	IN	O
a	DT	O
physiologically	NN	O
acceptable	MD	O
diluent	VB	O
with	VBN	O
a	IN	O
pharmaceutical	JJ	O
carrier	NNS	O
that	IN	O
can	DT	O
be	NN	O
a	CC	O
sterile	NN	O
liquid	IN	O
such	DT	O
as	NN	O
water,	IN	O
oils,	DT	O
saline,	RB	O
glycerol,	JJ	O
or	NN	O
ethanol.	IN	O
Additionally,	DT	O
auxiliary	JJ	O
substances,	NN	O
such	WDT	O
as	MD	O
wetting	VB	O
or	DT	O
emulsifying	JJ	O
agents,	NN	O
surfactants,	JJ	O
pH	IN	O
buffering	,	O
substances	,	O
and	,	O
the	,	O
like	CC	O
can	.	O
be	,	O
present	JJ	O
in	,	O
compositions.	JJ	O
Other	IN	O
components	VBG	O
of	CC	O
pharmaceutical	VBG	O
compositions	,	O
are	,	O
those	NN	O
of	NN	O
petroleum,	NNS	O
animal,	CC	O
vegetable,	DT	O
or	JJ	O
synthetic	MD	O
origin,	VB	O
for	JJ	O
example,	IN	O
peanut	.	O
oil,	JJ	O
soybean	NNS	O
oil,	IN	O
and	JJ	O
mineral	NNS	O
oil.	VBP	O
In	DT	O
general,	IN	O
glycols	,	O
such	,	O
as	,	O
propylene	CC	O
glycol	JJ	O
or	,	O
polyethylene	IN	O
glycol	,	O
are	JJ	O
preferred	,	O
liquid	NN	O
carriers,	,	O
particularly	CC	O
for	JJ	O
injectable	.	O
solutions.	IN	O
Antibodies	,	O
can	NNS	O
be	JJ	O
administered	IN	O
in	NN	O
the	NN	O
form	CC	O
of	NN	O
a	NNS	O
depot	VBP	O
injection	VBN	O
or	JJ	O
implant	,	O
preparation	RB	O
which	IN	O
can	JJ	O
be	.	O
formulated	NNS	O
in	MD	O
such	VB	O
a	VBN	O
manner	IN	O
as	DT	O
to	NN	O
permit	IN	O
a	DT	O
sustained	NN	O
release	NN	O
of	CC	O
the	JJ	O
active	NN	O
ingredient.	WDT	O
An	MD	O
exemplary	VB	O
composition	VBN	O
comprises	IN	O
monoclonal	JJ	O
antibody	DT	O
at	NN	O
5	IN	O
mg/mL,	TO	O
formulated	VB	O
in	DT	O
aqueous	JJ	O
buffer	NN	O
consisting	IN	O
of	DT	O
50	JJ	O
mM	.	O
L-histidine,	DT	O
150	JJ	O
mM	NN	O
NaCl,	VBZ	O
adjusted	JJ	O
to	NN	O
pH	IN	O
6.0	CD	O
with	,	O
HCl.	VBN	O
Compositions	IN	O
for	JJ	O
parenteral	NN	O
administration	NN	O
are	IN	O
typically	CD	O
substantially	JJ	O
sterile,	,	O
substantially	CD	O
isotonic	NN	O
and	,	O
manufactured	VBD	O
under	TO	O
GMP	VB	O
conditions	CD	O
of	IN	O
the	.	O
FDA	NNS	O
or	IN	O
similar	JJ	O
body.	NN	O
Compositions	VBP	O
may	RB	O
be	RB	O
prepared	,	O
as	RB	O
injectables,	JJ	O
either	CC	O
as	VBD	O
liquid	IN	O
solutions	NNP	O
or	NNS	O
suspensions;	IN	O
solid	DT	O
forms	NNP	O
suitable	CC	O
for	JJ	O
solution	.	O
in,	NNS	O
or	MD	O
suspension	VB	O
in,	VBN	O
liquid	IN	O
vehicles	,	O
prior	CC	O
to	IN	O
injection	JJ	O
can	NNS	O
also	CC	O
be	:	O
prepared.	JJ	O
The	NNS	O
preparation	JJ	O
also	IN	O
can	NN	O
be	,	O
emulsified	CC	O
or	NN	O
encapsulated	,	O
in	JJ	O
liposomes	NNS	O
or	RB	O
micro	TO	O
particles	NN	O
such	MD	O
as	RB	O
polylactide,	VB	O
polyglycolide,	.	O
or	DT	O
copolymer	NN	O
for	RB	O
enhanced	MD	O
adjuvant	VB	O
effect,	VBN	O
as	CC	O
discussed	VBN	O
above	IN	O
(see	NNS	O
Langer,	CC	B
Science	JJ	I
249,	NNS	I
1527	JJ	I
(1990)	IN	I
and	,	O
Hanes,	,	B
Advanced	CC	I
Drug	NN	I
Delivery	IN	I
Reviews	JJ	I
28,	JJ	I
97-119	,	I
(1997).	IN	I
The	VBN	O
agents	IN	O
of	VB	O
this	,	O
invention	NNP	O
can	,	O
be	CD	O
administered	)	O
in	CC	O
the	,	O
form	NNP	O
of	NNP	O
a	NNP	O
depot	NNP	O
injection	,	O
or	CD	O
implant	.	O
preparation	DT	O
which	NNS	O
can	IN	O
be	DT	O
formulated	NN	O
in	MD	O
such	VB	O
a	VBN	O
manner	IN	O
as	DT	O
to	NN	O
permit	IN	O
a	DT	O
sustained	NN	O
or	NN	O
pulsatile	CC	O
release	JJ	O
of	NN	O
the	WDT	O
active	MD	O
ingredient.	VB	O
Additional	VBN	O
formulations	IN	O
suitable	JJ	O
for	DT	O
other	NN	O
modes	IN	O
of	TO	O
administration	VB	O
include	DT	O
oral,	VBN	O
intranasal,	CC	O
and	JJ	O
pulmonary	NN	O
formulations,	IN	O
suppositories,	DT	O
and	JJ	O
transdermal	.	O
applications.	JJ	O
For	NNS	O
suppositories,	JJ	O
binders	IN	O
and	JJ	O
carriers	NNS	O
include,	IN	O
for	NN	O
example,	VBP	O
polyalkylene	,	O
glycols	,	O
or	CC	O
triglycerides;	JJ	O
such	,	O
suppositories	,	O
can	CC	O
be	JJ	O
formed	.	O
from	IN	O
mixtures	,	O
containing	NNS	O
the	CC	O
active	NNS	O
ingredient	,	O
in	IN	O
the	,	O
range	NN	O
of	NNS	O
0.5%	CC	O
to	:	O
10%,	JJ	O
preferably	NNS	O
1%-2%.	MD	O
Oral	VB	O
formulations	VBN	O
include	IN	O
excipients,	NNS	O
such	VBG	O
as	DT	O
pharmaceutical	JJ	O
grades	NN	O
of	IN	O
mannitol,	DT	O
lactose,	NN	O
starch,	IN	O
magnesium	NN	O
stearate,	TO	O
sodium	,	O
saccharine,	RB	O
cellulose,	.	O
and	JJ	O
magnesium	NNS	O
carbonate.	VBP	O
These	,	O
compositions	JJ	O
take	IN	O
the	JJ	O
form	NNS	O
of	IN	O
solutions,	,	O
suspensions,	,	O
tablets,	,	O
pills,	NN	O
capsules,	,	O
sustained	NN	O
release	,	O
formulations	,	O
or	CC	O
powders	NN	O
and	.	O
contain	DT	O
10%-95%	NNS	O
of	VBP	O
active	DT	O
ingredient,	NN	O
preferably	IN	O
25%-70%.	,	O
Topical	,	O
application	,	O
can	,	O
result	,	O
in	VBD	O
transdermal	NN	O
or	NNS	O
intradermal	CC	O
delivery.	NNS	O
Topical	CC	O
administration	VB	O
can	NN	O
be	IN	O
facilitated	JJ	O
by	,	O
co-administration	RB	O
of	.	O
the	JJ	O
agent	NN	O
with	MD	O
cholera	VB	O
toxin	IN	O
or	NN	O
detoxified	CC	O
derivatives	JJ	O
or	.	O
subunits	JJ	O
thereof	NN	O
or	MD	O
other	VB	O
similar	VBN	O
bacterial	IN	O
toxins	NN	O
(See	IN	O
Glenn	DT	B
et	NN	I
al.,	IN	I
Nature	NN	I
391,	NN	I
851	CC	I
(1998)).Co-administration	JJ	O
can	NNS	O
be	CC	O
achieved	NNS	O
by	VBP	O
using	CC	O
the	JJ	O
components	JJ	O
as	NN	O
a	NNS	O
mixture	VB	O
or	NNP	O
as	FW	O
linked	,	O
molecules	NNP	O
obtained	,	O
by	CD	O
chemical	.	O
crosslinking	NN	O
or	MD	O
expression	VB	O
as	VBN	O
a	IN	O
fusion	VBG	O
protein.	DT	O
Alternatively,	NNS	O
transdermal	IN	O
delivery	DT	O
can	NN	O
be	CC	O
achieved	IN	O
using	VBN	O
a	NNS	O
skin	VBN	O
patch	IN	O
or	NN	O
using	NN	O
transferosomes	CC	O
Paul	NN	B
et	IN	I
al.,	DT	I
Eur.	NN	I
J.	.	I
Immunol.	,	I
25,	JJ	I
3521-24	NN	I
(1995);	MD	I
Cevc	VB	B
et	VBN	I
al.,	VBG	I
Biochem.	DT	I
Biophys.	JJ	I
Acta	NN	I
1368,	CC	I
201-15	VBG	I
(1998)).(	NNS	O
VII.	NNP	O
Lewy	RB	O
Body	,	O
Diseases	.	O
Lewy	NNP	O
Body	.	O
Diseases	,	O
(LBD)	CD	O
are	:	O
characterized	NNP	O
by	FW	O
degeneration	,	O
of	.	O
the	.	O
dopaminergic	NNP	O
system,	,	O
motor	CD	O
alterations,	.	O
cognitive	.	O
impairment,	NNP	O
and	NNP	O
formation	NNP	O
of	NNP	O
Lewy	NNP	O
bodies	NNP	O
(LBs).	)	O
McKeith	VBP	B
et	VBN	I
al.,	IN	I
Clinical	NN	I
and	IN	I
pathological	DT	I
diagnosis	NN	I
of	,	I
dementia	NN	I
with	,	I
Lewy	JJ	I
bodies	,	I
(DLB):	CC	I
Report	NN	I
of	IN	I
the	NNP	I
CDLB	NNS	I
International	.	I
Workshop,	NNP	I
Neurology	FW	I
(1996)	,	I
47:1113-24).(	NNP	O
Lewy	CC	O
Bodies	JJ	O
are	NN	O
spherical	IN	O
protein	NN	O
deposits	IN	O
found	NNP	O
in	NNS	O
nerve	:	O
cells.	NN	O
Their	IN	O
presence	DT	O
in	NNP	O
the	NNP	O
brain	,	O
may	NNP	O
disrupt	)	O
the	.	O
brain's	NNP	O
normal	NNS	O
function	VBP	O
interrupting	JJ	O
the	NN	O
action	NNS	O
of	VBN	O
chemical	IN	O
messengers	NN	O
including	.	O
acetylcholine	PRP$	O
and	NN	O
dopamine.	IN	O
Lewy	DT	O
Body	NN	O
diseases	MD	O
include	VB	O
Parkinson's	DT	O
disease	POS	O
(including	JJ	O
idiopathic	NN	O
Parkinson's	VBG	O
disease	DT	O
(PD)),	NN	O
Diffuse	IN	O
Lewy	NN	O
Body	NNS	O
Disease	VBG	O
(DLBD)	NN	O
also	CC	O
known	.	O
as	NNP	O
Dementia	NNP	O
with	VBZ	O
Lewy	VBP	O
Bodies	POS	O
(DLB),	NN	O
Combined	VBG	O
Alzheimer's	JJ	O
and	POS	O
Parkinson	NN	O
disease	,	O
and	NNP	O
multiple	NNP	O
system	NNP	O
atrophy	NNP	O
(MSA).	)	O
DLBD	RB	O
shares	VBN	O
symptoms	IN	O
of	NNP	O
both	IN	O
Alzheimer's	NNP	O
and	NNP	O
Parkinson's	,	O
disease.	VBN	O
DLBD	POS	O
differs	CC	O
from	NNP	O
Parkinson's	NN	O
disease	CC	O
mainly	JJ	O
in	NN	O
the	NN	O
location	.	O
of	NNP	O
Lewy	NNS	O
Bodies.	NNS	O
In	IN	O
DLBD	DT	O
Lewy	POS	O
Bodies	CC	O
form	POS	O
mainly	.	O
in	NNP	O
the	NNS	O
cortex.	IN	O
In	POS	O
Parkinson's	NN	O
disease,	RB	O
they	IN	O
form	DT	O
in	NN	O
selected	IN	O
regions	NNP	O
throughout	.	O
the	IN	O
brain	NNP	O
stem,	NNP	O
midbrain,	NNP	O
and	NN	O
in	RB	O
advanced	IN	O
disease,	DT	O
cerebral	.	O
cortex.	IN	O
See,	POS	O
Braak	,	B
et	PRP	I
al.,	VBP	I
2003,	IN	I
“Staging	VBN	I
of	NNS	I
brain	IN	I
pathology	DT	I
related	NN	I
to	,	I
sporadic	,	I
Parkinson's	CC	I
disease”	IN	I
Neurobiology	JJ	I
of	,	I
Aging	JJ	I
24:197-211.	.	I
Other	,	O
Lewy	NNP	O
Body	FW	O
diseases	,	O
include	,	O
Pure	VBG	O
Autonomic	IN	O
Failure,	NN	O
Lewy	NN	O
body	VBN	O
dysphagia,	TO	O
Incidental	VB	O
LBD,	POS	O
Inherited	JJ	O
LBD	NNP	O
(e.g.,	IN	O
mutations	NNP	O
of	.	O
the	JJ	O
alpha-synuclein	NNP	O
gene,	NNP	O
PARK3	VBZ	O
and	VBP	O
PARK4)	NNP	O
and	NNP	O
Multiple	,	O
System	NNP	O
Atrophy	NN	O
(e.g.,	,	O
Olivopontocerebellar	NNP	O
Atrophy,	,	O
Striatonigral	NNP	O
Degeneration	NNP	O
and	,	O
Shy-Drager	NNS	O
Syndrome).	IN	O
VIII.	DT	O
Identification	JJ	O
of	,	O
Modulators	NNP	O
of	CC	O
Kinases	)	O
that	CC	O
Directly	NNP	O
or	NNP	O
Indirectly	NNP	O
Phosphorylate	,	O
Alpha-Synuclein	NNP	O
Agents	,	O
that	NNP	O
modulate	NNP	O
expression	CC	O
or	NNP	O
activity	.	O
of	.	O
a	NN	O
kinase	IN	O
that	NNS	O
directly	IN	O
or	NNS	O
indirectly	WDT	O
phosphorylates	NNP	O
alpha-synuclein	CC	O
can	NNP	O
be	NNP	O
identified	NNP	O
by	NNS	O
a	WDT	O
variety	VBP	O
of	NN	O
assays.	CC	O
Particularly	NN	O
preferred	IN	O
are	DT	O
agents	NN	O
that	WDT	O
inhibit	RB	O
kinases	CC	O
PLK2	RB	O
or	VBZ	O
GRK6,	NNS	O
or	MD	O
APEG1,	VB	O
CDC7L1,	VBN	O
MET	IN	O
GRK1,	DT	O
GRK2,	NN	O
GRK6,	IN	O
IKBKB,	.	O
CKII	RB	O
and	VBN	O
GRK7,	VBP	O
or	NNS	O
agents	IN	O
that	NN	O
activate	NNS	O
PRKG1,	NNP	O
MAPK13,	CC	O
and	,	O
GAK.	CC	O
Agents	,	O
that	,	O
modulate	NNP	O
expression	,	O
can	,	O
be	,	O
identified	,	O
in	NNP	O
cell-based	CC	O
assays	,	O
in	CC	O
which	NNS	O
an	WDT	O
agent	VBP	O
under	,	O
test	,	O
is	CC	O
introduced	.	O
into	NNS	O
a	WDT	O
cell	VBP	O
expressing	NN	O
alpha-synuclein	MD	O
and	VB	O
a	VBN	O
kinase	IN	O
that	JJ	O
directly	NNS	O
or	IN	O
indirectly	WDT	O
effects	DT	O
phosphorylation	NN	O
of	IN	O
the	NN	O
alpha-synuclein	VBZ	O
or	VBN	O
modulates	IN	O
levels	DT	O
of	NN	O
total	VBG	O
alpha-synuclein.	JJ	O
Optionally,	CC	O
particularly	DT	O
for	NN	O
PLK2,	WDT	O
synphilin	RB	O
can	CC	O
be	RB	O
expressed	NNS	O
as	NN	O
well	IN	O
to	DT	O
augment	JJ	O
activity	CC	O
of	VBZ	O
the	NNS	O
kinase.	IN	O
The	JJ	O
agent	.	O
can	,	O
be	RB	O
introduced	IN	O
directly	,	O
or	NN	O
in	MD	O
the	VB	O
form	VBN	O
of	RB	O
a	RB	O
nucleic	TO	O
acid	JJ	O
encoding	NN	O
the	IN	O
agent	DT	O
and	.	O
capable	DT	O
of	NN	O
expressing	MD	O
the	VB	O
agent.	VBN	O
The	RB	O
cell	CC	O
can	IN	O
naturally	DT	O
express	NN	O
the	IN	O
alpha-synuclein	DT	O
and	JJ	O
kinase	NN	O
or	VBG	O
one	DT	O
or	NN	O
both	CC	O
of	JJ	O
these	IN	O
can	VBG	O
be	DT	O
introduced	.	O
into	DT	O
the	NN	O
cell	MD	O
by	RB	O
transfection	VB	O
of	DT	O
a	NN	O
suitable	CC	O
nucleic	NN	O
acid.	CC	O
The	CD	O
effect	CC	O
of	DT	O
the	IN	O
agent	DT	O
on	MD	O
expression	VB	O
of	VBN	O
the	IN	O
kinase	DT	O
can	NN	O
be	IN	O
measured	NN	O
directly	IN	O
from	DT	O
the	JJ	O
level	JJ	O
of	.	O
the	DT	O
kinase	NN	O
or	IN	O
its	DT	O
mRNA,	NN	O
or	IN	O
indirectly	NN	O
by	IN	O
measuring	DT	O
the	NN	O
level	MD	O
of	VB	O
phosphorylated	VBN	O
alpha-synuclein	RB	O
or	IN	O
total	DT	O
alpha-synuclein	NN	O
as	IN	O
described	DT	O
above.	NN	O
The	CC	O
level	PRP$	O
of	,	O
kinase	CC	O
mRNA	RB	O
can	IN	O
be	VBG	O
assayed	DT	O
by	NN	O
a	IN	O
hybridization	JJ	O
type	NN	O
assay.	CC	O
The	JJ	O
level	JJ	O
of	IN	O
the	VBN	O
kinase	.	O
can	DT	O
be	NN	O
assayed	IN	O
by	NN	O
an	NN	O
immunoassay.	MD	O
Optionally,	VB	O
the	VBN	O
kinase	IN	O
is	DT	O
tagged	NN	O
with	NN	O
a	.	O
peptide	DT	O
label	NN	O
such	IN	O
as	DT	O
Flag™	NN	O
Hopp	MD	B
et	VB	I
al.,	VBN	I
BioTechnology	IN	I
6,	DT	I
1204-1210	.	I
(1988))	,	I
(to	DT	O
facilitate	NN	O
detection.	VBZ	O
An	VBN	O
agent	IN	O
that	DT	O
decrease	JJ	O
the	NN	O
level	JJ	O
of	IN	O
the	NNP	O
kinase,	NNP	O
decrease	RB	O
the	,	O
level	NNP	O
of	,	O
phosphorylation	CD	O
of	)	O
alpha-synuclein	TO	O
and/or	VB	O
decrease	.	O
the	DT	O
level	NN	O
of	WDT	O
total	VBZ	O
alpha-synuclein	DT	O
relative	NN	O
to	IN	O
similar	DT	O
control	,	O
cells	VB	O
not	DT	O
treated	NN	O
with	IN	O
an	NN	O
agent	IN	O
have	JJ	O
a	NN	O
pharmacological	NN	O
activity	DT	O
potentially	NN	O
useful	IN	O
for	JJ	O
treatment	JJ	O
of	NN	O
Lewy	TO	O
body	JJ	O
diseases.	NN	O
Agents	NNS	O
are	RB	O
also	VBN	O
screened	IN	O
for	DT	O
activity	NN	O
to	VBP	O
modulate	DT	O
activity	JJ	O
of	NN	O
a	RB	O
kinase	JJ	O
suspected	IN	O
of	NN	O
phosphorylating	IN	O
alpha-synuclein	NNP	O
or	NN	O
increasing	.	O
total	NNS	O
levels	VBP	O
of	RB	O
alpha-synuclein.	VBN	O
An	IN	O
initial	NN	O
screen	TO	O
can	VB	O
be	NN	O
performed	IN	O
to	DT	O
select	NN	O
a	VBN	O
subset	IN	O
of	VBG	O
agents	JJ	O
capable	CC	O
of	VBG	O
specifically	JJ	O
binding	NNS	O
to	IN	O
a	.	O
kinase.	DT	O
Such	JJ	O
an	NN	O
assay	MD	O
can	VB	O
be	VBN	O
performed	TO	O
in	VB	O
vitro	DT	O
using	NN	O
an	IN	O
isolated	NNS	O
kinase	JJ	O
or	IN	O
fragment	RB	O
thereof	VBG	O
having	TO	O
kinase	DT	O
activity.	.	O
In	JJ	O
one	DT	O
embodiment	NN	O
an	MD	O
agent	VB	O
that	VBN	O
reduces	IN	O
alpha-synuclein	NN	O
phosphorylation	VBG	O
in	DT	O
a	JJ	O
mammalian	NN	O
cell	CC	O
expressing	NN	O
alpha-synuclein,	NN	O
and	VBG	O
which	NN	O
may	.	O
be	IN	O
used	CD	O
as	NN	O
a	DT	O
therapeutic	NN	O
agent,	WDT	O
is	VBZ	O
identified	JJ	O
based	NN	O
on	IN	O
the	DT	O
following	JJ	O
criteria:	NN	O
a)	VBG	O
reduces	,	O
activity	CC	O
of	WDT	O
PLK2	MD	O
in	VB	O
a	VBN	O
cell	IN	O
expressing	DT	O
PLK2;	JJ	O
and	,	O
b)	VBZ	O
does	VBN	O
not	VBN	O
reduce	IN	O
activity	DT	O
of	JJ	O
PLK1	:	O
in	)	O
a	VBZ	O
cell	NN	O
expressing	IN	O
PLK1,	NNP	O
or	IN	O
reduces	DT	O
activity	NN	O
of	VBG	O
PLK1	:	O
at	CC	O
a	)	O
higher	VBZ	O
EC50	RB	O
than	VB	O
for	NN	O
PLK2;	IN	O
and/or	NNP	O
c)	IN	O
does	DT	O
not	NN	O
reduce	VBG	O
activity	,	O
of	CC	O
PLK3	VBZ	O
in	NN	O
a	IN	O
cell	NNP	O
expressing	IN	O
PLK3,	DT	O
or	JJR	O
reduces	NN	O
activity	IN	O
of	IN	O
PLK3	:	O
at	CC	O
a	)	O
higher	VBZ	O
EC50	RB	O
than	VB	O
for	NN	O
PLK2;	IN	O
and/or	NNP	O
d)	IN	O
does	DT	O
not	NN	O
reduce	VBG	O
activity	,	O
of	CC	O
PLK4	VBZ	O
in	NN	O
a	IN	O
cell	NNP	O
expressing	IN	O
PLK4,	DT	O
or	JJR	O
reduces	NN	O
activity	IN	O
of	IN	O
PLK4	:	O
at	CC	O
a	)	O
higher	VBZ	O
EC50	RB	O
than	VB	O
for	NN	O
PLK2.	IN	O
In	NNP	O
one	IN	O
embodiment	DT	O
an	NN	O
agent	VBG	O
is	,	O
selected	CC	O
that	VBZ	O
meets	NN	O
all	IN	O
of	NNP	O
criteria	IN	O
a-d.	DT	O
The	JJR	O
mammalian	NN	O
cell	IN	O
may	IN	O
be	.	O
a	IN	O
cell	CD	O
overexpressing	NN	O
alpha-synuclein	DT	O
(e.g.,	NN	O
transfected	VBZ	O
with	VBN	O
a	IN	O
vectors	VBZ	O
expressing	DT	O
exogenous,	IN	O
e.g.,	NNS	O
human,	.	O
alpha-synuclein).	DT	O
The	JJ	O
mammalian	NN	O
cell	MD	O
may	VB	O
be	DT	O
a	NN	O
neuronally-derived	VBG	O
cell	JJ	O
such	,	O
as,	VBN	O
for	IN	O
example,	DT	O
cells	NNS	O
from	VBG	O
mouse	,	O
cortical	,	O
cell	,	O
cultures,	.	O
rat	DT	O
ventral	JJ	O
mesencephalon	NN	O
cell	MD	O
cultures,	VB	O
or	DT	O
other	JJ	O
neuronal	NN	O
cells	JJ	O
from	,	O
humans	IN	O
or	,	O
non-human	NNS	O
mammals.	IN	O
Agents	NN	O
identified	JJ	O
by	NN	O
such	,	O
a	VB	O
screen	JJ	O
can	NN	O
then	NN	O
be	,	O
assayed	CC	O
functionally.	JJ	O
Agents	JJ	O
can	NNS	O
also	IN	O
be	NNS	O
directly	CC	O
assayed	JJ	O
functionally	.	O
without	NNS	O
the	VBN	O
binding	IN	O
assay.	JJ	O
For	DT	O
a	NN	O
kinase	MD	O
that	RB	O
directly	VB	O
phosphorylates	VBN	O
alpha-synuclein,	.	O
modulators	NNS	O
can	MD	O
be	RB	O
screened	VB	O
by	RB	O
an	VBN	O
in	RB	O
vitro	IN	O
assay	DT	O
combining	NN	O
the	.	O
kinase,	IN	O
alpha-synuclein,	DT	O
ATP	NN	O
and	WDT	O
the	RB	O
modulator	VBZ	O
in	,	O
comparison	NNS	O
with	MD	O
a	VB	O
control	VBN	O
in	IN	O
which	DT	O
the	IN	O
modulator	NN	O
is	VBP	O
omitted.	VBG	O
Optionally,	DT	O
synphilin	,	O
can	,	O
be	NNP	O
included	CC	O
as	DT	O
well	NN	O
to	IN	O
increase	NN	O
phosphorylation	IN	O
particularly	DT	O
if	NN	O
the	IN	O
kinase	WDT	O
is	DT	O
PLK2.	NN	O
The	VBZ	O
modulator	.	O
has	,	O
potentially	NN	O
useful	MD	O
pharmacological	VB	O
activity	VBN	O
if	RB	O
it	RB	O
reduces	TO	O
the	VB	O
level	NN	O
of	RB	O
phosphorylation	IN	O
beyond	DT	O
the	NN	O
margin	VBZ	O
of	.	O
typical	DT	O
experimental	NN	O
error	VBZ	O
relative	RB	O
to	JJ	O
the	JJ	O
control.	NN	O
Agents	IN	O
can	PRP	O
also	VBZ	O
be	DT	O
screened	NN	O
in	IN	O
cells	NN	O
expressing	IN	O
alpha-synuclein	DT	O
and	NN	O
the	IN	O
kinase	JJ	O
under	JJ	O
test,	NN	O
and	NN	O
optionally,	TO	O
particularly	DT	O
if	.	O
the	NNS	O
kinase	MD	O
is	RB	O
PLK2,	VB	O
synphilin.	VBN	O
Such	IN	O
screens	NNS	O
are	VBG	O
effective	NN	O
regardless	CC	O
of	DT	O
whether	NN	O
the	IN	O
kinase	,	O
phosphorylates	CC	O
alpha-synuclein	,	O
directly	RB	O
or	IN	O
indirectly,	DT	O
or	NN	O
otherwise	VBZ	O
affects	,	O
levels	.	O
of	JJ	O
alpha-synuclein.	NNS	O
Cells	VBP	O
are	JJ	O
contacted	NN	O
with	IN	O
the	IN	O
agent	DT	O
and	NN	O
levels	VBZ	O
of	JJ	O
total	RB	O
alpha-synuclein	CC	O
and	,	O
phosphorylated	CC	O
alpha-synuclein	RB	O
are	VBZ	O
measured,	NNS	O
as	IN	O
above,	.	O
relative	NNS	O
to	VBP	O
a	VBN	O
control	IN	O
cell	DT	O
not	NN	O
treated	CC	O
with	NNS	O
the	IN	O
agent.	JJ	O
A	JJ	O
reduction	CC	O
in	JJ	O
the	NNS	O
level	VBP	O
of	,	O
phosphorylated	IN	O
alpha-synuclein	,	O
or	JJ	O
total	TO	O
alpha-synuclein	DT	O
relative	NN	O
to	NN	O
the	RB	O
corresponding	VBN	O
level	IN	O
in	DT	O
a	.	O
control	DT	O
cell	NN	O
not	IN	O
treated	DT	O
with	NN	O
the	IN	O
agent,	JJ	O
beyond	NN	O
the	CC	O
margin	JJ	O
of	JJ	O
typical	NN	O
experimental	TO	O
error,	DT	O
is	JJ	O
an	NN	O
indication	IN	O
that	DT	O
the	NN	O
compound	NN	O
has	RB	O
pharmacological	VBN	O
activity	IN	O
potential	DT	O
useful	,	O
in	IN	O
treating	DT	O
Lewy	NN	O
body	IN	O
diseases.	JJ	O
Agents	JJ	O
may	,	O
also	VBZ	O
be	DT	O
screened	NN	O
in	IN	O
cells	DT	O
for	NN	O
ability	VBZ	O
to	JJ	O
reduce	NN	O
aggregation	JJ	O
of	JJ	O
alpha-synuclein	IN	O
in	VBG	O
the	NNP	O
cell.	NN	O
Agents	.	O
can	NNS	O
also	MD	O
be	RB	O
screened	VB	O
in	VBN	O
transgenic	IN	O
animal	NNS	O
models	IN	O
of	NN	O
Lewy	TO	O
body	VB	O
disease,	NN	O
alone	IN	O
or	NN	O
in	IN	O
combination	DT	O
with	.	O
the	NNS	O
other	MD	O
assays	RB	O
described	VB	O
above.	VBN	O
Total	IN	O
levels	JJ	O
of	JJ	O
alpha-synuclein,	NNS	O
phosphorylated	IN	O
alpha-synuclein	NNP	O
or	NN	O
Lewy-like	,	O
bodies	RB	O
or	CC	O
other	IN	O
indica	NN	O
of	IN	O
Lewy	DT	O
Body	JJ	O
pathology	NNS	O
or	VBN	O
symptoms	.	O
are	JJ	O
measured	NNS	O
in	IN	O
a	,	O
transgenic	VBN	O
animal	NN	O
treated	CC	O
with	JJ	O
an	NNS	O
agent	CC	O
under	JJ	O
test	NN	O
relative	IN	O
to	NNP	O
corresponding	NNP	O
levels	NN	O
in	CC	O
a	NNS	O
similar	VBP	O
control	VBN	O
animal	IN	O
not	DT	O
treated	JJ	O
with	NN	O
the	VBN	O
agent.	IN	O
A	DT	O
reduction	NN	O
in	IN	O
one	NN	O
or	NN	O
more	TO	O
of	VBG	O
these	NNS	O
levels	IN	O
is	DT	O
an	JJ	O
indication,	NN	O
the	NN	O
agent	RB	O
has	VBN	O
pharmacological	IN	O
activity	DT	O
potentially	.	O
useful	DT	O
in	NN	O
treating	IN	O
Lewy	CD	O
body	CC	O
diseases.	JJR	O
The	IN	O
kinase	DT	O
used	NNS	O
in	VBZ	O
the	DT	O
above	,	O
assays	DT	O
and	NN	O
cellular	VBZ	O
and	JJ	O
transgenic	NN	O
models	RB	O
is	JJ	O
preferably	IN	O
a	VBG	O
human	NNP	O
kinase	NN	O
having	.	O
a	DT	O
sequence	NN	O
in	VBN	O
one	IN	O
of	DT	O
the	JJ	O
references	NNS	O
or	CC	O
accession	JJ	O
numbers	CC	O
provided	JJ	O
in	NNS	O
this	VBZ	O
disclosure.	RB	O
However,	DT	O
allelic	JJ	O
(variants	NN	O
within	VBG	O
a	DT	O
species)	NN	O
and	IN	O
species	CD	O
variants	IN	O
(variants	DT	O
between	NNS	O
species)	CC	O
of	NN	O
such	NNS	O
a	VBN	O
kinase	IN	O
can	DT	O
also	.	O
be	,	O
used,	JJ	O
as	NNS	O
can	IN	O
variants	DT	O
having	)	O
at	CC	O
least	VBZ	O
90%	NNS	O
sequence	NNS	O
identity	IN	O
to	)	O
such	IN	O
a	PDT	O
kinase.	DT	O
For	NN	O
subsequent	MD	O
clinical	RB	O
use,	VB	O
agents	,	O
identified	IN	O
by	MD	O
such	NNS	O
assays	VBG	O
are	IN	O
capable	JJS	O
of	NN	O
modulating	NN	O
the	NN	O
activity	TO	O
or	PDT	O
expression	DT	O
of	.	O
a	IN	O
natural	JJ	O
kinase,	JJ	O
preferably	,	O
a	NNS	O
form	VBN	O
occurring	IN	O
in	JJ	O
humans.	NNS	O
IX.	VBP	O
Transgenic	JJ	O
Animal	IN	O
and	VBG	O
Cellular	DT	O
Models	NN	O
of	CC	O
Lewy	NN	O
Body	IN	O
Disease	DT	O
Transgenic	JJ	O
animal	,	O
models	RB	O
are	DT	O
useful	NN	O
for	VBG	O
testing	IN	O
the	.	O
capacity	.	O
of	NNP	O
kinases	NNP	O
to	CC	O
effect	NNP	O
phosphorylation	NNP	O
of	IN	O
alpha-synuclein	NNP	O
and	NNP	O
formation	NNP	O
of	NNP	O
Lewy-like	NN	O
bodies	NNS	O
as	VBP	O
described	JJ	O
above.	IN	O
Transgenic	VBG	O
animals	DT	O
are	NN	O
also	IN	O
useful	NNS	O
for	TO	O
screening	NN	O
agents	NN	O
for	IN	O
activity	JJ	O
in	CC	O
modulating	NN	O
phosphorylation	IN	O
or	JJ	O
production	NNS	O
of	IN	O
alpha-synuclein.	VBN	O
Particularly	.	O
preferred	JJ	O
are	NNS	O
agents	VBP	O
that	RB	O
inhibit	JJ	O
or	IN	O
are	VBG	O
suspected	NNS	O
of	IN	O
inhibiting	NN	O
kinases	IN	O
including	VBG	O
PLK2	NN	O
and	CC	O
GRK6,	NN	O
or	IN	O
APEG1,	.	O
CDC7L1,	RB	O
MET	VBN	O
GRK1,	VBP	O
GRK2,	NNS	O
GRK6,	WDT	O
IKBKB,	VBP	O
CKII	CC	O
and	VBP	O
GRK7.	VBN	O
Also	IN	O
preferred	VBG	O
are	NNS	O
agents	VBG	O
that	NNP	O
activate	CC	O
or	,	O
are	CC	O
suspected	,	O
of	,	O
activating	NNP	O
kinases	,	O
PRKG1,	,	O
MAPK13,	,	O
and	,	O
GAK.	NNP	O
Further,	CC	O
knockout	.	O
animals	RB	O
(i.e.,	VBN	O
animals	VBP	O
in	NNS	O
which	WDT	O
an	VBP	O
endogenous	CC	O
kinase	VBP	O
is	VBN	O
inactivated	IN	O
either	VBG	O
by	NNS	O
insertional	,	O
inactivation	,	O
or	CC	O
trans	.	O
inhibition	,	O
by	NN	O
an	NNS	O
siRNA,	,	O
zinc	NNS	O
finger	IN	O
protein	WDT	O
or	DT	O
the	JJ	O
like)	NN	O
are	VBZ	O
useful	VBN	O
for	RB	O
identifying	IN	O
the	JJ	O
effect	NN	O
of	CC	O
eliminating	NNS	O
activity	NN	O
of	IN	O
a	DT	O
kinase	,	O
on	NN	O
an	NN	O
animal.	NN	O
For	CC	O
example,	DT	O
analysis	)	O
of	VBP	O
a	JJ	O
PLK2-knockout	IN	O
mouse	VBG	O
can	DT	O
indicate	NN	O
whether	IN	O
inhibitors	VBG	O
of	NN	O
PLK2	IN	O
have	DT	O
any	NN	O
side	IN	O
effects.	DT	O
Analogous	.	O
knockouts	IN	O
can	,	O
reveal	NN	O
similar	IN	O
information	DT	O
for	JJ	O
other	NN	O
kinases.	MD	O
In	VB	O
general,	IN	O
transgenic	NNS	O
models	IN	O
have	NNP	O
a	VBP	O
genome	DT	O
comprising	NN	O
an	.	O
alpha-synuclein	JJ	O
transgene	NNS	O
in	MD	O
operable	VB	O
linkage	JJ	O
with	NN	O
one	IN	O
or	JJ	O
more	.	O
regulatory	IN	O
sequences	,	O
to	JJ	O
ensure	NNS	O
its	VBP	O
expression.	DT	O
Expression	NN	O
of	VBG	O
the	DT	O
transgene	JJ	O
leads	NN	O
to	IN	O
Lewy-body	JJ	O
like	NN	O
deposits	IN	O
of	CD	O
alpha-synuclein	CC	O
in	JJR	O
the	JJ	O
brain	NNS	O
of	TO	O
the	VB	O
animal.	PRP$	O
Several	.	O
such	NN	O
transgenic	IN	O
animals	DT	O
have	NN	O
been	VBZ	O
described	TO	O
in	NNP	O
the	IN	O
scientific	NNS	O
and	IN	O
patent	NN	O
literature	IN	O
(see	DT	O
Masliah	NN	B
et	IN	I
al.,	DT	I
Am.	.	I
J.	JJ	I
Pathol.	JJ	I
(1996)	JJ	I
148:201-10	NNS	I
and	VBP	O
Feany	VBN	B
et	VBN	I
al.,	IN	I
Nature	DT	I
(2000)	JJ	I
404:394-8)),	CC	O
U.S.	JJ	O
Pat.	NN	O
No.	VB	O
5,811,633	NNP	O
(for	FW	O
transgenic	,	O
animals	.	O
with	NNP	O
a	.	O
mutant	)	O
form	CD	O
of	CC	O
APP).	NNP	O
Some	VBP	O
transgenic	,	O
animals	NNP	O
express	)	O
variant	,	O
or	NNP	O
mutant	.	O
alpha-synuclein,	.	O
such	CD	O
as	IN	O
familial	NN	O
mutants	NNS	O
A30P,	IN	O
A53T,	DT	O
and	JJ	O
E46K	NN	O
of	IN	O
alpha	.	O
synuclein.	DT	O
Some	JJ	O
transgenic	NNS	O
animals	VBP	O
have	JJ	O
an	CC	O
additional	JJ	O
transgene,	,	O
such	JJ	O
as	IN	O
a	JJ	O
transgene	NNS	O
encoding	,	O
a	,	O
kinase	CC	O
as	NNP	O
described	IN	O
above.	JJ	O
Transgenic	.	O
animals	DT	O
bearing	JJ	O
a	NNS	O
transgene	VBP	O
expressing	DT	O
alpha-synuclein	JJ	O
protein	,	O
can	JJ	O
also	IN	O
be	DT	O
crossed	NN	O
with	VBG	O
other	DT	O
transgenic	NN	O
models	IN	O
of	VBN	O
neurogenic	.	O
disease,	JJ	O
such	NNS	O
as	VBG	O
models	DT	O
of	JJ	O
Alzheimer's	VBG	O
disease.	JJ	O
For	NN	O
example,	MD	O
transgenic	RB	O
animals	VB	O
bearing	VBN	O
a	IN	O
transgene	JJ	O
expressing	JJ	O
a	NNS	O
truncated	IN	O
alpha-synuclein	JJ	O
protein	,	O
can	JJ	O
be	IN	O
crossed	NNS	O
with	IN	O
transgenic	POS	O
animals	.	O
bearing	IN	O
a	,	O
transgene	JJ	O
expressed	NNS	O
APP	VBG	O
with	DT	O
a	NN	O
FAD	VBG	O
mutation	DT	O
as	JJ	O
described	JJ	O
by	NN	O
e.g.,	MD	O
Games	VB	B
et	VBN	I
al.,	IN	I
Nature	JJ	I
373,	NNS	I
523	VBG	I
(1995)	DT	I
McConlogue	NN	O
et	VBN	O
al.,	NNP	O
U.S.	IN	O
Pat.	DT	O
No.	NNP	O
5,612,486,	NN	O
Hsiao	IN	O
et	VBN	O
al.,	IN	O
Science	,	O
274,	NNP	O
99	FW	O
(1996);	,	O
Staufenbiel	NNP	B
et	,	I
al.,	CD	I
Proc.	)	I
Natl.	NNP	I
Acad.	CC	I
Sci.	,	I
USA	NNP	I
94,	.	I
13287-13292	.	I
(1997);	,	I
Sturchler-Pierrat	NNP	B
et	FW	I
al.,	,	I
Proc.	NNP	I
Natl.	,	I
Acad.	CD	I
Sci.	:	I
USA	NNP	I
94,	FW	I
13287-13292	,	I
(1997);	.	I
Borchelt	.	B
et	.	I
al.,	.	I
Neuron	NNP	I
19,	,	I
939-945	CD	I
(1997)).The	:	O
procedure	NNP	O
for	FW	O
performing	,	O
such	.	O
a	.	O
cross	.	O
is	.	O
described	NNP	O
by	,	O
e.g.,	CD	O
Masliah	:	B
et	NNP	I
al.,	FW	I
PNAS	,	I
USA	NNP	I
98:12245-12250	,	I
(2001),	CD	I
which	.	O
reports	DT	O
a	NN	O
cross	IN	O
between	VBG	O
transgenic	PDT	O
mice	DT	O
expressing	NN	O
a	VBZ	O
full	VBN	O
length	IN	O
alpha-synuclein	,	O
with	NNP	O
PDAPP	FW	O
mice	,	O
as	NNP	O
described	NNP	O
by	CD	O
Games	,	O
et	WDT	O
al	VBZ	O
Transgenic	DT	O
animals	NN	O
of	IN	O
the	JJ	O
invention	NN	O
are	VBG	O
preferably	DT	O
rodents,	JJ	O
such	NN	O
as	NN	O
mice	IN	O
or	NNP	O
rats,	NN	O
or	IN	O
insects,	VBN	O
such	IN	O
as	NNP	O
Drosophila.	FW	O
Transgenic	NN	O
animals	NNP	O
can	NNS	O
be	IN	O
produced	DT	O
by	NN	O
introduction	VBP	O
of	RB	O
a	,	O
transgene	JJ	O
at	IN	O
the	NNS	O
germline	CC	O
stage	,	O
in	CC	O
which	,	O
case	JJ	O
all	IN	O
or	.	O
substantially	JJ	O
all	NNS	O
(except	MD	O
for	VB	O
rare	VBN	O
loss	IN	O
through	NN	O
somatic	IN	O
mutation)	DT	O
of	NN	O
the	IN	O
cells	DT	O
of	NN	O
the	NN	O
transgenic	IN	O
animal	WDT	O
include	NN	O
the	DT	O
transgene	CC	O
integrated	RB	O
into	DT	O
the	IN	O
genome.	IN	O
Transgenes	JJ	O
can	NN	O
be	IN	O
introduced	JJ	O
by	)	O
microinjection,	IN	O
nuclear	DT	O
transfer	NNS	O
or	IN	O
viral	DT	O
infection	JJ	O
into	NN	O
cells	VBP	O
or	DT	O
animals.	NN	O
Adeno	VBN	O
Associated	IN	O
Viruses	DT	O
and	.	O
Lentiviruses	NNS	O
are	MD	O
particularly	VB	O
suitable	VBN	O
for	IN	O
the	,	O
latter.	JJ	O
Alternatively,	NN	O
transgenes	CC	O
can	JJ	O
be	NN	O
introduced	IN	O
by	NNS	O
viral	CC	O
infection	.	O
into	NNP	O
the	NNP	O
brain	NNP	O
of	CC	O
the	NNP	O
animal.	VBP	O
Such	RB	O
transgenes	JJ	O
are	IN	O
not	DT	O
part	.	O
of	,	O
the	NNS	O
germline	MD	O
of	VB	O
recipient	VBN	O
animals	IN	O
but	JJ	O
can	NN	O
be	IN	O
targeted	DT	O
to	NN	O
regions	IN	O
of	DT	O
the	.	O
brain	JJ	O
responsible	NNS	O
for	VBP	O
disease	RB	O
(e.g.,	NN	O
the	IN	O
substantia	DT	O
nigra).	NN	O
Such	IN	O
animal	NN	O
models	NNS	O
incorporate	CC	O
an	MD	O
alpha-synuclein	VB	O
into	VBN	O
the	TO	O
genome	NNS	O
of	IN	O
brain	DT	O
cells	NN	O
and	JJ	O
are	IN	O
disposed	NN	O
to	,	O
develop	DT	O
at	NN	O
least	.	O
one	JJ	O
characteristic	JJ	O
of	NNS	O
LBD	VBP	O
disease.	DT	O
Lentiviruses	JJ	O
provide	IN	O
a	DT	O
suitable	NN	O
vehicle	IN	O
for	NN	O
so	NNS	O
introducing	CC	O
an	VBP	O
alpha-synuclein	VBN	O
transgene	TO	O
into	VB	O
the	IN	O
brain	JJS	O
(see	CD	O
Brain	NN	B
Pathology	IN	I
13,	NNP	I
364-372	.	I
(2003);	NNS	I
Bjorklund,	VBP	B
Trends	DT	I
Neurosci.	JJ	I
26,	NN	I
386-92	IN	I
(2003),	RB	I
Lotharius	VBG	B
et	DT	I
al.,	JJ	I
J.	NN	I
Biol.	IN	I
Chem.	DT	I
277,	NN	I
38884-94	VB	I
(2002),	NNP	I
Zhou	NNP	B
et	,	I
al.,	CD	I
Brain	:	I
Research	,	I
866,	NNP	I
33-43	.	I
(2000)).Transgenic	,	O
animals	CD	O
can	,	O
also	NNP	O
include	FW	O
a	,	O
transgene	NNP	O
capable	.	O
of	.	O
expressing	,	O
one	CD	O
of	,	O
the	NNP	O
kinases	FW	O
of	,	O
the	NNP	O
invention	NNP	O
(e.g.,	,	O
a	CD	O
nucleic	.	O
acid	JJ	O
encoding	NNS	O
the	MD	O
kinase	RB	O
in	VB	O
operable	DT	O
linkage	NN	O
with	JJ	O
regulatory	IN	O
elements	VBG	O
to	CD	O
ensure	IN	O
its	DT	O
expression	NNS	O
in	IN	O
the	DT	O
brain	NN	O
of	,	O
an	DT	O
animal),	JJ	O
instead	NN	O
of	VBG	O
or	DT	O
as	NN	O
well	IN	O
as	JJ	O
a	NN	O
transgene	IN	O
expressing	JJ	O
alpha	NNS	O
synuclein.	TO	O
Optionally,	VB	O
a	PRP$	O
transgene	NN	O
expressing	IN	O
synphilin	DT	O
can	NN	O
be	IN	O
included	DT	O
as	,	O
well.	RB	O
Some	IN	O
cellular	CC	O
models	RB	O
express	RB	O
variant	IN	O
or	DT	O
mutant	NN	O
alpha-synuclein,	VBG	O
such	JJ	O
as	.	O
familial	,	O
mutants	DT	O
A30P,	NN	O
A53T,	VBG	O
and	NN	O
E46K	MD	O
of	VB	O
alpha	VBN	O
synuclein.	RB	O
Some	.	O
cells	DT	O
have	JJ	O
an	NNS	O
additional	VBP	O
transgene,	JJ	O
such	CC	O
as	JJ	O
a	,	O
transgene	JJ	O
encoding	IN	O
a	JJ	O
kinase	NNS	O
as	,	O
described	,	O
above,	CC	O
e.g.,	NNP	O
PLK2.	IN	O
Cellular	JJ	O
models	.	O
of	DT	O
Lewy	NNS	O
body	VBP	O
disease	DT	O
can	JJ	O
also	,	O
be	JJ	O
used	IN	O
in	DT	O
the	NN	O
screening	VBG	O
methods	DT	O
of	NN	O
the	IN	O
invention.	VBN	O
Cells	,	O
transfected	,	O
with	.	O
alpha-synuclein	JJ	O
form	NNS	O
inclusion	IN	O
bodies	NNP	O
containing	NN	O
aggregated	NN	O
alpha-synuclein.	MD	O
The	RB	O
transformed	VB	O
cells	VBN	O
are	IN	O
preferably	DT	O
neuronal	NN	O
cells,	NNS	O
such	IN	O
as	DT	O
GT1-7	.	O
neuronal	NNS	O
cells	VBN	O
Hsue	IN	B
et	JJ	I
al.	NN	I
Am.	NN	I
J.	NNS	I
Pathol.	VBG	I
157:401-410	JJ	I
(2000)),(	.	O
PC12	DT	O
cells	JJ	O
or	NNS	O
SY5Y	VBP	O
neuroblastoma	RB	O
cells.	JJ	O
PEAK	,	O
and/or	JJ	O
HCC	IN	O
cells	NNP	O
can	JJ	O
also	NNS	O
be	NNP	O
used	RB	O
(see	.	O
Example	.	O
10).	NNP	O
The	.	O
cells	CD	O
are	,	O
preferably	NNP	O
human	NNS	O
cells.	CC	O
A	NNP	O
vector	JJ	O
comprising	.	O
a	NNP	O
segment	NN	O
encoding	NNP	O
a	NNS	O
form	MD	O
of	RB	O
alpha-synuclein	VB	O
operably	VBN	O
linked	VB	O
to	NNP	O
one	.	O
or	DT	O
more	NNS	O
regulatory	VBP	O
sequences	RB	O
that	JJ	O
ensure	.	O
expression	DT	O
of	NN	O
the	VBG	O
expression	DT	O
is	NN	O
transfected	VBG	O
into	DT	O
the	NN	O
cells.	IN	O
Cells	JJ	O
can	RB	O
also	VBN	O
be	TO	O
transfected	CD	O
with	CC	O
a	JJR	O
nucleic	JJ	O
acid	NNS	O
encoding	WDT	O
a	VB	O
kinase	NN	O
of	IN	O
the	DT	O
invention	NN	O
as	VBZ	O
described	VBN	O
above.	IN	O
Transfected	DT	O
cells	.	O
can	NNS	O
be	MD	O
used	RB	O
to	VB	O
screen	VBN	O
agents	IN	O
for	DT	O
activity	JJ	O
in	NN	O
clearing	VBG	O
alpha-synuclein	DT	O
inclusions.	NN	O
An	IN	O
exemplary	DT	O
cellular	NN	O
model	IN	O
is	VBN	O
identified	.	O
in	VBN	O
Example	NNS	O
10	MD	O
in	VB	O
which	VBN	O
HCC	TO	O
neuronal	JJ	O
cells	NNS	O
are	IN	O
transfected	NN	O
with	IN	O
synuclein	VBG	O
and	JJ	O
PLK2	.	O
with	DT	O
the	JJ	O
result	JJ	O
that	NN	O
aggregation	VBZ	O
and	VBN	O
phosphorylation	IN	O
of	NNP	O
the	CD	O
synuclein	IN	O
matching	WDT	O
LB	NNP	O
formation	JJ	O
occurs.	NNS	O
In	VBP	O
order	VBN	O
to	IN	O
identify	NN	O
inhibitors	CC	O
of	NNP	O
the	IN	O
kinase,	DT	O
the	NN	O
cell	IN	O
is	NN	O
contacted	CC	O
with	NN	O
the	IN	O
inhibitor	DT	O
and	NN	O
a	VBG	O
reduction	NNP	O
in	NN	O
the	.	O
amount	IN	O
of	NN	O
phosphorylation	TO	O
and/or	VB	O
aggregation	NNS	O
is	IN	O
identified.	DT	O
X.	,	O
Alpha-Synuclein	DT	O
Isolation	NN	O
and	VBZ	O
Phosphorylation	VBN	O
Human	IN	O
alpha-synuclein	DT	O
is	NN	O
a	CC	O
polypeptide	DT	O
of	NN	O
140	IN	O
amino	DT	O
acids	NN	O
having	IN	O
the	NN	O
following	NN	O
amino	NN	O
acid	VBZ	O
sequence:	.	O
Ueda	JJ	B
et	NNP	I
al.,	NNP	I
Proc.	CC	I
Natl.	NNP	I
Acad.	NNP	I
Sci.	NN	I
USA	VBZ	I
(1993)	DT	I
90:11282-6);(	NN	O
GenBank	IN	O
accession	CD	O
number:	NN	O
P37840).	NNS	O
The	VBG	O
protein	DT	O
has	JJ	O
three	NN	O
recognized	JJ	O
domains,	:	O
a	NNP	O
KTKE	RB	O
repeat	,	O
domain	.	O
covering	.	O
amino	.	O
acids	.	O
1-61,	NNP	O
a	)	O
NAC	:	O
(Non-Amyloid	NNP	O
Component)	NN	O
domain	:	O
running	.	O
from	DT	O
about	NN	O
amino	VBZ	O
acids	CD	O
60-95,	VBN	O
and	,	O
a	DT	O
C-terminal	NNP	O
acidic	NN	O
domain	NN	O
running	VBG	O
from	JJ	O
about	NNS	O
amino	,	O
acid	DT	O
98	NNP	O
to	NNP	O
140.	)	O
Unless	VBP	O
otherwise	VBG	O
apparent	IN	O
from	IN	O
the	JJ	O
context,	NNS	O
reference	,	O
to	CC	O
alpha-synuclein	DT	O
includes	JJ	O
the	JJ	O
natural	NN	O
human	VBG	O
amino	IN	O
acid	IN	O
sequence	NN	O
indicated	NN	O
above	CD	O
as	TO	O
well	.	O
as	IN	O
analogs	RB	O
including	NN	O
allelic,	IN	O
species	DT	O
and	,	O
induced	NN	O
variants	TO	O
(e.g.,	JJ	O
E83Q,	VBZ	O
A90V,	DT	O
A76T)	JJ	O
having	JJ	O
at	NN	O
least	NN	O
90%	NN	O
sequence	VBD	O
identity	IN	O
to	RB	O
natural	RB	O
human	IN	O
alpha-synuclein.	NNS	O
Amino	VBG	O
acids	,	O
of	NNS	O
analogs	CC	O
are	JJ	O
assigned	NNS	O
the	,	O
same	,	O
numbers	,	O
as	)	O
corresponding	VBG	O
amino	IN	O
acids	JJS	O
in	NN	O
the	NN	O
natural	NN	O
human	TO	O
sequence	JJ	O
when	JJ	O
the	.	O
analog	NNP	O
and	NNS	O
human	IN	O
sequence	NNS	O
are	VBP	O
maximally	VBN	O
aligned.	DT	O
Analogs	JJ	O
typically	NNS	O
differ	IN	O
from	VBG	O
naturally	JJ	O
occurring	NNS	O
peptides	IN	O
at	DT	O
one,	JJ	O
two	JJ	O
or	NN	O
a	WRB	O
few	DT	O
positions,	NN	O
often	CC	O
by	JJ	O
virtue	NN	O
of	VBP	O
conservative	RB	O
substitutions.	.	O
Some	NNP	O
natural	RB	O
allelic	VBP	O
variants	IN	O
are	RB	O
genetically	VBG	O
associated	NNS	O
with	IN	O
hereditary	,	O
LBD.	CD	O
The	CC	O
term	DT	O
“allelic	JJ	O
variant”	,	O
is	RB	O
used	IN	O
to	NNS	O
refer	IN	O
to	JJ	O
variations	.	O
between	DT	O
genes	JJ	O
of	JJ	O
different	NNS	O
individuals	VBP	O
in	RB	O
the	VBN	O
same	IN	O
species	JJ	O
and	.	O
corresponding	DT	O
variations	NN	O
in	NNP	O
proteins	NN	O
encoded	VBZ	O
by	VBN	O
the	TO	O
genes.	VB	O
Allelic	TO	O
variants	NNS	O
include	IN	O
familial	NNS	O
mutants	IN	O
or	JJ	O
variants,	NNS	O
such	IN	O
as	DT	O
E46K,	JJ	O
A30P	NNS	O
and	CC	O
A53T	VBG	O
(the	NNS	O
first	IN	O
letter	NNS	O
indicates	VBN	O
the	IN	O
amino	DT	O
acid	.	O
in	JJ	O
SEQ	NNS	O
ID	VBP	O
NO:1,	JJ	O
the	NNS	O
number	CC	O
is	,	O
the	JJ	O
residue	IN	O
position	,	O
in	NNP	O
SEQ	CC	O
ID	NNP	O
NO:1,	DT	O
and	JJ	O
the	NN	O
second	VBZ	O
letter	DT	O
is	NN	O
the	NN	O
amino	IN	O
acid	NNP	O
in	NNP	O
the	,	O
allelic	DT	O
variant).	NN	O
Analogs	VBZ	O
can	DT	O
include	JJ	O
any	NN	O
combination	IN	O
of	NNP	O
allelic	NNP	O
variants.	,	O
The	CC	O
A53T	DT	O
variation	JJ	O
is	NN	O
associated	VBZ	O
with	DT	O
enhanced	NN	O
levels	NN	O
of	IN	O
phosphorylation	DT	O
at	JJ	O
position	.	O
129	NNS	O
of	MD	O
alpha-synuclein	VB	O
in	DT	O
an	NN	O
individual	IN	O
having	JJ	O
the	.	O
mutation	DT	O
relative	NNP	O
to	NN	O
the	VBZ	O
norm	VBN	O
of	IN	O
phosphorylation	JJ	O
in	NNS	O
undiseased	IN	O
individuals	NN	O
who	IN	O
lack	NN	O
the	CD	O
mutation.	IN	O
Alpha-synuclein,	NN	O
its	IN	O
fragments,	DT	O
and	JJ	O
analogs	VBG	O
can	DT	O
be	NN	O
synthesized	NN	O
by	TO	O
solid	DT	O
phase	NN	O
peptide	IN	O
synthesis	NN	O
or	IN	O
recombinant	JJ	O
expression,	NNS	O
or	WP	O
can	VBP	O
be	DT	O
obtained	.	O
from	,	O
natural	PRP$	O
sources.	,	O
Automatic	CC	O
peptide	NNS	O
synthesizers	MD	O
are	VB	O
commercially	VBN	O
available	IN	O
from	JJ	O
numerous	NN	O
suppliers,	JJ	O
such	NN	O
as	CC	O
Applied	JJ	O
Biosystems,	,	O
Foster	CC	O
City,	MD	O
Calif.	VB	O
Recombinant	VBN	O
expression	IN	O
can	JJ	O
be	.	O
in	NNP	O
bacteria,	NN	O
such	NNS	O
as	VBP	O
E.	RB	O
coli,	JJ	O
yeast,	IN	O
insect	JJ	O
cells	,	O
or	JJ	O
mammalian	IN	O
cells.	NNP	O
Procedures	,	O
for	NNP	O
recombinant	,	O
expression	NNP	O
are	NNP	O
described	NN	O
by	MD	O
Sambrook	VB	O
et	IN	O
al.,	,	O
Molecular	JJ	O
Cloning:	IN	O
A	NNP	O
Laboratory	,	O
Manual	,	O
C.S.H.P.	JJ	B
Press,	NNS	I
NY	CC	I
2d	JJ	I
ed.,	.	I
1989).(	NNS	O
A	IN	O
method	JJ	O
was	NN	O
developed	VBP	O
herein	VBN	O
to	IN	O
prepare	NNP	O
large	FW	O
amounts	,	O
of	JJ	O
wild-type	:	O
phospho-S129	DT	O
alpha-synuclein,	NNP	O
mutant	NNP	O
and/or	.	O
familial	,	O
forms	NNP	O
in	CD	O
a	,	O
bacterial	.	O
expression	DT	O
system.	NN	O
When	VBD	O
recombinant	VBN	O
hPLK2	NN	O
was	TO	O
co-expressed	VB	O
with	JJ	O
alpha-synuclein	NNS	O
in	IN	O
bacteria,	JJ	O
the	JJ	O
phospho-S129	,	O
alpha-synuclein	JJ	O
that	NN	O
was	JJ	O
produced	NNS	O
in	IN	O
the	DT	O
cell	JJ	O
was	NN	O
recovered	.	O
with	WRB	O
a	JJ	O
very	NN	O
high	VBD	O
yield	JJ	O
and	IN	O
purity.	JJ	O
This	IN	O
is	,	O
because,	DT	O
unlike	JJ	O
most	NN	O
E.	WDT	O
coli	VBD	O
proteins,	VBN	O
the	IN	O
alpha-synuclein	DT	O
could	NN	O
resist	VBD	O
heating.	VBN	O
After	IN	O
boiling	DT	O
of	RB	O
the	JJ	O
bacterial	NN	O
lysate,	CC	O
alpha-synuclein	.	O
purity	DT	O
reached	VBZ	O
about	,	O
95%	IN	O
before	JJS	O
chromatography.	NNP	O
To	JJ	O
co-express	,	O
recombinant	DT	O
protein	NN	O
in	MD	O
a	VB	O
bacterial	.	O
system,	IN	O
the	VBG	O
plasmids	IN	O
harboring	DT	O
each	JJ	O
gene	,	O
of	JJ	O
interest	NN	O
were	VBD	O
chosen	IN	O
be	NN	O
compatible	IN	O
within	.	O
the	TO	O
bacterial	JJ	O
cell	JJ	O
by	NN	O
ensuring	IN	O
that	DT	O
they	JJ	O
possessed	,	O
a	DT	O
different	NNS	O
origin	VBG	O
of	DT	O
replication	NN	O
and	IN	O
a	NN	O
different	VBD	O
antibiotic	VBN	O
selection.	VB	O
The	JJ	O
alpha-synuclein	IN	O
gene	DT	O
was	JJ	O
sub-cloned	NN	O
into	IN	O
a	VBG	O
pDEST24	IN	O
compatible	PRP	O
vector,	VBD	O
pCDF1b.	DT	O
BL21-DE3	JJ	O
bacteria	NN	O
were	IN	O
then	NN	O
co-transformed	CC	O
with	DT	O
both	JJ	O
the	JJ	O
pDEST24	.	O
containing	DT	O
wild-type	JJ	O
hPLK2	NN	O
or	VBD	O
hPLK2	VBN	O
constitutive	IN	O
mutant	DT	O
constructs	NN	O
without	JJ	O
a	,	O
GST	.	O
tag	JJ	O
and	NNS	O
the	VBD	O
pCDF1b/AS	RB	O
plasmid.	VBN	O
The	IN	O
bacterial	DT	O
lysates	DT	O
were	NN	O
boiled	VBG	O
and	JJ	O
the	NN	O
supernatant,	CC	O
expected	NN	O
to	JJ	O
contain	NN	O
alpha-synuclein	NNS	O
was	IN	O
analyzed	DT	O
by	NNP	O
Western	NN	O
blot	CC	O
with	DT	O
an	NN	O
anti-phospho-S129-alpha-synuclein	.	O
antibody	DT	O
(11A5),	JJ	O
by	NNS	O
using	VBD	O
the	VBN	O
SYPRO	CC	O
Ruby™	DT	O
and	,	O
ProZDiamond™	VBN	O
dyes	TO	O
(total	VB	O
protein	NN	O
and	VBD	O
phospho-Ser/Thr	VBN	O
specific	IN	O
dye	JJ	O
respectively),	NN	O
by	IN	O
SDS-PAGE	DT	O
and	JJ	O
by	NN	O
mass	,	O
spectrometry,	IN	O
with	VBG	O
the	DT	O
results	NNP	O
that	NNP	O
a	CC	O
fairly	NNP	O
pure	NNS	O
phospho-S129-alpha-synuclein	JJ	O
product	NN	O
was	CC	O
isolated	JJ	O
that,	JJ	O
upon	NN	O
analysis	,	O
by	IN	O
mass	NNP	O
spectrometry	CC	O
was	IN	O
revealed	NN	O
to	,	O
be	IN	O
more	DT	O
than	NNS	O
95%	IN	O
phosphorylated.	DT	O
To	RB	O
ensure	JJ	O
that	JJ	O
the	NN	O
final	VBD	O
product	VBN	O
was	,	O
100%	IN	O
phosphorylated	NN	O
and	IN	O
highly	NN	O
pure,	NN	O
the	VBD	O
supernatant	VBN	O
of	TO	O
the	VB	O
last	JJR	O
centrifugation	IN	O
was	NN	O
passed	.	O
through	TO	O
an	VB	O
11A5-sepharose-affinity	IN	O
purification	DT	O
column	JJ	O
one	NN	O
or	VBD	O
more	NN	O
times.	VBN	O
Any	CC	O
contamination	RB	O
was	,	O
removed	DT	O
using	NN	O
HPLC.	IN	O
XI.	DT	O
Examples	JJ	O
EXAMPLE	NN	O
1	VBD	O
Screen	VBN	O
for	IN	O
Kinases	DT	O
that	JJ	O
Modulate	NN	O
Alpha-Synuclein	NN	O
Phosphorylation	CD	O
To	CC	O
identify	JJR	O
the	.	O
kinase	DT	O
or	NN	O
kinases	VBD	O
that	VBN	O
phosphorylates	VBG	O
α-synuclein	.	O
at	.	O
serine-129	NNS	O
an	NNP	O
siRNA	CD	O
kinase	NNP	O
library	IN	O
(Ambion)	NNP	O
was	WDT	O
screened	NNP	O
on	NNP	O
cells	NNP	O
containing	TO	O
a	VB	O
quantifiable	DT	O
amount	NN	O
of	CC	O
phosphorylated	VBZ	O
α-synuclein.	DT	O
Human	VBZ	O
embryonic	JJ	O
kidney	IN	O
cell	JJ	O
line	DT	O
HEK293	JJ	O
cells	NN	O
(PEAK	NN	O
cells)	)	O
stably	VBD	O
transfected	VBN	O
with	IN	O
human	NNS	O
wild-type	VBG	O
α-synuclein	DT	O
under	JJ	O
control	NN	O
of	IN	O
a	JJ	O
CMV	.	O
promoter	NNP	O
(PEAK-Syn	JJ	O
cells)	NN	O
were	NN	O
transfected	NN	O
with	NNP	O
100	NNS	O
nM	NNP	O
siRNAs	)	O
targeting	RB	O
597	VBN	O
human	IN	O
kinases	JJ	O
and	JJ	O
were	JJ	O
assayed	IN	O
by	NN	O
ELISA	IN	O
assays	DT	O
to	NNP	O
quantitate	NN	O
total	NNP	O
and	)	O
phospho-synuclein	VBD	O
levels.	VBN	O
Ninety-five	IN	O
kinases	CD	O
with	NNS	O
siRNAs	VBD	O
that	VBG	O
altered	CD	O
the	JJ	O
percentage	NNS	O
of	CC	O
phosphorylated	VBD	O
alpha-synuclein	VBN	O
were	IN	O
identified	NNP	O
(see	NNS	O
Tables	TO	O
1-2).	VB	O
Of	JJ	O
those,	CC	O
28	JJ	O
belonged	.	O
to	JJ	O
the	NNS	O
class	IN	O
of	NN	O
kinases	WDT	O
that	VBD	O
phosphorylate	DT	O
serine	NN	O
residues	IN	O
and	JJ	O
hence	NNS	O
were	VBD	O
capable	VBN	O
of	VB	O
directly	NNP	O
phosphorylating	.	O
α-synuclein	IN	O
at	,	O
serine-129.	CD	O
Others	VBD	O
were	TO	O
tyrosine	DT	O
kinases.	NN	O
Although	IN	O
tyrosine	NNS	O
kinases	WDT	O
do	VBP	O
not	NN	O
phosphorylate	NNS	O
α-synuclein	CC	O
at	NN	O
ser-129	VBD	O
directly,	JJ	O
they	IN	O
can	RB	O
act	VBG	O
as	NN	O
upstream	IN	O
regulators	.	O
of	NNS	O
the	VBD	O
alpha-synuclein	JJ	O
kinase.	.	O
Two	IN	O
of	NN	O
these	NNS	O
ser/thr	VBP	O
kinases,	RB	O
casein	VB	O
kinase	NNS	O
2	IN	O
and	JJ	O
calcium/calmodulin	,	O
dependent	PRP	O
protein	MD	O
kinase	VB	O
II,	IN	O
have	JJ	O
been	NNS	O
reported	IN	O
to	DT	O
phosphorylate	JJ	O
α-synuclein	.	O
in	CD	O
vitro	IN	O
Pronin	DT	B
et	JJ	I
al,	,	I
J.	JJ	I
Biol.	NN	I
Chem.	CD	I
275:	CC	I
26515-26522	JJ	I
(2000),	NN	I
Okochoa	NN	B
et	NN	I
al,	,	I
J.	VBP	I
Biol.	VBN	I
Chem.	VBN	I
275:	TO	I
390-397	VB	I
(2000);	NNS	I
Nakajo	IN	B
et	NN	I
al,	NNP	I
Eur.	RB	I
J.	,	I
Biochem.	NNP	I
217:	.	I
1057-1063	.	I
(1993)	:	I
a(nd	CD	O
a	,	O
casein	NNP	O
kinase	FW	O
2	,	O
inhibitor	NNP	O
has	.	O
been	.	O
reported	:	O
to	CD	O
decrease	:	O
phospho-synuclein	NNP	O
levels	FW	O
in	,	O
cells	.	O
Okochoa	NNP	B
et	.	I
al,	:	I
2000).(	CD	O
Several	)	O
of	CC	O
the	DT	O
GRK	JJ	O
family	NN	O
members	CD	O
(although	NN	O
not	VBZ	O
GRK6)	VBN	O
have	VBN	O
been	TO	O
reported	VB	O
to	JJ	O
phosphorylate	NNS	O
alpha-synuclein	IN	O
in	NNS	O
vitro	NNP	O
Pronin	RB	B
et	,	I
al,	.	I
2000).(	JJ	O
GRK2	IN	O
expression	DT	O
in	NNP	O
flies	NN	O
has	NNS	O
been	IN	O
reported	RB	O
to	)	O
increase	VBP	O
phospho-synuclein	VBN	O
levels	VBN	O
Chen	TO	B
and	VB	I
Feany,	NNS	I
Nature	IN	I
Neurosci.	NN	I
8:	NNP	I
657-663	RB	I
(2005)).(	,	O
In	.	O
addition	NNP	O
to	NN	O
kinases	IN	O
that	NNS	O
lower	VBZ	O
phospho-synuclein	VBN	O
levels,	VBN	O
99	TO	O
kinases	VB	O
whose	JJ	O
siRNAs	NNS	O
altered	NNP	O
total	CC	O
α-synuclein	,	O
levels	NNP	O
in	.	O
the	:	O
PEAK-Syn	JJ	O
cells	.	O
were	IN	O
identified	NN	O
in	TO	O
Table	VB	O
2	DT	O
and	JJR	O
included	NN	O
fucokinase	,	O
(FUK),	CD	O
Genbank	NNS	O
number	WP$	O
NM—145059;	NN	O
Protein	VBD	O
Kinase	JJ	O
N1	JJ	O
(PRKCL1,	NNS	O
PKN1),	IN	O
Genbank	DT	O
number	NNP	O
NM—002741;	NNS	O
Doublecortin	VBD	O
and	VBN	O
CaM	IN	O
kinase-like	JJ	O
1	CD	O
(DCAMKL1)	CC	O
NM—004734;	VBD	O
Branched	NN	O
chain	,	O
Ketoacid	NNP	O
dehydrogenase	NN	O
kinase	:	O
(BCKDK)	NNP	O
NM—005881;	NNP	O
Aurora	NNP	O
Kinase	,	O
C	,	O
(AURKC,	NNP	O
STK13);	NN	O
NM—003160,	:	O
Kinase	NNP	O
suppressor	CC	O
of	NNP	O
ras	JJ	O
2	CD	O
(FLJ25965),	)	O
NM—173598;	:	O
FLJ32704;	NNP	O
MAP2K6;	NN	O
and	NNP	O
Tousled-like	NN	O
kinase	NN	O
2	)	O
(TLK2)	:	O
NM—006842.	NNP	O
The	NNP	O
mechanism	NNP	O
of	,	O
action	:	O
may	,	O
involve	NNP	O
either	NN	O
regulation	IN	O
of	NNS	O
alpha-synuclein	CD	O
turnover	,	O
or	:	O
synthesis	:	O
(See	:	O
Table	CC	O
2).	NNP	O
Tables	NN	O
1A,	CD	O
1B	)	O
and	.	O
1C	DT	O
show	NN	O
kinases	IN	O
whose	NN	O
inhibition	MD	O
modulates	VB	O
the	DT	O
phosphorylation	NN	O
at	IN	O
position	JJ	O
ser-129.	NN	O
Table	CC	O
1A,	NN	O
B,	NNP	O
and	NNP	O
C	.	O
differ	NNS	O
in	,	O
the	CD	O
type	CC	O
of	CD	O
kinase.	NN	O
Table	NNS	O
1A	WP$	O
shows	NN	O
kinases	VBZ	O
that	DT	O
can	NN	O
phosphorylate	IN	O
serine	NN	O
residues	.	O
and	JJ	O
often	,	O
tyrosine	,	O
and/or	CC	O
threonine	NNP	O
as	VBP	O
well.	IN	O
Table	DT	O
1B	NN	O
shows	IN	O
tyrosine	.	O
kinases	JJ	O
that	CD	O
cannot	NNS	O
(so	NNS	O
far	WDT	O
as	MD	O
is	VB	O
known)	NN	O
modify	NNS	O
serine	CC	O
residues.	RB	O
Table	JJ	O
1C	JJ	O
shows	NN	O
kinases	IN	O
not	.	O
known	JJ	O
to	CD	O
have	NNS	O
phosphorylate	VBP	O
proteins.	NNS	O
Kinases	WDT	O
from	RB	O
the	RB	O
upper	RB	O
portion	IN	O
of	VBZ	O
Table	)	O
1A	FW	O
are	NN	O
candidates	.	O
for	JJ	O
direct	CD	O
phosphorylation	NNS	O
of	VBZ	O
ser-129	RB	O
of	VBN	O
alpha-synuclein.	TO	O
Kinases	VB	O
from	JJ	O
the	.	O
upper	NNS	O
part	IN	O
of	DT	O
Table	JJ	O
1B	NN	O
are	IN	O
also	JJ	O
useful	CD	O
therapeutic	VBP	O
targets	NNS	O
via	IN	O
roles	JJ	O
indirectly	NN	O
phosphorylating	IN	O
alpha-synuclein.	NN	O
Proteins	IN	O
in	.	O
the	NNS	O
upper	IN	O
part	DT	O
of	JJ	O
Table	NN	O
1C	IN	O
are	JJ	O
also	CD	O
useful	VBP	O
therapeutic	RB	O
targets	JJ	O
for	JJ	O
the	NNS	O
same	IN	O
reason.	NNS	O
Cols.	RB	O
1,	VBG	O
2	.	O
and	NNS	O
3	IN	O
of	DT	O
each	JJ	O
table	NN	O
indicate	IN	O
the	JJ	O
gene	CD	O
name,	VBP	O
kinase	RB	O
name	JJ	O
and	JJ	O
Genbank	NNS	O
accession	IN	O
number	DT	O
of	JJ	O
kinases.	.	O
The	.	O
next	,	O
column	CD	O
indicates	CC	O
whether	CD	O
inhibiting	IN	O
expression	DT	O
of	NN	O
the	VBP	O
kinase	DT	O
decreased	NN	O
(“down”)	,	O
or	NN	O
increased	NN	O
(“up”)	CC	O
phosphorylation.	NNP	O
The	NN	O
next	NN	O
three	IN	O
columns	.	O
indicate	DT	O
the	JJ	O
number	NN	O
of	VBZ	O
standard	IN	O
deviations	VBG	O
the	NN	O
measured	IN	O
level	DT	O
of	NN	O
phosphorylation	VBD	O
departs	)	O
from	CC	O
the	VBN	O
mean	)	O
in	.	O
three	DT	O
independent	JJ	O
experiments.	CD	O
The	NN	O
final	VBP	O
two	DT	O
columns	NN	O
indicate	IN	O
the	JJ	O
kinase	NNS	O
family	DT	O
(i.e.,	JJ	O
amino	NN	O
acid	IN	O
specificity)	NN	O
and	NNS	O
group.	IN	O
Tables	DT	O
2	NN	O
and	IN	O
3	CD	O
show	JJ	O
kinases	.	O
whose	DT	O
inhibition	JJ	O
modulates	CD	O
the	NN	O
overall	VBP	O
levels	DT	O
of	NN	O
human	NN	O
alpha-synuclein	,	O
without	JJ	O
changing	VBP	O
the	)	O
percentage	CC	O
of	.	O
phosphorylation.	NNS	O
Table	CD	O
2	CC	O
shows	CD	O
all	NN	O
of	NNS	O
the	WP$	O
kinases	NN	O
with	VBZ	O
the	DT	O
strongest	JJ	O
reduction	NNS	O
in	IN	O
levels	JJ	O
of	NN	O
human	IN	O
alpha-synuclein.	VBG	O
The	DT	O
columns	NN	O
are	IN	O
labeled	.	O
similarly	JJ	O
to	CD	O
Tables	VBZ	O
1A,	DT	O
1B	IN	O
and	DT	O
1C.	NNS	O
Tables	IN	O
1A-C:	DT	O
Complete	JJS	O
list	NN	O
of	IN	O
Kinase	NNS	O
candidates	IN	O
that	JJ	O
reduce	.	O
phosphorylation	DT	O
EXAMPLE	NN	O
2	VBP	O
Verification	VBN	O
of	RB	O
Alpha-Synuclein	TO	O
Phosphorylation	NNP	O
Modulation	,	O
by	CD	O
Re-Screening	CC	O
and	.	O
by	NNS	O
qRT-PCR	:	O
The	JJ	O
kinases	NN	O
that	IN	O
showed	NNP	O
either	NNS	O
an	IN	O
increase	VB	O
or	NN	O
decrease	NNP	O
in	CD	O
alpha-synuclein	NNP	O
phosphorylation	IN	O
from	NNP	O
Example	NNP	O
1	NNP	O
were	IN	O
retested	NNP	O
to	CC	O
verify	IN	O
the	JJ	O
effect	DT	O
on	NNS	O
alpha-synuclein.	WDT	O
The	VBD	O
confirmation	DT	O
screen	DT	O
was	NN	O
performed	CC	O
using	NN	O
10	IN	O
nM	JJ	O
siRNA	NN	O
on	IN	O
the	JJ	O
targets	CD	O
identified	VBD	O
in	VBN	O
Example	TO	O
1	VB	O
along	DT	O
with	NN	O
several	IN	O
additional	.	O
kinases	DT	O
of	NN	O
interest.	NN	O
The	VBD	O
higher	VBN	O
concentration	VBG	O
of	CD	O
siRNA	JJ	O
in	NN	O
Example	IN	O
1	DT	O
was	NNS	O
used	VBN	O
to	IN	O
ensure	NNP	O
that	CD	O
marginal	IN	O
knockdown	IN	O
caused	JJ	O
by	JJ	O
poorly	NNS	O
designed	IN	O
siRNAs	.	O
could	DT	O
be	JJR	O
observed.	NN	O
By	IN	O
using	NN	O
a	IN	O
much	NNP	O
lower	CD	O
siRNA	VBD	O
concentration	VBN	O
in	TO	O
the	VB	O
confirmation	IN	O
screens,	JJ	O
the	NNS	O
chance	VBN	O
of	IN	O
effects	RB	O
due	VBN	O
to	NN	O
a	MD	O
general	VB	O
response	.	O
to	IN	O
the	VBG	O
siRNA	DT	O
itself	RB	O
could	JJR	O
be	JJ	O
much	NN	O
reduced.	IN	O
Some	DT	O
siRNAs	NN	O
that	,	O
were	DT	O
later	NN	O
reported	IN	O
by	NNS	O
Ambion	JJ	O
to	TO	O
be	DT	O
ineffective	JJ	O
were	NN	O
also	TO	O
re-screened	DT	O
(see	NN	O
replacement	PRP	O
library	MD	O
screen	VB	O
below).	RB	O
Finally,	.	O
some	DT	O
newly	NN	O
identified	WDT	O
kinases	VBD	O
were	RB	O
screened	VBN	O
and	IN	O
those	NNP	O
results	TO	O
were	VB	O
added	JJ	O
to	VBD	O
the	RB	O
pool	JJ	O
of	VB	O
results.	NN	O
The	JJ	O
kinases	NN	O
that	.	O
were	,	O
identified	DT	O
as	RB	O
candidates	VBN	O
were	NNS	O
tested	VBD	O
by	VBN	O
quantitative	CC	O
RT-PCR	DT	O
(qRT-PCR)	NNS	O
to	VBD	O
confirm	VBN	O
that	TO	O
they	DT	O
were	NN	O
actually	IN	O
present	.	O
in	DT	O
the	NNS	O
PEAK-Syn	WDT	O
cells	VBD	O
(see	VBN	O
Example	IN	O
6).	NNS	O
The	VBD	O
experimental	VBN	O
procedures	IN	O
and	JJ	O
results	NNP	O
for	)	O
the	TO	O
confirmation	VB	O
and	IN	O
rescreening	PRP	O
were	VBD	O
as	RB	O
follows:	JJ	O
Confirmation	IN	O
Screen	DT	O
The	NNP	O
results	NNS	O
for	VB	O
the	NNP	O
confirmation	.	O
screen	DT	O
were	JJ	O
grouped	NNS	O
into	CC	O
four	NNS	O
categories	IN	O
shown	DT	O
below:	NN	O
Completely	CC	O
Confirmed:	VBG	O
This	VBD	O
category	IN	O
included	:	O
the	NN	O
kinases	NNP	O
for	DT	O
which	NNS	O
all	IN	O
three	DT	O
siRNAs	NN	O
produced	NN	O
identical	VBD	O
phenotypes	VBN	O
in	IN	O
the	CD	O
10	NNS	O
nM	VBN	O
screen	:	O
and	RB	O
in	:	O
the	DT	O
100	NN	O
nM	VBD	O
screen.	DT	O
Mostly	NNS	O
Confirmed:	IN	O
This	WDT	O
category	DT	O
included	CD	O
the	NNS	O
kinases	VBD	O
for	JJ	O
which	NNS	O
⅔	IN	O
of	DT	O
the	CD	O
siRNAs	NN	O
produced	NN	O
identical	CC	O
phenotypes	IN	O
in	DT	O
the	CD	O
10	JJ	O
nM	.	O
and	RB	O
in	:	O
the	DT	O
100	NN	O
nM	VBD	O
screen,	DT	O
but	NNS	O
one	IN	O
third	WDT	O
did	NN	O
not;	IN	O
or,	DT	O
alternatively	NN	O
one	VBD	O
siRNA	JJ	O
result	NNS	O
was	IN	O
replicated,	DT	O
but	CD	O
for	NN	O
a	CC	O
second	IN	O
siRNA	DT	O
there	CD	O
was	NN	O
a	,	O
trend	CC	O
for	CD	O
the	NN	O
same	VBD	O
phenotype	:	O
but	,	O
with	RB	O
a	CD	O
different	NN	O
siRNA	NN	O
from	VBD	O
that	,	O
used	CC	O
in	IN	O
the	DT	O
original	JJ	O
screen.	NN	O
Partly	EX	O
Confirmed:	VBD	O
This	DT	O
category	NN	O
included	IN	O
the	DT	O
kinases	JJ	O
for	NN	O
which	CC	O
⅓	IN	O
of	DT	O
the	JJ	O
siRNAs	NN	O
produced	IN	O
the	DT	O
same	VBN	O
phenotype	IN	O
in	DT	O
the	JJ	O
10	.	O
nM	RB	O
screen	:	O
and	DT	O
in	NN	O
the	VBD	O
100	DT	O
nM	NNS	O
screen.	IN	O
Not	WDT	O
Confirmed:	NN	O
This	IN	O
category	DT	O
included	NN	O
the	VBD	O
kinases	DT	O
for	JJ	O
which	NN	O
either	IN	O
or	DT	O
both	CD	O
of	NN	O
the	NN	O
following	CC	O
occurred:	IN	O
The	DT	O
number	CD	O
of	JJ	O
kinases	.	O
that	RB	O
fell	:	O
into	DT	O
each	NN	O
category	VBD	O
was	DT	O
tabulated	NNS	O
and	IN	O
the	WDT	O
results	DT	O
are	CC	O
shown	DT	O
in	IN	O
Table	DT	O
3.	JJ	O
Seven	:	O
kinases	DT	O
were	NN	O
completely	IN	O
confirmed,	NNS	O
and	WDT	O
they	VBD	O
are	IN	O
listed	DT	O
in	NN	O
Table	VBD	O
4.	VBN	O
Of	CC	O
these	DT	O
seven,	NNS	O
only	VBP	O
three	VBN	O
were	IN	O
identified	JJ	O
as	.	O
possessing	JJ	O
the	NNS	O
qualities	VBD	O
to	RB	O
be	,	O
good	CC	O
candidates	PRP	O
for	VBP	O
a	VBN	O
kinase	IN	O
that	JJ	O
directly	.	O
phosphorylates	IN	O
alpha-synuclein	DT	O
at	,	O
ser-129.	RB	O
This	CD	O
is	VBD	O
because	VBN	O
only	IN	O
three	VBG	O
were	DT	O
both	NNS	O
ser/thr	TO	O
kinases	VB	O
and	JJ	O
decreased	NNS	O
phospho	IN	O
alpha-synuclein	DT	O
levels	NN	O
when	WDT	O
the	RB	O
kinase	VBZ	O
levels	NN	O
were	IN	O
reduced	.	O
by	DT	O
the	VBZ	O
specific	IN	O
siRNA.	RB	O
These	CD	O
included:	VBD	O
APEG1,	DT	O
which	JJ	O
is	NNS	O
believed	CC	O
to	JJ	O
play	NN	O
a	NN	O
role	NNS	O
in	WRB	O
growth	DT	O
and	NN	O
differentiation	NNS	O
of	VBD	O
smooth	VBN	O
muscle,	IN	O
PLK2	DT	O
(SNK),	JJ	O
which	.	O
is	DT	O
expressed	:	O
in	,	O
brain	WDT	O
and	VBZ	O
is	VBN	O
believed	TO	O
to	VB	O
play	DT	O
a	NN	O
role	IN	O
in	NN	O
normal	CC	O
cell	NN	O
division,	IN	O
and	JJ	O
CDC7L1,	,	O
a	NNP	O
cell	,	O
division	WDT	O
cycle	VBZ	O
protein	VBN	O
with	IN	O
kinase	NN	O
activity.	CC	O
Of	VBZ	O
the	VBN	O
three,	TO	O
PLK2	VB	O
was	DT	O
of	NN	O
the	IN	O
most	JJ	O
interest	NN	O
due	,	O
to	CC	O
its	,	O
role	DT	O
and	NN	O
localization	NN	O
in	NN	O
cells,	NN	O
such	IN	O
as	NN	O
activated	.	O
neurons.	IN	O
Alpha-synuclein	DT	O
is	,	O
a	NNP	O
synaptic-associated	VBD	O
protein	IN	O
thought	DT	O
to	RBS	O
be	NN	O
involved	JJ	O
in	TO	O
synaptic	PRP$	O
plasticity	NN	O
and	CC	O
vesicular	NN	O
transport.	IN	O
Thus,	,	O
PLK2	JJ	O
was	IN	O
identified	JJ	O
as	.	O
a	NNP	O
very	VBZ	O
good	DT	O
candidate	JJ	O
for	NN	O
a	VBD	O
kinase	TO	O
that	VB	O
directly	VBN	O
phosphorylates	IN	O
α-synuclein.	JJ	O
Key	NN	O
to	CC	O
shading:	JJ	O
Table	.	O
4	,	O
shows	NNP	O
the	VBD	O
seven	VBN	O
candidates	IN	O
whose	DT	O
results	RB	O
were	JJ	O
completely	NN	O
replicated	IN	O
at	DT	O
10	NN	O
nM.	WDT	O
Only	RB	O
the	VBZ	O
first	.	O
three	NNP	O
were	TO	O
identified	:	O
as	NN	O
having	CD	O
strong	VBZ	O
potential	DT	O
to	CD	O
be	NNS	O
a	WP$	O
direct	NNS	O
kinase,	VBD	O
because	RB	O
they	VBN	O
are	IN	O
ser/thr	CD	O
kinases	.	O
that	RB	O
reduce	DT	O
phospho-synuclein	JJ	O
levels	CD	O
when	VBD	O
the	VBN	O
kinase	IN	O
level	VBG	O
is	JJ	O
reduced.	NN	O
There	TO	O
were	VB	O
29	DT	O
kinases	JJ	O
that	,	O
fell	IN	O
into	PRP	O
the	VBP	O
mostly	JJ	O
confirmed	NNS	O
category,	WDT	O
12	VB	O
of	NN	O
which	NNS	O
were	WRB	O
candidates	DT	O
for	NN	O
a	NN	O
direct	VBZ	O
kinase.	.	O
These	EX	O
are	VBD	O
listed	CD	O
in	NNS	O
Table	WDT	O
5.	VBD	O
There	IN	O
were	DT	O
17	RB	O
additional	VBN	O
kinases	,	O
that	CD	O
were	IN	O
mostly	WDT	O
confirmed	VBD	O
at	NNS	O
10	IN	O
nM.	DT	O
Although	JJ	O
not	.	O
likely	DT	O
to	VBP	O
be	VBN	O
a	IN	O
direct	JJ	O
kinase,	.	O
these	EX	O
could	VBD	O
play	CD	O
a	JJ	O
role	NNS	O
in	WDT	O
the	VBD	O
regulation	RB	O
of	VBN	O
a	IN	O
direct	CD	O
kinase	.	O
and	IN	O
are	RB	O
listed	JJ	O
in	TO	O
Table	VB	O
6.	DT	O
Twenty-two	JJ	O
kinases	,	O
fell	DT	O
into	MD	O
the	VB	O
partly	DT	O
confirmed	NN	O
category.	IN	O
The	DT	O
ser/thr	NN	O
kinases	IN	O
that	DT	O
decreased	JJ	O
phospho	NN	O
alpha-synuclein	CC	O
(i.e.	VBP	O
potentially	VBN	O
a	IN	O
direct	JJ	O
kinase	.	O
for	JJ	O
alpha-synuclein)	NNS	O
are	VBD	O
listed	IN	O
in	DT	O
Table	RB	O
8,	VBN	O
and	.	O
the	DT	O
remaining	NN	O
potentially	VBZ	O
regulatory	IN	O
kinases	VBD	O
are	JJ	O
listed	JJ	O
in	.	O
Table	RB	O
8.	DT	O
The	JJ	O
ser/thr	NN	O
kinases	IN	O
shown	)	O
in	VBP	O
Table	VBN	O
5	IN	O
were	JJ	O
identified	,	O
as	CC	O
having	DT	O
potential	VBG	O
to	RB	O
be	JJ	O
a	NNS	O
direct	VBP	O
kinase	VBN	O
that	IN	O
phosphorylates	JJ	O
alpha-synuclein	.	O
because	DT	O
they	NN	O
significantly	VBZ	O
reduced	VBN	O
phospho-synuclein	IN	O
levels	JJ	O
when	CD	O
the	VBD	O
kinase	VBN	O
level	IN	O
was	VBG	O
reduced.	JJ	O
⅔	TO	O
of	VB	O
the	DT	O
siRNAs	JJ	O
produced	NN	O
identical	WDT	O
results	VBZ	O
at	RB	O
10	IN	O
nM	PRP	O
as	RB	O
they	VBD	O
did	JJ	O
at	NNS	O
100	WRB	O
nM,	DT	O
and	NN	O
as	NN	O
such,	VBD	O
were	.	O
designated	NN	O
as	IN	O
Mostly	DT	O
Confirmed	NN	O
hits.	VBD	O
The	JJ	O
kinases	NNS	O
in	IN	O
Table	CD	O
6	NNS	O
were	IN	O
designated	PRP	O
as	VBD	O
Mostly	IN	O
Confirmed,	CD	O
because	,	O
⅔	CC	O
of	IN	O
the	,	O
siRNAs	VBD	O
produced	VBN	O
identical	IN	O
results	NNP	O
at	NNP	O
10	.	O
nM	DT	O
and	NNS	O
100	IN	O
nM	JJ	O
concentration	CD	O
of	VBD	O
siRNA.	VBN	O
However,	IN	O
because	NNP	O
they	,	O
did	IN	O
not	NN	O
produce	IN	O
the	DT	O
appropriate	NN	O
phenotype	VBD	O
or	JJ	O
were	NNS	O
the	IN	O
wrong	CD	O
class	NNS	O
of	CC	O
kinase	CD	O
(i.e.	JJ	O
tyr	NN	O
or	IN	O
non-protein	.	O
kinase	,	O
as	IN	O
opposed	PRP	O
to	VBD	O
a	RB	O
ser/thr	VB	O
kinase),	DT	O
they	JJ	O
were	NN	O
identified	CC	O
as	VBD	O
not	DT	O
likely	JJ	O
to	NN	O
be	IN	O
a	NN	O
direct	.	O
kinase	NN	O
that	CC	O
phosphorylates	JJ	O
ser-129	NN	O
on	IN	O
alpha-synuclein.	VBN	O
Instead,	TO	O
they	DT	O
may	JJ	O
be	,	O
upstream	PRP	O
modulators	VBD	O
of	VBN	O
alpha-synuclein	IN	O
phosphorylation.	RB	O
The	JJ	O
ser/thr	TO	O
kinases	VB	O
in	DT	O
Table	JJ	O
7	NN	O
were	WDT	O
identified	VBZ	O
as	JJ	O
having	IN	O
potential	.	O
to	,	O
be	PRP	O
a	MD	O
direct	VB	O
kinase	JJ	O
that	NNS	O
phosphorylates	IN	O
alpha-synuclein	JJ	O
because	.	O
they	DT	O
significantly	NN	O
reduced	VBZ	O
phospho-synuclein	IN	O
levels	JJ	O
when	CD	O
the	VBD	O
kinase	VBN	O
levels	IN	O
were	VBG	O
reduced.	JJ	O
Only	TO	O
⅓	VB	O
of	DT	O
the	JJ	O
siRNAs	NN	O
produced	WDT	O
identical	VBZ	O
results	RB	O
at	IN	O
10	PRP	O
nM	RB	O
as	VBD	O
they	JJ	O
did	NNS	O
at	WRB	O
100	DT	O
nM,	NN	O
and	NNS	O
as	VBD	O
such,	.	O
were	RB	O
designated	NN	O
as	IN	O
Partly	DT	O
Confirmed	NN	O
hits.	VBD	O
Several	JJ	O
candidates	NNS	O
had	IN	O
contradictory	CD	O
results	NNS	O
and,	IN	O
thus,	PRP	O
were	VBD	O
identified	IN	O
as	CD	O
having	,	O
less	CC	O
potential	IN	O
to	,	O
be	VBD	O
a	VBN	O
direct	IN	O
kinase	NNP	O
for	NNP	O
alpha-synuclein.	.	O
The	JJ	O
kinases	NNS	O
in	VBD	O
Table	JJ	O
8	NNS	O
were	,	O
identified	,	O
as	VBD	O
having	VBN	O
less	IN	O
potential	VBG	O
to	JJR	O
be	JJ	O
direct	TO	O
kinases	VB	O
in	DT	O
the	JJ	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	.	O
at	DT	O
ser-129	NNS	O
but	IN	O
could	JJ	O
be	CD	O
upstream	VBD	O
modulators	VBN	O
of	IN	O
alpha-synuclein	VBG	O
phosphorylation.	JJR	O
⅓	JJ	O
of	TO	O
the	VB	O
siRNAs	JJ	O
produced	NNS	O
identical	IN	O
results	DT	O
at	NN	O
10	IN	O
nM	NN	O
as	IN	O
they	JJ	O
did	CC	O
at	MD	O
100	VB	O
nM,	JJ	O
and	NNS	O
as	IN	O
such,	JJ	O
were	.	O
designated	NN	O
as	IN	O
Partly	DT	O
Confirmed	NN	O
hits.	VBD	O
However,	JJ	O
several	NNS	O
had	IN	O
contradictory	CD	O
results	NNS	O
and,	IN	O
thus,	PRP	O
were	VBD	O
designated	IN	O
as	CD	O
having	,	O
less	CC	O
potential	IN	O
to	,	O
be	VBD	O
direct	VBN	O
kinases	IN	O
of	NNP	O
alpha-synuclein.	NNP	O
Forty-two	.	O
kinases	,	O
did	JJ	O
not	VBD	O
have	JJ	O
their	NNS	O
initial	,	O
results	,	O
confirmed	VBD	O
at	VBN	O
10	IN	O
nM.	VBG	O
Of	JJR	O
these,	JJ	O
19	TO	O
fell	VB	O
into	JJ	O
category	NNS	O
(a)	IN	O
listed	.	O
above,	JJ	O
and	NNS	O
are	VBD	O
listed	RB	O
in	VB	O
Table	PRP$	O
9.	JJ	O
At	NNS	O
10	VBD	O
nM,	IN	O
none	CD	O
of	.	O
the	IN	O
three	,	O
siRNAs	CD	O
at	VBD	O
10	IN	O
nM	NN	O
produced	)	O
any	VBN	O
change	,	O
in	CC	O
the	VBP	O
phospho-alpha-synuclein	VBN	O
phenotype,	IN	O
indicating	JJ	O
that	.	O
the	IN	O
results	CD	O
for	,	O
these	NN	O
kinases	IN	O
from	DT	O
the	CD	O
100	NN	O
nM	IN	O
screen	CD	O
were	NNS	O
possibly	VBD	O
due	DT	O
to	NN	O
off-target	IN	O
effects.	DT	O
Twenty-three	JJ	O
kinases	,	O
(Table	VBG	O
10)	IN	O
produced	DT	O
the	NNS	O
opposite	IN	O
effect	DT	O
on	NNS	O
phospho-alpha-synuclein	IN	O
levels	DT	O
at	CD	O
10	NNS	O
nM	NN	O
than	VBD	O
at	RB	O
100	JJ	O
nM	TO	O
siRNA.	JJ	O
There	.	O
is	JJ	O
a	NNS	O
possibility	JJ	O
that	)	O
the	VBD	O
results	DT	O
at	JJ	O
10	NN	O
nM	IN	O
were	NN	O
the	NNS	O
true	IN	O
effects	CD	O
due	NNS	O
to	IN	O
the	IN	O
fact	CD	O
that	JJ	O
at	.	O
100	EX	O
nM	VBZ	O
results	DT	O
are	NN	O
sometimes	IN	O
masked	DT	O
by	NNS	O
off-target	IN	O
effects.	CD	O
This	NNS	O
can	VBD	O
happen	DT	O
at	JJ	O
the	NNS	O
much	JJ	O
higher	TO	O
siRNA	DT	O
concentration.	NN	O
Alternatively,	IN	O
the	IN	O
true	CD	O
effect	JJ	O
may	NNS	O
have	VBP	O
been	RB	O
seen	VBN	O
at	IN	O
the	JJ	O
higher	.	O
concentration.	DT	O
In	MD	O
any	VB	O
case,	IN	O
these	DT	O
kinases	RB	O
were	JJR	O
designated	JJ	O
as	.	O
less	,	O
likely	DT	O
to	JJ	O
be	NN	O
direct	MD	O
kinases	VB	O
of	VBN	O
alpha-synuclein.	VBN	O
The	IN	O
nineteen	DT	O
kinases	JJR	O
shown	.	O
in	IN	O
Table	DT	O
9	,	O
had	DT	O
no	NNS	O
significant	VBD	O
reactivity	VBN	O
at	IN	O
10	RBR	O
nM	JJ	O
compared	TO	O
to	VB	O
controls.	JJ	O
Thus,	NNS	O
it	IN	O
is	.	O
possible	DT	O
that	JJ	O
the	NNS	O
change	VBN	O
in	IN	O
phospho-synuclein	JJ	O
levels	CD	O
observed	VBD	O
at	DT	O
100	JJ	O
nM	NN	O
was	IN	O
due	CD	O
to	NNS	O
off-target	VBN	O
effects	TO	O
caused	.	O
by	,	O
high	PRP	O
concentrations	VBZ	O
of	JJ	O
siRNA.	IN	O
GPRK5	DT	O
and	NN	O
GPRK7	IN	O
were	JJ	O
not	NNS	O
candidates	VBN	O
in	IN	O
the	CD	O
original	NN	O
100	VBD	O
nM	JJ	O
screen,	TO	O
but	JJ	O
were	NNS	O
analyzed	VBN	O
at	IN	O
10	JJ	O
nM	NNS	O
siRNA	IN	O
because	.	O
of	NNP	O
additional	CC	O
interest	NNP	O
in	VBD	O
their	RB	O
role	NNS	O
in	IN	O
alpha-synuclein	DT	O
phosphorylation.	JJ	O
The	CD	O
results	JJ	O
for	,	O
the	CC	O
kinases	VBD	O
in	VBN	O
Table	IN	O
10	CD	O
were	JJ	O
not	NN	O
confirmed	IN	O
at	IN	O
10	JJ	O
nM	NN	O
because	IN	O
they	PRP$	O
had	NN	O
the	IN	O
opposite	JJ	O
effect	.	O
on	DT	O
phospho-synuclein	NNS	O
levels	IN	O
from	DT	O
that	NNS	O
seen	IN	O
at	JJ	O
100	CD	O
nM.	VBD	O
However,	RB	O
it	VBN	O
is	IN	O
possible	CD	O
that	NNS	O
the	IN	O
results	PRP	O
at	VBD	O
10	DT	O
nM	JJ	O
siRNA	NN	O
were	IN	O
the	NN	O
true	NNS	O
results,	IN	O
and	DT	O
that	VBN	O
the	IN	O
high	CD	O
concentration	.	O
(100	,	O
nM)	PRP	O
of	VBZ	O
siRNA	JJ	O
was	IN	O
masking	DT	O
the	NNS	O
true	IN	O
effects.	CD	O
It	JJ	O
is	NN	O
also	VBD	O
possible	DT	O
that	JJ	O
the	,	O
initial	CC	O
effects	IN	O
observed	DT	O
at	JJ	O
100	NN	O
nM	CD	O
were	)	O
the	IN	O
true	NN	O
effects.	VBD	O
These	VBG	O
were	DT	O
designated	JJ	O
as	.	O
likely	PRP	O
to	VBZ	O
be	RB	O
direct	JJ	O
kinases	IN	O
of	DT	O
alpha-synuclein	JJ	O
and	NNS	O
set	VBD	O
aside	IN	O
to	CD	O
be	NNS	O
tested	VBD	O
further	DT	O
at	JJ	O
a	.	O
later	DT	O
date.	VBD	O
Replacement	VBN	O
and	IN	O
Up-Dated	JJ	O
Library	TO	O
Screens	VB	O
Because	JJ	O
some	NNS	O
siRNAs	IN	O
used	JJ	O
in	CC	O
the	VBD	O
initial	RB	O
screen	TO	O
were	VB	O
later	VBN	O
identified	RB	O
as	IN	O
being	DT	O
of	JJ	O
poor	.	O
quality,	NN	O
screens	CC	O
were	JJ	O
performed	NNP	O
at	NNP	O
both	IN	O
concentrations	DT	O
with	NNS	O
replacement	VBN	O
siRNAs.	IN	O
The	DT	O
data	JJ	O
for	NN	O
the	VBD	O
replacement	RB	O
siRNAs	VBN	O
was	IN	O
used	VBG	O
to	IN	O
replace	JJ	O
the	,	O
data	NNS	O
for	VBD	O
that	VBN	O
specific	IN	O
siRNA	DT	O
result	NNS	O
from	IN	O
the	NN	O
original	.	O
screen.	DT	O
Statistical	NN	O
data	IN	O
was	DT	O
tabulated	NN	O
for	NN	O
the	VBD	O
three	VBN	O
siRNAs	TO	O
for	VB	O
each	DT	O
kinase,	NN	O
and	IN	O
using	DT	O
this,	JJ	O
nine	NN	O
additional	NN	O
kinases	IN	O
were	DT	O
identified	JJ	O
as	.	O
candidates	NNP	O
from	NN	O
the	VBD	O
original	VBN	O
screen	IN	O
that	DT	O
were	CD	O
missed	NN	O
in	IN	O
the	DT	O
primary	,	O
screen.	CC	O
These	VBG	O
were	,	O
retested,	CD	O
and	JJ	O
two	NNS	O
of	VBD	O
the	VBN	O
kinases	IN	O
were	NNS	O
partially	IN	O
confirmed	DT	O
at	JJ	O
10	NN	O
nM	WDT	O
siRNA.	VBD	O
These	VBN	O
were	IN	O
BCKDK	DT	O
and	JJ	O
FLJ25965	.	O
(KSR2).	DT	O
During	VBD	O
the	,	O
process,	CC	O
a	CD	O
number	IN	O
of	DT	O
new	NNS	O
kinases	VBD	O
were	RB	O
identified	VBN	O
and	IN	O
siRNAs	CD	O
became	JJ	O
available.	.	O
These	DT	O
were	VBD	O
tested	NNP	O
as	CC	O
in	NNP	O
Example	.	O
1	IN	O
as	DT	O
an	,	O
AMBION	DT	O
Up-Dates	NN	O
library	IN	O
and	JJ	O
new	NNS	O
kinase	VBD	O
candidates	VBN	O
were	CC	O
identified.	JJ	O
Many	VBD	O
of	.	O
the	DT	O
newly	VBD	O
identified	VBN	O
kinases	IN	O
fell	IN	O
under	NNP	O
the	CD	O
GO	IN	O
(Gene	DT	O
Ontology	NNP	O
Consortium)	NNP	O
classification.	NN	O
As	CC	O
such,	JJ	O
it	NN	O
was	NNS	O
difficult	VBD	O
to	.	O
find	JJ	O
detailed	IN	O
information	DT	O
on	RB	O
some	VBN	O
of	NNS	O
these	VBD	O
kinases.	IN	O
Several	DT	O
of	NNP	O
the	NNP	O
genes	NNP	O
included	)	O
in	.	O
this	IN	O
category	,	O
were	PRP	O
not	VBD	O
true	JJ	O
kinases,	TO	O
but	VB	O
were	JJ	O
kinase	NN	O
binding	IN	O
proteins	DT	O
or	IN	O
adaptor	DT	O
proteins.	.	O
At	JJ	O
10	IN	O
nM	DT	O
siRNA,	NNS	O
thirteen	VBD	O
kinases	IN	O
were	DT	O
confirmed	NN	O
to	VBD	O
be	RB	O
candidates	JJ	O
for	,	O
directly	CC	O
acting	VBD	O
on	VBN	O
alpha-synuclein.	VBG	O
Two	NNS	O
of	CC	O
these	NN	O
were	.	O
likely	IN	O
candidates	CD	O
for	JJ	O
being	,	O
a	JJ	O
direct	NNS	O
kinase,	VBD	O
see	VBN	O
Table	TO	O
11.	VB	O
The	NNS	O
remaining	IN	O
eleven	RB	O
were	VBG	O
designated	IN	O
as	.	O
possible	CD	O
indirect	IN	O
regulators	DT	O
of	VBD	O
phospho-synuclein	JJ	O
levels,	NNS	O
see	IN	O
Table	VBG	O
11.	DT	O
Table	JJ	O
11	,	O
provides	VBP	O
Genbank	JJ	O
accession	.	O
numbers	DT	O
for	VBG	O
the	NN	O
kinase	VBD	O
sequences	VBN	O
as	IN	O
deposited	JJ	O
in	JJ	O
Genbank	NNS	O
as	IN	O
of	NN	O
Nov.	,	O
1,	VBP	O
2005.	JJ	O
A	.	O
summary	JJ	O
of	CD	O
the	VBZ	O
results	NNP	O
showing	NN	O
the	NNS	O
kinase	IN	O
siRNAs	DT	O
that	NN	O
were	VBZ	O
identified	RB	O
and	VBN	O
verified	IN	O
in	NNP	O
Examples	IN	O
1	IN	O
and	NNP	O
2	,	O
are	.	O
shown	DT	O
in	NN	O
Tables	IN	O
12	DT	O
and	NNS	O
13.	VBG	O
From	DT	O
these	NN	O
results,	NN	O
PLK2,	WDT	O
APEG1,	VBD	O
CDC7L1,	VBN	O
MET,	CC	O
IKBKB,	VBN	O
CKII,	IN	O
GRK1,	NNP	O
2,	CD	O
6	CC	O
and	CD	O
7	VBP	O
were	VBN	O
identified	IN	O
as	NNP	O
kinases	CD	O
that	CC	O
are	.	O
very	IN	O
likely	DT	O
to	,	O
phosphorylate	,	O
alpha-synuclein	,	O
directly	,	O
or	,	O
indirectly.	,	O
The	,	O
kinases	,	O
that	,	O
were	CD	O
identified	CC	O
as	CD	O
having	VBD	O
siRNAs	VBN	O
that	IN	O
increased	NNS	O
alpha-synuclein	WDT	O
phosphorylation	VBP	O
(PRKG1,	RB	O
MAPK13,	JJ	O
and	TO	O
GAK)	VB	O
could	JJ	O
very	RB	O
well	CC	O
be	.	O
negative	DT	O
regulators	NNS	O
of	WDT	O
alpha-synuclein	VBD	O
phosphorylation.	VBN	O
Tables	IN	O
12	VBG	O
and	NN	O
13:	WDT	O
Summary	VBD	O
of	JJ	O
Confirmation	NN	O
Studies	,	O
In	,	O
the	CC	O
following	)	O
examples,	MD	O
in	RB	O
vitro	RB	O
kinase	VB	O
assays	JJ	O
were	NNS	O
performed	IN	O
on	JJ	O
a	.	O
number	NNS	O
of	CD	O
the	CC	O
potential	:	O
targets	NN	O
identified	IN	O
in	NNP	O
Examples	NNPS	O
1	IN	O
and	DT	O
2.	JJ	O
EXAMPLE	,	O
3	IN	O
Identification	JJ	O
of	NN	O
Direct	NNS	O
Phosphorylation	VBD	O
of	VBN	O
Alpha-Synuclein	IN	O
In	DT	O
Vitro	NN	O
To	IN	O
determine	DT	O
which	JJ	O
of	NNS	O
the	VBN	O
kinase(s)	IN	O
from	NNP	O
the	CD	O
siRNA	CC	O
screen	.	O
directly	RB	O
phosphorylated	CD	O
alpha-synuclein,	NNP	O
purified	IN	O
kinases	NNP	O
were	NNP	O
incubated	IN	O
with	NNP	O
alpha-synuclein	IN	O
in	NNP	O
in	TO	O
vitro	VB	O
kinase	WDT	O
reactions.	IN	O
These	DT	O
results	)	O
showed	IN	O
that	DT	O
PLK2,	NN	O
GRK2,	NN	O
5,	RB	O
6.	VBD	O
and	,	O
7	JJ	O
(GPRK2,	NNS	O
5,	VBD	O
6	VBN	O
and	IN	O
7)	NN	O
were	IN	O
all	IN	O
capable	JJ	O
of	NN	O
phosphorylating	.	O
alpha-synuclein	DT	O
specifically	NNS	O
at	VBD	O
serine	IN	O
129	,	O
and	,	O
did	,	O
not	CD	O
phosphorylate	CC	O
serine	CD	O
87	,	O
in	,	O
vitro,	CD	O
showing	CC	O
that	)	O
they	VBD	O
could	DT	O
directly	JJ	O
phosphorylate	IN	O
alpha-synuclein.	VBG	O
MET,	JJ	O
CDC7L1,	RB	O
and	IN	O
IKBKB	JJ	O
were	CD	O
shown	CC	O
to	VBD	O
be	RB	O
incapable	VB	O
of	NN	O
directly	CD	O
phosphorylating	IN	O
alpha-synuclein	,	O
(FIGS.	VBG	O
1A-C).	IN	O
Assay	PRP	O
conditions	MD	O
for	RB	O
testing	VB	O
recombinant	.	O
kinase	,	O
activities	,	O
toward	CC	O
recombinant	NNP	O
alpha-synuclein	VBD	O
at	VBN	O
serine	TO	O
129	VB	O
were	JJ	O
established	IN	O
and	RB	O
found	VBG	O
to	NN	O
be	.	O
reproducible	.	O
by	NNP	O
immunoblot	NNS	O
and	IN	O
ELISA	VBG	O
analyses.	JJ	O
Commercially	NN	O
available	NNS	O
recombinant	IN	O
kinases	JJ	O
were	NN	O
used	IN	O
when	JJ	O
possible.	CD	O
Those	VBD	O
that	VBN	O
were	CC	O
not	VBN	O
available	TO	O
were	VB	O
produced	JJ	O
as	IN	O
indicated	NN	O
by	CC	O
recombinant	NNP	O
means.	.	O
In	RB	O
FIGS.	JJ	O
1A-C,	JJ	O
recombinant	NNS	O
kinases	VBD	O
were	VBN	O
included	WRB	O
in	.	O
the	DT	O
in	WDT	O
vitro	VBD	O
alpha-synuclein	RB	O
(AS)	JJ	O
assay	VBD	O
by	VBN	O
standardizing	IN	O
kinase	VBN	O
to	IN	O
alpha-synuclein	NN	O
substrate	.	O
at	IN	O
a	.	O
constant	,	O
molar	JJ	O
ratio	NNS	O
(derived	VBD	O
from	VBN	O
MW	IN	O
of	DT	O
predicted	IN	O
mature	JJ	O
protein)	JJ	O
in	)	O
each	VBP	O
reaction	IN	O
(1:200;	VBG	O
kinase:	NN	O
recombinant	TO	O
alpha-synuclein	JJ	O
kinase—rAS).	NN	O
−control,	IN	O
+kinase;	DT	O
In	JJ	O
FIG.	NN	O
1A,	NN	O
a	VBN	O
probe	IN	O
for	NNP	O
total	IN	O
alpha-synuclein	JJ	O
(AS)	NN	O
(mAb	)	O
Syn-1;	IN	O
0.1	DT	O
μg/mL)	NN	O
was	:	O
used	:	O
indicating	JJ	O
equivalent	JJ	O
substrate	.	O
in	,	O
each	:	O
reaction;	IN	O
In	.	O
FIG.	,	O
1B,	DT	O
a	NN	O
parallel	IN	O
blot	JJ	O
was	JJ	O
probed	)	O
for	JJ	O
5129	:	O
phosphorylation	CD	O
(mAb	)	O
11A5	VBD	O
1	VBN	O
μg/mL).	VBG	O
Prominent	JJ	O
signals	NN	O
came	IN	O
from	DT	O
GRK6,	:	O
CKI,	IN	O
CKII	.	O
and	,	O
PLK2	DT	O
(not	JJ	O
previously	NN	O
tested	VBD	O
by	VBN	O
activity	IN	O
normalization).	CD	O
In	NN	O
FIG.	JJ	O
1C,	CD	O
a	CD	O
parallel	.	O
blot	JJ	O
probed	NNS	O
for	VBD	O
S87	IN	O
phosphorylation	,	O
(pAb,	,	O
ELADW-110	NNP	O
5	CC	O
μg/mL).	NNP	O
A	RB	O
signal	RB	O
was	VBN	O
detected	IN	O
only	NN	O
with	.	O
CKI	IN	O
phosphorylation.	.	O
In	,	O
FIGS.	DT	O
1D-F,	JJ	O
a	NN	O
more	VBD	O
focused	IN	O
study	NNP	O
was	NN	O
performed	,	O
with	JJ	O
recombinant	CD	O
kinases	.	O
from	DT	O
the	NN	O
GPCR-receptor	VBD	O
kinase	VBN	O
(GRK)	RB	O
family	IN	O
and	NNP	O
PLK2	.	O
were	IN	O
included	.	O
in	,	O
the	DT	O
in	RBR	O
vitro	JJ	O
alpha-synuclein	NN	O
(AS)	VBD	O
assay	VBN	O
by	IN	O
standardizing	JJ	O
kinase	NNS	O
to	IN	O
AS	DT	O
substrate	NNP	O
at	NN	O
a	)	O
constant	NN	O
molar	CC	O
ratio	NNP	O
(derived	VBD	O
from	VBN	O
MW	IN	O
of	DT	O
predicted	IN	O
mature	JJ	O
protein)	JJ	O
in	)	O
each	VBP	O
reaction	IN	O
(1:200;	VBG	O
kinase:	NN	O
rAS).	TO	O
−control,	NNP	O
+kinase;	NN	O
CAM	IN	O
kinases	DT	O
served	JJ	O
as	NN	O
negative	NN	O
controls	VBN	O
while	IN	O
CKI	NNP	O
and	IN	O
II	JJ	O
served	NN	O
as	)	O
positive	IN	O
controls.	DT	O
In	NN	O
FIG.	:	O
1D,	:	O
a	.	O
probe	,	O
for	:	O
total	NNP	O
AS	VBZ	O
(mAb	VBD	O
Syn-1;	IN	O
0.1	JJ	O
μg/mL)	NNS	O
was	IN	O
used	NNP	O
indicating	CC	O
equivalent	NNP	O
substrate	VBD	O
in	IN	O
each	JJ	O
reaction;	.	O
In	IN	O
FIG.	.	O
1E,	,	O
a	DT	O
parallel	NN	O
blot	IN	O
probed	JJ	O
for	NNP	O
5129	IN	O
phosphorylation	:	O
(mAb	CD	O
11	)	O
A5	VBD	O
1	VBN	O
μg/mL).	VBG	O
Prominent	JJ	O
signals	NN	O
came	IN	O
from	DT	O
all	:	O
GRKs	IN	O
except	.	O
for	,	O
GRK7.	DT	O
A	JJ	O
specificity	NN	O
between	VBN	O
GRK	IN	O
members	CD	O
could	NN	O
be	JJ	O
seen	CD	O
with	NNP	O
signal	CD	O
and	.	O
can	JJ	O
be	NNS	O
represented	VBD	O
as:	IN	O
CKI>GRK6>PLK2>GRK4>GRK5>GRK2.	DT	O
In	NNP	O
FIG.	IN	O
1F,	IN	O
a	.	O
parallel	DT	O
blot	NN	O
probed	IN	O
for	NNP	O
S87	NNS	O
phosphorylation	MD	O
(pAb,	VB	O
ELADW-110	VBN	O
5	IN	O
μg/mL).	JJ	O
Signal	CC	O
was	MD	O
detected	VB	O
only	VBN	O
with	:	O
CKI	.	O
phosphorylation.	IN	O
The	.	O
assay	,	O
conditions	DT	O
are	JJ	O
defined	NN	O
in	VBD	O
Table	IN	O
14	NNP	O
and	NN	O
were	,	O
held	JJ	O
constant	CD	O
for	.	O
all	NNP	O
kinases	VBD	O
tested.	VBN	O
All	RB	O
of	IN	O
the	NNP	O
kinases	.	O
listed	DT	O
were	JJ	O
available	NNS	O
as	VBP	O
tagged/recombinant	VBN	O
protein	IN	O
with	JJ	O
the	CD	O
exception	CC	O
of	VBD	O
CDC7L1,	VBN	O
PRKG1	JJ	O
and	IN	O
APEG.	DT	O
Those	NNS	O
putative	.	O
targets	DT	O
were	IN	O
expressed	DT	O
in	NNS	O
an	VBN	O
in	VBD	O
vitro	JJ	O
translation	IN	O
system	JJ	O
and	NN	O
tested	IN	O
in	DT	O
the	NN	O
in	IN	O
vitro	,	O
AS	NNP	O
assay	CC	O
without	.	O
protein	DT	O
concentration	JJ	O
or	NNS	O
activity	VBD	O
measurements.	VBN	O
The	IN	O
Standard	DT	O
Conditions	IN	O
were:	NN	O
40	NN	O
mM	NN	O
MOPS-NaOH;	CC	O
1	VBN	O
mM	IN	O
EDTA	DT	O
MgCl	IN	O
10	NN	O
mM	IN	O
pH	NN	O
8.0,	IN	O
0.1%	JJ	O
BME;	NN	O
0.01%	CC	O
Brij-35;	NN	O
5	.	O
ug	DT	O
BSA,	NNP	O
100	NNPS	O
uM	:	O
ATP	CD	O
(5×[substrate]),	JJ	O
100	:	O
uL	CD	O
volume;	NN	O
300	NNP	O
ng	NNP	O
r-wt-AS	CD	O
(208	NN	O
nM),	NN	O
(1:200	,	O
kinase:	NN	O
AS	:	O
or	NN	O
activity	:	O
normalized	CD	O
0.03	JJ	O
U/rxn,	,	O
34	CD	O
C;	JJ	O
17	NNP	O
hrs.	,	O
Further,	CD	O
those	JJ	O
kinases	:	O
with	CD	O
varying	IN	O
levels	NN	O
of	CD	O
significance/confirmation	,	O
from	CD	O
combined	:	O
screening	IN	O
data	CC	O
were	NN	O
purchased	VBN	O
as	CD	O
recombinant,	,	O
tagged	CD	O
protein,	:	O
annotated	CD	O
and	.	O
incorporated	,	O
into	DT	O
a	NNS	O
table	IN	O
format	VBG	O
for	NNS	O
the	IN	O
purposes	NN	O
of	IN	O
establishing	VBN	O
in	VBG	O
vitro	NNS	O
assays	VBD	O
that	VBN	O
were	IN	O
comparable	,	O
based	VBD	O
upon	,	O
normalization	VBN	O
to	CC	O
activity	VBN	O
units	IN	O
(determined	DT	O
by	JJ	O
the	NN	O
manufacturer	IN	O
from	DT	O
synthetic	NNS	O
substrates)	IN	O
or	VBG	O
substrate:enzyme	IN	O
molar	NN	O
ratios	NNS	O
determined	WDT	O
from	VBD	O
MW	JJ	O
and	VBN	O
reaction	IN	O
volume.	NN	O
The	TO	O
details	NN	O
of	NNS	O
reaction	VBN	O
conditions	IN	O
are	DT	O
stipulated	NN	O
in	IN	O
Table	JJ	O
14.	)	O
Kin.=kinase.	CC	O
For	NN	O
Confirmation:	JJ	O
Most=mostly,	NNS	O
Part=partially,	VBN	O
del=deleted,	IN	O
conf=confirmed.	NNP	O
Kinase	CC	O
activity	NN	O
was	.	O
initially	DT	O
tested	NNS	O
against	IN	O
AS	NN	O
by	NNS	O
activity	VBP	O
units	VBN	O
as	IN	O
determined	JJ	O
from	.	O
non-native	.	O
substrates	IN	O
(peptides	:	O
or	,	O
casein).	,	O
This	,	O
method	.	O
was	NNP	O
used	NN	O
to	VBD	O
get	RB	O
a	VBN	O
rough	IN	O
estimate	NNP	O
as	IN	O
to	NN	O
specificity	NNS	O
between	IN	O
kinases	VBN	O
and	IN	O
whether	JJ	O
AS	NNS	O
was	NNS	O
an	CC	O
in	.	O
vitro	DT	O
substrate	NN	O
for	VBD	O
the	VBN	O
kinase	TO	O
panel.	VB	O
The	DT	O
results	JJ	O
of	NN	O
this	IN	O
study	TO	O
are	NN	O
found	IN	O
in	NNS	O
FIGS.	CC	O
2	IN	O
and	NNP	O
3.	VBD	O
At	DT	O
the	IN	O
time	NN	O
of	NN	O
this	IN	O
experiment,	DT	O
only	NN	O
a	.	O
portion	DT	O
of	NNS	O
available	IN	O
kinases	DT	O
were	NN	O
obtained	VBP	O
and	VBN	O
⅔	IN	O
kinases	.	O
from	CD	O
the	CC	O
“most	.	O
probable	IN	O
7	DT	O
confirmed”	NN	O
were	IN	O
included	DT	O
(PLK2	,	O
was	RB	O
not	DT	O
tested).	NN	O
The	IN	O
most	JJ	O
prominent	NNS	O
result	VBD	O
came	VBN	O
from	CC	O
GRK6	JJ	O
(G-protein	NNS	O
coupled	IN	O
receptor	DT	O
kinase	NNP	O
6).	JJ	O
CKI	CD	O
gave	NN	O
a	VBD	O
modest	VBN	O
signal	NNP	O
and	VBD	O
CKII	RB	O
was	.	O
not	DT	O
detectable.	RBS	O
Because	JJ	O
both	NN	O
CK	VBD	O
kinases	IN	O
are	NNP	O
known	NNP	O
to	VBD	O
phosphorylate	NN	O
5129	NN	O
AS,	.	O
normalization	NNP	O
by	VBD	O
activity	DT	O
units	JJ	O
was	NN	O
biased	CC	O
against	NNP	O
those	VBD	O
kinases	RB	O
which	.	O
had	IN	O
higher	DT	O
specific	NNP	O
activity	NNS	O
for	VBP	O
tested	VBN	O
substrates	TO	O
vs	VB	O
AS.	CD	O
This	,	O
was	NN	O
likely	IN	O
the	NN	O
situation	NNS	O
for	VBD	O
GRK6	VBN	O
which	IN	O
might	DT	O
have	NNS	O
preferred	WDT	O
AS	VBD	O
as	RBR	O
a	JJ	O
substrate	NN	O
rather	IN	O
than	VBN	O
the	NNS	O
peptide	RB	O
substrate	.	O
which	DT	O
defined	VBD	O
its	JJ	O
activity	DT	O
units.	NN	O
In	IN	O
the	NNP	O
following	WDT	O
examples,	MD	O
in	VB	O
vitro	VBN	O
kinase	NNP	O
assays	IN	O
were	DT	O
performed	NN	O
on	RB	O
a	IN	O
number	DT	O
of	NN	O
the	NN	O
potential	WDT	O
targets	VBD	O
identified	PRP$	O
in	NN	O
Examples	.	O
1	IN	O
and	DT	O
2.	JJ	O
To	,	O
correct	IN	O
for	JJ	O
the	NN	O
activity	NNS	O
bias,	VBD	O
kinases	VBN	O
were	IN	O
retested	DT	O
and	NN	O
newly	IN	O
procured	DT	O
kinases	JJ	O
were	NNS	O
put	VBN	O
into	IN	O
an	NNP	O
assay	CD	O
that	CC	O
normalized	.	O
for	TO	O
molarity.	VB	O
This	IN	O
gave	DT	O
a	NN	O
better	,	O
measurement	NNS	O
of	VBD	O
stoichiometric	VBN	O
ratios	CC	O
between	RB	O
enzyme	VBN	O
and	NNS	O
substrate,	VBD	O
thus	VBN	O
reporting	IN	O
the	DT	O
phosphorylation	NN	O
event	WDT	O
as	VBD	O
a	IN	O
function	.	O
of	DT	O
AS/kinase	VBD	O
interaction.	DT	O
This	RBR	O
was	NN	O
in	IN	O
contrast	JJ	O
to	NNS	O
the	IN	O
event	NN	O
in	CC	O
which	,	O
unrelated	RB	O
substrate/kinase	VBG	O
phosphorylation	DT	O
was	NN	O
measured.	NN	O
FIGS.	IN	O
3A-C	DT	O
illustrate	NN	O
a	IN	O
more	NNP	O
realistic	.	O
view	DT	O
of	VBD	O
AS	IN	O
phosphorylation	NN	O
with	TO	O
roughly	DT	O
equivalent	NN	O
levels	IN	O
of	WDT	O
phospho	JJ	O
ser-129	NN	O
between	NN	O
CKI,	VBD	O
GRK6	.	O
and	.	O
PLK2	JJ	O
(one	NN	O
of	DT	O
7	RBR	O
highly	JJ	O
confirmed).	NN	O
With	IN	O
the	NNP	O
exception	NN	O
of	IN	O
CKI,	RB	O
none	JJ	O
of	NNS	O
the	IN	O
tested	JJ	O
kinases	NN	O
were	IN	O
capable	,	O
of	NNP	O
phosphorylating	CC	O
AS	NNP	O
at	CD	O
the	IN	O
ser-87	CD	O
residue.	RB	O
This	.	O
observation	IN	O
confirmed	DT	O
the	NN	O
specificity/preference	IN	O
of	,	O
these	NN	O
kinases	IN	O
for	DT	O
the	JJ	O
ser-129	NNS	O
site	VBD	O
and/or	JJ	O
the	IN	O
low	VBG	O
preference/inaccessibility	NNP	O
for	IN	O
the	DT	O
ser-87	JJ	O
site.	.	O
However,	DT	O
CKI	NN	O
has	VBD	O
been	DT	O
reported	NN	O
to	IN	O
phosphorylate	DT	O
at	NNS	O
both	IN	O
sites.	DT	O
Effect	JJ	O
of	NN	O
Acidic	IN	O
Phospholipid	DT	O
on	JJ	O
the	NN	O
Assay	IN	O
Results	DT	O
The	JJ	O
significant	.	O
levels	,	O
of	NNP	O
activity	VBZ	O
by	VBN	O
GRK6	VBN	O
and	TO	O
PLK2	VB	O
(polo-like	IN	O
kinase	DT	O
phylogenetically	.	O
related	NN	O
to	IN	O
the	NNP	O
GRK	NNP	O
family)	IN	O
in	DT	O
the	NNP	O
in	NNP	O
vitro	DT	O
assay	JJ	O
combined	NNS	O
with	IN	O
the	NN	O
identification	IN	O
of	NNP	O
PLK2,	CC	O
GRK2	NNP	O
and	JJ	O
GRK1	NN	O
as	RB	O
decreasers	VBN	O
of	TO	O
phosphorylation	DT	O
in	NNP	O
the	)	O
RNAi	IN	O
screen,	DT	O
prompted	IN	O
a	JJ	O
more	NN	O
comprehensive	VBN	O
survey	IN	O
of	DT	O
other	NN	O
GRK	IN	O
members.	,	O
FIGS.	NNP	O
4A	CC	O
and	NNP	O
B	IN	O
indicate	NNS	O
the	IN	O
results	NN	O
of	IN	O
GRK	DT	O
2,	NNP	O
4,	,	O
5,	VBD	O
6,	DT	O
7	RBR	O
and	JJ	O
PLK2	NN	O
compared	IN	O
in	JJ	O
the	NNP	O
in	.	O
vitro	.	O
assay.	CD	O
This	CC	O
preference	NNP	O
could	VBP	O
be	DT	O
represented	NNS	O
as	IN	O
CKI>GRK6>PLK2>GRK4>GRK5>GRK2.	NNP	O
GRK	,	O
7	,	O
was	,	O
not	,	O
able	CD	O
to	CC	O
phosphorylate	NNP	O
at	VBN	O
appreciable	IN	O
levels.	DT	O
All	IN	O
GRKs	JJ	O
were	.	O
unable	DT	O
to	NN	O
phosphorylate	MD	O
at	VB	O
ser-87	VBN	O
pointing	IN	O
to	.	O
a	NNP	O
specificity	CD	O
for	VBD	O
the	RB	O
acidic	JJ	O
sequence	TO	O
flanking	VB	O
amino	IN	O
acid	JJ	O
129.	.	O
These	DT	O
reactions	NNP	O
were	VBD	O
quantitated	JJ	O
and	TO	O
confirmed	VB	O
by	IN	O
ELISA	JJ	O
measurements.	VBG	O
These	TO	O
values	DT	O
more	NN	O
or	IN	O
less	DT	O
agreed	JJ	O
with	NN	O
the	VBG	O
immunoblot	JJ	O
data	JJ	O
with	.	O
an	DT	O
apparent	NNS	O
decrease	VBD	O
in	VBN	O
PLK2	CC	O
level	VBN	O
vs	IN	O
GRKs.	NNP	O
It	.	O
is	DT	O
likely	NNS	O
that	RBR	O
most	CC	O
of	JJR	O
the	VBN	O
AS	IN	O
substrate	DT	O
was	NN	O
depleted	NNS	O
(phosphorylated)	IN	O
based	DT	O
on	JJ	O
the	NN	O
assay	IN	O
design	NNP	O
(300	NN	O
ng	NN	O
AS,	.	O
210	PRP	O
nM	VBZ	O
for	JJ	O
17	IN	O
hr).	JJS	O
The	IN	O
positive	DT	O
effect	NNP	O
of	NN	O
acidic	VBD	O
phospholipids	VBN	O
on	)	O
the	VBN	O
phosphorylation	IN	O
of	DT	O
AS	NN	O
has	NN	O
been	CD	O
previously	RB	O
reported	,	O
Pronin	CD	B
et.	NN	I
al.	IN	I
JBC	CD	I
275(34):	.	I
26515-26522	DT	I
(2000)	JJ	I
and	NN	O
a	IN	O
pronounced	JJ	O
effect	NNS	O
on	IN	O
GRK	DT	O
2	NN	O
and	IN	O
5	NNP	O
was	VBZ	O
observed.	VBN	O
Because	RB	O
of	VBN	O
this	NNP	O
report	.	O
and	.	O
the	RB	O
many	:	O
studies	JJ	O
indicating	)	O
that	CC	O
acidic	DT	O
phospholipids	JJ	O
modulate	NN	O
AS	IN	O
conformation,	NNP	O
a	CD	O
mixture	CC	O
of	CD	O
phosphatidylcholine	VBD	O
(PC):	.	O
phosphatidylserine	IN	O
(PS):	IN	O
phosphatidyl-inositol-phosphate-3	DT	O
(PIP3)	NN	O
was	CC	O
generated	DT	O
and	JJ	O
incorporated	NNS	O
into	VBG	O
the	IN	O
established	JJ	O
in	NNS	O
vitro	NN	O
assay.	IN	O
The	,	O
lipid	DT	O
mixture	NN	O
was	IN	O
shown	NN	O
to	:	O
increase	NN	O
signal	:	O
for	NN	O
almost	)	O
all	VBD	O
of	VBN	O
the	CC	O
kinases	VBN	O
tested.	IN	O
The	DT	O
addition	VBN	O
of	IN	O
a	JJ	O
lipid	.	O
environment	DT	O
is	JJ	O
likely	NN	O
to	VBD	O
imitate	VBN	O
the	TO	O
membrane	VB	O
surface	NN	O
in	IN	O
a	RB	O
cell	DT	O
where	IN	O
AS	DT	O
and	NNS	O
GRKs	.	O
are	DT	O
likely	NN	O
to	IN	O
associate.	DT	O
Without	JJ	O
being	NN	O
bound	VBZ	O
by	JJ	O
the	TO	O
following	VB	O
theory,	DT	O
it	NN	O
is	NN	O
probably	IN	O
due	DT	O
to	NN	O
a	WRB	O
favorable	NNP	O
exposure	CC	O
of	NNP	O
the	VBP	O
C-term	JJ	O
of	TO	O
AS	.	O
upon	IN	O
lipid	VBG	O
binding	VBN	O
of	IN	O
the	DT	O
N-term	JJ	O
helices	,	O
of	PRP	O
AS.	VBZ	O
Interestingly,	RB	O
the	JJ	O
lipid	TO	O
effect	DT	O
of	JJ	O
ser-87	NN	O
phosphorylation	IN	O
(as	DT	O
see	NNP	O
by	IN	O
the	NNP	O
CKI	IN	O
reaction)	JJ	O
led	NN	O
to	IN	O
a	DT	O
decrease	NNP	O
in	NNS	O
the	IN	O
level	.	O
of	,	O
phosphorylation.	DT	O
This	JJ	O
may	NN	O
be	IN	O
the	JJ	O
result	NN	O
of	IN	O
epitope	NN	O
masking	IN	O
by	DT	O
lipid	NNP	O
interaction	)	O
if	VBD	O
ser-87	TO	O
is	DT	O
buried	NN	O
upon	IN	O
helix	DT	O
interaction.	NN	O
EXAMPLE	IN	O
4	.	O
Identification	DT	O
of	MD	O
Direct	VB	O
Phosphorylation	DT	O
of	NN	O
Alpha-Synuclein	IN	O
in	NN	O
Cell	NN	O
Lines	IN	O
Because	JJ	O
kinases	NN	O
can	IN	O
be	JJ	O
more	VBZ	O
promiscuous	VBN	O
in	IN	O
vitro	NN	O
than	.	O
they	RB	O
are	CD	O
in	NNP	O
cells,	IN	O
an	NNP	O
assay	NNP	O
was	IN	O
performed	NNP	O
in	IN	O
cell	NNP	O
lines	NNP	O
to	IN	O
confirm	NNS	O
the	MD	O
direct	VB	O
interaction	RBR	O
with	JJ	O
alpha-synuclein.	IN	O
cDNAs	NN	O
for	IN	O
the	PRP	O
kinases	VBP	O
that	IN	O
phosphorylated	,	O
alpha-synuclein	DT	O
in	NN	O
vitro	VBD	O
from	VBN	O
Example	IN	O
3	NN	O
were	NNS	O
transfected	TO	O
into	VB	O
the	DT	O
PEAK-Syn	JJ	O
cell	NN	O
line	IN	O
to	.	O
see	NN	O
which	IN	O
was	DT	O
capable	NNS	O
of	WDT	O
phosphorylating	VBD	O
alpha-synuclein	RB	O
ser-129	IN	O
in	NN	O
cells.	IN	O
The	JJ	O
results	CD	O
showed	VBD	O
that	VBN	O
GRK6	IN	O
and,	DT	O
to	NNP	O
an	NN	O
even	NN	O
greater	TO	O
extent,	VB	O
PLK2	WDT	O
were	VBD	O
able	JJ	O
to	IN	O
mediate	VBG	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
cells	.	O
(FIG.	DT	O
6).	NNS	O
cDNA	VBD	O
clones	IN	O
for	NNP	O
PLK2,	,	O
GPRK6,	TO	O
APEG1,	DT	O
CDC7	RB	O
and	JJR	O
PRKG1	,	O
were	NNP	O
obtained	VBD	O
from	JJ	O
Origene.	TO	O
The	VB	O
cDNA	JJ	O
was	NN	O
transcribed	IN	O
and	NNS	O
transfected	.	O
into	.	O
PEAK-Syn	NN	O
cells	NNS	O
using	IN	O
Lipofectamine	,	O
2000™	,	O
(Invitrogen).	,	O
For	NNP	O
each	CC	O
cDNA	NNP	O
analyzed,	VBD	O
12	VBN	O
wells	IN	O
of	.	O
a	DT	O
96-well	NN	O
plate	VBD	O
were	VBN	O
transfected,	CC	O
along	VBN	O
with	IN	O
12	NNP	O
control	NNS	O
wells	VBG	O
of	NNP	O
untransfected	CD	O
cells.	.	O
Cells	IN	O
were	DT	O
harvested	NN	O
at	,	O
48	CD	O
hrs	NNS	O
post-transfection	IN	O
as	DT	O
per	JJ	O
the	NN	O
ELISA	VBD	O
screening	,	O
protocol,	IN	O
and	IN	O
analyzed	CD	O
by	NN	O
ELISA	NNS	O
for	IN	O
total	JJ	O
and	.	O
phospho-synuclein,	NNS	O
and	VBD	O
values	VBN	O
were	IN	O
normalized	CD	O
for	JJ	O
total	NN	O
protein.	IN	O
For	IN	O
those	DT	O
kinase	NNP	O
targets	NN	O
not	,	O
commercially	CC	O
available	VBN	O
as	IN	O
recombinant	NNP	O
proteins	IN	O
(namely	JJ	O
APEG,	CC	O
PRKGI	,	O
and	CC	O
CDC7LI),	NNS	O
an	VBD	O
in	VBN	O
vitro	IN	O
cell-free	JJ	O
reticulocyte	.	O
system	IN	O
(Promega)	DT	O
was	NNP	O
employed	NNS	O
to	RB	O
express	RB	O
protein	JJ	O
from	IN	O
human	JJ	O
full-length	NNS	O
cDNA	RB	O
clones	,	O
(Origene).	NNP	O
Proper	CC	O
sequence	,	O
was	DT	O
determined	IN	O
and	JJ	O
DNA	JJ	O
prepared.	NN	O
PLK2	NN	O
and	)	O
GRK6	VBD	O
cDNA	VBN	O
was	TO	O
also	VB	O
included	NN	O
in	IN	O
the	JJ	O
study	JJ	O
as	NN	O
positive	NNS	O
controls.	.	O
The	NNP	O
percentage	NN	O
of	VBD	O
phospho-synuclein	VBN	O
in	CC	O
untransfected	NNP	O
cells	.	O
was	NNP	O
calculated	CC	O
to	NNP	O
be	NN	O
7.8%.	VBD	O
The	RB	O
percentage	VBN	O
of	IN	O
phospho-synuclein	DT	O
for	NN	O
the	IN	O
cells	JJ	O
transfected	.	O
with	DT	O
APEG1,	NN	O
CDC7	IN	O
and	NN	O
PRKG1	IN	O
cDNA	JJ	O
was	NNS	O
only	VBD	O
marginally	VBN	O
higher	TO	O
than	VB	O
untransfected	.	O
cells	DT	O
at	NN	O
8.9%.	IN	O
These	NN	O
kinases	IN	O
were	DT	O
considered	NNS	O
to	VBN	O
have	IN	O
produced	,	O
a	NNP	O
negative	CC	O
result	NNP	O
in	NN	O
altering	VBD	O
phospho-synuclein	RB	O
levels,	RB	O
and	JJR	O
were	IN	O
considered	JJ	O
negative	NNS	O
controls	IN	O
for	.	O
experimental	DT	O
purposes,	NNS	O
as	VBD	O
they	VBN	O
were	TO	O
subjected	VB	O
to	VBN	O
the	DT	O
same	JJ	O
rigors	NN	O
of	IN	O
transfection	VBG	O
that	JJ	O
the	,	O
other	CC	O
kinases	VBD	O
were	VBN	O
exposed	JJ	O
to	NNS	O
cDNA	IN	O
to	JJ	O
PLK2	,	O
was	IN	O
transfected	PRP	O
into	VBD	O
293-synuclein	VBN	O
cells.	TO	O
Cells	DT	O
were	JJ	O
harvested	NNS	O
48	IN	O
hrs	NN	O
following	IN	O
transfection	DT	O
and	JJ	O
analyzed	NNS	O
by	VBD	O
ELISA	VBN	O
for	TO	O
total	VB	O
and	TO	O
phospho-synuclein	NNP	O
levels.	VBD	O
ELISA	VBN	O
values	IN	O
were	JJ	O
corrected	.	O
for	NNS	O
total	VBD	O
protein	VBN	O
levels.	CD	O
Overexpression	NN	O
of	VBG	O
PLK2	NN	O
resulted	CC	O
in	VBN	O
a	IN	O
dramatic	NNP	O
increase	IN	O
in	JJ	O
phospho-synuclein	CC	O
levels,	JJ	O
increasing	.	O
phospho-synuclein	NN	O
expression	NNS	O
by	VBD	O
4.3-fold	VBN	O
above	IN	O
expression	JJ	O
in	NN	O
untransfected	.	O
cells.	NN	O
It	IN	O
is	NNP	O
likely	VBD	O
that	IN	O
when	DT	O
a	JJ	O
direct	NN	O
kinase	IN	O
that	JJ	O
phosphorylates	,	O
α-synuclein	VBG	O
is	JJ	O
introduced	NN	O
into	IN	O
the	JJ	O
cell	IN	O
an	NN	O
increase	IN	O
in	JJ	O
phospho-synuclein	.	O
levels	PRP	O
would	VBZ	O
be	JJ	O
observed.	IN	O
This	WRB	O
was	DT	O
the	JJ	O
case	NN	O
for	WDT	O
both	VBZ	O
GPRK6	NN	O
and	VBZ	O
PLK2	VBN	O
(FIG.	IN	O
6).	DT	O
The	NN	O
percent	DT	O
phospho-synuclein	NN	O
in	IN	O
cells	JJ	O
transfected	NNS	O
with	MD	O
GPRK6	VB	O
cDNA	.	O
increased	DT	O
dramatically,	VBD	O
from	DT	O
8.9%	NN	O
to	IN	O
18.9%.	DT	O
This	NNP	O
increase	CC	O
is	NNP	O
significant	.	O
to	.	O
9.25	DT	O
standard	NN	O
deviations	NN	O
above	IN	O
the	NNS	O
percent	VBN	O
phospho-synuclein	IN	O
observed	NNP	O
for	NN	O
the	VBD	O
negative	,	O
kinases.	IN	O
The	NN	O
increase	TO	O
in	.	O
phospho-synuclein	DT	O
levels	NN	O
for	VBZ	O
the	JJ	O
PLK2-transfected	TO	O
cells	CD	O
was	JJ	O
even	NNS	O
more	IN	O
dramatic,	DT	O
increasing	NN	O
the	NN	O
percent	VBD	O
phospho-synuclein	IN	O
almost	DT	O
four-fold	JJ	O
to	.	O
33.2%.	DT	O
This	NN	O
represents	IN	O
an	JJ	O
extremely	NNS	O
significant	IN	O
change,	DT	O
an	JJ	O
increase	NNS	O
of	VBD	O
22.75	RB	O
standard	RBR	O
deviations	,	O
above	VBG	O
the	DT	O
phospho-synuclein	NN	O
levels	JJ	O
observed	RB	O
for	JJ	O
the	TO	O
negative	.	O
kinases.	DT	O
This	VBZ	O
dramatic	DT	O
increase	RB	O
was	JJ	O
by	,	O
far	DT	O
the	NN	O
largest	IN	O
change	CD	O
observed	JJ	O
previously	NNS	O
in	IN	O
using	DT	O
this	JJ	O
assay.	NNS	O
This	VBN	O
data	IN	O
strongly	DT	O
indicates	JJ	O
GPRK6,	.	O
and	DT	O
especially	JJ	O
PLK2	NN	O
as	VBD	O
very	IN	O
solid	RB	O
contenders	DT	O
as	JJS	O
direct	NN	O
kinases	VBD	O
responsible	RB	O
for	IN	O
phosphorylating	VBG	O
α-synuclein.	DT	O
Thus,	.	O
as	DT	O
shown	NN	O
in	RB	O
FIG.	VBZ	O
6,	,	O
when	CC	O
GPRK6	RB	O
cDNA	NNP	O
is	IN	O
transfected	RB	O
into	JJ	O
HEK-synuclein	NNS	O
cells,	IN	O
the	JJ	O
expression	VBZ	O
of	JJ	O
phospho-synuclein	IN	O
increases	VBG	O
2-fold.	.	O
Introduction	,	O
of	IN	O
PLK2	VBN	O
cDNA	IN	O
into	.	O
cells	,	O
results	WRB	O
in	NNP	O
an	NN	O
even	VBZ	O
more	VBN	O
dramatic	IN	O
increase	NNP	O
in	,	O
phospho-synuclein	DT	O
expression,	NN	O
a	IN	O
change	JJ	O
of	NNS	O
almost	.	O
four-fold	NN	O
above	IN	O
control	NNP	O
values.	NN	O
EXAMPLE	IN	O
5	NNS	O
Phosphorylation	NNS	O
by	IN	O
PLK2	DT	O
(SNK)	RB	O
GRK6,	RBR	O
CKII	JJ	O
and	NN	O
IKBKB	IN	O
The	JJ	O
data	,	O
in	DT	O
Example	NN	O
4	IN	O
was	RB	O
further	JJ	O
substantiated	IN	O
for	NN	O
PLK2	.	O
by	RB	O
showing	CD	O
that	NN	O
PLK2	IN	O
siRNAs	NNP	O
reduced	)	O
alpha-synuclein	,	O
phosphorylation.	NNP	O
This	CC	O
strengthened	NNP	O
the	DT	O
data	NN	O
showing	IN	O
that	NNP	O
PLK2	CD	O
is	VBD	O
a	RB	O
likely	VBN	O
candidate	IN	O
as	NNP	O
a	IN	O
cellular	VBG	O
kinase	IN	O
that	NNP	O
directly	VBD	O
phosphorylates	VBN	O
alpha-synuclein	JJ	O
at	.	O
Serine	DT	O
129	VBD	O
(Tables	DT	O
2	NNS	O
and	VBG	O
12).	IN	O
HEK	NNP	O
293	VBZ	O
cells	DT	O
stably	JJ	O
transfected	NN	O
with	IN	O
alpha-synuclein	DT	O
were	JJ	O
transfected	NN	O
with	WDT	O
10	RB	O
nM	VBZ	O
and	NN	O
100	IN	O
nM	NNP	O
of	CD	O
SmartPool	NNP	O
siRNAs	CD	O
(Dharmacon).	CC	O
SmartPool	.	O
siRNAs	$	O
include	CD	O
4	NNS	O
individual	RB	O
siRNAs	VBD	O
to	IN	O
a	JJ	O
specific	VBD	O
target.	VBN	O
Thus,	IN	O
the	CD	O
actual	NNS	O
concentration	CC	O
of	CD	O
each	NN	O
of	IN	O
the	NNP	O
four	NN	O
siRNAs	.	O
transfected	NNP	O
into	VBD	O
cells	VBP	O
was	CD	O
2.5	JJ	O
nM	NN	O
and	TO	O
25	DT	O
nM	JJ	O
respectively.	.	O
The	,	O
results	DT	O
in	JJ	O
FIG.	NN	O
7	IN	O
show	DT	O
that	IN	O
PLK2	DT	O
significantly	CD	O
decreased	NN	O
phospho-synuclein	VBD	O
levels,	IN	O
a	NNS	O
change	VBD	O
of	CD	O
approximately	NN	O
25%.	CC	O
At	CD	O
10	NN	O
nM,	.	O
but	DT	O
not	NNS	O
at	IN	O
100	.	O
nM	CD	O
of	NN	O
siRNA,	WDT	O
GPRK6	NNP	O
significantly	RB	O
increased	VBD	O
the	JJ	O
percentage	,	O
of	DT	O
phospho-synuclein	NN	O
by	IN	O
one	RB	O
standard	.	O
deviation	IN	O
above	CD	O
the	,	O
mean	CC	O
of	RB	O
the	IN	O
control	CD	O
negative	NN	O
kinases	IN	O
(FIG.	,	O
7).	NNP	O
This	RB	O
is	VBD	O
the	DT	O
opposite	NN	O
effect	IN	O
to	NN	O
what	IN	O
was	CD	O
previously	JJ	O
observed	NN	O
in	IN	O
the	DT	O
primary	NN	O
siRNA	IN	O
screen	DT	O
and	NN	O
may	JJ	O
be	NNS	O
due	.	O
to	.	O
the	DT	O
quality	VBZ	O
of	DT	O
the	JJ	O
siRNA	NN	O
used	TO	O
in	WP	O
the	VBD	O
first	RB	O
or	VBN	O
second	IN	O
assays.	DT	O
These	JJ	O
results	NN	O
were	NN	O
confirmed	CC	O
by	MD	O
immunohistochemistry.	VB	O
The	JJ	O
significant	TO	O
knockdown	DT	O
of	NN	O
phospho-synuclein	IN	O
levels	DT	O
by	NN	O
different	VBN	O
siRNAs	IN	O
from	DT	O
a	JJ	O
different	CC	O
source,	JJ	O
independently	.	O
confirms	DT	O
and	NNS	O
solidifies	VBD	O
the	VBN	O
data,	IN	O
and	.	O
substantiates	DT	O
the	JJ	O
role	NN	O
of	IN	O
PLK2	JJ	O
as	NNS	O
a	IN	O
direct	JJ	O
kinase	NN	O
that	IN	O
phosphorylates	DT	O
α-synuclein.	JJ	O
These	,	O
experiments	RB	O
were	VBZ	O
then	CC	O
performed	VBZ	O
on	DT	O
two	,	O
other	CC	O
kinases	VBZ	O
identified	DT	O
in	NN	O
the	IN	O
screens	NNP	O
to	IN	O
be	DT	O
of	JJ	O
interest,	NN	O
casein	WDT	O
kinase	VBZ	O
two	.	O
(CKII)	DT	O
and	NNS	O
IKBKB.	VBD	O
The	RB	O
individual	VBN	O
CKII	IN	O
catalytic	CD	O
subunits	JJ	O
were	NNS	O
hits	VBN	O
in	IN	O
the	DT	O
primary	NNS	O
siRNA	TO	O
screen	VB	O
(see	IN	O
Example	,	O
1	JJ	O
and	NN	O
Table	CD	O
1B)	)	O
and	CC	O
confirmed	.	O
at	DT	O
the	JJ	O
10	NNP	O
mM	JJ	O
siRNA	NNS	O
screen.	VBD	O
It	NNS	O
was	IN	O
of	DT	O
interest	JJ	O
to	NN	O
determine	NN	O
if	VB	O
the	NNP	O
individual	CD	O
CKII	CC	O
subunits	NNP	O
α1	)	O
and	CC	O
α′,	VBN	O
when	IN	O
cotransfected	DT	O
with	CD	O
PLK2	NN	O
or	NN	O
each	.	O
other,	PRP	O
had	VBD	O
additive	IN	O
effects	NN	O
on	TO	O
alpha-synuclein	VB	O
phosphorylation.	IN	O
Transfections	DT	O
were	JJ	O
performed	NNP	O
using	NNS	O
the	NNP	O
individual	CC	O
CKII	,	O
subunits	WRB	O
A	VBN	O
(α1)	IN	O
and	NNP	O
B	CC	O
(α′),	DT	O
cotransfected	,	O
with	VBD	O
PLK2	JJ	O
or	NNS	O
each	IN	O
other.	JJ	O
Overexpression	.	O
of	NNS	O
these	VBD	O
catalytic	VBN	O
subunits	VBG	O
increased	DT	O
phospho-synuclein	JJ	O
levels	NNP	O
by	VBZ	O
1.75	NNP	O
and	)	O
1	CC	O
standard	NNP	O
deviations	,	O
respectively	VBN	O
(the	IN	O
effect	NNP	O
was	CC	O
not	DT	O
additive).	.	O
When	NN	O
each	IN	O
of	DT	O
the	JJ	O
individual	NNS	O
subunits	VBD	O
was	NN	O
co-transfected	NNS	O
with	IN	O
PLK2,	CD	O
the	CC	O
levels	CD	O
of	JJ	O
phospho-synuclein	NNS	O
increased	RB	O
over	DT	O
that	NN	O
of	VBD	O
PLK2	RB	O
alone	.	O
(18.6%	WRB	O
phospho-synuclein)	DT	O
by	IN	O
1.25	DT	O
standard	JJ	O
deviations	NNS	O
each	VBD	O
to	JJ	O
22.8%	IN	O
phospho-synuclein.	,	O
However	DT	O
when	NNS	O
both	IN	O
subunits	NN	O
were	VBN	O
co-transfected	IN	O
with	DT	O
PLK2	IN	O
phospho-synuclein	NNP	O
levels	RB	O
were	NN	O
not	)	O
significantly	IN	O
increased	CD	O
above	JJ	O
that	NNS	O
for	DT	O
PLK2	TO	O
alone	NN	O
(21.4%	.	O
phospho-synuclein).	RB	O
IKBKB	WRB	O
siRNA	DT	O
knockdown	NNS	O
resulted	VBD	O
in	JJ	O
a	IN	O
significant	NNP	O
decrease	NN	O
in	NNS	O
alpha-synuclein	VBD	O
phosphorylation	RB	O
so	RB	O
this	VBN	O
gene	IN	O
was	DT	O
tested	IN	O
for	NNP	O
capacity	RB	O
to	NN	O
phosphorylate	.	O
alpha	NNP	O
synuclein.	VBD	O
Transfections	RP	O
and	VBN	O
ELISA	IN	O
analysis	DT	O
were	JJ	O
performed	NN	O
as	IN	O
per	JJ	O
standard	NN	O
procedure.	IN	O
Previous	DT	O
in	NN	O
vitro	VBD	O
experiments	VBN	O
demonstrated	IN	O
that	NN	O
IKBKB	TO	O
was	VB	O
not	JJ	O
a	.	O
direct	NNS	O
synuclein	CC	O
kinase	NNP	O
as	NN	O
it	VBD	O
did	VBN	O
not	IN	O
phosphorylate	IN	O
synuclein	JJ	O
in	.	O
a	JJ	O
direct	IN	O
kinase	JJ	O
assay	NNS	O
(see	VBD	O
Example	IN	O
3),	NNP	O
but	VBD	O
may	RB	O
be	DT	O
an	JJ	O
upstream	NN	O
regulator	NN	O
of	IN	O
synuclein	PRP	O
phosphorylation.	VBD	O
Thus,	RB	O
IKBKB	VB	O
was	NN	O
over-expressed	IN	O
in	DT	O
HEK-syn	JJ	O
cells	NN	O
to	NN	O
identify	VB	O
the	NNP	O
effect	,	O
on	CC	O
phosphorylation	MD	O
of	VB	O
synuclein.	DT	O
Following	JJ	O
introduction	NN	O
of	IN	O
IKBKB	JJ	O
cDNA	.	O
into	,	O
cells,	NNP	O
synuclein	VBD	O
phosphorylation	JJ	O
increased	IN	O
from	NNP	O
8.3%	NNS	O
in	TO	O
the	VB	O
negative	DT	O
(empty	NN	O
vector)	IN	O
control	NN	O
to	IN	O
21.5%,	.	O
a	VBG	O
2.6-fold	NN	O
increase.	IN	O
This	NNP	O
represented	NN	O
an	IN	O
increase	,	O
in	JJ	O
synuclein	NN	O
phosphorylation	VBD	O
that	IN	O
was	NN	O
significant	IN	O
to	DT	O
almost	JJ	O
53	JJ	O
standard	)	O
deviations.	NN	O
The	TO	O
PLK2	,	O
positive	DT	O
control	JJ	O
increased	.	O
synuclein	DT	O
phosphorylation	VBD	O
to	DT	O
65.8%,	NN	O
an	IN	O
almost	JJ	O
8-fold	NN	O
increase	WDT	O
in	VBD	O
phosphorylation	JJ	O
(significant	TO	O
to	RB	O
230	CD	O
standard	JJ	O
deviations).	.	O
Although	DT	O
the	NNP	O
effect	JJ	O
on	NN	O
synuclein	VBD	O
phosphorylation	JJ	O
was	NN	O
much	TO	O
more	,	O
modest	DT	O
for	RB	O
IKBKA,	JJ	O
a	NN	O
related	IN	O
kinase,	NN	O
(1.2	JJ	O
fold)	TO	O
than	CD	O
for	JJ	O
IKBKB,	.	O
it	IN	O
was	DT	O
still	NN	O
significant	IN	O
to	NN	O
1.4	NN	O
standard	VBD	O
deviations.	RB	O
EXAMPLE	JJR	O
6	JJ	O
Synphilin	IN	O
as	,	O
an	DT	O
Alternative	JJ	O
Therapeutic	,	O
Target	CD	O
Synphilin	)	O
is	IN	O
a	IN	O
synuclein-associated	,	O
protein	PRP	O
that	VBD	O
has	RB	O
been	JJ	O
shown	TO	O
to	CD	O
bind	JJ	O
alpha-synuclein.	.	O
To	RB	O
determine	CD	O
if	NNP	O
the	IN	O
presence	DT	O
of	NNP	O
synphilin	NNP	O
can	NNP	O
enhance	NNP	O
the	VBZ	O
phosphorylation	DT	O
of	JJ	O
alpha-synuclein,	NN	O
it	WDT	O
was	VBZ	O
over-expressed	VBN	O
in	VBN	O
HEK	TO	O
cells	VB	O
with	.	O
and	TO	O
without	VB	O
alpha-synuclein	IN	O
and	DT	O
PLK2.	NN	O
Transfections	IN	O
were	NN	O
performed	MD	O
according	VB	O
to	DT	O
standard	NN	O
protocol,	IN	O
followed	,	O
by	PRP	O
alpha-synuclein	VBD	O
ELISA	JJ	O
and	IN	O
analysis.	NNP	O
Cells	NNS	O
were	IN	O
also	CC	O
harvested	IN	O
for	JJ	O
Western	CC	O
blot	.	O
analysis.	NNS	O
Transfected	VBD	O
cell	VBN	O
lysates	VBG	O
were	TO	O
analyzed	JJ	O
for	,	O
total	VBN	O
synuclein	IN	O
using	JJ	O
1H7	NNP	O
antibody	CC	O
and	.	O
phospho-serine	NNS	O
129	VBD	O
synuclein	RB	O
using	VBN	O
11A5	IN	O
antibody	JJ	O
(See	NN	O
WO	.	O
05047860).	VBN	O
The	NN	O
total	NNS	O
amount	VBD	O
of	VBN	O
DNA	IN	O
transfected	JJ	O
into	NN	O
cells	VBG	O
remained	CD	O
constant	NN	O
at	CC	O
0.16	JJ	O
μg/well	CD	O
of	NN	O
a	VBG	O
96-well	CD	O
plate.	NN	O
The	NNP	O
type	NNP	O
of	.	O
DNA	DT	O
introduced	JJ	O
into	NN	O
cells	IN	O
varied,	NNP	O
with	VBD	O
empty	IN	O
vector	NNS	O
being	VBN	O
used	JJ	O
to	IN	O
make	CD	O
up	NN	O
the	IN	O
full	DT	O
quota	JJ	O
of	.	O
DNA.	DT	O
Varying	NN	O
concentrations	IN	O
of	NN	O
alpha-synuclein,	VBN	O
PLK2,	IN	O
and	NNS	O
synphilin	,	O
cDNA	IN	O
were	JJ	O
introduced	NN	O
into	VBG	O
naïve	VBN	O
HEK	TO	O
cells.	VB	O
Cells	RP	O
transfected	DT	O
with	JJ	O
all	NN	O
three	IN	O
showed	.	O
a	VBG	O
slight	NNS	O
increase	IN	O
in	,	O
total	,	O
synuclein.	CC	O
For	NN	O
phospho-synuclein,	NN	O
the	VBD	O
levels	VBN	O
in	IN	O
untransfected	JJ	O
cells	NNP	O
were	.	O
below	NNS	O
the	VBN	O
limit	IN	O
of	DT	O
quantitation.	CD	O
Introducing	VBD	O
alpha-synuclein	DT	O
alone	JJ	O
yielded	NN	O
5.2%	IN	O
phospho-synuclein,	JJ	O
which	.	O
was	IN	O
marginally	,	O
less	DT	O
than	NNS	O
co-transfection	IN	O
of	JJ	O
synuclein	NNS	O
with	VBD	O
synphilin	IN	O
(5.4%	DT	O
phospho-synuclein).	NN	O
Co-transfection	IN	O
of	.	O
PLK2	VBG	O
and	JJ	O
synuclein	RB	O
yielded	VBD	O
levels	NN	O
similar	,	O
those	WDT	O
observed	VBD	O
for	RB	O
transfecting	JJR	O
PLK2	IN	O
into	NN	O
HEK-syn	IN	O
stable	NN	O
cells,	IN	O
60%	NN	O
phospho-synuclein.	NN	O
Strikingly,	.	O
concurrent	NN	O
over-expression	IN	O
of	NNP	O
all	CC	O
three	RB	O
cDNA's	VBN	O
(PLK2,	NNS	O
synuclein	JJ	O
and	DT	O
synphilin)	VBN	O
resulted	IN	O
in	VBG	O
83.3%	NNP	O
phospho-synuclein	IN	O
in	NNP	O
the	JJ	O
HEK	,	O
cells.	NN	O
Thus,	.	O
synphilin	,	O
increased	JJ	O
synuclein	NN	O
phosphorylation	IN	O
in	DT	O
PLK2,	CD	O
alpha-synuclein	POS	O
over-expressed	,	O
HEK	NN	O
cells.	CC	O
Increased	)	O
phosphorylation	VBD	O
of	IN	O
alpha	NN	O
synuclein	NN	O
in	IN	O
the	DT	O
presence	NNP	O
of	.	O
synphilin	,	O
can	NN	O
be	VBD	O
explained	JJ	O
by	NN	O
synphilin	IN	O
binding	,	O
to	JJ	O
the	JJ	O
PLK2	NNP	O
polo-box	.	O
thereby	VBN	O
facilitating	NN	O
phosphorylation	IN	O
of	JJ	O
synuclein	NN	O
by	IN	O
PLK2.	DT	O
Synuclein	NN	O
itself	IN	O
is	NN	O
unlikely	MD	O
to	VB	O
bind	VBN	O
the	IN	O
polo-box	NN	O
domain.	NN	O
EXAMPLE	TO	O
7	DT	O
PLK2	NNP	O
Activity:	JJ	O
Phosphorylation	NN	O
of	VBG	O
Alpha	NN	O
Synuclein	IN	O
and	NN	O
Familial	IN	O
Mutants	.	O
of	NNP	O
Alpha	PRP	O
Synuclein	VBZ	O
To	JJ	O
analyze	TO	O
PLK2	VB	O
phosphorylation	DT	O
of	JJ	O
a	.	O
number	RB	O
of	CD	O
known	NNP	O
familial	:	O
mutants	NN	O
of	IN	O
alpha	NNP	O
synuclein,	NNP	O
in	CC	O
vitro	NNP	O
studies	NNP	O
were	IN	O
performed	NNP	O
and	NNP	O
the	TO	O
phosphorylation	VB	O
of	NNP	O
the	NN	O
alpha	IN	O
synuclein	DT	O
and	NN	O
mutants	IN	O
analyzed.	VBN	O
The	JJ	O
familial	NNS	O
mutants	IN	O
(FPD)	NN	O
were	,	O
A30P,	IN	O
A53T,	JJ	O
and	NNS	O
E46K.	VBD	O
All	VBN	O
in	CC	O
vitro	DT	O
reactions	NN	O
were	IN	O
performed	DT	O
using	NN	O
the	NN	O
following	CC	O
conditions,	NNS	O
10	.	O
mM	DT	O
MgCl2,	JJ	O
100	NNS	O
μM	)	O
ATP,	VBD	O
27	,	O
mM	,	O
HEPES,	CC	O
250	.	O
ng/ml	DT	O
PLK2,	IN	O
1/50	JJ	O
dilution	NNS	O
of	VBD	O
Protease	VBN	O
Inhibitor	VBG	O
solution	DT	O
(1	JJ	O
tablet	,	O
in	CD	O
1	NN	O
ml	,	O
of	CD	O
reaction	NN	O
buffer),	,	O
40	CD	O
mM	NN	O
Nitrophenylphosphate,	,	O
1	CD	O
mg/ml	NN	O
of	,	O
95%	CD	O
Type	NN	O
II-S	IN	O
Phosphatidylcholine	NNP	O
from	NNP	O
soybean,	NN	O
and	CD	O
10,	NN	O
100,	IN	O
or	CD	O
1000	NN	O
nM	IN	O
alpha	NN	O
synuclein	,	O
(AS).	CD	O
The	NN	O
reaction	,	O
was	CD	O
incubated	NN	O
at	IN	O
37°	NN	O
C.	NNP	O
The	NNP	O
activity	NNP	O
was	IN	O
analyzed	,	O
by	CC	O
autoradiography.	,	O
PLK2	,	O
was	CC	O
found	CD	O
to	JJ	O
be	NN	O
more	NN	O
active	.	O
against	DT	O
wild-type	NN	O
alpha	VBD	O
synuclein	VBN	O
than	IN	O
beta	CD	O
synuclein.	NNP	O
Further,	DT	O
the	NN	O
mutant	VBD	O
alpha-synucleins	VBN	O
were	IN	O
phosphorylated	.	O
more	NNP	O
at	VBD	O
a	VBN	O
given	TO	O
concentration	VB	O
(especially	RBR	O
at	JJ	O
lower	IN	O
concentrations)	JJ	O
than	NN	O
WT.	NN	O
A	IN	O
trend	NN	O
of	.	O
PLK2	,	O
activity	DT	O
was	JJ	O
identified	NNS	O
with	VBD	O
PLK2	VBN	O
activity	JJR	O
being	IN	O
highest	DT	O
with	VBN	O
FPD	NN	O
mutants,	RB	O
followed	IN	O
by	JJR	O
wild-type	)	O
alpha	IN	O
synuclein,	.	O
and	DT	O
minimally	NN	O
against	IN	O
beta	NNP	O
synuclein.	NN	O
This	VBD	O
order	VBN	O
is	IN	O
consistent	NNP	O
with	NN	O
a	VBG	O
mechanism	JJS	O
by	IN	O
which	NNP	O
phosphorylation	,	O
of	VBN	O
alpha	IN	O
synuclein	JJ	O
drives	NN	O
Lewy	,	O
body	CC	O
formation	RB	O
and	IN	O
subsequent	NN	O
pathology.	.	O
EXAMPLE	DT	O
8	NN	O
Confirmation	VBZ	O
of	JJ	O
the	IN	O
Presence	DT	O
of	NN	O
Kinases	IN	O
in	WDT	O
HEK-Synuclein	NN	O
and	IN	O
SY5Y-Synuclein	JJ	O
Cells	NN	O
qRT-PCR	NNS	O
was	NNP	O
performed	NN	O
to	NN	O
determine	CC	O
if	JJ	O
the	.	O
kinases	RB	O
of	CD	O
interest	NN	O
were	IN	O
expressed	DT	O
in	NNP	O
HEK-synuclein	IN	O
and	NNP	O
SY5Y-synuclein	IN	O
cells.	NNP	O
In	CC	O
Table	NNP	O
15	NNP	O
all	NN	O
samples	VBD	O
were	VBN	O
normalized	TO	O
to	VB	O
GAPDH	IN	O
expression.	DT	O
In	NNS	O
addition,	IN	O
two	NN	O
of	VBD	O
the	VBN	O
negative	IN	O
kinases	NNP	O
were	CC	O
analyzed	NNP	O
in	.	O
each	IN	O
experiment	JJ	O
as	CD	O
a	DT	O
reference.	NNS	O
Of	VBD	O
the	VBN	O
24	TO	O
potential	NNP	O
direct	.	O
kinase	IN	O
candidates	,	O
tested,	CD	O
20	IN	O
were	DT	O
detected	JJ	O
in	NNS	O
the	VBD	O
HEK293-synuclein	VBN	O
cells,	IN	O
including	DT	O
PLK2.	NN	O
Thus,	IN	O
the	DT	O
remaining	.	O
completely	IN	O
confirmed	DT	O
kinases	CD	O
were	JJ	O
detected	JJ	O
in	NN	O
the	NNS	O
cells	,	O
(FIG.	CD	O
9).	VBD	O
Four	VBN	O
of	IN	O
the	DT	O
potential	NNP	O
direct	,	O
kinases	VBG	O
tested,	.	O
GPRK1,	,	O
GPRK7,	DT	O
ERK8	VBG	O
and	RB	O
RIPK3,	VBN	O
were	NNS	O
not	VBD	O
detected.	VBN	O
GPRK6	IN	O
was	DT	O
barely	NNS	O
detectable.	.	O
The	.	O
qRT-PCR	CD	O
was	IN	O
performed	DT	O
as	JJ	O
follows:	JJ	O
the	NNS	O
mRNA	,	O
levels	,	O
were	,	O
normalized	NNP	O
to	CC	O
GAPDH	,	O
mRNA	VBD	O
expression	RB	O
levels.	.	O
Total	NNP	O
RNA	VBD	O
was	RB	O
purified	.	O
from	DT	O
a	NN	O
cell	VBD	O
pellet	VBN	O
using	IN	O
the	:	O
QIAGEN	DT	O
RNeasy	NN	O
Kit	NNS	O
and	VBD	O
protocol.	VBN	O
Primer-probe	TO	O
sets	NNP	O
for	NNP	O
24	NN	O
of	.	O
the	JJ	O
potential	NNP	O
direct	VBD	O
kinases	VBN	O
and	IN	O
the	DT	O
four	NN	O
indirect	NN	O
completely	VBG	O
confirmed	DT	O
kinases	NNP	O
were	NNP	O
ordered	NNP	O
from	CC	O
Applied	.	O
Biosystems	NNP	O
(TaqMan	NNS	O
Gene	IN	O
Expression	CD	O
Assays),	IN	O
along	DT	O
with	JJ	O
reverse	JJ	O
transcriptase,	NNS	O
RNase	CC	O
inhibitors	DT	O
and	CD	O
standard	NN	O
PCR	RB	O
reagents.	VBN	O
A	NNS	O
one-step	VBD	O
RT-PCR/qRT-PCR	VBN	O
reaction	IN	O
as	NNP	O
performed	NNP	O
an	NNP	O
ABI7500	NNP	O
Real-Time	NNP	O
PCR	,	O
machine	IN	O
for	IN	O
each	JJ	O
primer-probe	,	O
set	NNP	O
using	NNS	O
20	CC	O
ng	JJ	O
or	NNP	O
200	.	O
ng	DT	O
total	JJ	O
RNA	JJ	O
using	NN	O
the	IN	O
following	VBN	O
cycling	DT	O
conditions:	NNP	O
48°	JJ	O
C./30	NNP	O
mins	NN	O
(RT-PCR	IN	O
step),	DT	O
95°	NN	O
C./10	VBN	O
mins	VBG	O
(denature),	CD	O
then	NN	O
40	CC	O
cycles	CD	O
of	JJ	O
95°	JJ	O
C./15	NNP	O
secs,	VBG	O
60°	DT	O
C./1	VBG	O
min.	NN	O
For	:	O
each	CD	O
primer-probe	NNP	O
set,	NNS	O
an	NNP	O
RT-negative	,	O
reaction	CD	O
and	NNP	O
PCR-negative	NNS	O
reaction	,	O
was	RB	O
performed.	CD	O
The	NNS	O
RT-negative	IN	O
controls	CD	O
for	NNP	O
background	,	O
amplification	CD	O
of	NNP	O
DNA	.	O
(not	IN	O
RNA)	DT	O
that	NN	O
is	,	O
contaminating	DT	O
the	JJ	O
purified	NN	O
RNA.	CC	O
The	JJ	O
PCR-negative	NN	O
control	VBD	O
was	.	O
to	DT	O
ensure	JJ	O
all	NNS	O
of	IN	O
the	NN	O
PCR	NN	O
reagents	IN	O
were	NNP	O
free	RB	O
of	)	O
contaminating	WDT	O
RNA	VBZ	O
and	VBG	O
DNA,	DT	O
and	JJ	O
should	.	O
have	DT	O
had	JJ	O
no	NN	O
signal.	VBD	O
All	TO	O
three	VB	O
of	DT	O
the	IN	O
completely	DT	O
confirmed	NNP	O
potential	NNS	O
direct	VBD	O
kinases,	JJ	O
along	IN	O
with	VBG	O
the	NNP	O
four	CC	O
indirect	,	O
completely	CC	O
confirmed	MD	O
kinases	VB	O
were	VBD	O
easily	DT	O
detected	.	O
in	DT	O
SY5Y-synuclein	CD	O
cells,	IN	O
indicating	DT	O
this	RB	O
cell	VBN	O
line	JJ	O
may	JJ	O
be	,	O
a	IN	O
viable	IN	O
option	DT	O
for	CD	O
a	NN	O
neuronally-derived	RB	O
cell	VBN	O
line	NNS	O
for	VBD	O
further	RB	O
experimental	VBN	O
analysis	IN	O
of	NNP	O
kinases.	,	O
EXAMPLE	VBG	O
9	DT	O
Identification	NN	O
of	NN	O
Increased	MD	O
Phosphorylation	VB	O
of	DT	O
Alpha-Synuclein	JJ	O
in	NN	O
293	IN	O
Cells	DT	O
and	JJ	O
Neuronally-Derived	NN	O
Cell	NN	O
Lines	IN	O
PLK2	JJ	O
and	JJ	O
GRK	NN	O
were	IN	O
overexpressed	.	O
in	RB	O
293	CD	O
cells	NNP	O
stably	IN	O
transfected	VBN	O
with	NN	O
alpha	IN	O
synuclein.	NNP	O
ELISA	IN	O
and	CD	O
Western	NNS	O
blot	CC	O
were	NNP	O
performed	NNP	O
to	NNP	O
identify	NNP	O
increase	CC	O
in	NNP	O
phospho-synuclein	VBD	O
with	VBN	O
PLK	IN	O
and	CD	O
GRK	NNS	O
kinases	RB	O
and	VBD	O
an	IN	O
increase	JJ	O
in	.	O
phosphorylation	NNP	O
was	CC	O
demonstrated.	JJ	O
A	NN	O
second	VBD	O
method	VBN	O
was	TO	O
used	VB	O
to	NN	O
confirm	IN	O
the	JJ	O
increase	IN	O
using	NNP	O
the	CC	O
same	NNP	O
biotinylated	NNS	O
antibodies	CC	O
used	DT	O
in	NN	O
the	IN	O
ELISA	NN	O
for	VBD	O
immunostaining	.	O
(11A5)	DT	O
in	JJ	O
293	NN	O
cells.	VBD	O
This	VBN	O
method	TO	O
also	VB	O
demonstrated	DT	O
an	NN	O
increase	VBG	O
in	DT	O
phospho-synuclein	JJ	O
in	JJ	O
cells	NNS	O
transfected	VBN	O
with	IN	O
PLK2	DT	O
and	NNP	O
to	IN	O
a	VBG	O
lesser	)	O
extent	IN	O
GRK.	CD	O
The	.	O
increase	DT	O
was	NN	O
detected	RB	O
in	VBD	O
a	DT	O
small	NN	O
population	IN	O
of	JJ	O
cells	IN	O
that	NNS	O
brightly	VBN	O
stain	IN	O
for	NNP	O
11A5,	CC	O
not	TO	O
a	DT	O
general	JJR	O
increase	NN	O
in	.	O
all	DT	O
cells.	NN	O
The	VBD	O
amount	VBN	O
of	IN	O
total	DT	O
synuclein	JJ	O
(measured	NN	O
using	IN	O
the	NNS	O
5C12	WDT	O
antibody)	RB	O
did	VBP	O
not	IN	O
appear	,	O
to	RB	O
change.	DT	O
This	JJ	O
was	NN	O
a	IN	O
significant	DT	O
increase	.	O
in	DT	O
phosphorylation	NN	O
in	IN	O
the	JJ	O
293	NN	O
cells.	VBN	O
Thus,	VBG	O
it	DT	O
was	CD	O
of	)	O
interest	VBD	O
to	RB	O
see	VB	O
if	TO	O
the	.	O
results	DT	O
could	VBD	O
be	DT	O
repeated	JJ	O
in	NN	O
neuroblastoma	IN	O
cells.	NN	O
To	IN	O
identify	DT	O
that	CD	O
the	.	O
dramatic	,	O
upregulation	PRP	O
of	VBD	O
phospho-synuclein	IN	O
observed	NN	O
with	TO	O
PLK2	VB	O
and	IN	O
GPRK6	DT	O
occurs	NNS	O
in	MD	O
neuronally-derived	VB	O
cells,	VBN	O
the	IN	O
same	JJ	O
experiment	.	O
was	TO	O
performed	VB	O
in	IN	O
human	DT	O
neuroblastoma	JJ	O
cells	NN	O
(SY5Y	IN	O
cells).	JJ	O
Immunostaining	VBN	O
results	IN	O
showed	NNP	O
that	CC	O
PLK2	NNP	O
caused	VBZ	O
an	IN	O
increase	JJ	O
in	,	O
the	DT	O
phospho-synuclein	JJ	O
in	NN	O
a	VBD	O
small	VBN	O
population	IN	O
of	JJ	O
cells,	NN	O
in	NNS	O
a	NNP	O
very	.	O
similar	VBG	O
pattern	NNS	O
to	VBD	O
the	IN	O
293	NNP	O
cell	VBD	O
experiments.	DT	O
Quantitation	NN	O
was	IN	O
performed	DT	O
by	NN	O
immunohistochemistry	IN	O
using	DT	O
the	JJ	O
ArrayScan™	NN	O
in	IN	O
two	,	O
ways.	IN	O
First	DT	O
all	RB	O
cells	JJ	O
were	NN	O
counted	TO	O
and	DT	O
did	CD	O
not	NN	O
show	.	O
any	NN	O
difference.	VBD	O
Then	VBN	O
just	IN	O
the	NN	O
bright	VBG	O
cells	DT	O
were	NNP	O
counted	IN	O
and	CD	O
this	.	O
analysis	RB	O
showed	DT	O
about	NNS	O
a	VBD	O
5-10	VBN	O
fold	CC	O
increase	VBD	O
in	RB	O
the	VB	O
number	DT	O
of	.	O
11A5	RB	O
positive	RB	O
cells	DT	O
that	JJ	O
were	NNS	O
PLK	VBD	O
transfected,	VBN	O
with	CC	O
a	DT	O
slight	NN	O
increase	VBD	O
with	IN	O
GRK6	DT	O
as	JJ	O
well.	JJ	O
The	NN	O
cDNA	IN	O
transfection	DT	O
experiment	NN	O
is	IN	O
repeated	CD	O
in	JJ	O
HCC	NNS	O
cells	WDT	O
and	VBD	O
immunohistochemistry	NNP	O
is	,	O
performed	IN	O
with	DT	O
a	JJ	O
variety	NN	O
of	IN	O
alpha-synuclein	NNP	O
antibodies	RB	O
on	.	O
the	DT	O
cells	NN	O
that	NN	O
have	NN	O
been	VBZ	O
transfected	VBN	O
with	IN	O
PLK2	NNP	O
and	NNS	O
GPRK6.	CC	O
Cells	NN	O
may	VBZ	O
be	VBN	O
treated	IN	O
with	DT	O
additional	NN	O
reagents	IN	O
to	JJ	O
mimic	NNS	O
the	IN	O
pathology	DT	O
of	NNS	O
Parkinson's	WDT	O
disease;	VBP	O
such	VBN	O
reagents	VBN	O
could	IN	O
include,	NNP	O
for	CC	O
example,	.	O
rotenone,	NNS	O
paraquat,	MD	O
hydrogen	VB	O
peroxide,	VBN	O
or	IN	O
ferric	JJ	O
chloride.	NNS	O
In	TO	O
this	VB	O
way,	DT	O
inclusion	NN	O
formation	IN	O
and/or	POS	O
alpha-synuclein	:	O
aggregation	JJ	O
is	NNS	O
observed	MD	O
in	,	O
these	IN	O
cells.	,	O
Antibodies	,	O
used	,	O
to	NN	O
look	,	O
for	CC	O
inclusions/aggregation	JJ	O
include	.	O
LB509,	IN	O
SYN-1,	DT	O
11A5	,	O
and	NN	O
ELADW-110.	NN	O
Next,	IN	O
cDNA	JJ	O
for	NN	O
PLK2	VBZ	O
and	VBN	O
GPRK6	IN	O
siRNA	DT	O
is	.	O
transfected	NNS	O
in	VBN	O
primary	TO	O
neuronal	VB	O
cultures	IN	O
in	NN	O
preparation	VBP	O
for	,	O
introducing	,	O
targets	CD	O
into	CC	O
a	.	O
mouse	,	O
model.	NN	O
The	IN	O
method	NNP	O
is	CC	O
performed	NNP	O
as	NN	O
in	VBZ	O
Example	VBN	O
4.	IN	O
qRT-PCR	JJ	O
is	JJ	O
performed	NNS	O
(as	IN	O
in	NN	O
Example	IN	O
2)	VBG	O
using	NNS	O
SY5Y-synuclein	IN	O
RNA.	DT	O
SY5Y-synuclein	NN	O
cells	.	O
are	DT	O
derived	NN	O
from	VBZ	O
neuroblastoma	VBN	O
cells	IN	O
and	IN	O
have	NNP	O
been	CD	O
stably	NN	O
transfected	VBZ	O
with	VBN	O
a	IN	O
WT-synuclein	IN	O
vector.	NNP	O
EXAMPLE	)	O
10	VBG	O
Distribution	NNP	O
of	.	O
Lentivirus-Expressed	JJ	O
Alpha-Synuclein	NNS	O
in	VBP	O
Human	VBN	O
Cortical	IN	O
Culture	JJ	O
(HCC)—a	NNS	O
Cellular	CC	O
Model	VBP	O
for	VBN	O
Lewy	RB	O
Body	VBN	O
Disease	IN	O
Of	DT	O
interest	JJ	O
was	.	O
the	RB	O
identification	CD	O
of	NNP	O
a	IN	O
cellular	JJ	O
model	NNP	O
for	IN	O
Lewy	NNP	O
body	NNP	O
disease	NNP	O
and/or	VBP	O
for	JJ	O
PD	NNP	O
pathology.	IN	O
Thus,	NNP	O
lentivirus-mediated	NNP	O
expression	NNP	O
of	IN	O
alpha-synuclein	NN	O
in	VBD	O
human	DT	O
cortical	NN	O
cultures	IN	O
was	DT	O
used	JJ	O
to	NN	O
establish	IN	O
a	NNP	O
model	NN	O
of	NN	O
alpha-synuclein	NN	O
deposition	IN	O
in	NNP	O
vivo.	.	O
Experiments	,	O
were	JJ	O
performed	NN	O
on	IN	O
donors,	NN	O
and	IN	O
HCC	JJ	O
cells	JJ	O
overexpressing	NNS	O
wild-type	VBD	O
and	VBN	O
variant	TO	O
alpha-synuclein	VB	O
to	DT	O
fractionate	NN	O
the	IN	O
cells	JJ	O
and	NN	O
localize	IN	O
wild-type	.	O
alpha-synuclein	NNS	O
and	VBD	O
variant	VBN	O
alpha-synuclein	IN	O
within	,	O
the	CC	O
cells.	NNP	O
In	NNS	O
one	VBG	O
experiment	JJ	O
aggregation	CC	O
of	JJ	O
alpha	NN	O
synuclein	TO	O
in	VB	O
a	DT	O
manner	NNS	O
matching	CC	O
LB	VB	O
disease	JJ	O
was	JJ	O
observed	CC	O
in	JJ	O
the	NN	O
HCC	IN	O
cells.	DT	O
Further,	.	O
in	IN	O
one	CD	O
experiment	JJ	O
when	NN	O
PLK2	IN	O
was	JJ	O
expressed,	NN	O
the	IN	O
phosphorylation	DT	O
of	NN	O
alpha-synuclein	VBG	O
as	NNP	O
well	NN	O
as	VBD	O
the	VBN	O
aggregation	IN	O
increased.	DT	O
In	NNP	O
other	.	O
experiments	,	O
this	IN	O
was	CD	O
not	NN	O
observed.	WRB	O
Further	NNP	O
experiments	VBD	O
were	,	O
performed	DT	O
to	NN	O
determine	IN	O
whether	NN	O
extending	RB	O
culture	RB	O
might	IN	O
increase	DT	O
the	NN	O
accumulation	.	O
of	IN	O
overexpressed	JJ	O
synuclein,	NNS	O
and	DT	O
would	VBD	O
stress	RB	O
the	.	O
cells,	JJ	O
which	NNS	O
also	VBD	O
might	VBN	O
favor	TO	O
synuclein	VB	O
deposition	IN	O
or	VBG	O
toxicity.	NN	O
Accordingly,	MD	O
HCC	VB	O
were	DT	O
transduced	NN	O
with	IN	O
viral	JJ	O
vectors	,	O
expressing	CC	O
WT,	MD	O
A53T,	VB	O
S129A	DT	O
or	,	O
both	WDT	O
A53T/S129A	RB	O
alpha-synuclein	MD	O
mutants.	VB	O
Following	JJ	O
transfection	NN	O
cells	CC	O
were	.	O
grown	,	O
in	NNP	O
vitro	VBD	O
for	VBN	O
9,	IN	O
16	JJ	O
or	NNS	O
23	VBG	O
days	,	O
before	,	O
collecting	NNP	O
and	CC	O
fractionating.	DT	O
ELISA	NNP	O
results	NN	O
were	.	O
normalized	VBG	O
to	NN	O
protein	NNS	O
concentration	VBD	O
and	VBN	O
showed	IN	O
an	NN	O
accumulation	IN	O
of	,	O
synuclein	CD	O
in	CC	O
the	CD	O
soluble	NNS	O
fraction	IN	O
with	VBG	O
increasing	CC	O
time.	.	O
Somewhat	JJ	O
greater	NNS	O
accumulation	VBD	O
was	VBN	O
observed	TO	O
with	VB	O
the	NN	O
S129A	CC	O
mutant.	VBD	O
When	DT	O
further	NN	O
experiments	IN	O
were	NN	O
performed	IN	O
with	DT	O
WT,	JJ	O
119-truncated,	NN	O
and	IN	O
E46K	VBG	O
AS,	.	O
the	RB	O
results	JJR	O
were	NN	O
as	VBD	O
follows.	VBN	O
The	IN	O
higher	DT	O
the	NNP	O
expression	.	O
of	WRB	O
wild-type	JJ	O
the	NNS	O
larger	VBD	O
the	VBN	O
portion	IN	O
of	,	O
alpha	,	O
synuclein	CC	O
recovered	NNP	O
in	,	O
the	DT	O
soluble	NNS	O
fraction.	VBD	O
E46K	IN	O
synuclein	.	O
showed	DT	O
a	JJR	O
50-100%	DT	O
increase	NN	O
in	IN	O
the	JJ	O
amount	DT	O
of	JJR	O
phosphorylated	DT	O
alpha-synuclein.	NN	O
However,	IN	O
the	NN	O
E46K	NN	O
mutation	VBD	O
did	IN	O
not	DT	O
markedly	JJ	O
affect	.	O
relative	NNP	O
amounts	NN	O
of	VBD	O
synuclein	DT	O
recovered	NN	O
in	NN	O
the	IN	O
membrane-bound	DT	O
or	NN	O
insoluble	IN	O
fractions.	JJ	O
Expression	.	O
of	,	O
119-truncated	DT	O
alpha	NNP	O
synuclein	NN	O
led	VBD	O
to	RB	O
a	RB	O
slight	JJ	O
increase	JJ	O
in	NNS	O
the	IN	O
relative	NN	O
amount	VBN	O
accumulating	IN	O
in	DT	O
the	NN	O
insoluble	CC	O
fraction	JJ	O
(about	.	O
3	NN	O
fold	IN	O
higher	JJ	O
relative	NN	O
to	NN	O
WT).	VBD	O
The	TO	O
increase	DT	O
is	JJ	O
expected	NN	O
in	IN	O
view	DT	O
of	JJ	O
the	NN	O
published	VBG	O
results	IN	O
suggesting	DT	O
that	JJ	O
truncated	NN	O
synuclein	IN	O
forms	CD	O
fibrils	NN	O
much	JJR	O
more	JJ	O
readily	TO	O
in	.	O
vitro	DT	O
than	NN	O
does	VBZ	O
full-length	VBN	O
Murray	IN	B
et	NN	I
al.	IN	I
2003	DT	I
Biochemistry	VBN	I
42:8530).(	NNS	O
The	VBG	O
119	IN	O
truncation	VBD	O
resulted	NN	O
in	NNS	O
an	VBP	O
increased	RB	O
association	JJR	O
with	RB	O
membranes	IN	O
consistent	NN	O
with	IN	O
the	VBZ	O
N-terminal	JJ	O
domain	NNP	O
being	RB	O
responsible	.	O
for	CD	O
association	NNP	O
with	.	O
lipid	DT	O
bilayers.	CD	O
The	NN	O
increased	VBD	O
association	IN	O
with	DT	O
membranes	VBN	O
may	NN	O
mitigate	IN	O
the	NNS	O
increased	JJ	O
tendency	IN	O
of	DT	O
the	JJ	O
soluble	NN	O
protein	VBG	O
to	JJ	O
aggregate.	IN	O
The	NN	O
response	IN	O
of	JJ	O
the	.	O
insoluble	DT	O
fraction	VBN	O
to	NN	O
increases	IN	O
in	NNS	O
levels	MD	O
of	VB	O
soluble	DT	O
synuclein	JJ	O
on	NN	O
overexpression	IN	O
and	DT	O
to	JJ	O
truncation,	NN	O
a	TO	O
change	.	O
favoring	DT	O
aggregation,	NN	O
suggest	IN	O
that	DT	O
it	JJ	O
provides	NN	O
a	TO	O
way	NNS	O
to	IN	O
identify	NNS	O
factors	IN	O
affecting	JJ	O
aggregation	NN	O
in	IN	O
the	NN	O
intraneuronal	CC	O
milieu.	TO	O
The	,	O
increased	DT	O
alpha-synuclein	NN	O
in	VBG	O
the	,	O
soluble	VBP	O
compartment	IN	O
might	PRP	O
be	VBZ	O
shifting	DT	O
the	NN	O
alpha-synuclein	TO	O
to	VB	O
a	NNS	O
potentially	VBG	O
more	NN	O
vulnerable	IN	O
compartment,	DT	O
leading	JJ	O
to	.	O
changes	DT	O
which	VBN	O
could	NN	O
result	IN	O
in	DT	O
increased	JJ	O
deposition.	NN	O
Since	MD	O
the	VB	O
kinases	VBG	O
proposed	DT	O
to	JJ	O
phosphorylate	TO	O
alpha-synuclein	DT	O
at	RB	O
Ser129	RBR	O
are	JJ	O
soluble,	,	O
it	VBG	O
seems	TO	O
likely	NNS	O
that	WDT	O
the	MD	O
soluble	VB	O
alpha-synuclein	IN	O
is	JJ	O
more	.	O
accessible	IN	O
to	DT	O
phosphorylation	NNS	O
as	VBN	O
well.	TO	O
Additional	VB	O
experiments	NN	O
are	IN	O
performed	NNP	O
to	VBP	O
identify	,	O
inhibitors	PRP	O
of	VBZ	O
the	JJ	O
phosphorylation	IN	O
and/or	DT	O
aggregation	JJ	O
in	NN	O
this	VBZ	O
cellular	RBR	O
model	JJ	O
by	TO	O
expressing	NN	O
the	RB	O
inhibitors	.	O
in	JJ	O
the	NNS	O
cells	VBP	O
and	VBN	O
identifying	TO	O
a	VB	O
reduction	NNS	O
in	IN	O
the	DT	O
phosphorylation	NN	O
and/or	NN	O
aggregation.	NN	O
EXAMPLE	IN	O
11	DT	O
Analysis	JJ	O
of	NN	O
Endogenous	IN	O
Kinase	VBG	O
Activity	DT	O
in	NNS	O
Alpha-Synuclein	IN	O
Knock-Out	DT	O
Mice	NNS	O
The	CC	O
utilization	VBG	O
of	DT	O
an	NN	O
alpha-synuclein	IN	O
knockout	DT	O
(alpha-synuclein	NN	O
KO)	NN	O
mouse	.	O
brain	RB	O
for	CD	O
the	NN	O
identification	IN	O
of	JJ	O
a	NNP	O
putative	NNP	O
alpha-synuclein	IN	O
kinase	NNP	O
has	NNP	O
the	NNP	O
advantage	DT	O
over	NN	O
the	IN	O
siRNA	DT	O
screen	JJ	O
in	NN	O
the	JJ	O
following	)	O
ways:	NN	O
1)	NN	O
the	IN	O
use	DT	O
of	NN	O
brain	IN	O
material	DT	O
provides	JJ	O
relevant	JJ	O
and	NN	O
possibly	VBZ	O
higher	DT	O
levels	NN	O
of	IN	O
brain-specific	DT	O
kinase	NN	O
activity	NN	O
which	IN	O
the	DT	O
HEK	JJ	O
cell	:	O
line	)	O
may	DT	O
not	NN	O
provide;	IN	O
2)	NN	O
cofactors	NN	O
may	VBZ	O
be	JJ	O
present	CC	O
in	RB	O
brain	JJR	O
(lipid,	NNS	O
protein,	IN	O
etc.)	JJ	O
which	NN	O
may	NN	O
not	WDT	O
be	DT	O
present	NNP	O
in	NN	O
cells	NN	O
and	MD	O
3)	RB	O
absence	:	O
of	)	O
any	NNS	O
endogenous	MD	O
alpha-synuclein	VB	O
which	JJ	O
could	IN	O
be	NN	O
detected	,	O
as	,	O
a	)	O
phosphorylated	WDT	O
AS.	MD	O
The	RB	O
inclusion	VB	O
of	JJ	O
25-50	IN	O
μg	NNS	O
of	CC	O
extracts	)	O
(soluble	NN	O
and	IN	O
detergent	DT	O
soluble)	JJ	O
with	NN	O
recombinant	WDT	O
alpha-synuclein	MD	O
(rAS)	VB	O
was	VBN	O
assessed	IN	O
with	DT	O
250	VBN	O
μM	.	O
ATP	DT	O
to	NN	O
determine	IN	O
if	JJ	O
appreciable	NN	O
kinase	IN	O
activity	NNS	O
was	JJ	O
present	CC	O
in	JJ	O
crude	)	O
material.	IN	O
FIG.	JJ	O
8A	NN	O
shows	)	O
total	VBD	O
alpha-synuclein	VBN	O
in	IN	O
each	CD	O
reaction	NNS	O
indicating	NNP	O
equivalent	TO	O
loadings	VB	O
of	IN	O
rAS.	JJ	O
In	NN	O
FIG.	NN	O
8B,	VBD	O
the	JJ	O
levels	IN	O
of	JJ	O
phospho-ser-129	.	O
alpha-synuclein	.	O
were	CD	O
investigated.	NNS	O
The	JJ	O
rAS	JJ	O
in	IN	O
both	DT	O
TBS	NN	O
(sucrose	VBG	O
soluble)	JJ	O
and	NNS	O
TX	IN	O
(Triton-S	.	O
100	IN	O
soluble)	.	O
extracts	,	O
was	DT	O
phosphorylated,	NNS	O
with	IN	O
roughly	JJ	O
twice	NNS	O
the	VBD	O
level	.	O
of	DT	O
signal	NN	O
from	IN	O
the	DT	O
TBS	NNP	O
material	JJ	O
than	)	O
the	CC	O
TX	NNP	O
(although	NNP	O
reactions	CD	O
were	)	O
not	VBZ	O
normalized	VBD	O
for	,	O
protein).	IN	O
Phosphorylation	RB	O
levels	RB	O
were	DT	O
increased	NN	O
by	IN	O
addition	NN	O
of	IN	O
CKI	DT	O
but	NNP	O
were	NN	O
not	IN	O
significantly	DT	O
affected	NNP	O
by	IN	O
the	NNS	O
addition	VBD	O
of	RB	O
phospholipids	VBN	O
from	IN	O
soybean.	.	O
An	NN	O
identical	NNS	O
blot	VBD	O
was	VBN	O
probed	IN	O
for	NN	O
ser-87	IN	O
phosphorylation	NNP	O
in	CC	O
FIG.	VBD	O
9B.	RB	O
This	RB	O
pAb	VBN	O
presents	IN	O
cross-reactivity	DT	O
with	NN	O
rAS	IN	O
at	NNS	O
100	IN	O
ng,	.	O
thus	DT	O
levels	JJ	O
above	NN	O
background	VBD	O
indicate	VBN	O
true	IN	O
phosphorylation	JJ	O
at	NN	O
the	IN	O
ser-87	.	O
site.	.	O
In	DT	O
both	JJ	O
TBS	VBZ	O
and	NN	O
TX	IN	O
reactions	NN	O
there	IN	O
is	CD	O
no	,	O
significant	RB	O
phosphorylation	NNS	O
at	IN	O
this	NN	O
site	VBP	O
whereas	JJ	O
the	NN	O
CKI	IN	O
spike	DT	O
achieved	JJ	O
phosphorylation	.	O
at	IN	O
appreciable	DT	O
levels.	NNP	O
These	CC	O
experiments	NNP	O
suggest	NNS	O
that	EX	O
measurable	VBZ	O
and	DT	O
real	JJ	O
kinase	NN	O
activit(ies)	IN	O
are	DT	O
present	NN	O
in	VBZ	O
the	DT	O
soluble	NNP	O
and	NN	O
membrane	VBD	O
fractions	NN	O
of	IN	O
KO	JJ	O
mouse	.	O
brain	DT	O
and	NNS	O
are	VBP	O
specific	IN	O
to	JJ	O
the	CC	O
ser-129	JJ	O
site	NN	O
compared	)	O
to	VBP	O
ser-87.	JJ	O
The	IN	O
potential	DT	O
exists	JJ	O
for	CC	O
phosphorylation	JJ	O
at	NNS	O
other	IN	O
serine	NNP	O
or	NN	O
threonine	NN	O
sites	CC	O
in	VBP	O
alpha-synuclein	JJ	O
but	TO	O
antibodies	DT	O
are	JJ	O
not	NN	O
yet	VBN	O
available	TO	O
to	.	O
detect	DT	O
such	JJ	O
modifications.	NNS	O
Thus,	IN	O
measurable	NN	O
levels	IN	O
of	JJ	O
ser-129	NN	O
specific	CC	O
kinase	VB	O
activity/activities	NNS	O
are	IN	O
present	JJ	O
in	CC	O
alpha-synuclein	NNS	O
KO	VBP	O
mouse	RB	O
brain	RB	O
extracts	JJ	O
and	TO	O
could	VB	O
serve	JJ	O
as	.	O
starting	,	O
material	JJ	O
for	NNS	O
purification	IN	O
of	JJ	O
a	JJ	O
kinase	NN	O
from	NNS	O
the	VBP	O
brain.	JJ	O
In	IN	O
FIGS.	JJ	O
8A,	NNP	O
8B,	NN	O
9A	NN	O
and	NNS	O
9B,	CC	O
cortices	MD	O
of	VB	O
alpha-synuclein	IN	O
KO	VBG	O
mouse	NN	O
brain	IN	O
were	NN	O
Dounce	IN	O
homogenized	DT	O
to	NN	O
obtain	IN	O
200	DT	O
mM	.	O
sucrose	IN	O
soluble	.	O
and	,	O
0.1%	,	O
Triton	CD	O
X-100	CC	O
soluble	,	O
extracts	NNS	O
with	IN	O
protease	JJ	O
and	NNP	O
phosphatase	NN	O
inhibitors	NN	O
present.	VBD	O
20	NNP	O
μl	VBN	O
of	TO	O
sample	VB	O
(100	CD	O
μl	NNS	O
total	JJ	O
volume	JJ	O
of	CC	O
reaction)	NN	O
was	NNP	O
incubated	NNP	O
with	JJ	O
2.4	NNS	O
μg	IN	O
of	NN	O
wt-rAS	CC	O
in	NN	O
the	NNS	O
presence	.	O
or	CD	O
absence	NN	O
of	IN	O
1000	NN	O
units	CD	O
of	NNP	O
casein	JJ	O
kinase	NN	O
I(CKI)	IN	O
as	)	O
a	VBD	O
positive	VBN	O
control,	IN	O
and/or	CD	O
200	NNS	O
μg	IN	O
of	NN	O
phosphatidycholine	IN	O
(PC;	DT	O
soybean	NN	O
lecithin)	CC	O
to	NN	O
increase	IN	O
kinase	CD	O
activiti(es).	NNS	O
Reactions	IN	O
were	JJ	O
loaded	NN	O
on	)	O
SDS-PAGE	IN	O
(130	DT	O
ng	JJ	O
total	,	O
AS)	RB	O
and	CD	O
immunoblotted	NN	O
with	IN	O
Syn-1	NN	O
(total	:	O
Syn;	CC	O
0.1	)	O
ug/ml),	TO	O
11A5	VB	O
(phospho	NN	O
ser-129;	.	O
1	NNS	O
μg/ml)	VBD	O
or	VBN	O
ELADW110	IN	O
(phospho	NNP	O
ser-87;	CD	O
2	RB	O
μg/mL).	JJ	O
The	)	O
above	CC	O
data	VBN	O
shows	IN	O
that	NNP	O
PLK2	JJ	O
other	:	O
direct	CD	O
and/or	,	O
indirect	CD	O
kinases	JJ	O
(such	:	O
as	CD	O
GRK6),	)	O
and	CC	O
modulators	NNP	O
such	JJ	O
as	:	O
synphilin	CD	O
are	.	O
novel	DT	O
targets	NN	O
for	NN	O
therapeutic	NNS	O
intervention	IN	O
in	NNP	O
DLB	JJ	O
and	JJ	O
PD.	NN	O
PLK2	NN	O
is	NNS	O
a	JJ	O
preferred	IN	O
target	,	O
because	CC	O
it	NNS	O
can	JJ	O
directly	IN	O
phosphorylate	NN	O
alpha-synuclein	VBP	O
specifically	JJ	O
at	NNS	O
ser-129.	IN	O
EXAMPLE	JJ	O
12	NN	O
Effect	IN	O
of	NNP	O
Overexpression	CC	O
of	.	O
PLK	NNP	O
Family	VBZ	O
Members	DT	O
on	JJ	O
Synuclein	NN	O
Phosphorylation	IN	O
Overexpression	PRP	O
of	MD	O
PLK	RB	O
family	VB	O
members	JJ	O
PLK1,	RB	O
2	IN	O
and	.	O
3,	RB	O
but	CD	O
not	NNP	O
PLK4,	IN	O
increased	NNP	O
synuclein	IN	O
phosphorylation	NNP	O
above	NNP	O
the	NNP	O
level	IN	O
of	NNP	O
the	NNP	O
endogenous	NNP	O
kinase	IN	O
in	NNP	O
HEK-293	NN	O
cells.	NNS	O
Methods	,	O
HEK-293	CD	O
naïve	CC	O
cells	,	O
were	CC	O
transfected	RB	O
with	,	O
an	VBD	O
expression	JJ	O
vector	NN	O
encoding	IN	O
PLK1,	DT	O
PLK2,	NN	O
PLK3,	IN	O
or	DT	O
PLK4	JJ	O
under	NN	O
the	IN	O
control	NNP	O
of	.	O
a	NNS	O
CMV	NNP	O
promoter,	NN	O
or	NNS	O
empty	VBD	O
vector,	VBN	O
together	IN	O
with	DT	O
an	NN	O
expression	NN	O
vector	VBG	O
encoding	,	O
WT-synuclein.	,	O
All	,	O
vectors	CC	O
had	NNP	O
the	IN	O
sequence	DT	O
coding	NN	O
for	IN	O
the	DT	O
protein	NNP	O
of	,	O
interest.	CC	O
Transfection	JJ	O
was	,	O
accomplished	RB	O
using	IN	O
Lipofectamine	DT	O
2000	NN	O
(Invitrogen,	NN	O
Carlsbad,	VBG	O
Calif.)	.	O
with	DT	O
0.08	NNS	O
μg	VBD	O
vector.	DT	O
Cells	NN	O
were	NN	O
washed	IN	O
and	DT	O
harvested	NN	O
48	IN	O
hours	.	O
post-transfection.	NN	O
A	VBD	O
Micro	VBN	O
BCA	VBG	O
(Pierce)	JJ	O
total	CD	O
protein	,	O
assay	,	O
and	)	O
total	IN	O
synuclein	CD	O
and	NNS	O
phospho-synuclein	.	O
ELISAs	NNS	O
were	VBD	O
performed	VBN	O
on	CC	O
each	VBN	O
plate	CD	O
of	NNS	O
treated	.	O
cells.	DT	O
Results	NNP	O
Results	NNP	O
are	)	O
summarized	VBP	O
in	JJ	O
Table	NN	O
16.	CC	O
PLK2	JJ	O
Over-expression	NN	O
of	CC	O
PLK2	JJ	O
in	NNP	O
the	VBD	O
293	VBN	O
cells	IN	O
yielded	DT	O
similar	NN	O
results	IN	O
to	JJ	O
those	.	O
observed	NNS	O
in	NNS	O
previous	VBP	O
experiments,	VBN	O
resulting	IN	O
in	JJ	O
a	.	O
21-fold	NNP	O
increase	NNP	O
in	IN	O
synuclein	NNP	O
phosphorylation,	IN	O
from	DT	O
2%	CD	O
to	NNS	O
42.3%.	VBD	O
PLK3	JJ	O
The	NNS	O
over-expression	TO	O
of	DT	O
PLK3	VBN	O
generated	IN	O
an	JJ	O
even	,	O
more	VBG	O
striking	IN	O
39-fold	DT	O
increase	JJ	O
in	NN	O
synuclein	IN	O
phosphorylation,	JJ	O
from	,	O
2%	IN	O
to	NN	O
79.2%	TO	O
phospho-synuclein.	.	O
However,	VB	O
knockdown	DT	O
of	NN	O
PLK3	IN	O
does	NNP	O
not	VBD	O
decrease	DT	O
the	RB	O
percentage	RBR	O
of	JJ	O
phosphorylated	JJ	O
synuclein	NN	O
in	IN	O
the	JJ	O
293	,	O
cells	IN	O
(see	NN	O
Example	TO	O
13,	NN	O
infra).	.	O
PLK3	,	O
is	NN	O
structurally	IN	O
most	NNP	O
similar	VBZ	O
to	RB	O
PLK2	VB	O
of	DT	O
all	NN	O
the	IN	O
PLK	JJ	O
family	NN	O
members,	IN	O
so	DT	O
even	CD	O
if	NNS	O
PLK3	VB	O
is	NNP	O
not	,	O
the	.	O
synuclein	NNP	O
kinase,	VBZ	O
it	RB	O
may	RBS	O
be	JJ	O
able	TO	O
to	NNP	O
perform	IN	O
the	PDT	O
same	DT	O
physiological	NNP	O
tasks	NN	O
as	,	O
PLK2.	RB	O
It	RB	O
has	IN	O
been	NNP	O
proposed	VBZ	O
that	RB	O
in	DT	O
the	NN	O
absence	,	O
of	PRP	O
PLK2	MD	O
expression,	VB	O
PLK3	JJ	O
can	TO	O
functionally	VB	O
compensate	DT	O
for	JJ	O
the	JJ	O
absent	NNS	O
PLK2	IN	O
(Smith	.	O
et	PRP	O
al.,	VBZ	O
2006,	VBN	O
“Epigenetic	VBN	O
inactivation	IN	O
implies	IN	O
a	DT	O
tumor	NN	O
suppressor	IN	O
function	NNP	O
in	,	O
hematologic	NNP	O
malignancies	MD	O
for	RB	O
Polo-like	VB	O
kinase	IN	O
2	DT	O
but	NN	O
not	NNP	O
Polo-like	NNP	O
kinase	FW	O
3.Cell	,	O
Cycle.”	,	O
Cell	JJ	O
Cycle	NN	O
5:1262-4).	VBZ	O
In	DT	O
addition,	NN	O
over-expression	NN	O
experiments	NN	O
can	IN	O
yield	JJ	O
off-target	NNS	O
and	IN	O
non-physiological	NNP	O
effects	NN	O
and	CD	O
results	CC	O
should	RB	O
be	NNP	O
substantiated	NN	O
through	CD	O
additional	NNP	O
experimentation	NNP	O
such	NNP	O
as	.	O
siRNA	IN	O
knockdown	,	O
or	JJ	O
in	NNS	O
vitro	MD	O
transcription/translation	VB	O
experiments.	JJ	O
PLK1	CC	O
Over-expression	JJ	O
of	NNS	O
PLK1	CC	O
resulted	NNS	O
in	MD	O
a	VB	O
two-fold	VBN	O
increase	IN	O
in	JJ	O
the	NN	O
percent	JJ	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
(from	CC	O
2%	IN	O
to	JJ	O
4.1%).	NN	O
While	.	O
not	NNP	O
as	NNP	O
robust	IN	O
an	NNP	O
increase	VBD	O
in	IN	O
synuclein	DT	O
phosphorylation	JJ	O
as	NN	O
the	IN	O
21-fold	DT	O
increase	NN	O
with	IN	O
PLK2	JJ	O
or	NN	O
39-fold	IN	O
increase	NN	O
with	TO	O
PLK3	.	O
over-expression,	IN	O
it	RB	O
is	IN	O
still	NN	O
significant.	DT	O
However,	NN	O
as	IN	O
noted	JJ	O
above,	NN	O
overexpression	IN	O
of	DT	O
proteins	JJ	O
can	NN	O
yield	IN	O
results	NNP	O
that	CC	O
do	JJ	O
not	NN	O
accurately	IN	O
represent	NNP	O
the	,	O
physiological	PRP	O
state	VBZ	O
within	RB	O
cells	.	O
and	,	O
tissues.	IN	O
Over-expression	VBN	O
of	,	O
genes	NN	O
can	IN	O
produce	NNS	O
off-target	MD	O
effects	VB	O
and	NNS	O
can	WDT	O
result	VBP	O
in	RB	O
erroneous	RB	O
localizations	VBP	O
within	DT	O
cells	JJ	O
that	NN	O
do	IN	O
not	NNS	O
characterize	CC	O
the	.	O
true	NN	O
physiological	IN	O
state,	NNS	O
and	MD	O
results	VB	O
of	JJ	O
over-expression	NNS	O
experiments	CC	O
should	MD	O
be	VB	O
substantiated	IN	O
with	JJ	O
additional	NNS	O
experimentation	IN	O
such	NNS	O
as	WDT	O
siRNA	VBP	O
knockdown	RB	O
or	VB	O
in	DT	O
vitro	JJ	O
transcription/translation	JJ	O
experiments.	,	O
PLK4	CC	O
Over-expression	NNS	O
of	IN	O
PLK4	JJ	O
did	NNS	O
not	MD	O
change	VB	O
the	VBN	O
percentage	IN	O
of	JJ	O
synuclein	NN	O
phosphorylation	JJ	O
in	IN	O
293	JJ	O
cells.	NN	O
The	CC	O
structure	IN	O
of	JJ	O
PLK4	NN	O
is	.	O
much	NNP	O
different	NNP	O
from	IN	O
those	NNP	O
of	VBD	O
the	RB	O
other	VB	O
PLKs,	DT	O
and	NN	O
has	IN	O
only	JJ	O
a	NN	O
single	IN	O
polo	CD	O
box	.	O
domain	DT	O
rather	NN	O
than	IN	O
the	NNP	O
two	VBZ	O
that	JJ	O
the	JJ	O
other	IN	O
three	DT	O
family	IN	O
members	DT	O
have.	JJ	O
The	,	O
results	CC	O
do	VBZ	O
not	RB	O
exclude	DT	O
the	JJ	O
possibility	NN	O
that	NN	O
in	NN	O
other	RB	O
tissue	IN	O
types,	DT	O
PLK4	CD	O
may	IN	O
be	DT	O
able	JJ	O
to	CD	O
phosphorylate	NN	O
synuclein.	NNS	O
In	.	O
Vitro	DT	O
Biochemical	NNS	O
Assays	VBP	O
In	RB	O
vitro	VB	O
biochemical	DT	O
assays	NN	O
using	IN	O
each	IN	O
of	JJ	O
the	NN	O
four	,	O
PLK	NNP	O
family	MD	O
members	VB	O
as	JJ	O
the	TO	O
kinase	VB	O
to	.	O
phosphorylate	IN	O
synuclein	NNP	O
were	NNP	O
conducted.	NNP	O
The	IN	O
results	NNP	O
(not	JJ	O
shown)	NNS	O
mirror	VBG	O
the	DT	O
cell-based	IN	O
ovewrexpression	DT	O
assays	CD	O
described	NNP	O
above,	NN	O
with	NNS	O
PLK1	IN	O
being	DT	O
able	NN	O
to	TO	O
phosphorylate	VB	O
synuclein	NNS	O
moderately,	VBD	O
PLK2	.	O
and	DT	O
PLK3	NNS	O
having	RB	O
extremely	)	O
robust	VBP	O
phosphorylation	DT	O
of	JJ	O
synuclein,	NN	O
and	NNS	O
PLK4	VBN	O
exhibiting	,	O
no	IN	O
ability	NNP	O
to	VBG	O
phosphorylate	JJ	O
synuclein.	TO	O
EXAMPLE	VB	O
13	NN	O
siRNA	,	O
Knockdown	NNP	O
of	CC	O
PLK	NNP	O
Family	VBG	O
Members	RB	O
HEK-293	JJ	O
naïve	NN	O
cells	IN	O
were	,	O
transfected	CC	O
with	NNP	O
40	VBG	O
nM,	DT	O
100	NN	O
nM	TO	O
and	VB	O
200	.	O
nM	RB	O
of	CD	O
Dharmacon	JJ	O
On	NNP	O
Target	IN	O
Plus	NNP	O
Smart	NNP	O
Pool	NNP	O
siRNAs	NNP	O
(Darmacon,	JJ	O
Lafayette,	NNS	O
Colo.)	VBD	O
designed	VBN	O
to	IN	O
knock	CD	O
down	,	O
the	CD	O
expression	NN	O
of	CC	O
each	CD	O
of	NN	O
the	IN	O
four	NNP	O
PLK	IN	O
family	NNP	O
members.	NNP	O
The	NNP	O
transfection	NNP	O
was	NN	O
performed	,	O
using	,	O
Lipofectamine	)	O
2000	VBN	O
(Invitrogen	TO	O
Carlsbad,	VB	O
Calif.).	RP	O
Cells	DT	O
were	NN	O
washed	IN	O
and	DT	O
harvested	IN	O
48	DT	O
hours	CD	O
post-transfection.	NNP	O
A	NN	O
Micro	.	O
BCA	DT	O
(Pierce)	NN	O
total	VBD	O
protein	VBN	O
assay	VBG	O
and	JJ	O
total	CD	O
synuclein	NNP	O
and	,	O
phospho-synuclein	.	O
ELISAs	NNS	O
were	VBD	O
performed	VBN	O
on	CC	O
each	VBN	O
plate	CD	O
of	NNS	O
treated	.	O
cells.	DT	O
PLK2	NNP	O
The	NNP	O
results	)	O
of	VBP	O
the	JJ	O
siRNA	NN	O
knockdown	CC	O
experiment	JJ	O
are	NN	O
summarized	CC	O
in	JJ	O
FIG.	NNP	O
10.	VBD	O
In	VBN	O
agreement	IN	O
with	DT	O
what	NN	O
we	IN	O
have	JJ	O
observed	.	O
previously	VB	O
for	DT	O
PLK2	NNS	O
siRNA	IN	O
inhibition	DT	O
(see	NN	O
Example	JJ	O
5)	NN	O
knockdown	VBP	O
resulted	VBN	O
in	IN	O
a	.	O
25%	.	O
decrease	IN	O
in	NN	O
the	IN	O
percentage	WP	O
of	PRP	O
phosphorylated	VBP	O
synuclein	VBN	O
in	RB	O
the	IN	O
293	NNP	O
cells.	NN	O
PLK3	NN	O
The	VB	O
knockdown	NNP	O
of	)	O
PLK3	NN	O
also	VBD	O
had	IN	O
no	DT	O
effect	NN	O
on	NN	O
synuclein	IN	O
phosphorylation,	DT	O
which	NN	O
is	IN	O
not	JJ	O
in	NN	O
agreement	IN	O
with	DT	O
the	CD	O
PLK3	.	O
overexpression	VB	O
data.	DT	O
This	NN	O
may	IN	O
be	NNP	O
due	RB	O
to	VBD	O
the	DT	O
fact	NN	O
that	IN	O
overexpression	NN	O
can	,	O
be	WDT	O
somewhat	VBZ	O
promiscuous,	RB	O
and	IN	O
not	NN	O
indicative	IN	O
of	DT	O
the	NNP	O
true	NN	O
physiological	.	O
state	DT	O
within	MD	O
cells.	VB	O
It	JJ	O
may	TO	O
also	DT	O
be	NN	O
that	IN	O
PLK3	NN	O
is	MD	O
not	VB	O
the	RB	O
synuclein	,	O
kinase	CC	O
in	RB	O
293	JJ	O
cells,	IN	O
but	DT	O
it	JJ	O
could	JJ	O
still	NN	O
be	IN	O
the	.	O
synuclein	PRP	O
kinase	MD	O
in	RB	O
neurons	VB	O
or	IN	O
other	NNP	O
cells	VBZ	O
due	RB	O
to	DT	O
the	NN	O
potential	NN	O
for	IN	O
isoform	CD	O
switching	,	O
between	CC	O
cell	PRP	O
types.	MD	O
Thus,	RB	O
although	VB	O
PLK3	DT	O
knockdown	JJ	O
does	NN	O
not	IN	O
reduce	NNS	O
synuclein	CC	O
phosphorylation	JJ	O
as	NNS	O
we	JJ	O
would	TO	O
expect	DT	O
from	NN	O
inhibition	IN	O
of	NN	O
the	NN	O
synuclein	IN	O
kinase,	NN	O
it	.	O
does	,	O
not	IN	O
completely	NNP	O
eliminate	NN	O
PLK3	VBZ	O
as	RB	O
being	VB	O
the	JJR	O
correct	NN	O
PLK	IN	O
family	PRP	O
member	MD	O
as	VB	O
the	IN	O
synuclein	NN	O
kinase	IN	O
in	DT	O
neurons.	NN	O
PLK1	,	O
Cells	PRP	O
treated	VBZ	O
with	RB	O
PLK1	RB	O
siRNA	VB	O
showed	NNP	O
a	IN	O
40%	VBG	O
decrease	DT	O
in	NN	O
the	NNP	O
total	NN	O
protein	NN	O
levels	IN	O
compared	DT	O
to	NN	O
the	NN	O
negative	IN	O
siRNA	.	O
control,	NNP	O
indicating	NNP	O
that	VBD	O
treatment	IN	O
of	NNP	O
cells	NN	O
with	VBD	O
PLK1	DT	O
siRNA	NN	O
inhibits	NN	O
proliferation	IN	O
of	DT	O
cells.	JJ	O
This	NN	O
has	NNS	O
been	VBN	O
noted	TO	O
in	DT	O
the	JJ	O
literature,	NN	O
and	,	O
confirms	VBG	O
the	IN	O
role	NN	O
of	IN	O
PLK1	NNS	O
in	IN	O
mitosis.	NNP	O
Taking	VBP	O
into	NNS	O
account	NN	O
this	IN	O
change	.	O
in	DT	O
total	VBZ	O
protein	VBN	O
levels,	VBN	O
knockdown	IN	O
of	DT	O
PLK1	,	O
transcript	CC	O
results	VBZ	O
in	DT	O
a	NN	O
60-90%	IN	O
increase	NNP	O
in	IN	O
the	.	O
percentage	VBG	O
of	IN	O
phospho-synuclein.	NN	O
This	DT	O
indicates	NN	O
that	IN	O
PLK1	JJ	O
is	NN	O
negative	,	O
regulator	NN	O
of	IN	O
synuclein	NNP	O
phosphorylation.	NN	O
It	NNS	O
appears	IN	O
that	DT	O
when	NN	O
PLK1	NN	O
is	IN	O
present	DT	O
in	NN	O
cell,	IN	O
it	.	O
regulates	DT	O
PLK2	VBZ	O
or	IN	O
it's	NNP	O
upstream	VBZ	O
pathway	JJ	O
and	NN	O
accordingly	IN	O
the	JJ	O
level	.	O
of	PRP	O
PLK2-mediated	VBZ	O
phosphorylation	IN	O
of	WRB	O
synuclein.	NNP	O
This	VBZ	O
increase	JJ	O
in	IN	O
phospho-synuclein	,	O
with	PRP	O
PLK1	VBZ	O
knockdown	NNP	O
has	CC	O
been	VBZ	O
observed	JJ	O
in	NN	O
two	CC	O
independent	RB	O
experiments,	DT	O
and	NN	O
is	IN	O
intriguing	JJ	O
as	NN	O
a	IN	O
potential	.	O
regulator	DT	O
of	NN	O
PLK2-driven	IN	O
synuclein	JJ	O
phosphorylation.	IN	O
PLK4	NNP	O
Knockdown	NN	O
of	VBZ	O
PLK4	VBN	O
with	VBN	O
siRNA	IN	O
had	CD	O
no	JJ	O
effect	,	O
on	CC	O
synuclein	VBZ	O
phosphorylation,	VBG	O
in	IN	O
accord	DT	O
with	JJ	O
the	NN	O
PLK4	IN	O
overexpression	NNP	O
data	NN	O
above	.	O
(Example	NNP	O
11).	NNP	O
EXAMPLE	IN	O
14	NNP	O
Treatment	IN	O
of	NN	O
Primary	VBD	O
Neuronal	DT	O
Cultures	NN	O
with	IN	O
Kinase	NN	O
Inhibitors	,	O
The	IN	O
effect	NN	O
on	IN	O
levels	DT	O
of	NNP	O
serine-129	NN	O
synuclein	NNS	O
was	IN	O
tested	NNP	O
for	.	O
kinase	NNP	O
inhibitors	CD	O
with	NNP	O
various	IN	O
specificities	NNP	O
in	NNP	O
rat	NNP	O
and	IN	O
mouse	NNP	O
primary	NNPS	O
cortical	DT	O
cell	NN	O
culture	IN	O
was	NNS	O
tested.	IN	O
Table	JJ	O
17	NN	O
shows	VBD	O
the	VBN	O
inhibitors	IN	O
used	NN	O
in	NNS	O
the	IN	O
experiment:	JJ	O
Preparation	NNS	O
of	IN	O
Mouse	NN	O
Neuronal	CC	O
Cell	NN	O
Cultures	JJ	O
Mouse	JJ	O
cortical	NN	O
cultures	NN	O
from	VBD	O
fetal	.	O
(i)	JJ	O
Swiss-Webster,	CD	O
(ii)	VBZ	O
C56BL/6	DT	O
WT	NNS	O
and	VBN	O
(iii)	IN	O
C56BL/6	DT	O
E46K-Synuclein	:	O
Trangenic	NN	O
mice	IN	O
were	NNP	O
prepared	NNP	O
and	NNP	O
maintained	NNP	O
in	NNP	O
B27/DMEM/1%	JJ	O
Penicillin-Streptomycin	NNS	O
at	IN	O
37°	JJ	O
C./10%	)	O
CO2	,	O
for	)	O
three	NNP	O
to	NNP	O
fourteen	CC	O
days	)	O
and	NNP	O
then	NNP	O
treated	NNP	O
with	NN	O
kinase	VBD	O
inhibitors.	JJ	O
Cultures	CC	O
were	VBN	O
exposed	IN	O
to	NN	O
inhibitors	NNP	O
for	IN	O
two	CD	O
hours	NN	O
in	NNP	O
B27/DMEM/1%	IN	O
Penicillin-Streptomycin.	CD	O
Cells	TO	O
were	VB	O
immediately	NNS	O
washed	CC	O
in	RB	O
100	VBD	O
μL	IN	O
of	NN	O
PBS	.	O
plus	NNS	O
Mg2+	VBD	O
and	VBN	O
Ca2+,	TO	O
and	NNS	O
harvested	IN	O
in	CD	O
ice-cold	NNS	O
CEB	IN	O
minus	NN	O
EGTA	.	O
plus	NNS	O
protease	VBD	O
inhibitors,	RB	O
frozen	VBN	O
on	IN	O
dry	CD	O
ice	NN	O
and	IN	O
stored	NNP	O
at	CC	O
−80°	NNP	O
C.	CC	O
until	,	O
processed.	CC	O
A	VBD	O
Micro	IN	O
BCA	JJ	O
(Pierce)	NNP	O
total	NN	O
protein	NNP	O
assay,	CC	O
and	JJ	O
total	,	O
synuclein	VBP	O
and	IN	O
phospho-synuclein	JJ	O
ELISAs	NN	O
were	CC	O
performed	VBN	O
on	IN	O
each	NNP	O
plate	NNP	O
of	IN	O
treated	.	O
cells	DT	O
using	NNP	O
standard	NNP	O
methods.	)	O
Preparation	VBP	O
of	JJ	O
Rat	,	O
Neuronal	CC	O
Cell	JJ	O
Cultures	NN	O
Rat	CC	O
Ventral	JJ	O
Mesencephalon	NNP	O
(RVM)	VBD	O
cultures	VBN	O
were	IN	O
prepared	DT	O
from	NN	O
E15	IN	O
Wistar	JJ	O
rats.	NNS	O
The	VBG	O
RVM	JJ	O
cultures	.	O
were	NN	O
cultured	IN	O
for	NNP	O
2	NNP	O
days	NNP	O
and	NNP	O
transduced	NNP	O
with	NNP	O
0.75	NNP	O
MOI	)	O
E46K-Synuclein	NNS	O
lentivirus	VBD	O
alone,	VBN	O
or	IN	O
0.75	NNP	O
MOI	NNP	O
E46K-Synuclein	.	O
lentivirus	DT	O
plus	NNP	O
0.75	NNS	O
MOI	VBD	O
ca-PLK2	VBN	O
lentivirus.	IN	O
The	CD	O
mid-brain	NNS	O
region,	CC	O
ventral	VBD	O
mesencephalon,	IN	O
from	CD	O
embryonic	NNP	O
day	NNP	O
15	NN	O
Wistar	,	O
rats	CC	O
were	CD	O
dissected	NNP	O
and	NNP	O
pooled	NN	O
for	CC	O
processing	CD	O
for	NNP	O
culture	JJ	O
as	.	O
described	DT	O
previously	JJ	O
in	,	O
Steven	JJ	B
et	,	I
al.,	IN	I
2001,	JJ	I
Genetics	NN	I
10:1317-24	CD	I
w